,sentence_text,e1_text,e2_text,relation_type,normalized_sentence
0,"Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.",calcium,EMCYT,mechanism,Milk milk products DRUG rich foods drugs may impair absorption BRAND .
1,"Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. ",Echistatin,contortrostatin,effect,DRUG_N alone effect tyrosine phosphorylation T24 cells dose dependently inhibits effects DRUG_N added simultaneously.
2,"Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. ",Flavoridin,contortrostatin,effect,DRUG_N alone found effect CAS completely block DRUG_N induced phosphorylation protein MDA MB 435 cells.
3,The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.,allopurinol,ampicillin,effect,concurrent administration DRUG DRUG increases substantially incidence rashes patients receiving drugs compared patients receiving ampicillin alone.
4,It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.,ampicillin,allopurinol,effect,known whether potentiation DRUG rashes due DRUG hyperuricemia present patients.
5,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",broad-spectrum antibiotics,contraceptives,effect,common GROUP AUGMENTIN XR may reduce efficacy oral GROUP
6,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",AUGMENTIN XR,contraceptives,effect,common broad spectrum antibiotics BRAND may reduce efficacy oral GROUP
7,Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.,ROMAZICON,cyclic antidepressants,effect,Particular caution necessary using BRAND cases mixed drug overdosage since toxic effects (such convulsions cardiac dysrhythmias) drugs taken overdose (especially GROUP ) may emerge reversal benzodiazepine effect flumazenil.
8,"Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.",ROMAZICON,benzodiazepine,effect,Although BRAND exerts slight intrinsic anticonvulsant effect abrupt suppression protective effect GROUP agonist give rise convulsions epileptic patients.
9,ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.,ROMAZICON,benzodiazepines,effect,BRAND blocks central effects GROUP competitive interaction receptor level.
10,"The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.",zopiclone,ROMAZICON,effect,effects nonbenzodiazepine agonists benzodiazepine receptors DRUG triazolopyridazines others also blocked BRAND .
11,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,antiarrhythmics,advise,Caution advised BRAND coadministered medications prolong QT interval (e.g. certain GROUP thioridazine) lead electrolyte abnormalities (such diuretics amphotericin B).
12,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,thioridazine,advise,Caution advised BRAND coadministered medications prolong QT interval (e.g. certain antiarrhythmics DRUG ) lead electrolyte abnormalities (such diuretics amphotericin B).
13,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,diuretics,advise,Caution advised BRAND coadministered medications prolong QT interval (e.g. certain antiarrhythmics thioridazine) lead electrolyte abnormalities (such GROUP amphotericin B).
14,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,amphotericin B,advise,Caution advised BRAND coadministered medications prolong QT interval (e.g. certain antiarrhythmics thioridazine) lead electrolyte abnormalities (such diuretics DRUG ).
15,"Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ",naloxone,beta-endorphin,effect,Intrathecal injection DRUG doses 0.4 40 micrograms caused dose related blockade inhibition tail flick response induced intraventricular injection DRUG_N high dose naloxone (40 micrograms) completely blocked tail flick inhibition induced intraventricular beta endorphin (16 micrograms).
16,"Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ",naloxone,beta-endorphin,effect,Intrathecal injection naloxone doses 0.4 40 micrograms caused dose related blockade inhibition tail flick response induced intraventricular injection beta endorphin high dose DRUG (40 micrograms) completely blocked tail flick inhibition induced intraventricular DRUG_N (16 micrograms).
17,"On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). ",naloxone,morphine,effect,hand intrathecal DRUG (12 120 micrograms) weak effect tail flick inhibition induced intraventricular DRUG (40 micrograms).
18,Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ,naloxone,beta-endorphin,effect,Intraventricular injection DRUG doses 1.2 12 micrograms equally antagonized dose dependent manner tail flick inhibition induced intraventricular DRUG_N morphine.
19,Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ,naloxone,morphine,effect,Intraventricular injection DRUG doses 1.2 12 micrograms equally antagonized dose dependent manner tail flick inhibition induced intraventricular beta endorphin DRUG .
20,Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.,steroids,aspirin,effect,Rarely salicylate toxicity may occur patients discontinue GROUP concurrent high dose BRAND therapy.
21,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",Barbiturates,fludrocortisone acetate,mechanism,GROUP phenytoin rifampin increased metabolic clearance DRUG induction hepatic enzymes.
22,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",phenytoin,fludrocortisone acetate,mechanism,Barbiturates DRUG rifampin increased metabolic clearance DRUG induction hepatic enzymes.
23,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",rifampin,fludrocortisone acetate,mechanism,Barbiturates phenytoin DRUG increased metabolic clearance DRUG induction hepatic enzymes.
24,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",Oxytocin,dinoprost,effect,DRUG oxytocics (concurrent use DRUG may result uterine hypertonus possibly causing uterine rupture cervical laceration especially absence adequate cervical dilatation;
25,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",oxytocics,dinoprost,effect,Oxytocin GROUP (concurrent use DRUG may result uterine hypertonus possibly causing uterine rupture cervical laceration especially absence adequate cervical dilatation;
26,Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.,acetaminophen,Isoniazid,effect,Acetaminophen: report severe DRUG toxicity reported patient receiving DRUG .
27,It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.,isoniazid,acetaminophen,effect,believed toxicity may resulted previously unrecognized interaction DRUG DRUG molecular basis interaction proposed.
28,"Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.",isoniazid,acetaminophen,mechanism,Furthermore proposed DRUG resulted induction P 450IIE1 patients liver turn resulted greater proportion ingested DRUG converted toxic metabolites.
29,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Isoniazid,carbamazepine,mechanism,Carbamazepine: DRUG known slow metabolism DRUG increase serum levels Carbamazepine levels determined prior concurrent administration isoniazid signs symptoms carbamazepine toxicity monitored closely appropriate dosage adjustment anticonvulsant made.
30,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Carbamazepine,isoniazid,advise,Carbamazepine: Isoniazid known slow metabolism carbamazepine increase serum levels DRUG levels determined prior concurrent administration DRUG signs symptoms carbamazepine toxicity monitored closely appropriate dosage adjustment anticonvulsant made.
31,Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.,Ketoconazole,Isoniazid,int,Ketoconazole: Potential interaction DRUG DRUG may exist.
32,Phenytoin: Isoniazid may increase serum levels of phenytoin.,Isoniazid,phenytoin,mechanism,Phenytoin: DRUG may increase serum levels DRUG .
33,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.",isoniazid,theophylline,mechanism,Therophylline: recent study shown concomitan administration DRUG DRUG may cause elevated plasma levels theophylline instances slight decrease elimination isoniazid.
34,Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.,valproate,isoniazid,mechanism,Valproate: recent case study shown possible increase plasma level DRUG co administered DRUG .
35,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.",isoniazid,valproate,advise,Plasma valproate concentration monitored DRUG DRUG co administered appropriate dosage adjustments valproate made.
36,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,aminoglycosides,advise,Co administration BRAND GROUP agents interfering neuromuscular transmission (e.g. curare like compounds) performed caution effect toxin may potentiated.
37,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,curare-like compounds,advise,Co administration BRAND aminoglycosides agents interfering neuromuscular transmission (e.g. GROUP ) performed caution effect toxin may potentiated.
38,"Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.",bosentan,Ortho-Novum,mechanism,Hormonal Contraceptives Including Oral Injectable Transdermal Implantable Contraceptives: interaction study demonstrated co administration DRUG oral hormonal contraceptive BRAND produced average decreases norethindrone ethinyl estradiol levels 14% 31% respectively.
39,"Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.",hormonal contraceptives,TRACLEER,effect,Therefore GROUP including oral injectable transdermal implantable forms may reliable BRAND co administered.
40,Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.,bosentan,cyclosporine A,mechanism,Steady state DRUG plasma concentrations 3 4 fold higher absence DRUG .
41,The concomitant administration of bosentan and cyclosporine A is contraindicated.,bosentan,cyclosporine A,advise,concomitant administration DRUG DRUG contraindicated.
42,Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.,bosentan,cyclosporine A,mechanism,Co administration DRUG decreased plasma concentrations DRUG (a CYP3A4 substrate) approximately 50%.
43,Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.,tacrolimus,bosentan,mechanism,Co administration DRUG DRUG resulted markedly increased plasma concentrations bosentan animals.
44,Caution should be exercised if tacrolimus and bosentan are used together.,tacrolimus,bosentan,advise,Caution exercised DRUG DRUG used together.
45,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.",TRACLEER,glyburide,advise,Therefore concomitant administration BRAND DRUG contraindicated alternative hypoglycemic agents considered.
46,Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.,bosentan,glyburide,mechanism,Co administration DRUG decreased plasma concentrations DRUG approximately 40%.
47,Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.,Bosentan,hypoglycemic agents,mechanism,DRUG also expected reduce plasma concentrations oral GROUP predominantly metabolized CYP2C9 CYP3A4.
48,"Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",bosentan,ketoconazole,mechanism,Ketoconazole: Co administration DRUG 125 mg b.i.d. DRUG potent CYP3A4 inhibitor increased plasma concentrations bosentan approximately 2 fold.
49,"Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",bosentan,simvastatin,mechanism,Simvastatin Statins: Co administration DRUG decreased plasma concentrations DRUG (a CYP3A4 substrate) active hydroxy acid metabolite approximately 50%.
50,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,statins,mechanism,DRUG also expected reduce plasma concentrations GROUP significant metabolism CYP3A4 lovastatin atorvastatin.
51,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,lovastatin,mechanism,DRUG also expected reduce plasma concentrations statins significant metabolism CYP3A4 DRUG atorvastatin.
52,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,atorvastatin,mechanism,DRUG also expected reduce plasma concentrations statins significant metabolism CYP3A4 lovastatin DRUG .
53,Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.,statins,TRACLEER,advise,Patients using CYP3A4 metabolized GROUP cholesterol levels monitored BRAND initiated see whether statin dose needs adjustment.
54,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,S-warfarin,mechanism,Warfarin: Co administration DRUG 500 mg b.i.d. 6 days decreased plasma concentrations DRUG (a CYP2C9 substrate) R warfarin (a CYP3A4 substrate) 29 38% respectively.
55,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,R-warfarin,mechanism,Warfarin: Co administration DRUG 500 mg b.i.d. 6 days decreased plasma concentrations warfarin (a CYP2C9 substrate) DRUG (a CYP3A4 substrate) 29 38% respectively.
56,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,orphenadrine,int,Therefore potential exists drug interaction BRAND drugs affect CYP2B6 isoenzyme (e.g. DRUG cyclophosphamide).
57,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,cyclophosphamide,int,Therefore potential exists drug interaction BRAND drugs affect CYP2B6 isoenzyme (e.g. orphenadrine DRUG ).
58,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,carbamazepine,mechanism,systematically studied certain drugs may induce metabolism DRUG (e.g. DRUG phenobarbital phenytoin).
59,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenobarbital,mechanism,systematically studied certain drugs may induce metabolism DRUG (e.g. carbamazepine DRUG phenytoin).
60,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenytoin,mechanism,systematically studied certain drugs may induce metabolism DRUG (e.g. carbamazepine phenobarbital DRUG ).
61,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.",bupropion,desipramine,mechanism,study 15 male subjects (ages 19 35 years) extensive metabolizers CYP2D6 isoenzyme daily doses DRUG given 150 mg twice daily followed single dose 50 mg DRUG increased Cmax AUC t1/2 desipramine average approximately 2 5 2 fold respectively.
62,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antidepressants,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain GROUP (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
63,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,nortriptyline,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. DRUG imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
64,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,imipramine,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline DRUG desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
65,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,desipramine,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine DRUG paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
66,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,paroxetine,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine DRUG fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
67,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,fluoxetine,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine DRUG sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
68,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,sertraline,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine DRUG ) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
69,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antipsychotics,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) GROUP (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
70,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,haloperidol,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. DRUG risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
71,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,risperidone,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol DRUG thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
72,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,thioridazine,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone DRUG ) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
73,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,beta-blockers,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) GROUP (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
74,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,metoprolol,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. DRUG ) Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
75,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,Type 1C antiarrhythmics,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) GROUP (e.g. propafenone flecainide) approached caution initiated lower end dose range concomitant medication.
76,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,propafenone,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. DRUG flecainide) approached caution initiated lower end dose range concomitant medication.
77,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,flecainide,advise,Therefore co administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e.g. nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e.g. haloperidol risperidone thioridazine) beta blockers (e.g. metoprolol) Type 1C antiarrhythmics (e.g. propafenone DRUG ) approached caution initiated lower end dose range concomitant medication.
78,MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .,bupropion,phenelzine,effect,MAO Inhibitors: Studies animals demonstrate acute toxicity DRUG enhanced MAO inhibitor DRUG .
79,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,levodopa,effect,Levodopa Amantadine: Limited clinical data suggest higher incidence adverse experiences patients receiving DRUG concurrently either DRUG amantadine.
80,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,amantadine,effect,Levodopa Amantadine: Limited clinical data suggest higher incidence adverse experiences patients receiving DRUG concurrently either levodopa DRUG .
81,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,levodopa,advise,Administration BRAND Tablets patients receiving either DRUG amantadine concurrently undertaken caution using small initial doses small gradual dose increases.
82,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,amantadine,advise,Administration BRAND Tablets patients receiving either levodopa DRUG concurrently undertaken caution using small initial doses small gradual dose increases.
83,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antipsychotics,advise,Drugs Lower Seizure Threshold: Concurrent administration BRAND agents (e.g. GROUP antidepressants theophylline systemic steroids etc.) lower seizure threshold undertaken extreme caution.
84,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antidepressants,advise,Drugs Lower Seizure Threshold: Concurrent administration BRAND agents (e.g. antipsychotics GROUP theophylline systemic steroids etc.) lower seizure threshold undertaken extreme caution.
85,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,theophylline,advise,Drugs Lower Seizure Threshold: Concurrent administration BRAND agents (e.g. antipsychotics antidepressants DRUG systemic steroids etc.) lower seizure threshold undertaken extreme caution.
86,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,steroids,advise,Drugs Lower Seizure Threshold: Concurrent administration BRAND agents (e.g. antipsychotics antidepressants theophylline systemic GROUP etc.) lower seizure threshold undertaken extreme caution.
87,"Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.",alcohol,WELLBUTRIN,effect,Alcohol: post marketing experience rare reports adverse neuropsychiatric events reduced alcohol tolerance patients drinking DRUG treatment BRAND .
88,The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS),alcohol,WELLBUTRIN,advise,consumption DRUG treatment BRAND minimized avoided (also see href= bupropz_od.htm#CI CONTRAINDICATIONS)
89,Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.,TNF antagonist,ORENCIA,effect,Concurrent administration GROUP BRAND associated increased risk serious infections significant additional efficacy use TNF antagonists alone.
90,Concurrent therapy with ORENCIA and TNF antagonists is not recommended.,ORENCIA,TNF antagonists,advise,Concurrent therapy BRAND GROUP recommended.
91,"There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.",ORENCIA,anakinra,advise,insufficient experience assess safety efficacy BRAND administered concurrently DRUG therefore use recommended.
92,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,cholestyramine,leflunomide,mechanism,Cholestyramine Charcoal Administration DRUG activated charcoal patients (n=13) volunteers (n=96) resulted rapid significant decrease plasma M1 (the active metabolite DRUG ) concentration .
93,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,activated charcoal,leflunomide,mechanism,Cholestyramine Charcoal Administration cholestyramine DRUG patients (n=13) volunteers (n=96) resulted rapid significant decrease plasma M1 (the active metabolite DRUG ) concentration .
94,"In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.",ARAVA,methotrexate,effect,small (n=30) combination study BRAND DRUG 2 3 fold elevation liver enzymes seen 5 30 patients.
95,"Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.",ARAVA,rifampin,mechanism,Rifampin: Following concomitant administration single dose BRAND subjects receiving multiple doses DRUG M1 peak levels increased (~40%) seen ARAVA given alone.
96,"Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.",ARAVA,rifampin,advise,potential ARAVA levels continue increase multiple dosing caution used patients receiving BRAND DRUG .
97,Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.,ARAVA,warfarin,effect,Warfarin: Increased INR (International Normalized Ratio) BRAND DRUG co administered rarely reported.
98,Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.,dobutamine,b-blocking drug,effect,Animal studies indicate DRUG may ineffective patient recently received GROUP .
99,"Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.",dobutamine,nitroprusside,effect,Preliminary studies indicate concomitant use DRUG DRUG results higher cardiac output usually lower pulmonary wedge pressure either drug used alone.
100,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,dicumarol,advise,Therefore DRUG given DRUG warfarin sodium period least 5 hours last intravenous dose 24 hours last subcutaneous dose elapse blood drawn valid prothrombin time obtained.
101,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,warfarin sodium,advise,Therefore DRUG given dicumarol DRUG period least 5 hours last intravenous dose 24 hours last subcutaneous dose elapse blood drawn valid prothrombin time obtained.
102,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",acetylsalicylic acid,heparin sodium,effect,Platelet inhibitors: Drugs DRUG dextran phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving DRUG .
103,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dextran,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid DRUG phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving DRUG .
104,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",phenylbutazone,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran DRUG ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving DRUG .
105,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",ibuprofen,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone DRUG indomethacin dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving DRUG .
106,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",indomethacin,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen DRUG dipyridamole hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving DRUG .
107,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dipyridamole,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin DRUG hydroxychloroquine others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving DRUG .
108,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",hydroxychloroquine,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin dipyridamole DRUG others interfere platelet aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving DRUG .
109,The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.,heparin,antithrombin III,effect,anticoagulant effect DRUG enhanced concurrent treatment DRUG (human) patients hereditary antithrombin III deficiency.
110,"Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).",heparin,antithrombin III,advise,Thus order avoid bleeding reduced dosage DRUG recommended treatment DRUG (human).
111,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",Digitalis,heparin sodium,effect,Drugs Decreasing Heparin Effect: GROUP tetracyclines nicotine antihistamines may partially counteract anticoagulant action DRUG .
112,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",tetracyclines,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis GROUP nicotine antihistamines may partially counteract anticoagulant action DRUG .
113,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",nicotine,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis tetracyclines DRUG antihistamines may partially counteract anticoagulant action DRUG .
114,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",antihistamines,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis tetracyclines nicotine GROUP may partially counteract anticoagulant action DRUG .
115,Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.,tricyclic antidepressants,cimetidine,mechanism,Steady state serum concentrations GROUP reported fluctuate significantly DRUG either added deleted drug regimen.
116,"Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.",tricyclic antidepressants,cimetidine,effect,Serious anticholinergic symptoms (severe dry mouth urinary retention blurred vision) associated elevations serum levels GROUP DRUG added drug regimen.
117,"In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.",tricyclic antidepressants,cimetidine,mechanism,addition higher expected steady state serum concentrations GROUP observed therapy initiated patients already taking DRUG .
118,"In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.",cimetidine,tricyclic antidepressants,mechanism,well controlled patients undergoing concurrent therapy DRUG decrease steady state serum concentrations GROUP may occur cime tidine therapy discontinued.
119,The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.,tricyclic antidepressants,cimetidine,effect,therapeutic efficacy GROUP may compromised patients DRUG discontinued.
120,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",antidepressants,fluoxetine hydrochloride,mechanism,greater 2 fold increases previously stable plasma levels GROUP including nortriptyline DRUG administered combination agents.
121,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",nortriptyline,fluoxetine hydrochloride,mechanism,greater 2 fold increases previously stable plasma levels antidepressants including DRUG DRUG administered combination agents.
122,Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.,reserpine,tricyclic antidepressant,effect,Administration DRUG therapy GROUP shown produce stimulating effect depressed patients.
123,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,anticholinergic drugs,advise,Close supervision careful adjustment dosage required DRUG used GROUP sympathomimetic drugs.
124,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,sympathomimetic drugs,advise,Close supervision careful adjustment dosage required DRUG used anticholinergic drugs GROUP .
125,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,antidepressants,advise,Therefore co administration GROUP drugs metabolized isoenzyme including GROUP phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
126,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,phenothiazines,advise,Therefore co administration GROUP drugs metabolized isoenzyme including antidepressants GROUP carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
127,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,carbamazepine,advise,Therefore co administration GROUP drugs metabolized isoenzyme including antidepressants phenothiazines DRUG Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
128,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,Type 1C antiarrhythmics,advise,Therefore co administration GROUP drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine GROUP (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
129,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,propafenone,advise,Therefore co administration GROUP drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg DRUG flecainide encainide) inhibit enzyme (eg quinidine) approached caution.
130,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,flecainide,advise,Therefore co administration GROUP drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone DRUG encainide) inhibit enzyme (eg quinidine) approached caution.
131,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,encainide,advise,Therefore co administration GROUP drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide DRUG ) inhibit enzyme (eg quinidine) approached caution.
132,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,quinidine,advise,Therefore co administration GROUP drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg DRUG ) approached caution.
133,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,CNS depressants,advise,Although specific drug interaction studies conducted BRAND possibility additive potentiating effect GROUP (alcohol barbiturates opiates sedatives anesthetics) considered.
134,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,alcohol,advise,Although specific drug interaction studies conducted BRAND possibility additive potentiating effect CNS depressants ( DRUG barbiturates opiates sedatives anesthetics) considered.
135,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,barbiturates,advise,Although specific drug interaction studies conducted BRAND possibility additive potentiating effect CNS depressants (alcohol GROUP opiates sedatives anesthetics) considered.
136,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,opiates,advise,Although specific drug interaction studies conducted BRAND possibility additive potentiating effect CNS depressants (alcohol barbiturates GROUP sedatives anesthetics) considered.
137,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,sedatives,advise,Although specific drug interaction studies conducted BRAND possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates GROUP anesthetics) considered.
138,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,anesthetics,advise,Although specific drug interaction studies conducted BRAND possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives GROUP ) considered.
139,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.,Tricyclic antidepressants,clonidine,effect,GROUP reported blunt hypotensive effect systemic DRUG .It known whether concurrent use agents ALPHAGAN P humans lead resulting interference IOP lowering effect.
140,"Interactions of cobalt and iron in absorption and retention.
",cobalt,iron,mechanism,Interactions DRUG DRUG absorption retention.
141,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ,iron,cobalt,mechanism,Additional DRUG significantly inhibited absorption DRUG dietary cobalt treatments.
142,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ,iron,cobalt,mechanism,Additional DRUG significantly inhibited absorption cobalt dietary DRUG treatments.
143,The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. ,Fe,cobalt,mechanism,lower rate absorption groups receiving 446 mg DRUG instead 48 mg Fe per kg diet resulted decreased renal excretion DRUG .
144,"Consequently, the effect of iron on the retention of cobalt was lower than on absorption. ",iron,cobalt,mechanism,Consequently effect DRUG retention DRUG lower absorption.
145,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ketoconazole,advise,daily dose BRAND exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. DRUG itraconazole ritonavir nelfinavir clarithromycin nefazadone) .
146,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,itraconazole,advise,daily dose BRAND exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole DRUG ritonavir nelfinavir clarithromycin nefazadone) .
147,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ritonavir,advise,daily dose BRAND exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole itraconazole DRUG nelfinavir clarithromycin nefazadone) .
148,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,nelfinavir,advise,daily dose BRAND exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole itraconazole ritonavir DRUG clarithromycin nefazadone) .
149,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,clarithromycin,advise,daily dose BRAND exceed 7.5 mg coadministered potent CYP3A4 inhibitors (e.g. ketoconazole itraconazole ritonavir nelfinavir DRUG nefazadone) .
150,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,flecainide,advise,Caution taken BRAND used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window DRUG thioridazine tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
151,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,thioridazine,advise,Caution taken BRAND used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window flecainide DRUG tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
152,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,tricyclic antidepressants,advise,Caution taken BRAND used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window flecainide thioridazine GROUP (see CLINICAL PHARMACOLOGY).
153,"The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.",ENABLEX,anticholinergic agents,effect,concomitant use BRAND GROUP may increase frequency and/or severity dry mouth constipation blurred vision anticholinergic pharmacological effects.
154,Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.,ETHYOL,antihypertensive medications,advise,Special consideration given administration BRAND patients receiving GROUP drugs could cause potentiate hypotension.
155,Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.,Tiagabine,valproate,mechanism,Valproate: DRUG causes slight decrease (about 10%) steady state DRUG concentrations.
156,Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.,tiagabine,carbamazepine,mechanism,Effects Antiepilepsy Drugs (AEDs) GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking DRUG without enzyme inducing AEDs.
157,Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.,tiagabine,phenytoin,mechanism,Phenytoin: Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking DRUG without enzyme inducing AEDs.
158,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,phenobarbital,mechanism,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking DRUG (primidone) without enzyme inducing AEDs.
159,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,primidone,mechanism,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking phenobarbital ( DRUG ) without enzyme inducing AEDs.
160,"Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.",valproate,tiagabine,mechanism,Valproate: addition tiagabine patients taking valproate chronically effect tiagabine pharmacokinetics DRUG significantly decreased DRUG binding vitro 96.3 94.8% resulted increase approximately 40% free tiagabine concentration.
161,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",ethanol,tiagabine,advise,possible additive effects drugs may depress nervous system DRUG triazolam used cautiously combination DRUG .
162,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",triazolam,tiagabine,advise,possible additive effects drugs may depress nervous system ethanol DRUG used cautiously combination DRUG .
163,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Acetaminophen,int,DRUG may interact following: DRUG (e.g. Tylenol) (with long term high dose use)
164,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Tylenol,int,DRUG may interact following: Acetaminophen (e.g. BRAND ) (with long term high dose use)
165,"- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics",antidiabetics,sulfapyridine,effect,Antidiabetics oral (diabetes medicine take mouth) Use oral GROUP DRUG may increase chance side effects affecting blood and/or side effects oral antidiabetics
166,"- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate",methotrexate,sulfapyridine,effect,Methotrexate (e.g. Mexate) Use DRUG DRUG may increase chance side effects affecting liver and/or side effects methotrexate
167,"- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood",methyldopa,sulfapyridine,effect,Methyldopa (e.g. Aldomet) Use DRUG DRUG may increase chance side effects affecting liver and/or blood
168,"- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",phenytoin,sulfapyridine,effect,Phenytoin (e.g. Dilantin) Use DRUG DRUG may increase chance side effects affecting liver and/or side effects phenytoin
169,Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.,theophylline,quinolones,mechanism,Elevated plasma levels DRUG reported concomitant use GROUP .
170,There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.,theophylline,quinolone,effect,reports theophylline related side effects patients concomitant DRUG GROUP therapy.
171,Quinolones have also been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,GROUP also shown interfere metabolism DRUG .
172,"Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.",cinoxacin,caffeine,advise,Although interaction reported cinoxacin caution exercised DRUG given concomitantly DRUG containing products.
173,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",Antacids,quinolones,mechanism,GROUP sucralfate substantially interfere absorption GROUP resulting low urine levels.
174,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",sucralfate,quinolones,mechanism,Antacids DRUG substantially interfere absorption GROUP resulting low urine levels.
175,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,iron,mechanism,Also concomitant administration GROUP products containing DRUG multivitamins containing zinc Videx (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
176,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,zinc,mechanism,Also concomitant administration GROUP products containing iron multivitamins containing DRUG Videx (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
177,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,Videx,mechanism,Also concomitant administration GROUP products containing iron multivitamins containing zinc BRAND (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
178,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,didanosine,mechanism,Also concomitant administration GROUP products containing iron multivitamins containing zinc Videx ( DRUG ) chewable/buffered tablets pediatric powder oral solution may result low urine levels.
179,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,anticoagulants,effect,GROUP including cinoxacin may enhance effects oral GROUP warfarin derivatives.
180,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,warfarin,effect,GROUP including cinoxacin may enhance effects oral anticoagulants DRUG derivatives.
181,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,anticoagulants,effect,Quinolones including DRUG may enhance effects oral GROUP warfarin derivatives.
182,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,warfarin,effect,Quinolones including DRUG may enhance effects oral anticoagulants DRUG derivatives.
183,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,nonsteroidal anti-inflammatory drug,effect,Seizures reported patients taking another GROUP GROUP fenbufen concurrently.
184,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,fenbufen,effect,Seizures reported patients taking another GROUP nonsteroidal anti inflammatory drug DRUG concurrently.
185,Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.,cinoxacin,nonsteroidal anti-inflammatory agents,advise,Physicians provided information increase awareness potential serious interactions DRUG certain GROUP administered concomitantly.
186,Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated cyclosporine serum levels reported concomitant use GROUP DRUG .
187,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,aluminum,mechanism,Administration GROUP antacids containing DRUG magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
188,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,magnesium,mechanism,Administration GROUP antacids containing aluminum DRUG calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
189,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,calcium,mechanism,Administration GROUP antacids containing aluminum magnesium DRUG sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
190,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,sucralfate,mechanism,Administration GROUP antacids containing aluminum magnesium calcium DRUG metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
191,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,Administration GROUP antacids containing aluminum magnesium calcium sucralfate metal cations DRUG multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
192,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,multivitamins,mechanism,Administration GROUP antacids containing aluminum magnesium calcium sucralfate metal cations iron GROUP containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
193,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,Administration GROUP antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing DRUG zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
194,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,zinc,mechanism,Administration GROUP antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron DRUG formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
195,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,VIDEX,mechanism,Administration GROUP antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations BRAND (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
196,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,didanosine,mechanism,Administration GROUP antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX ( DRUG ) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption quinolones resulting systemic concentrations considerably lower desired.
197,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,caffeine,mechanism,Caffeine Theobromine DRUG like quinolones may inhibit metabolism DRUG theobromine.
198,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,theobromine,mechanism,Caffeine Theobromine DRUG like quinolones may inhibit metabolism caffeine DRUG .
199,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,caffeine,mechanism,Caffeine Theobromine Grepafloxacin like GROUP may inhibit metabolism DRUG theobromine.
200,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,theobromine,mechanism,Caffeine Theobromine Grepafloxacin like GROUP may inhibit metabolism caffeine DRUG .
201,Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.,Grepafloxacin,theophylline,mechanism,Theophylline: DRUG competitive inhibitor metabolism DRUG .
202,Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.,grepafloxacin,theophylline,mechanism,Serum theophylline concentrations increase DRUG initiated patient maintained DRUG .
203,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",theophylline,grepafloxacin,advise,initiating multi day course grepafloxacin patient maintained theophylline DRUG maintenance dose halved period concurrent use DRUG monitoring serum theophylline concentrations initiated guide dosage adjustments.
204,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolones,warfarin,effect,However GROUP reported enhance effects DRUG derivatives prothrombin time suitable anticoagulation test monitored closely quinolone antimicrobial administered warfarin derivatives.
205,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,However quinolones reported enhance effects warfarin derivatives prothrombin time suitable anticoagulation test monitored closely GROUP administered DRUG derivatives.
206,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.",grepafloxacin,theophylline,mechanism,Drugs Metabolized Cytochrome P450 Enzymes drug interaction study evaluating effect grepafloxacin theophylline indicates DRUG inhibits DRUG metabolism mediated CYP1A2.
207,"In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.",quinolones,cyclosporine,mechanism,addition GROUP reported decrease CYP3A4 mediated metabolism DRUG .
208,Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.,nonsteroidal anti inflammatory drug,quinolone,effect,Nonsteroidal Anti inflammatory Drugs (NSAIDs): concomitant administration GROUP GROUP may increase risks CNS stimulation convulsions.
209,"Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.",quinolones,antidiabetic agent,effect,Antidiabetic Agents: Disturbances blood glucose including hyperglycemia hypoglycemia reported patients treated concomitantly GROUP GROUP .
210,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,anticholinergics,effect,concurrent use BRAND Injection GROUP medications anticholinergic activity phenothiazines antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects.
211,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,phenothiazines,effect,concurrent use BRAND Injection anticholinergics medications anticholinergic activity GROUP antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects.
212,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,antiparkinson drugs,effect,concurrent use BRAND Injection anticholinergics medications anticholinergic activity phenothiazines GROUP tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects.
213,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,tricyclic antidepressants,effect,concurrent use BRAND Injection anticholinergics medications anticholinergic activity phenothiazines antiparkinson drugs GROUP may intensify antimuscarinic effects may result increase anticholinergic side effects.
214,Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.,Robinul,potassium chloride,mechanism,Concomitant administration BRAND Injection DRUG wax matrix may increase severity potassium chloride induced gastrointestinal lesions result slower gastrointestinal transit time.
215,"When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.",beta-adrenergic receptor blocking agents,Anesthetics,int,administered concurrently following drugs may interact GROUP : GROUP general: exaggeration hypotension induced general anesthetics.
216,Elevated plasma levels of theophylline have been reported with concomitant quinolone use.,theophylline,quinolone,mechanism,Elevated plasma levels DRUG reported concomitant GROUP use.
217,There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.,quinolones,theophylline,effect,reports theophylline related side effects patients concomitant therapy GROUP DRUG .
218,Quinolones have been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,GROUP shown interfere metabolism DRUG .
219,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",Quinolones,warfarin,effect,GROUP including nalidixic acid may enhance effects oral anticoagulant DRUG derivatives.
220,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",nalidixic acid,warfarin,effect,Quinolones including DRUG may enhance effects oral anticoagulant DRUG derivatives.
221,Nitrofurantoin interferes with the therapeutic action of nalidixic acid.,Nitrofurantoin,nalidixic acid,effect,DRUG interferes therapeutic action DRUG .
222,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Videx,quinolones,mechanism,BRAND (Didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption GROUP resulting systemic levels considerably lower desired.
223,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Didanosine,quinolones,mechanism,Videx ( DRUG ) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption GROUP resulting systemic levels considerably lower desired.
224,Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated serum levels cyclosporine reported concomitant use GROUP DRUG .
225,"Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.",cephalexin,metformin,mechanism,Metformin: healthy subjects given single 500 mg doses DRUG DRUG plasma metformin mean cmax AUC increased average 34% 24% respectively metformin mean renal clearance decreased 14%.
226,"Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.",cephalexin,metformin,mechanism,Although observed study adverse effects could potentially arise co administration DRUG DRUG inhibition tubular secretion via organic cationic transporter systems.
227,"Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.",cephalexin,metformin,advise,Accordingly careful patient monitoring dose adjustment metformin recommended patients concomitantly taking DRUG DRUG .
228,"Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.",cephalexin,probenecid,mechanism,Probenecid: b lactams renal excretion DRUG inhibited DRUG .
229,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Monoamine oxidase inhibitors,int,Drug Interactions: DRUG may interact drugs like GROUP (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
230,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,MAOI,int,Drug Interactions: DRUG may interact drugs like Monoamine oxidase inhibitors ( GROUP ): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
231,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",MAOI,flupenthixol,effect,Drug Interactions: Flupenthixol may interact drugs like Monoamine oxidase inhibitors (MAOI): GROUP could theoretically affect DRUG pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
232,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Ethanol,effect,Drug Interactions: Flupenthixol may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: DRUG DRUG cause additive CNS depression Tricyclic antidepressants: Flupenthixol increases effect Tricyclic antidepressants
233,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Tricyclic antidepressants,effect,Drug Interactions: Flupenthixol may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics Arecoline Eproxindine Ethanol: Flupenthixol Ethanol cause additive CNS depression Tricyclic antidepressants: DRUG increases effect GROUP
234,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",Curariform muscle relaxants,Coly-Mycin M,effect,BRAND (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated BRAND Parenteral.
235,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",tubocurarine,Coly-Mycin M,effect,Curariform muscle relaxants (eg DRUG ) drugs including ether succinylcholine gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated BRAND Parenteral.
236,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",succinylcholine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether DRUG gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated BRAND Parenteral.
237,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",gallamine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine DRUG decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated BRAND Parenteral.
238,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",decamethonium,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine DRUG sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated BRAND Parenteral.
239,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",sodium citrate,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium DRUG potentiate neuromuscular blocking effect used extreme caution patients treated BRAND Parenteral.
240,Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.,Sodium cephalothin,Coly-Mycin M,effect,DRUG may enhance nephrotoxicity BRAND Parenteral.
241,The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.,sodium cephalothin,Coly-Mycin M,advise,concomitant use DRUG BRAND Parenteral avoided.
242,"Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.",diuretics,PRINIVIL,effect,Hypotension Patients Diuretic Therapy: Patients GROUP especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy BRAND .
243,The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.,diuretic,PRINIVIL,effect,possibility hypotensive effects PRINIVIL minimized either discontinuing GROUP increasing salt intake prior initiation treatment BRAND .
244,"If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.",diuretic,PRINIVIL,advise,necessary continue GROUP initiate therapy BRAND dose 5 mg daily provide close medical supervision initial dose blood pressure stabilized.
245,"When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.",diuretic,PRINIVIL,effect,GROUP added therapy patient receiving BRAND additional antihypertensive effect usually observed.
246,Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.,ACE inhibitor,diuretic,advise,Studies ACE inhibitors combination diuretics indicate dose GROUP reduced given GROUP .
247,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.",non-steroidal anti-inflammatory drugs,lisinopril,effect,Non steroidal Anti inflammatory Agents: patients compromised renal function treated GROUP co administration DRUG may result deterioration renal function.
248,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,ACE inhibitors,effect,Reports suggest GROUP may diminish antihypertensive effect GROUP including lisinopril.
249,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,lisinopril,effect,Reports suggest GROUP may diminish antihypertensive effect ACE inhibitors including DRUG .
250,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking GROUP concomitantly GROUP .
251,Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.,PRINIVIL,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: BRAND attenuates potassium loss caused GROUP .
252,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium-sparing diuretics,effect,Use BRAND GROUP (e.g. spironolactone triamterene amiloride) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
253,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,spironolactone,effect,Use BRAND potassium sparing diuretics (e.g. DRUG triamterene amiloride) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
254,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,triamterene,effect,Use BRAND potassium sparing diuretics (e.g. spironolactone DRUG amiloride) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
255,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,amiloride,effect,Use BRAND potassium sparing diuretics (e.g. spironolactone triamterene DRUG ) potassium supplements potassium containing salt substitutes may lead significant increases serum potassium.
256,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium,effect,Use BRAND potassium sparing diuretics (e.g. spironolactone triamterene amiloride) DRUG supplements potassium containing salt substitutes may lead significant increases serum potassium.
257,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,Lithium: Lithium toxicity reported patients receiving DRUG concomitantly drugs cause elimination sodium including GROUP .
258,Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.,lithium,ACE inhibitor,effect,Lithium toxicity usually reversible upon discontinuation DRUG GROUP .
259,It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.,PRINIVIL,lithium,advise,recommended serum lithium levels monitored frequently BRAND administered concomitantly DRUG .
260,The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.,butalbital,monoamine oxidase (MAO) inhibitors,effect,CNS effects DRUG may enhanced GROUP .
261,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,narcotic analgesic,effect,DRUG acetaminophen caffeine may enhance effects of: GROUP alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
262,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,alcohol,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics DRUG general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
263,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,anesthetics,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general GROUP tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
264,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,tranquilizers,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics GROUP chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
265,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,chlordiazepoxide,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers DRUG sedative hypnotics CNS depressants causing increased CNS depression.
266,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,sedative-hypnotics,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide GROUP CNS depressants causing increased CNS depression.
267,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,CNS depressants,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics GROUP causing increased CNS depression.
268,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,narcotic analgesic,effect,Butalbital DRUG caffeine may enhance effects of: GROUP alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
269,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,alcohol,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics DRUG general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
270,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,anesthetics,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general GROUP tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
271,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,tranquilizers,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics GROUP chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
272,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,chlordiazepoxide,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers DRUG sedative hypnotics CNS depressants causing increased CNS depression.
273,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,sedative-hypnotics,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide GROUP CNS depressants causing increased CNS depression.
274,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,CNS depressants,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics GROUP causing increased CNS depression.
275,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,narcotic analgesic,effect,Butalbital acetaminophen DRUG may enhance effects of: GROUP alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
276,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,alcohol,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics DRUG general anesthetics tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
277,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,anesthetics,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general GROUP tranquilizers chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
278,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,tranquilizers,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics GROUP chlordiazepoxide sedative hypnotics CNS depressants causing increased CNS depression.
279,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,chlordiazepoxide,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers DRUG sedative hypnotics CNS depressants causing increased CNS depression.
280,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,sedative-hypnotics,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide GROUP CNS depressants causing increased CNS depression.
281,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,CNS depressants,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative hypnotics GROUP causing increased CNS depression.
282,Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.,Buforin II,azithromycin,effect,DRUG_N may active inhibiting Cryptosporidium parvum growth vitro upon combination either DRUG minocycline.
283,Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.,Buforin II,minocycline,effect,DRUG_N may active inhibiting Cryptosporidium parvum growth vitro upon combination either azithromycin DRUG .
284,"CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.",Sonata,ethanol,effect,CNS Active Drugs Ethanol: BRAND 10 mg potentiated CNS impairing effects DRUG 0.75 g/kg balance testing reaction time 1 hour ethanol administration digit symbol substitution test (DSST) symbol copying test variability component divided attention test 2.5 hours ethanol administration.
285,Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,imipramine,effect,Imipramine: Coadministration single doses BRAND 20 mg DRUG 75 mg produced additive effects decreased alertness impaired psychomotor performance 2 4 hours administration.
286,Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,thioridazine,effect,Thioridazine: Coadministration single doses BRAND 20 mg DRUG 50 mg produced additive effects decreased alertness impaired psychomotor performance 2 4 hours administration.
287,"Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.",zaleplon,promethazine,mechanism,Promethazine: Coadministration single dose DRUG DRUG (10 25 mg respectively) resulted 15% decrease maximal plasma concentrations zaleplon change area plasma concentration time curve.
288,"Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.",rifampin,zaleplon,mechanism,Multiple dose administration potent CYP3A4 inducer DRUG (600 mg every 24 hours q24h 14 days) however reduced DRUG Cmax AUC approximately 80%.
289,"Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.",zaleplon,erythromycin,mechanism,Coadministration single oral doses DRUG DRUG (10 mg 800 mg respectively) strong selective CYP3A4 inhibitor produced 34% increase zaleplons maximal plasma concentrations 20% increase area plasma concentration time curve.
290,Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.,ketoconazole,zaleplon,mechanism,strong selective CYP3A4 inhibitors DRUG also expected increase exposure DRUG .
291,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.",Cimetidine,zaleplon,mechanism,Drugs Inhibit Aldehyde Oxidase CYP3A4 Cimetidine: DRUG inhibits aldehyde oxidase (in vitro) CYP3A4 (in vitro vivo) primary secondary enzymes respectively responsible DRUG metabolism.
292,Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.,Sonata,cimetidine,mechanism,Concomitant administration BRAND (10 mg) DRUG (800 mg) produced 85% increase mean Cmax AUC zaleplon.
293,"A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.",INSPRA,ketoconazole,mechanism,pharmacokinetic study evaluating administration single dose BRAND 100 mg DRUG 200 mg BID potent inhibitor CYP3A4 pathway showed 1.7 fold increase Cmax eplerenone 5.4 fold increase AUC eplerenone.
294,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,erythromycin,mechanism,Administration DRUG CYP3A4 inhibitors (e.g. DRUG 500 mg BID verapamil 240 mg QD saquinavir 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
295,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,verapamil,mechanism,Administration DRUG CYP3A4 inhibitors (e.g. erythromycin 500 mg BID DRUG 240 mg QD saquinavir 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
296,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,saquinavir,mechanism,Administration DRUG CYP3A4 inhibitors (e.g. erythromycin 500 mg BID verapamil 240 mg QD DRUG 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
297,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,fluconazole,mechanism,Administration DRUG CYP3A4 inhibitors (e.g. erythromycin 500 mg BID verapamil 240 mg QD saquinavir 1200 mg TID DRUG 200 mg QD) resulted increases Cmax eplerenone ranging 1.4 1.6 fold AUC 2.0 2.9 fold.
298,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,ACE inhibitors,effect,ACE Inhibitors Angiotensin II Receptor Antagonists (Hypertension) clinical studies patients hypertension addition BRAND 50 100 mg GROUP angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09 0.13 mEq/L).
299,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,angiotensin II receptor antagonists,effect,ACE Inhibitors Angiotensin II Receptor Antagonists (Hypertension) clinical studies patients hypertension addition BRAND 50 100 mg ACE inhibitors GROUP increased mean serum potassium slightly (about 0.09 0.13 mEq/L).
300,In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.,INSPRA,enalapril,effect,study diabetics microalbuminuria BRAND 200 mg combined ACE inhibitor DRUG 10 mg increased frequency hyperkalemia (serum potassium 5.5 mEq/L) 17% enalapril alone 38%.
301,Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.,INSPRA,lithium,advise,Serum lithium levels monitored frequently BRAND administered concomitantly DRUG .
302,The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.,potassium-sparing antihypertensives,NSAIDs,effect,administration GROUP GROUP shown reduce antihypertensive effect patients result severe hyperkalemia patients impaired renal function.
303,"Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.",INSPRA,NSAIDs,advise,Therefore BRAND GROUP used concomitantly patients observed determine whether desired effect blood pressure obtained.
304,Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.,Aminoglutethimide,corticosteroids,effect,Aminoglutethimide: DRUG may diminish adrenal suppression GROUP .
305,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,amphotericin B,advise,Amphotericin B injection potassium depleting agents: GROUP administered concomitantly potassium depleting agents (e.g. DRUG diuretics) patients observed closely development hypokalemia.
306,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,diuretics,advise,Amphotericin B injection potassium depleting agents: GROUP administered concomitantly potassium depleting agents (e.g. amphotericin B GROUP ) patients observed closely development hypokalemia.
307,"In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.",amphotericin B,hydrocortisone,effect,addition cases reported concomitant use DRUG DRUG followed cardiac enlargement congestive heart failure.
308,Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.,Macrolide antibiotics,corticosteroid,mechanism,Antibiotics: GROUP reported cause significant decrease GROUP clearance.
309,Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.,anticholinesterase agents,corticosteroids,effect,Anticholinesterases: Concomitant use GROUP GROUP may produce severe weakness patients myasthenia gravis.
310,"If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.",anticholinesterase agents,corticosteroid,advise,possible GROUP withdrawn least 24 hours initiating GROUP therapy.
311,"Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.",corticosteroids,warfarin,effect,Anticoagulants oral: Co administration GROUP DRUG usually results inhibition response warfarin although conflicting reports.
312,"Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.",corticosteroids,antidiabetic agents,effect,Antidiabetics: GROUP may increase blood glucose concentrations dosage adjustments GROUP may required.
313,Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.,Cholestyramine,corticosteroids,mechanism,Cholestyramine: DRUG may increase clearance GROUP .
314,Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.,cyclosporine,corticosteroids,effect,Cyclosporine: Increased activity DRUG GROUP may occur two used concurrently.
315,"Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.",Ephedrine,corticosteroids,mechanism,Ephedrine: DRUG may enhance metabolic clearance GROUP resulting decreased blood levels lessened physiologic activity thus requiring increase corticosteroid dosage.
316,"Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.",Estrogens,corticosteroids,mechanism,Estrogens including oral contraceptives: GROUP may decrease hepatic metabolism certain GROUP thereby increasing effect.
317,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",barbiturates,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. GROUP phenytoin carbamazepine rifampin) may enhance metabolism GROUP require dosage corticosteroid increased.
318,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",phenytoin,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. barbiturates DRUG carbamazepine rifampin) may enhance metabolism GROUP require dosage corticosteroid increased.
319,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",carbamazepine,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. barbiturates phenytoin DRUG rifampin) may enhance metabolism GROUP require dosage corticosteroid increased.
320,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",rifampin,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g. barbiturates phenytoin carbamazepine DRUG ) may enhance metabolism GROUP require dosage corticosteroid increased.
321,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",ketoconazole,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e.g. DRUG macrolide antibiotics erythromycin) potential result increased plasma concentrations GROUP .
322,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",macrolide antibiotics,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e.g. ketoconazole GROUP erythromycin) potential result increased plasma concentrations GROUP .
323,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",erythromycin,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e.g. ketoconazole macrolide antibiotics DRUG ) potential result increased plasma concentrations GROUP .
324,"Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.",Ketoconazole,corticosteroids,mechanism,Ketoconazole: DRUG reported decrease metabolism certain GROUP 60% leading increased risk corticosteroid side effects.
325,"In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.",ketoconazole,corticosteroid,effect,addition DRUG alone inhibit adrenal DRUG synthesis may cause adrenal insufficiency corticosteroid withdrawal.
326,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,aspirin,corticosteroids,effect,Nonsteroidal anti inflammatory agents (NSAIDS): Concomitant use BRAND (or nonsteroidal antiinflammatory agents) GROUP increases risk gastrointestinal side effects.
327,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,nonsteroidal antiinflammatory agents,corticosteroids,effect,Nonsteroidal anti inflammatory agents (NSAIDS): Concomitant use aspirin (or GROUP ) GROUP increases risk gastrointestinal side effects.
328,Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.,Aspirin,corticosteroids,advise,BRAND used cautiously conjunction GROUP hypoprothrombinemia.
329,The clearance of salicylates may be increased with concurrent use of corticosteroids.,salicylates,corticosteroids,mechanism,clearance GROUP may increased concurrent use GROUP .
330,"Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.",phenytoin,dexamethasone,mechanism,Phenytoin: post marketing experience reports increases decreases DRUG levels DRUG co administration leading alterations seizure control.
331,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,live vaccines,effect,Vaccines: Patients GROUP therapy may exhibit diminished response toxoids live inactivated GROUP due inhibition antibody response.
332,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,inactivated vaccines,effect,Vaccines: Patients GROUP therapy may exhibit diminished response toxoids live GROUP due inhibition antibody response.
333,Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.,Corticosteroids,live attenuated vaccines,effect,GROUP may also potentiate replication organisms contained GROUP .
334,Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.,vaccines,corticosteroid,advise,Routine administration GROUP toxoids deferred GROUP therapy discontinued possible.
335,Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.,temazepam,ethanol,mechanism,Acid catalyzed ethanolysis DRUG anhydrous aqueous DRUG solutions.
336,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. ",temazepam,ethanol,mechanism,addition pharmacological interaction report describes novel chemical reaction DRUG (a benzodiazepine) DRUG acidic conditions similar found vivo resulting 3 ethoxylated product.
337,"The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. ",alcohol,"3-hydroxy-1,4-benzodiazepine",mechanism,results raise possibility ethanolysis reaction may occur stomach people consume DRUG GROUP regular basis.
338,"Enhanced theophylline clearance secondary to phenytoin therapy.
",theophylline,phenytoin,mechanism,Enhanced DRUG clearance secondary DRUG therapy.
339,This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. ,theophylline,phenytoin,mechanism,report describes two cases DRUG clearance accelerated markedly concomitant DRUG administration.
340,"With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.",phenytoin,theophylline,effect,combined use clinicians aware DRUG added potential reexacerbation pulmonary symptomatology due lowered serum DRUG concentrations.
341,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,CENTRAL NERVOUS SYSTEM DEPRESSANTS,effect,POTENTIATING ACTION DRUG MUST CONSIDERED DRUG USED CONJUNCTION GROUP NARCOTICS NON NARCOTIC ANALGESICS BARBITURATES.
342,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NARCOTICS,effect,POTENTIATING ACTION DRUG MUST CONSIDERED DRUG USED CONJUNCTION CENTRAL NERVOUS SYSTEM DEPRESSANTS GROUP NON NARCOTIC ANALGESICS BARBITURATES.
343,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NON-NARCOTIC ANALGESICS,effect,POTENTIATING ACTION DRUG MUST CONSIDERED DRUG USED CONJUNCTION CENTRAL NERVOUS SYSTEM DEPRESSANTS NARCOTICS GROUP BARBITURATES.
344,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,BARBITURATES,effect,POTENTIATING ACTION DRUG MUST CONSIDERED DRUG USED CONJUNCTION CENTRAL NERVOUS SYSTEM DEPRESSANTS NARCOTICS NON NARCOTIC ANALGESICS GROUP .
345,Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.,central nervous system depressants,hydroxyzine,advise,Therefore GROUP administered concomitantly DRUG dosage reduced.
346,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",Amantadine,clidinium,effect,DRUG tricyclic antidepressants MAOIs may increase anticholinergic effect DRUG .
347,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",tricyclic antidepressants,clidinium,effect,Amantadine GROUP MAOIs may increase anticholinergic effect DRUG .
348,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",MAOIs,clidinium,effect,Amantadine tricyclic antidepressants GROUP may increase anticholinergic effect DRUG .
349,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,phenothiazines,effect,DRUG may decrease effect GROUP levodopa ketoconazole.
350,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,levodopa,effect,DRUG may decrease effect phenothiazines DRUG ketoconazole.
351,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,ketoconazole,effect,DRUG may decrease effect phenothiazines levodopa DRUG .
352,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent administration DRUG GROUP may result elevated serum levels oxyphenbutazone.
353,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,diabetic patients metabolic effects GROUP may decrease blood glucose therefore DRUG requirements.
354,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,anticonvulsant,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long term GROUP therapy (eg phenytoin carbamazepine phenobarbital) healthy volunteers.
355,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenytoin,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long term anticonvulsant therapy (eg DRUG carbamazepine phenobarbital) healthy volunteers.
356,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,carbamazepine,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long term anticonvulsant therapy (eg phenytoin DRUG phenobarbital) healthy volunteers.
357,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenobarbital,mechanism,Anticonvulsants: pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long term anticonvulsant therapy (eg phenytoin carbamazepine DRUG ) healthy volunteers.
358,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",NSAIDs,aspirin,advise,Aspirin: GROUP concomitant administration Ponstel BRAND generally recommended potential increased adverse effects.
359,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",Ponstel,aspirin,advise,Aspirin: NSAIDs concomitant administration BRAND BRAND generally recommended potential increased adverse effects.
360,Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.,NSAIDs,methotrexate,mechanism,Methotrexate: GROUP reported competitively inhibit DRUG accumulation rabbit kidney slices.
361,Caution should be used when NSAIDs are administered concomitantly with methotrexate.,NSAIDs,methotrexate,advise,Caution used GROUP administered concomitantly DRUG .
362,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.,NSAIDs,ACE inhibitors,effect,ACE inhibitors: Reports suggest GROUP may diminish antihypertensive effect GROUP .
363,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking GROUP concomitantly GROUP .
364,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect DRUG thiazides patients.
365,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect furosemide GROUP patients.
366,"During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.",Ponstel,furosemide,advise,concomitant therapy BRAND DRUG patient observed closely signs renal failure well assure diuretic efficacy.
367,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: GROUP produced elevation plasma DRUG levels reduction renal lithium clearance.
368,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: GROUP produced elevation plasma lithium levels reduction renal DRUG clearance.
369,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,advise,Thus GROUP DRUG administered concurrently subjects observed carefully signs lithium toxicity.
370,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.",warfarin,NSAIDs,effect,Warfarin: effects DRUG GROUP GI bleeding synergistic users drugs together risk serious GI bleeding higher users either drug alone.
371,"Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.",magnesium hydroxide,mefenamic acid,mechanism,Antacids: single dose study (n=6) ingestion antacid containing 1.7 gram DRUG 500 mg DRUG increased Cmax AUC mefenamic acid 125% 36% respectively. number compounds inhibitors CYP2C9 including fluconazole lovastatin trimethoprim.
372,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,warfarin,effect,Oral Anticoagulants: normal volunteers concomitant administration DRUG DRUG acenocoumarol phenprocoumon resulted prolongation prothrombin time.
373,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,acenocoumarol,effect,Oral Anticoagulants: normal volunteers concomitant administration DRUG warfarin DRUG phenprocoumon resulted prolongation prothrombin time.
374,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,phenprocoumon,effect,Oral Anticoagulants: normal volunteers concomitant administration DRUG warfarin acenocoumarol DRUG resulted prolongation prothrombin time.
375,This may occur because diflunisal competitively displaces coumarins from protein binding sites.,diflunisal,coumarins,mechanism,may occur DRUG competitively displaces GROUP protein binding sites.
376,"Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.",diflunisal,anticoagulants,advise,Accordingly DRUG administered oral GROUP prothrombin time closely monitored several days concomitant drug administration.
377,"Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.",diflunisal,hydrochlorothiazide,mechanism,Hydrochlorothiazide: normal volunteers concomitant administration DRUG DRUG resulted significantly increased plasma levels hydrochlorothiazide.
378,Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.,Diflunisal,hydrochlorothiazide,effect,DRUG decreased hyperuricemic effect DRUG .
379,Diflunisal decreased the hyperuricemic effect of furosemide.,Diflunisal,furosemide,effect,DRUG decreased hyperuricemic effect DRUG .
380,Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.,antacids,diflunisal,mechanism,Antacids: Concomitant administration GROUP may reduce plasma levels DRUG .
381,"Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.",diflunisal,acetaminophen,mechanism,Acetaminophen: normal volunteers concomitant administration DRUG DRUG resulted approximate 50% increase plasma levels acetaminophen.
382,"Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.",diflunisal,acetaminophen,advise,Since acetaminophen high doses associated hepatotoxicity concomitant administration DRUG DRUG used cautiously careful monitoring patients.
383,"Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",diflunisal,acetaminophen,effect,Concomitant administration DRUG DRUG dogs rats approximately 2 times recommended maximum human therapeutic dose (40 52 mg/kg/day diflunisal/acetaminophen) resulted greater gastrointestinal toxicity either drug administered alone.
384,Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.,diflunisal,methotrexate,advise,Methotrexate: Caution used DRUG administered concomitantly DRUG .
385,Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,Nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,GROUP reported decrease tubular secretion DRUG potentiate toxicity.
386,"Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",nonsteroial anti-inflammatory drugs,cyclosporine,mechanism,Cyclosporine: Administration GROUP concomitantly DRUG associated increase cyclosporine induced toxicity possibly due decreased synthesis renal prostacyclin.
387,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,GROUP used caution patients taking DRUG renal function carefully monitored.
388,Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.,diflunisal,indomethacin,mechanism,Nonsteroidal Anti Inflammatory Drugs: administration DRUG normal volunteers receiving DRUG decreased renal clearance significantly increased plasma levels indomethacin.
389,In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.,indomethacin,diflunisal,effect,patients combined use DRUG DRUG associated fatal gastrointestinal hemorrhage.
390,"Therefore, indomethacin and diflunisal should not be used concomitantly.",indomethacin,diflunisal,advise,Therefore DRUG DRUG used concomitantly.
391,"The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",diflunisal,NSAIDs,effect,concomitant use DRUG tablets GROUP recommended due increased possibility gastrointestinal toxicity little increase efficacy.
392,"Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.",diflunisal,aspirin,mechanism,Aspirin: normal volunteers small decrease diflunisal levels observed multiple doses DRUG BRAND administered concomitantly.
393,Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.,diflunisal,sulindac,mechanism,Sulindac: concomitant administration DRUG DRUG normal volunteers resulted lowering plasma levels active sulindac sulfide metabolite approximately one third.
394,"Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.",diflunisal,naproxen,mechanism,Naproxen: concomitant administration DRUG DRUG normal volunteers effect plasma levels naproxen significantly decreased urinary excretion naproxen glucuronide metabolite.
395,Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.,Lincomycin,neuromuscular blocking agents,effect,DRUG shown neuromuscular blocking properties may enhance action GROUP .
396,Antagonism between lincomycin and erythromycin in vitro has been demonstrated.,lincomycin,erythromycin,effect,Antagonism DRUG DRUG vitro demonstrated.
397,"Rifampin and warfarin: a drug interaction.
",Rifampin,warfarin,int,DRUG DRUG : drug interaction.
398,The drug interaction between warfarin and rifampin is not well known. ,warfarin,rifampin,int,drug interaction DRUG DRUG well known.
399,Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. ,Rifampin,warfarin,mechanism,DRUG reported increase DRUG requirements human subjects ingesting agents simultaneously.
400,The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ,rifampin,warfarin,mechanism,concomitant administration DRUG DRUG resulted need unusually high maintenance dose warfarin (20 mg per day) order produce therapeutic effect.
401,Withdrawal of rifampin decreased the warfarin requirement by 50%. ,rifampin,warfarin,mechanism,Withdrawal DRUG decreased DRUG requirement 50%.
402,"This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. ",rifampin,warfarin,mechanism,effect may mediated ability DRUG induce microsomal enzymes thus catabolism DRUG .
403,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,rifampin,warfarin,effect,effect DRUG DRUG requirement patient appeared maximal 5 7 days initiation rifampin extended similar length time rifampin withdrawal.
404,Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.,amantadine,central nervous system stimulants,advise,Careful observation required DRUG administered concurrently GROUP .
405,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",Zarontin,antiepileptic drugs,int,Since BRAND (ethosuximide) may interact concurrently administered GROUP periodic serum level determinations drugs may necessary (eg ethosuximide may elevate phenytoin serum levels valproic acid reported increase decrease ethosuximide levels).
406,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,antiepileptic drugs,int,Since Zarontin ( DRUG ) may interact concurrently administered GROUP periodic serum level determinations drugs may necessary (eg ethosuximide may elevate phenytoin serum levels valproic acid reported increase decrease ethosuximide levels).
407,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,phenytoin,mechanism,Since Zarontin (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg DRUG may elevate DRUG serum levels valproic acid reported increase decrease ethosuximide levels).
408,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",valproic acid,ethosuximide,mechanism,Since Zarontin (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg ethosuximide may elevate phenytoin serum levels DRUG reported increase decrease DRUG levels).
409,Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.,NIMBEX,succinylcholine,effect,Administration 0.1 mg/kg (2 x ED95) BRAND 10% 95% recovery following intubating dose DRUG (1 mg/kg) produced 95% neuromuscular block.
410,The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.,NIMBEX,succinylcholine,effect,time onset maximum block following BRAND approximately 2 minutes faster prior administration DRUG .
411,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.,succinylcholine,NIMBEX,effect,Infusion requirements NIMBEX patients administered DRUG prior infusions BRAND comparable slightly greater succinylcholine administered.
412,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses BRAND decrease required infusion rate NIMBEX.
413,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX decrease required infusion rate BRAND .
414,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane DRUG administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses BRAND decrease required infusion rate NIMBEX.
415,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane DRUG administered nitrous oxide/oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX decrease required infusion rate BRAND .
416,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane enflurane administered DRUG /oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses BRAND decrease required infusion rate NIMBEX.
417,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane enflurane administered DRUG /oxygen achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses NIMBEX decrease required infusion rate BRAND .
418,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",enflurane,NIMBEX,advise,long surgical procedures DRUG isoflurane anesthesia less frequent maintenance dosing lower maintenance doses reduced infusion rates BRAND may necessary.
419,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",isoflurane,NIMBEX,advise,long surgical procedures enflurane DRUG anesthesia less frequent maintenance dosing lower maintenance doses reduced infusion rates BRAND may necessary.
420,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,NIMBEX,effect,drugs may enhance neuromuscular blocking action GROUP BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
421,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,antibiotics,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain GROUP (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
422,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,aminoglycosides,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. GROUP tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
423,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,tetracyclines,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides GROUP bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
424,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,bacitracin,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines DRUG polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
425,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,polymyxins,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin GROUP lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
426,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lincomycin,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins DRUG clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
427,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,clindamycin,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin DRUG colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
428,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,colistin,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin DRUG sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
429,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,sodium colistemethate,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin DRUG ) magnesium salts lithium local anesthetics procainamide quinidine.
430,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,magnesium,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) GROUP salts lithium local anesthetics procainamide quinidine.
431,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lithium,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts DRUG local anesthetics procainamide quinidine.
432,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,anesthetics,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local GROUP procainamide quinidine.
433,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,procainamide,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics DRUG quinidine.
434,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,quinidine,effect,drugs may enhance neuromuscular blocking action GROUP NIMBEX include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide DRUG .
435,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,antibiotics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain GROUP (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
436,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,aminoglycosides,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. GROUP tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
437,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,tetracyclines,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides GROUP bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
438,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,bacitracin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines DRUG polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
439,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,polymyxins,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin GROUP lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
440,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lincomycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins DRUG clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
441,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,clindamycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin DRUG colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
442,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,colistin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin DRUG sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine.
443,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,sodium colistemethate,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin DRUG ) magnesium salts lithium local anesthetics procainamide quinidine.
444,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,magnesium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) GROUP salts lithium local anesthetics procainamide quinidine.
445,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lithium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts DRUG local anesthetics procainamide quinidine.
446,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,anesthetics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local GROUP procainamide quinidine.
447,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,procainamide,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics DRUG quinidine.
448,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,quinidine,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide DRUG .
449,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,phenytoin,effect,Resistance neuromuscular blocking action GROUP demonstrated patients chronically administered DRUG carbamazepine.
450,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,carbamazepine,effect,Resistance neuromuscular blocking action GROUP demonstrated patients chronically administered phenytoin DRUG .
451,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",phenytoin,NIMBEX,effect,effects chronic DRUG carbamazepine therapy action BRAND unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
452,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",carbamazepine,NIMBEX,effect,effects chronic phenytoin DRUG therapy action BRAND unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
453,Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.,Starlix,tolbutamide,mechanism,BRAND potential inhibitor CYP2C9 isoenzyme vivo indicated ability inhibit vitro metabolism DRUG .
454,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,Starlix,effect,Certain drugs including GROUP (NSAIDs) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action BRAND oral antidiabetic drugs.
455,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,antidiabetic drugs,effect,Certain drugs including GROUP (NSAIDs) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral GROUP .
456,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents ( GROUP ) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action BRAND oral antidiabetic drugs.
457,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents ( GROUP ) salicylates monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral GROUP .
458,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) GROUP monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action BRAND oral antidiabetic drugs.
459,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) GROUP monoamine oxidase inhibitors non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral GROUP .
460,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates GROUP non selective beta adrenergic blocking agents may potentiate hypoglycemic action BRAND oral antidiabetic drugs.
461,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates GROUP non selective beta adrenergic blocking agents may potentiate hypoglycemic action Starlix oral GROUP .
462,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,Starlix,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors GROUP may potentiate hypoglycemic action BRAND oral antidiabetic drugs.
463,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors GROUP may potentiate hypoglycemic action Starlix oral GROUP .
464,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,Starlix,effect,Certain drugs including GROUP corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action BRAND oral antidiabetic drugs.
465,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,antidiabetic drugs,effect,Certain drugs including GROUP corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action Starlix oral GROUP .
466,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,Starlix,effect,Certain drugs including thiazides GROUP thyroid products sympathomimetics may reduce hypoglycemic action BRAND oral antidiabetic drugs.
467,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,antidiabetic drugs,effect,Certain drugs including thiazides GROUP thyroid products sympathomimetics may reduce hypoglycemic action Starlix oral GROUP .
468,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,Starlix,effect,Certain drugs including thiazides corticosteroids GROUP sympathomimetics may reduce hypoglycemic action BRAND oral antidiabetic drugs.
469,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,antidiabetic drugs,effect,Certain drugs including thiazides corticosteroids GROUP sympathomimetics may reduce hypoglycemic action Starlix oral GROUP .
470,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,Starlix,effect,Certain drugs including thiazides corticosteroids thyroid products GROUP may reduce hypoglycemic action BRAND oral antidiabetic drugs.
471,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,antidiabetic drugs,effect,Certain drugs including thiazides corticosteroids thyroid products GROUP may reduce hypoglycemic action Starlix oral GROUP .
472,Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.,dexamethasone,albendazole,mechanism,Dexamethasone: Steady state trough concentrations albendazole sulfoxide 56% higher 8 mg DRUG coadministered dose DRUG (15 mg/kg/day) eight neurocysticercosis patients.
473,"Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",praziquantel,albendazole sulfoxide,mechanism,Praziquantel: fed state DRUG (40 mg/kg) increased mean maximum plasma concentration area curve DRUG 50% healthy subjects (n=10) compared separate group subjects (n=6) given albendazole alone.
474,Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).,Albendazole sulfoxide,cimetidine,mechanism,Cimetidine: DRUG concentrations bile cystic fluid increased (about 2 fold) hydatid cyst patients treated DRUG (10 mg/kg/day) (n=7) compared albendazole (20 mg/kg/day) alone (n=12).
475,"Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.",duloxetine,fluvoxamine,mechanism,Inhibitors CYP1A2: Concomitant use DRUG DRUG inhibitor CYP1A2 results approximately 6 fold increase AUC 2.5 fold increase Cmax duloxetine.
476,"Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.",Paroxetine,duloxetine,mechanism,DRUG (20 mg QD) increased concentration DRUG (40 mg QD) 60% greater degrees inhibition expected higher doses paroxetine.
477,"When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.",duloxetine,desipramine,mechanism,DRUG administered (at dose 60 mg BID) conjunction single 50 mg dose DRUG CYP2D6 substrate AUC desipramine increased 3 fold.
478,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,antidepressants,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain GROUP (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
479,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,tricyclic antidepressants,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants ( GROUP [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
480,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,TCAs,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [ GROUP ] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
481,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,nortriptyline,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] DRUG amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
482,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,amitriptyline,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline DRUG imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
483,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,imipramine,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline DRUG ) phenothiazines Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
484,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,phenothiazines,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) GROUP Type 1C antiarrhythmics (e.g. propafenone flecainide) approached caution.
485,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,Type 1C antiarrhythmics,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines GROUP (e.g. propafenone flecainide) approached caution.
486,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,propafenone,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. DRUG flecainide) approached caution.
487,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,flecainide,advise,Therefore co administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e.g. propafenone DRUG ) approached caution.
488,Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.,TCA,Duloxetine,advise,Plasma TCA concentrations may need monitored dose TCA may need reduced GROUP co administered DRUG .
489,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.",Duloxetine,thioridazine,advise,risk serious ventricular arrhythmias sudden death potentially associated elevated plasma levels thioridazine DRUG DRUG co administered.
490,Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.,naproxen sodium,Neurontin,mechanism,Naproxen: Coadministration (N=18) DRUG capsules (250 mg) BRAND (125 mg) appears increase amount gabapentin absorbed 12% 15%.
491,Hydrocodone increases gabapentin AUC values by 14%.,Hydrocodone,gabapentin,mechanism,DRUG increases DRUG AUC values 14%.
492,"Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.",morphine,Neurontin,mechanism,Morphine: literature article reported 60 mg controlled release DRUG capsule administered 2 hours prior 600 mg BRAND capsule (N=12) mean gabapentin AUC increased 44% compared gabapentin administered without morphine.
493,Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.,cimetidine,gabapentin,mechanism,Cimetidine: presence DRUG 300 mg QID (N=12) mean apparent oral clearance DRUG fell 14% creatinine clearance fell 10%.
494,"Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.",cimetidine,gabapentin,mechanism,Thus DRUG appeared alter renal excretion DRUG creatinine endogenous marker renal function.
495,This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.,gabapentin,cimetidine,mechanism,small decrease excretion DRUG DRUG expected clinical importance.
496,The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;,norethindrone,gabapentin,mechanism,Cmax DRUG 13% higher coadministered DRUG ;
497,Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.,Maalox,gabapentin,mechanism,Antacid (Maalox ): BRAND reduced bioavailability DRUG (N=16) 20%.
498,This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.,gabapentin,Maalox,mechanism,decrease bioavailability 5% DRUG administered 2 hours BRAND .
499,It is recommended that gabapentin be taken at least 2 hours following Maalox administration.,gabapentin,Maalox,advise,recommended DRUG taken least 2 hours following BRAND administration.
500,"Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).",Zalcitabine,ZDV,effect,DRUG also significant effect intracellular phosphorylation DRUG shown vitro peripheral blood mononuclear cells two cell lines (U937 Molt 4).
501,"Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.",lamivudine,zalcitabine,effect,Lamivudine: vitro studies peripheral blood mononuclear cells U937 Molt 4 cells revealed DRUG significantly inhibited DRUG phosphorylation dose dependent manner.
502,Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);,Zalcitabine,lamivudine,effect,DRUG inhibited DRUG phosphorylation high concentration ratios (10 100);
503,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.",zalcitabine,lamivudine,effect,vitro studies suggest concomitant administration DRUG DRUG humans may result sub therapeutic concentrations active phosphorylated zalcitabine may lead decreased antiretroviral effect zalcitabine.
504,Concomitant use of zalcitabine and lamivudine is not recommended.,zalcitabine,lamivudine,advise,Concomitant use DRUG DRUG recommended.
505,Concomitant use of HIVID with didanosine is not recommended.,HIVID,didanosine,advise,Concomitant use DRUG DRUG recommended.
506,Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.,pentamidine,HIVID,effect,Death due fulminant pancreatitis possibly related intravenous DRUG DRUG reported.
507,"If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.",pentamidine,HIVID,advise,intravenous DRUG required treat Pneumocystis carinii pneumonia treatment DRUG interrupted.
508,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,HIVID,effect,Amphotericin Foscarnet Aminoglycosides: Drugs DRUG foscarnet aminoglycosides may increase risk developing peripheral neuropathy DRUG associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure).
509,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,zalcitabine,mechanism,Amphotericin Foscarnet Aminoglycosides: Drugs DRUG foscarnet aminoglycosides may increase risk developing peripheral neuropathy HIVID associated adverse events interfering renal clearance DRUG (thereby raising systemic exposure).
510,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,HIVID,effect,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin DRUG aminoglycosides may increase risk developing peripheral neuropathy DRUG associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure).
511,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,zalcitabine,mechanism,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin DRUG aminoglycosides may increase risk developing peripheral neuropathy HIVID associated adverse events interfering renal clearance DRUG (thereby raising systemic exposure).
512,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,HIVID,effect,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet GROUP may increase risk developing peripheral neuropathy DRUG associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure).
513,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,zalcitabine,mechanism,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet GROUP may increase risk developing peripheral neuropathy HIVID associated adverse events interfering renal clearance DRUG (thereby raising systemic exposure).
514,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",probenecid,zalcitabine,mechanism,Probenecid Cimetidine: Concomitant administration DRUG cimetidine decreases elimination DRUG likely inhibition renal tubular secretion zalcitabine.
515,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",cimetidine,zalcitabine,mechanism,Probenecid Cimetidine: Concomitant administration probenecid DRUG decreases elimination DRUG likely inhibition renal tubular secretion zalcitabine.
516,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,magnesium,advise,clinical significance reduction known hence DRUG recommended ingested simultaneously DRUG /aluminum containing antacids.
517,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,aluminum,advise,clinical significance reduction known hence DRUG recommended ingested simultaneously magnesium/ DRUG containing antacids.
518,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,antacids,advise,clinical significance reduction known hence DRUG recommended ingested simultaneously magnesium/aluminum containing GROUP .
519,Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.,zalcitabine,metoclopramide,mechanism,Metoclopramide: Bioavailability mildly reduced (approximately 10%) DRUG DRUG coadministered.
520,Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.,Doxorubicin,zalcitabine,effect,Doxorubicin: DRUG caused decrease DRUG phosphorylation ( 50% inhibition total phosphate formation) U937/Molt 4 cells.
521,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",Gastrointestinal acidifying agents,amphetamines,mechanism,Acidifying agents: GROUP (guanethidine reserpine glutamic acid HCl ascorbic acid fruit juices etc.) lower absorption GROUP .
522,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",guanethidine,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents ( DRUG reserpine glutamic acid HCl ascorbic acid fruit juices etc.) lower absorption GROUP .
523,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",reserpine,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine DRUG glutamic acid HCl ascorbic acid fruit juices etc.) lower absorption GROUP .
524,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",glutamic acid HCl,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine DRUG ascorbic acid fruit juices etc.) lower absorption GROUP .
525,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",ascorbic acid,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine glutamic acid HCl DRUG fruit juices etc.) lower absorption GROUP .
526,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",Urinary acidifying agents,amphetamine,mechanism,GROUP (ammonium chloride sodium acid phosphate etc.) increase concentration ionized species DRUG molecule thereby increasing urinary excretion.
527,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,Urinary acidifying agents ( DRUG sodium acid phosphate etc.) increase concentration ionized species DRUG molecule thereby increasing urinary excretion.
528,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,Urinary acidifying agents (ammonium chloride DRUG etc.) increase concentration ionized species DRUG molecule thereby increasing urinary excretion.
529,Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic blockers: GROUP inhibited GROUP .
530,"Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.",sodium bicarbonate,amphetamines,mechanism,Alkalinizing agents: Gastrointestinal alkalinizing agents ( DRUG etc.) increase absorption DRUG .
531,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",acetazolamide,amphetamine,mechanism,Urinary alkalinizing agents ( DRUG thiazides) increase concentration non ionized species DRUG molecule thereby decreasing urinary excretion.
532,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",thiazides,amphetamine,mechanism,Urinary alkalinizing agents (acetazolamide GROUP ) increase concentration non ionized species DRUG molecule thereby decreasing urinary excretion.
533,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,tricyclic,effect,Antidepressants tricyclic: GROUP may enhance activity GROUP sympathomimetic agents;
534,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,Antidepressants tricyclic: GROUP may enhance activity tricyclic GROUP ;
535,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,DRUG DRUG protriptyline possibly tricyclics cause striking sustained increases concentration amphetamine brain;
536,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,DRUG desipramine DRUG possibly tricyclics cause striking sustained increases concentration amphetamine brain;
537,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,DRUG desipramine protriptyline possibly GROUP cause striking sustained increases concentration amphetamine brain;
538,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,MAO inhibitors: GROUP well metabolite furazolidone slow GROUP metabolism.
539,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,MAO inhibitors: MAOI antidepressants well metabolite DRUG slow GROUP metabolism.
540,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines: GROUP may counteract sedative effect GROUP .
541,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives: GROUP may antagonize hypotensive effects GROUP .
542,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,Chlorpromazine: DRUG blocks dopamine norepinephrine reuptake thus inhibiting central stimulant effects GROUP used treat amphetamine poisoning.
543,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide: GROUP may delay intestinal absorption DRUG .
544,"Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,Haloperidol: DRUG blocks dopamine norepinephrine reuptake thus inhibiting central stimulant effects GROUP .
545,Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium carbonate: stimulatory effects GROUP may inhibited DRUG .
546,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine: GROUP potentiate analgesic effect DRUG .
547,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.",amphetamines,acidifying agents,mechanism,Methenamine therapy: Urinary excretion GROUP increased efficacy reduced GROUP used methenamine therapy.
548,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine: GROUP enhance adrenergic effect DRUG .
549,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital: GROUP may delay intestinal absorption DRUG ;
550,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin: GROUP may delay intestinal absorption DRUG ;
551,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,Propoxyphene: cases DRUG overdosage GROUP CNS stimulation potentiated fatal convulsions occur.
552,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum alkaloids: GROUP inhibit hypotensive effect GROUP .
553,Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.,Amphetamines,corticosteroid,,Drug/Laboratory Test Interactions: GROUP cause significant elevation plasma GROUP levels.
554,Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.,erythromycin,loratadine,mechanism,Plasma concentrations (AUC 0 24 hrs) DRUG decreased 15% coadministration DRUG relative observed erythromycin alone.
555,"In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.",AED,oxcarbazepine,mechanism,addition several GROUP cytochrome P450 inducers decrease plasma concentrations DRUG MHD.
556,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.",phenytoin,Trileptal,mechanism,1 nc denotes mean change less 10% 2 Pediatrics 3 Mean increase adults high Trileptal doses vivo plasma levels DRUG increased 40% BRAND given doses 1200 mg/day.
557,"Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.",Trileptal,phenytoin,advise,Therefore using doses BRAND greater 1200 mg/day adjunctive therapy decrease dose DRUG may required.
558,"The increase of phenobarbital level, however, is small (15%) when given with Trileptal.",phenobarbital,Trileptal,mechanism,increase DRUG level however small (15%) given BRAND .
559,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).",Trileptal,contraceptive,mechanism,Hormonal contraceptives Co administration BRAND oral GROUP shown influence plasma concentrations two hormonal components ethinylestradiol (EE) levonorgestrel (LNG).
560,"Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.",Trileptal,hormonal contraceptives,effect,Therefore concurrent use BRAND GROUP may render contraceptives less effective.
561,"Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].",Trileptal,felodipine,mechanism,Calcium Antagonists: repeated co administration BRAND AUC DRUG lowered 28% [90% CI: 20 33].
562,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.,thiazide diuretics,dihydrotachysterol,effect,Administration GROUP hypoparathyroid patients concurrently treated DRUG may cause hypercalcemia.
563,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,alcohol,effect,DRUG may enhance CNS depressive effects DRUG barbiturates sedatives
564,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,barbiturates,effect,DRUG may enhance CNS depressive effects alcohol GROUP sedatives
565,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,sedatives,effect,DRUG may enhance CNS depressive effects alcohol barbiturates GROUP
566,- Lofexidine may enhance the effects of anti-hypertensive drug therapy,Lofexidine,anti-hypertensive drug,effect,DRUG may enhance effects GROUP therapy
567,- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.,tricyclic antidepressants,lofexidine,effect,Concomitant use GROUP may reduce efficacy DRUG .
568,"Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.",cefditoren pivoxil,antacids,advise,Although clinical significance known recommended DRUG taken concomitantly GROUP .
569,"H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",famotidine,cefditoren pivoxil,mechanism,H2 Receptor Antagonists: Co administration single dose intravenously administered DRUG (20 mg) reduced oral absorption single 400 mg dose DRUG administered following meal evidenced 27% decrease mean Cmax 22% decrease mean AUC.
570,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",b-lactam antibiotics,cefditoren pivoxil,mechanism,Probenecid: GROUP co administration probenecid DRUG resulted increase plasma exposure cefditoren 49% increase mean Cmax 122% increase mean AUC 53% increase half life.
571,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",probenecid,cefditoren pivoxil,mechanism,Probenecid: b lactam antibiotics co administration DRUG DRUG resulted increase plasma exposure cefditoren 49% increase mean Cmax 122% increase mean AUC 53% increase half life.
572,"Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
",glycine,glutamate,effect,Interaction DRUG DRUG development spontaneous motility chick embryos.
573,The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ,glycine,glutamate,effect,successive application DRUG (5 10 mg/kg egg weight (e.w.) DRUG (15 mg/kg e.w.) 10 min interval significantly increased activation spontaneous motility 17 day old chick embryos comparison effect glutamate alone.
574,Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.,Ocupress,beta-adrenergic blocking agent,advise,BRAND used caution patients receiving GROUP orally potential additive effects systemic beta blockade.
575,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.",beta-blocker,reserpine,advise,Close observation patient recommended GROUP administered patients receiving catecholamine depleting drugs DRUG possible additive effects production hypotension and/or marked bradycardia may produce vertigo syncope postural hypotension.
576,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",calcium channel blockers,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg GROUP dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
577,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",dapsone,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers DRUG disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
578,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",disopyramide,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone DRUG quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
579,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide DRUG amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
580,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",amiodarone,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine DRUG quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
581,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinidine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone DRUG warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
582,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",warfarin,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine DRUG tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
583,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",tacrolimus,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin DRUG cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
584,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",cyclosporine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus DRUG ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
585,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",ergot derivatives,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine GROUP pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
586,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",pimozide,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives DRUG carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
587,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",carbamazepine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide DRUG fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
588,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",fentanyl,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine DRUG alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
589,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alfentanyl,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl DRUG alprazolam triazolam) may elevated plasma concentrations coadministered DRUG ;
590,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alprazolam,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl DRUG triazolam) may elevated plasma concentrations coadministered DRUG ;
591,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",triazolam,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam DRUG ) may elevated plasma concentrations coadministered DRUG ;
592,"Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.",INVIRASE,ritonavir,advise,Since BRAND coadministered DRUG ritonavir label reviewed additional drugs coadministered.
593,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenobarbital,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg DRUG phenytoin dexamethasone carbamazepine) may result decreased plasma levels DRUG .
594,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenytoin,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital DRUG dexamethasone carbamazepine) may result decreased plasma levels DRUG .
595,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",dexamethasone,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital phenytoin DRUG carbamazepine) may result decreased plasma levels DRUG .
596,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",carbamazepine,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital phenytoin dexamethasone DRUG ) may result decreased plasma levels DRUG .
597,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,antibiotics,effect,vitro mixing GROUP beta lactamtype GROUP (penicillins cephalosporins) may result significant mutual inactivation.
598,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,penicillins,effect,vitro mixing GROUP beta lactamtype antibiotics ( GROUP cephalosporins) may result significant mutual inactivation.
599,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,cephalosporins,effect,vitro mixing GROUP beta lactamtype antibiotics (penicillins GROUP ) may result significant mutual inactivation.
600,"Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.",aminoglycoside,penicillin,mechanism,Even GROUP GROUP type drug administered separately different routes reduction aminoglycoside serum half life serum levels reported patients impaired renal function patients normal renal function.
601,Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.,acitretin,ethanol,mechanism,Ethanol:Clinical evidence shown etretinate formed concurrent ingestion DRUG DRUG .
602,"Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",acitretin,glibenclamide,effect,Glibenclamide: study 7 healthy male volunteers DRUG treatment potentiated blood glucose lowering effect DRUG (a sulfonylurea similar chlorpropamide) 3 7 subjects.
603,"However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.",acitretin,progestin,effect,However established DRUG interferes contraceptive effect microdosed DRUG minipill preparations.
604,Microdosed minipill progestin preparations are not recommended for use with Soriatane.,progestin,Soriatane,advise,Microdosed minipill DRUG preparations recommended use DRUG .
605,Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.,methotrexate,etretinate,effect,Methotrexate: increased risk hepatitis reported result combined use DRUG DRUG .
606,"Consequently, the combination of methotrexate with acitretin is also contraindicated.",methotrexate,acitretin,advise,Consequently combination DRUG DRUG also contraindicated.
607,"Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.",acitretin,phenytoin,mechanism,Phenytoin: DRUG given concurrently DRUG protein binding phenytoin may reduced.
608,"Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.",acitretin,tetracyclines,effect,Tetracyclines: Since DRUG GROUP cause increased intracranial pressure combined use contraindicated.
609,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,vitamin A,acitretin,advise,Vitamin oral retinoids: Concomitant administration GROUP and/or oral retinoids DRUG must avoided risk hypervitaminosis A.
610,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,retinoids,acitretin,advise,Vitamin oral retinoids: Concomitant administration vitamin and/or oral GROUP DRUG must avoided risk hypervitaminosis A.
611,Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.,Cerubidine,doxorubicin,effect,Use BRAND patient previously received DRUG increases risk cardiotoxicity.
612,Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.,Cerubidine,doxorubicin,advise,BRAND used patients previously received recommended maximum cumulative doses DRUG Cerubidine.
613,Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.,Cyclophosphamide,Cerubidine,effect,DRUG used concurrently BRAND may also result increased cardiotoxicity.
614,"However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).",Argatroban,warfarin,effect,However concomitant use DRUG DRUG (5 7.5 mg initial oral dose followed 2.5 6 mg/day orally 6 10 days) results prolongation prothrombin time (PT) International Normalized Ratio (INR).
615,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,antiplatelet agents,effect,Co administration: Concomitant use DRUG GROUP thrombolytics anticoagulants may increase risk bleeding.
616,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,thrombolytics,effect,Co administration: Concomitant use DRUG antiplatelet agents GROUP anticoagulants may increase risk bleeding.
617,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,anticoagulants,effect,Co administration: Concomitant use DRUG antiplatelet agents thrombolytics GROUP may increase risk bleeding.
618,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE inhibitors: Reports suggest GROUP may diminish antihypertensive effect GROUP .
619,"In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.",VIOXX,benazepril,effect,patients mild moderate hypertension administration 25 mg daily BRAND ACE inhibitor DRUG 10 40 mg 4 weeks associated average increase mean arterial pressure 3 mm Hg compared ACE inhibitor alone.
620,This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.,VIOXX,ACE inhibitors,advise,interaction given consideration patients taking BRAND concomitantly GROUP .
621,"Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.",aspirin,VIOXX,effect,Aspirin: Concomitant administration low dose BRAND BRAND may result increased rate GI ulceration complications compared use VIOXX alone.
622,"Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",cimetidine,rofecoxib,mechanism,Cimetidine: Co administration high doses DRUG [800 mg twice daily] increased Cmax DRUG 21% AUC0 120hr 23% t1/2 15%.
623,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect DRUG thiazides patients.
624,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect furosemide GROUP patients.
625,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: GROUP produced elevation plasma DRUG levels reduction renal lithium clearance.
626,"Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",VIOXX,lithium,advise,Thus BRAND DRUG administered concurrently subjects observed carefully signs lithium toxicity.
627,"At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.",VIOXX,methotrexate,mechanism,higher recommended doses BRAND 75 mg administered daily 10 days increased plasma concentrations 23% measured AUC0 24hr patients receiving DRUG 7.5 15 mg/week rheumatoid arthritis.
628,"At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",methotrexate,rofecoxib,mechanism,24 hours postdose similar proportion patients treated methotrexate alone (94%) subsequently treated DRUG co administered 75 mg DRUG (88%) methotrexate plasma concentrations measurable limit (5 ng/mL).
629,Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.,VIOXX,methotrexate,advise,Standard monitoring methotrexate related toxicity continued BRAND DRUG administered concomitantly.
630,"Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.",VIOXX,rifampin,mechanism,Rifampin: Co administration BRAND DRUG 600 mg daily potent inducer hepatic metabolism produced approximate 50% decrease rofecoxib plasma concentrations.
631,"Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.",VIOXX,theophylline,mechanism,Theophylline BRAND 12.5 25 50 mg administered daily 7 days increased plasma DRUG concentrations (AUC(0 )) 38 60% healthy subjects administered single 300 mg dose theophylline.
632,Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.,VIOXX,theophylline,advise,Adequate monitoring theophylline plasma concentrations considered therapy BRAND initiated changed patients receiving DRUG .
633,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.",VIOXX,warfarin,advise,Warfarin: Anticoagulant activity monitored particularly first days initiating changing BRAND therapy patients receiving DRUG similar agents since patients increased risk bleeding complications.
634,"In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.",warfarin,rofecoxib,effect,single multiple dose studies healthy subjects receiving DRUG DRUG prothrombin time (measured INR) increased approximately 8% 11%.
635,"In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.",VIOXX,warfarin,effect,post marketing experience bleeding events reported predominantly elderly association increases prothrombin time patients receiving BRAND concurrently DRUG .
636,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,phenothiazines,advise,BRAND administered concurrently D2 antagonists GROUP butyrophenones thioxanthines metoclopramide.
637,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,butyrophenones,advise,BRAND administered concurrently D2 antagonists phenothiazines GROUP thioxanthines metoclopramide.
638,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,thioxanthines,advise,BRAND administered concurrently D2 antagonists phenothiazines butyrophenones GROUP metoclopramide.
639,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,metoclopramide,advise,BRAND administered concurrently D2 antagonists phenothiazines butyrophenones thioxanthines DRUG .
640,"When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.",lansoprazole,theophylline,mechanism,DRUG administered concomitantly DRUG (CYP1A2 CYP3A) minor increase (10%) clearance theophylline seen.
641,"Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.",theophylline,lansoprazole,advise,Nonetheless individual patients may require additional titration DRUG dosage DRUG started stopped ensure clinically effective blood levels.
642,"In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.",proton pump inhibitors,sucralfate,mechanism,single dose crossover study examining lansoprazole 30 mg omeprazole 20 mg administered alone concomitantly sucralfate 1 gram absorption GROUP delayed bioavailability reduced 17% 16% respectively administered concomitantly DRUG .
643,"Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.",proton pump inhibitors,sucralfate,advise,Therefore GROUP taken least 30 minutes prior DRUG .
644,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ketoconazole,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e.g. DRUG ampicillin esters iron salts digoxin).
645,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ampicillin,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e.g. ketoconazole DRUG esters iron salts digoxin).
646,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,iron,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e.g. ketoconazole ampicillin esters DRUG salts digoxin).
647,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,digoxin,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e.g. ketoconazole ampicillin esters iron salts DRUG ).
648,"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
",Fluvoxamine,tolbutamide,mechanism,DRUG inhibits CYP2C9 catalyzed biotransformation DRUG .
649,"RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ",fluvoxamine,tolbutamide,mechanism,RESULTS: treatment DRUG statistically significant decrease median total clearance DRUG 845 mL/h 688 mL/h among volunteers received 75 mg/d.
650,"In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. ",(-)-NANM,morphine,effect,species DRUG_N (+) NANM antagonized rate decreasing effects DRUG FI FR responding.
651,"In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; ",(-)-NANM,naloxone,effect,monkeys effects DRUG_N (+) NANM PCP antagonized DRUG ;
652,the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ,naloxone,(-)-NANM,effect,doses DRUG required antagonize effects DRUG_N 100 times higher required antagonize effects morphine.
653,the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ,naloxone,morphine,effect,doses DRUG required antagonize effects ( ) NANM 100 times higher required antagonize effects DRUG .
654,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ",Haloperidol,(+)-NANM,effect,DRUG reduced eliminated increases FI responding produced intermediate doses either DRUG_N PCP pigeons antagonize decreases FI FR responding produced high doses PCP either stereoisomer NANM.
655,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ",Haloperidol,PCP,effect,DRUG reduced eliminated increases FI responding produced intermediate doses either (+) NANM DRUG_N pigeons antagonize decreases FI FR responding produced high doses PCP either stereoisomer NANM.
656,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,Phenurone,advise,Considerable caution exercised BRAND administered concurrently BRAND (phenacemide) since paranoid symptoms reported therapy combination.
657,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,phenacemide,advise,Considerable caution exercised BRAND administered concurrently Phenurone ( DRUG ) since paranoid symptoms reported therapy combination.
658,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,phenytoin,int,two way interaction GROUP DRUG coumarin anticoagulants suggested.
659,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,coumarin anticoagulant,int,two way interaction GROUP phenytoin GROUP suggested.
660,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin,mechanism,Presumably DRUG acts stimulator GROUP metabolism reported cause decreased serum levels coumarin anticoagulants increased prothrombin proconvertin concentrations.
661,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin anticoagulants,mechanism,Presumably DRUG acts stimulator coumarin metabolism reported cause decreased serum levels GROUP increased prothrombin proconvertin concentrations.
662,"Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.",coumarin anticoagulants,phenytoin,mechanism,Conversely GROUP reported increase serum levels prolong serum half life DRUG inhibiting metabolism.
663,Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.,PEGANONE,coumarin anticoagulants,advise,Caution therefore advised administering BRAND patients receiving GROUP .
664,Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.,warfarin-type anticoagulant,griseofulvin,advise,Patients GROUP therapy may require dosage adjustment anticoagulant DRUG therapy.
665,Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.,barbiturates,griseofulvin,effect,Concomitant use GROUP usually depresses DRUG activity may necessitate raising dosage.
666,The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.,griseofulvin,contraceptives,effect,concomitant administration DRUG reported reduce efficacy oral GROUP increase incidence breakthrough bleeding.
667,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acetaminophen,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. DRUG acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
668,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acyclovir,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen DRUG angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
669,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,angiotensin-converting enzyme inhibitors,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir GROUP aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
670,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,aminosalicylic acid,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors DRUG barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
671,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,barbiturates,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid GROUP benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
672,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,benzodiazepines,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates GROUP bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
673,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,bumetanide,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines DRUG clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
674,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,clofibrate,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide DRUG methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
675,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,methotrexate,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate DRUG famotidine furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
676,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,famotidine,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate DRUG furosemide nonsteroidal anti inflammatory agents theophylline zidovudine).
677,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,furosemide,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine DRUG nonsteroidal anti inflammatory agents theophylline zidovudine).
678,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,nonsteroidal anti-inflammatory,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide GROUP agents theophylline zidovudine).
679,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,theophylline,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents DRUG zidovudine).
680,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,zidovudine,mechanism,Probenecid : DRUG known interact metabolism renal tubular excretion many drugs (e.g. acetaminophen acyclovir angiotensin converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti inflammatory agents theophylline DRUG ).
681,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.,Zidovudine,probenecid,advise,DRUG either temporarily discontinued decreased 50% coadministered DRUG day VISTIDE infusion.
682,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,aminoglycosides,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous GROUP (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
683,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,tobramycin,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. DRUG gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
684,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,gentamicin,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin DRUG amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
685,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amikacin,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin DRUG ) amphotericin B foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
686,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amphotericin B,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) DRUG foscarnet intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
687,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,foscarnet,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B DRUG intravenous pentamidine vancomycin non steroidal anti inflammatory agents] contraindicated.
688,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,pentamidine,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous DRUG vancomycin non steroidal anti inflammatory agents] contraindicated.
689,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,vancomycin,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine DRUG non steroidal anti inflammatory agents] contraindicated.
690,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,non-steroidal anti-inflammatory agents,advise,Nephrotoxic agents : Concomitant administration BRAND agents nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin GROUP ] contraindicated.
691,"However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.",UROXATRAL,alpha-blockers,advise,However interactions may expected BRAND used combination GROUP .
692,Dimenhydrinate may decrease emetic response to apomorphine.,Dimenhydrinate,apomorphine,effect,DRUG may decrease emetic response DRUG .
693,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: DRUG reported reduce intestinal absorption GROUP ;
694,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration DRUG phenobarbital affect plasma concentrations vitamin may reduce endogenous plasma levels DRUG /ergocalcitriol accelerating metabolism.
695,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration phenytoin DRUG affect plasma concentrations vitamin may reduce endogenous plasma levels DRUG /ergocalcitriol accelerating metabolism.
696,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,reports shown concomitant administration GROUP GROUP causes hypercalcemia.
697,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: GROUP dosage must determined care patients undergoing treatment GROUP hypercalcemia patients may precipitate cardiac arrhythmias.
698,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: DRUG may inhibit synthetic catabolic enzymes GROUP .
699,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,Corticosteroids: relationship functional antagonism exists GROUP promote calcium absorption GROUP inhibit calcium absorption.
700,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,Magnesium: DRUG containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy GROUP patients chronic renal dialysis.
701,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,Magnesium: Magnesium containing preparations (eg GROUP ) may cause hypermagnesemia therefore taken therapy GROUP patients chronic renal dialysis.
702,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,ERGAMISOL,alcohol,effect,BRAND (levamisole hydrochloride) reported produce ANTABUSE like side effects given concomitantly DRUG .
703,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,levamisole hydrochloride,alcohol,effect,ERGAMISOL ( DRUG ) reported produce ANTABUSE like side effects given concomitantly DRUG .
704,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.",levamisole,warfarin sodium,advise,reports prolongation prothrombin time beyond therapeutic range patients taking concurrent DRUG DRUG suggested prothrombin time monitored carefully dose warfarin sodium coumarin like drugs adjusted accordingly patients taking drugs.
705,"The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. ",GL,antibiotics,effect,antimicrobial combinations DRUG_N four GROUP resulted additive effect instances synergism two instances antagonism two instances.
706,Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.,GL,cefazolin,effect,Synergism observed DRUG_N combined DRUG Bacillus subtilis Klebsiella oxytoca.
707,Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.,azathioprine,allopurinol,mechanism,Use Allopurinol: principal pathway detoxification DRUG inhibited DRUG .
708,"Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.",azathioprine,allopurinol,advise,Patients receiving DRUG DRUG concomitantly dose reduction azathioprine approximately 1/3 1/4 usual dose.
709,Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.,angiotensin converting enzyme inhibitors,azathioprine,effect,Use Angiotensln Converting Enzyme Inhibitors: use GROUP control hypertension patients DRUG reported induce severe leukopenia.
710,"Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
",diltiazem,sirolimus,mechanism,Pharmacokinetic interaction single oral doses DRUG DRUG healthy volunteers.
711,"RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ",sirolimus,diltiazem,mechanism,RESULTS: geometric mean (90% confidence interval) whole blood DRUG area plasma concentration time curve increased 60% (35% 90%) 736 1178 ng x h/mL maximum concentration increased 43% (14% 81%) 67 96 ng/mL DRUG coadministration whereas mean elimination half life sirolimus decreased slightly 79 67 hours.
712,"Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. ",sirolimus,diltiazem,mechanism,Apparent oral clearance volume distribution sirolimus decreased 38% 45% respectively DRUG given DRUG .
713,"CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ",diltiazem,sirolimus,mechanism,CONCLUSIONS: Single dose DRUG coadministration leads higher DRUG exposure presumably inhibition first pass metabolism sirolimus.
714,"Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.",sirolimus,diltiazem,advise,pronounced intersubject variability extent DRUG DRUG interaction whole blood sirolimus concentrations monitored closely patients treated two drugs.
715,Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. ,InsP(3),RR,effect,Administering DRUG_N together DRUG_N (100 500 microM) inhibited InsP(3) induced responses (both Ca(2+) current responses) dose dependent fashion.
716,Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. ,RR,InsP(3),effect,Pretreatment megakaryocytes extracellular DRUG_N (50 microM) also inhibited DRUG_N induced responses.
717,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",psychotropic medications,LEXAPRO,advise,Alcohol Although LEXAPRO potentiate cognitive motor effects alcohol clinical trial GROUP use alcohol patients taking BRAND recommended.
718,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",alcohol,LEXAPRO,advise,Alcohol Although LEXAPRO potentiate cognitive motor effects alcohol clinical trial psychotropic medications use DRUG patients taking BRAND recommended.
719,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,NSAID,effect,Epidemiological studies case control cohort design demonstrated association use GROUP interfere serotonin reuptake occurrence upper gastrointestinal bleeding also shown concurrent use GROUP aspirin potentiated risk bleeding.
720,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,aspirin,effect,Epidemiological studies case control cohort design demonstrated association use GROUP interfere serotonin reuptake occurrence upper gastrointestinal bleeding also shown concurrent use NSAID BRAND potentiated risk bleeding.
721,"Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",citalopram,cimetidine,mechanism,Cimetidine subjects received 21 days 40 mg/day racemic DRUG combined administration 400 mg/day DRUG 8 days resulted increase citalopram AUC Cmax 43% 39% respectively.
722,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",lithium,escitalopram,effect,DRUG may enhance serotonergic effects DRUG caution exercised LEXAPRO lithium coadministered.
723,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",LEXAPRO,lithium,advise,lithium may enhance serotonergic effects escitalopram caution exercised BRAND DRUG coadministered.
724,"Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",pimozide,citalopram,effect,Pimozide Celexa controlled study single dose DRUG 2 mg co administered racemic DRUG 40 mg given daily 11 days associated mean increase QTc values approximately 10 msec compared pimozide given alone.
725,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",selective serotonin reuptake inhibitor,sumatriptan,effect,Sumatriptan rare postmarketing reports describing patients weakness hyperreflexia incoordination following use GROUP (SSRI) DRUG .
726,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",SSRI,sumatriptan,effect,Sumatriptan rare postmarketing reports describing patients weakness hyperreflexia incoordination following use selective serotonin reuptake inhibitor ( GROUP ) DRUG .
727,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,SSRI,advise,concomitant treatment DRUG GROUP (e.g. fluoxetine fluvoxamine paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
728,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluoxetine,advise,concomitant treatment DRUG SSRI (e.g. DRUG fluvoxamine paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
729,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluvoxamine,advise,concomitant treatment DRUG SSRI (e.g. fluoxetine DRUG paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
730,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,paroxetine,advise,concomitant treatment DRUG SSRI (e.g. fluoxetine fluvoxamine DRUG sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised.
731,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,sertraline,advise,concomitant treatment DRUG SSRI (e.g. fluoxetine fluvoxamine paroxetine DRUG citalopram escitalopram) clinically warranted appropriate observation patient advised.
732,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,citalopram,advise,concomitant treatment DRUG SSRI (e.g. fluoxetine fluvoxamine paroxetine sertraline DRUG escitalopram) clinically warranted appropriate observation patient advised.
733,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,escitalopram,advise,concomitant treatment DRUG SSRI (e.g. fluoxetine fluvoxamine paroxetine sertraline citalopram DRUG ) clinically warranted appropriate observation patient advised.
734,"Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.",carbamazepine,escitalopram,mechanism,Although trough citalopram plasma levels unaffected given enzyme inducing properties carbamazepine possibility DRUG might increase clearance DRUG considered two drugs coadministered.
735,"Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",citalopram,ketoconazole,mechanism,Ketoconazole Combined administration racemic DRUG (40 mg) DRUG (200 mg) decreased Cmax AUC ketoconazole 21% 10% respectively significantly affect pharmacokinetics citalopram.
736,"However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.",escitalopram,desipramine,mechanism,However limited vivo data suggesting modest CYP2D6 inhibitory effect escitalopram i.e. coadministration DRUG (20 mg/day 21 days) tricyclic antidepressant DRUG (single dose 50 mg) substrate CYP2D6 resulted 40% increase Cmax 100% increase AUC desipramine.
737,Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).,LEXAPRO,metoprolol,mechanism,Metoprolol Administration 20 mg/day BRAND 21 days healthy volunteers resulted 50% increase Cmax 82% increase AUC beta adrenergic blocker DRUG (given single dose 100 mg).
738,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,citalopram,advise,Concomitant Administration Racemic Citalopram Citalopram Since DRUG active isomer racemic DRUG (Celexa) two agents coadministered.
739,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,Celexa,advise,Concomitant Administration Racemic Citalopram Citalopram Since DRUG active isomer racemic citalopram ( BRAND ) two agents coadministered.
740,"However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.",EXTRANEAL,insulin,advise,However appropriate monitoring blood glucose performed initiating BRAND diabetic patients DRUG dosage adjusted needed.
741,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,hypotensive drugs,effect,hypotensive effect DRUG augmented GROUP including ganglionic blocking agents negative inotropic agents inhaled anesthetics.
742,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,ganglionic blocking agents,effect,hypotensive effect DRUG augmented hypotensive drugs including GROUP negative inotropic agents inhaled anesthetics.
743,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,anesthetics,effect,hypotensive effect DRUG augmented hypotensive drugs including ganglionic blocking agents negative inotropic agents inhaled GROUP .
744,CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.,eszopiclone,ethanol,effect,CNS Active Drugs Ethanol additive effect psychomotor performance seen coadministration DRUG DRUG 0.70 g/kg 4 hours ethanol administration.
745,Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.,eszopiclone,olanzapine,effect,Olanzapine: Coadministration DRUG 3 mg DRUG 10 mg produced decrease DSST scores.
746,"The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.",eszopiclone,ketoconazole,mechanism,AUC DRUG increased 2.2 fold coadministration DRUG potent inhibitor CYP3A4 400 mg daily 5 days.
747,"Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.",zopiclone,rifampicin,mechanism,Drugs Induce CYP3A4 (Rifampicin) Racemic DRUG exposure decreased 80% concomitant useof DRUG potent inducer CYP3A4.
748,Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.,sympathomimetic agents,FORADIL,effect,Concomitant administration GROUP may potentiate undesirable effects BRAND .
749,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,monoamine oxidase inhibitors,advise,Monoamine Oxidase Inhibitors Tricyclic Antidepressants: BRAND administered extreme caution patients treated GROUP tricyclic antidepressants action formoterol cardiovascular system may potentiated agents.
750,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,tricyclic antidepressants,advise,Monoamine Oxidase Inhibitors Tricyclic Antidepressants: BRAND administered extreme caution patients treated monoamine oxidase inhibitors GROUP action formoterol cardiovascular system may potentiated agents.
751,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",xanthine derivatives,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment GROUP steroids diuretics may potentiate possible hypokalemic effect GROUP
752,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",steroids,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives GROUP diuretics may potentiate possible hypokalemic effect GROUP
753,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",diuretics,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives steroids GROUP may potentiate possible hypokalemic effect GROUP
754,"During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.",TAMBOCOR,digoxin,mechanism,administration multiple oral doses BRAND healthy subjects stabilized maintenance dose DRUG 13% 19% increase plasma digoxin levels occurred six hours postdose.
755,"In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.",TAMBOCOR,propranolol,mechanism,study involving healthy subjects receiving BRAND DRUG concurrently plasma flecainide levels increased 20% propranolol levels increased 30% compared control values.
756,The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.,TAMBOCOR,propranolol,effect,effects concomitant administration BRAND DRUG PR interval less additive.
757,"Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.",beta blockers,flecainide,effect,Nevertheless possibility additive negative inotropic effects GROUP DRUG recognized.
758,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenytoin,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( DRUG phenobarbital carbamazepine ) indicate 30% increase rate DRUG elimination.
759,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenobarbital,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( phenytoin DRUG carbamazepine ) indicate 30% increase rate DRUG elimination.
760,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",carbamazepine,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( phenytoin phenobarbital DRUG ) indicate 30% increase rate DRUG elimination.
761,"In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.",cimetidine,flecainide,mechanism,healthy subjects receiving DRUG (1 gm daily) one week plasma DRUG levels increased 30% half life increased 10%.
762,"When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.",amiodarone,flecainide,mechanism,DRUG added DRUG therapy plasma flecainide levels may increase two fold patients flecainide dosage reduced.
763,"Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;",quinidine,flecainide,mechanism,Drugs inhibit cytochrome P450IID6 DRUG might increase plasma concentrations DRUG patients chronic flecainide therapy;
764,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",disopyramide,TAMBOCOR,advise,drugs negative inotropic properties effects coadministration TAMBOCOR unknown neither DRUG verapamil administered concurrently BRAND unless judgment physician benefits combination outweigh risks.
765,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",verapamil,TAMBOCOR,advise,drugs negative inotropic properties effects coadministration TAMBOCOR unknown neither disopyramide DRUG administered concurrently BRAND unless judgment physician benefits combination outweigh risks.
766,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",D.H.E. 45,peripheral vasoconstrictors,effect,Vasoconstrictors: BRAND (dihydroergotamine mesylate) Injection USP used GROUP combination may cause synergistic elevation blood pressure.
767,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",dihydroergotamine mesylate,peripheral vasoconstrictors,effect,Vasoconstrictors: D.H.E. 45 ( DRUG ) Injection USP used GROUP combination may cause synergistic elevation blood pressure.
768,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,D.H.E. 45,effect,Sumatriptan: DRUG reported cause coronary artery vasospasm effect could additive BRAND (dihydroergotamine mesylate) Injection USP.
769,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,dihydroergotamine mesylate,effect,Sumatriptan: DRUG reported cause coronary artery vasospasm effect could additive D.H.E. 45 ( DRUG ) Injection USP.
770,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,D.H.E. 45,advise,DRUG BRAND (dihydroergotamine mesylate) Injection USP taken within 24 hours other..
771,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,dihydroergotamine mesylate,advise,DRUG D.H.E. 45 ( DRUG ) Injection USP taken within 24 hours other..
772,"Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",propranolol,ergotamine,effect,Beta Blockers: Although results clinical study indicate safe problem associated administration D.H.E. 45 (dihydroergotamine mesylate) Injection USP subjects already receiving propranolol reports DRUG may potentiate vasoconstrictive action DRUG blocking vasodilating property epinephrine.
773,"Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.",Nicotine,ergot,effect,Nicotine: DRUG may provoke vasoconstriction patients predisposing greater ischemic response DRUG therapy.
774,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",ergot alkaloid class,macrolide class,mechanism,Macrolide Antibiotics (e. g. erythromycin troleandomycin): Agents GROUP D.H.E. 45 (dihydroergotamine mesylate) Injection USP member shown interact antibiotics GROUP resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction.
775,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",D.H.E. 45,macrolide class,mechanism,Macrolide Antibiotics (e. g. erythromycin troleandomycin): Agents ergot alkaloid class BRAND (dihydroergotamine mesylate) Injection USP member shown interact antibiotics GROUP resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction.
776,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",dihydroergotamine mesylate,macrolide class,mechanism,Macrolide Antibiotics (e. g. erythromycin troleandomycin): Agents ergot alkaloid class D.H.E. 45 ( DRUG ) Injection USP member shown interact antibiotics GROUP resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction.
777,Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.,ergotamine,antibiotics,effect,Vasospastic reactions reported therapeutic doses DRUG containing drugs co administered GROUP .
778,"SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.",5-HT1 agonists,SSRIs,effect,SSRIs: Weakness hyperreflexia incoordination reported rarely GROUP co administered GROUP (e. g.
779,"In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; ",ouabain,PTX,effect,presence DRUG (10( 5) M) DRUG_N (10( 8) M) failed cause first contraction;
780,"When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. ",ouabain,phentolamine,effect,DRUG applied muscle presence DRUG first second contractile responses PTX abolished.
781,Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. ,ouabain,PTX,effect,Exposure muscle DRUG (10( 5) M) markedly increased DRUG_N induced release.
782,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).",Kineret,etanercept,effect,study patients active RA treated 24 weeks concurrent BRAND DRUG therapy 7% rate serious infections observed higher observed etanercept alone (0%).
783,Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).,Kineret,etanercept,effect,Two percent patients treated concurrently BRAND DRUG developed neutropenia (ANC 1 x 109/L).
784,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antiarrhythmics,advise,Drugs Coadministered BRAND GROUP : amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
785,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,amiodarone,advise,Drugs Coadministered BRAND Antiarrhythmics: DRUG quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
786,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,quinidine,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone DRUG Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
787,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antihistamines,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine GROUP : astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
788,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,astemizole,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: DRUG terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
789,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,terfenadine,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole DRUG Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
790,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,ergot derivatives,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: GROUP Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
791,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antimycobacterial agents,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives GROUP : rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
792,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,rifampin,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: DRUG Benzodiazepines midazolam triazolam GI motility agents: cisapride
793,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Benzodiazepines,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin GROUP midazolam triazolam GI motility agents: cisapride
794,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,midazolam,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines DRUG triazolam GI motility agents: cisapride
795,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,triazolam,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam DRUG GI motility agents: cisapride
796,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,cisapride,advise,Drugs Coadministered BRAND Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: DRUG
797,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,Antimycobacterial agents,advise,Drugs Require Dose Reduction Coadminstered BRAND GROUP : rifabutin
798,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,rifabutin,advise,Drugs Require Dose Reduction Coadminstered BRAND Antimycobacterial agents: DRUG
799,"therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.",VIRACEPT,terfenadine,advise,therefore BRAND administered concurrently DRUG potential serious and/or life threatening cardiac arrhythmias.
800,"Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.",VIRACEPT,astemizole,advise,similar interaction likely BRAND also administered concurrently DRUG .
801,Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.,indinavir,VIRACEPT,mechanism,Indinavir: Coadministration DRUG BRAND resulted 83% increase nelfinavir plasma AUC 51% increase indinavir plasma A.C.
802,Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.,ritonavir,VIRACEPT,mechanism,Ritonavir: Coadministration DRUG BRAND resulted 152% increase nelfinavir plasma AUC little change ritonavir plasma A.C.
803,Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.,saquinavir,VIRACEPT,mechanism,Saquinavir: Coadministration DRUG (using experimental soft gelatin capsule formulation saquinavir 1200mg) BRAND resulted 18% increase nelfinavir plasma AUC 4 fold increase saquinavir plasma A.C.
804,Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.,ketoconazole,VIRACEPT,mechanism,Ketoconazole: Coadministration DRUG BRAND resulted 35% increase nelfinavir plasma A.C.
805,"therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.",nelfinavir,didanosine,advise,therefore DRUG administered (with food) one hour two hours DRUG .
806,A dose adjustment is not needed when zidovudine is administered with VIRACEPT.,zidovudine,VIRACEPT,advise,dose adjustment needed DRUG administered BRAND .
807,Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.,rifabutin,VIRACEPT,mechanism,Rifabutin: Coadministration DRUG BRAND resulted 32% decrease nelfinavir plasma AUC 207% increase rifabutin plasma A.C.
808,It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.,rifabutin,VIRACEPT,advise,recommended dose DRUG reduced one half usual dose administered BRAND .
809,Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.,rifampin,VIRACEPT,mechanism,Rifampin: Coadministration DRUG BRAND resulted 82% decrease nelfinavir plasma A.C.
810,VIRACEPT and rifampin should not be coadministered.,VIRACEPT,rifampin,advise,BRAND DRUG coadministered.
811,Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.,VIRACEPT,OVCON-35,mechanism,Ethinyl Estradiol Norethindrone: Coadministration BRAND BRAND resulted 47% decrease ethinyl estradiol 18% decrease norethindrone plasma concentrations.
812,Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.,rauwolfia alkaloid,MAO inhibitors,effect,Taking GROUP taking within 2 weeks taking GROUP may increase risk central nervous system depression may cause severe high blood pressure reaction.
813,Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.,ELSPAR,methotrexate,effect,Tissue culture animal studies indicate BRAND diminish abolish effect DRUG malignant cells.14 effect methotrexate activity persists long plasma asparagine levels suppressed.
814,"These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.",methotrexate,ELSPAR,advise,results would seem dictate clinical use DRUG BRAND period following ELSPAR therapy plasma asparagine levels normal.
815,"Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.",MONUROL,metoclopramide,mechanism,Metoclopramide: coadministered BRAND DRUG drug increases gastrointestinal motility lowers serum concentration urinary excretion fosfomycin.
816,"Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.",Vitamin D3,arsenate,mechanism,DRUG administration rachitic chicks effective significantly elevating duodenal DRUG_N absorption acting primarily enhance serosal transport.
817,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,acetaminophen,int,DRUG may interact following medications: DRUG (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
818,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tylenol,int,DRUG may interact following medications: acetaminophen ( BRAND ) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
819,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antibiotics,int,DRUG may interact following medications: acetaminophen (Tylenol) GROUP ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
820,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,ampicillin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics DRUG tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
821,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,tetracycline,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin DRUG anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
822,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,anticonvulsants,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline GROUP (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
823,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Dilantin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants ( BRAND Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
824,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Phenobarbital,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin DRUG Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
825,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tegretol,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital BRAND Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
826,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Trileptal,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol BRAND Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
827,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Topamax,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal BRAND Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
828,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Felbatol,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax BRAND ) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
829,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antifungals,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) GROUP (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
830,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Gris-PEG,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals ( BRAND Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
831,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Nizoral,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG BRAND Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
832,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sporanox,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral BRAND ) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
833,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,atorvastatin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) DRUG (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
834,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Lipitor,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin ( BRAND ) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
835,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,clofibrate,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) DRUG (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
836,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Atromid-S,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate ( BRAND ) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
837,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,cyclosporine,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) DRUG (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
838,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Neoral,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine ( BRAND Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
839,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sandimmune,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral BRAND ) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
840,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,protease inhibitors,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified GROUP (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
841,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Agenerase,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors ( BRAND Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
842,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Crixivan,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase BRAND Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
843,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Fortovase,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan BRAND Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
844,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Invirase,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase BRAND Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
845,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kaletra,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase BRAND Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
846,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Norvir,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra BRAND Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
847,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Viracept,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir BRAND ) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
848,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,morphine,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) DRUG (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
849,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Astramorph,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine ( BRAND Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
850,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kadian,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph BRAND MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
851,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,MS Contin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian BRAND ) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
852,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,phenylbutazone,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) DRUG prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
853,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,prednisolone,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone DRUG (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
854,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Prelone,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone ( BRAND ) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
855,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifadin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) BRAND (rifampin) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
856,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifampin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin ( DRUG ) St. Johns wort temazepam theophylline (Theo Dur) vitamin C.
857,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,temazepam,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort DRUG theophylline (Theo Dur) vitamin C.
858,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,theophylline,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam DRUG (Theo Dur) vitamin C.
859,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Theo-Dur,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline ( BRAND ) vitamin C.
860,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,vitamin C,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St. Johns wort temazepam theophylline (Theo Dur) DRUG .
861,"For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.",vitamin K antagonists,nilutamide,advise,example GROUP administered concomitantly DRUG prothrombin time carefully monitored necessary dosage vitamin K antagonists reduced.
862,Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.,L-glutamine,human growth hormone,mechanism,Human growth hormone Concomitant use DRUG DRUG may enhance nutrient absorption severe short bowel syndrome.
863,Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.,L-glutamine,indomethacin,effect,Indomethacin Concomitant use DRUG DRUG may ameliorate increased intestinal permeability caused indomethacin.
864,Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.,methotrexate,L-glutamine,effect,Methotrexate one report DRUG may decrease possible effectiveness supplemental DRUG chemotherapy induced mucositis.
865,"In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.",methotrexate,L-glutamine,effect,another report nine patients breast cancer reported decreased symptoms DRUG related toxicity given supplemental DRUG dose 0.5 gram/kilogram/day.
866,"Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.",L-glutamine,paclitaxel,effect,Paclitaxel one report DRUG dose 10 grams three times daily given 24 hours receiving DRUG appeared prevent development myalgia arthralgia adverse reactions paclitaxel.
867,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,ketoconazole,mechanism,However co administration DRUG either DRUG erythromycin led increased plasma concentrations fexofenadine.
868,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,erythromycin,mechanism,However co administration DRUG either ketoconazole DRUG led increased plasma concentrations fexofenadine.
869,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,ketoconazole,fexofenadine,mechanism,studies indicate DRUG erythromycin co administration enhances DRUG gastrointestinal absorption.
870,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,erythromycin,fexofenadine,mechanism,studies indicate ketoconazole DRUG co administration enhances DRUG gastrointestinal absorption.
871,"This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.",ketoconazole,fexofenadine,mechanism,observed increase bioavailability fexofenadine may due transport related effects p glycoprotein. vivo animal studies also suggest addition enhancing absorption DRUG decreases DRUG gastrointestinal secretion erythromycin may also decrease biliary excretion.
872,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,aluminum,mechanism,Drug Interactions Antacids Administration 120 mg DRUG (2 x 60 mg capsule) within 15 minutes DRUG magnesium containing antacid (Maalox ) decreased fexofenadine AUC 41% cmax 43%.
873,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,magnesium,mechanism,Drug Interactions Antacids Administration 120 mg DRUG (2 x 60 mg capsule) within 15 minutes aluminum DRUG containing antacid (Maalox ) decreased fexofenadine AUC 41% cmax 43%.
874,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,antacid,mechanism,Drug Interactions Antacids Administration 120 mg DRUG (2 x 60 mg capsule) within 15 minutes aluminum magnesium containing GROUP (Maalox ) decreased fexofenadine AUC 41% cmax 43%.
875,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,Maalox,mechanism,Drug Interactions Antacids Administration 120 mg DRUG (2 x 60 mg capsule) within 15 minutes aluminum magnesium containing antacid ( BRAND ) decreased fexofenadine AUC 41% cmax 43%.
876,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,aluminum,advise,BRAND taken closely time DRUG magnesium containing antacids.
877,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,magnesium,advise,BRAND taken closely time aluminum DRUG containing antacids.
878,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",narcotic analgesic,DILAUDID,effect,Patients receiving GROUP general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly BRAND may exhibit additive CNS depression.
879,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",anesthetics,DILAUDID,effect,Patients receiving narcotic analgesics general GROUP phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly BRAND may exhibit additive CNS depression.
880,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",phenothiazines,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics GROUP tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly BRAND may exhibit additive CNS depression.
881,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tranquilizers,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines GROUP sedative hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly BRAND may exhibit additive CNS depression.
882,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",sedative-hypnotics,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers GROUP tricyclic antidepressants CNS depressants (including alcohol) concomitantly BRAND may exhibit additive CNS depression.
883,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tricyclic antidepressants,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics GROUP CNS depressants (including alcohol) concomitantly BRAND may exhibit additive CNS depression.
884,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",CNS depressants,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants GROUP (including alcohol) concomitantly BRAND may exhibit additive CNS depression.
885,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",alcohol,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics tricyclic antidepressants CNS depressants (including DRUG ) concomitantly BRAND may exhibit additive CNS depression.
886,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,aspirin,advise,taking DRUG tell doctor taking following medicines: BRAND another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
887,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salicylate,advise,taking DRUG tell doctor taking following medicines: aspirin another GROUP magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
888,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium/choline salicylate,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate DRUG (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
889,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Trilisate,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate ( BRAND ) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
890,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salsalate,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) DRUG (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
891,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Disalcid,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate ( BRAND others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
892,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,choline salicylate,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) DRUG (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
893,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Arthropan,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate ( DRUG ) magnesium salicylate (Magan) bismuth subsalicylate (Pepto Bismol);
894,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium salicylate,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) DRUG (Magan) bismuth subsalicylate (Pepto Bismol);
895,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Magan,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate ( BRAND ) bismuth subsalicylate (Pepto Bismol);
896,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,bismuth subsalicylate,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) DRUG (Pepto Bismol);
897,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Pepto-Bismol,advise,taking DRUG tell doctor taking following medicines: aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate ( BRAND );
898,HEMABATE may augment the activity of other oxytocic agents.,HEMABATE,oxytocic agents,effect,BRAND may augment activity GROUP .
899,"Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.",Furosemide,aminoglycoside antibiotics,effect,DRUG may increase ototoxic potential GROUP especially presence impaired renal function.
900,Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.,Furosemide,ethacrynic acid,advise,DRUG used concomitantly DRUG possibility ototoxicity.
901,"Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.",salicylates,furosemide,effect,Patients receiving high doses GROUP concomitantly DRUG rheumatic disease may experience salicylate toxicity lower doses competitive renal excretory sites.
902,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,tubocurarine,effect,DRUG tendency antagonize skeletal muscle relaxing effect DRUG may potentiate action succinylcholine.
903,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,succinylcholine,effect,DRUG tendency antagonize skeletal muscle relaxing effect tubocurarine may potentiate action DRUG .
904,Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally given GROUP reduce lithiums renal clearance add high risk lithium toxicity.
905,Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.,Furosemide,antihypertensive drugs,effect,DRUG may add potentiate therapeutic effect GROUP .
906,Furosemide may decrease arterial responsiveness to norepinephrine.,Furosemide,norepinephrine,effect,DRUG may decrease arterial responsiveness DRUG .
907,Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.,sucralfate,furosemide,effect,Tablets Simultaneous administration DRUG DRUG tablets may reduce natriuretic antihypertensive effects furosemide.
908,The intake of furosemide and sucralfate should be separated by at least two hours.,furosemide,sucralfate,advise,intake DRUG DRUG separated least two hours.
909,"Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.",furosemide,acetylsalicylic acid,effect,Tablets Injection Oral Solution One study six subjects demonstrated combination DRUG DRUG temporarily reduced creatinine clearance patients chronic renal insufficiency.
910,"There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.",furosemide,NSAIDs,effect,case reports patients developed increased BUN serum creatinine serum potassium levels weight gain DRUG used conjunction GROUP .
911,Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.,indomethacin,furosemide,effect,Literature reports indicate coadministration DRUG may reduce natriuretic antihypertensive effects DRUG patients inhibiting prostaglandin synthesis.
912,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.,indomethacin,furosemide,advise,Patients receiving DRUG DRUG observed closely determine desired diuretic and/or antihypertensive effect furosemide achieved.
913,Warfarin: Meclofenamate sodium enhances the effect of warfarin.,Warfarin,Meclofenamate sodium,effect,DRUG : DRUG enhances effect warfarin.
914,"Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.",meclofenamate sodium,warfarin,advise,Therefore DRUG given patient receiving DRUG dosage warfarin reduced prevent excessive prolongation prothrombin time.
915,"Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.",aspirin,meclofenamate sodium,mechanism,Aspirin: Concurrent administration BRAND may lower DRUG plasma levels possibly competing protein binding sites.
916,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent administration DRUG GROUP may result elevated serum levels oxyphenbutazone.
917,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,diabetic patients metabolic effects GROUP may decrease blood glucose therefore DRUG requirements.
918,"This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. ",phenytoin,quetiapine,mechanism,study demonstrated potent cytochrome P450 enzyme inducer DRUG indeed marked effect metabolism DRUG resulting 5 fold increase clearance administered concomitantly patients DSM IV diagnosed schizophrenia schizoaffective disorder bipolar disorder.
919,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",Chloramphenicol,penicillins,effect,Bacteriostatic Antibiotics: DRUG erythromycins sulfonamides tetracyclines may interfere bactericidal effect GROUP .
920,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",erythromycins,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol DRUG sulfonamides tetracyclines may interfere bactericidal effect GROUP .
921,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",sulfonamides,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol erythromycins GROUP tetracyclines may interfere bactericidal effect GROUP .
922,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",tetracyclines,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol erythromycins sulfonamides GROUP may interfere bactericidal effect GROUP .
923,Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.,Probenecid,ampicillin,mechanism,DRUG : May decrease renal tubular secretion DRUG resulting increased blood levels and/or ampicillin toxicity.
924,"Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.",bepridil hydrochloride,digoxin,mechanism,Digoxin: controlled studies healthy volunteers DRUG either effect (one study) associated modest increases 30% (two studies) steady state serum DRUG concentrations.
925,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,Anti-arrhythmics,bepridil hydrochloride,effect,GROUP tricyclic anti depressants could exaggerate prolongation QT interval observed DRUG .
926,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,tricyclic anti-depressants,bepridil hydrochloride,effect,Anti arrhythmics GROUP could exaggerate prolongation QT interval observed DRUG .
927,Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.,Cardiac glycosides,bepridil hydrochloride,effect,GROUP could exaggerate depression AV nodal conduction observed DRUG .
928,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,DRUG bacteriostatic antibiotic may antagonize bactericidal effect DRUG concurrent use drugs avoided.
929,The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. ,DCG-IV,PCP,effect,effects DRUG_N strong completely depressed DRUG_N induced hyperlocomotion.
930,"Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary",hydroxyurea,uricosuric medication,effect,Since DRUG may raise serum uric acid level dosage adjustment GROUP may necessary
931,Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.,probenecid,penciclovir,mechanism,Concurrent use DRUG drugs significantly eliminated active renal tubular secretion may result increased plasma concentrations DRUG .
932,Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.,aminoglycoside antibiotics,cephalosporin antibiotics,effect,Nephrotoxicity reported following concomitant administration GROUP GROUP .
933,Concomitant administration of probenecid doubled the AUC for cefprozil.,probenecid,cefprozil,mechanism,Concomitant administration DRUG doubled AUC DRUG .
934,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",Diphenoxylate HCl,MAO inhibitors,int,DRUG atropine sulfate may interact GROUP studies male rats diphenoxylate hydrochloride found inhibit hepatic microsomal enzyme system dose 2 mg/kg/day.
935,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",atropine sulfate,MAO inhibitors,int,Diphenoxylate HCl DRUG may interact GROUP studies male rats diphenoxylate hydrochloride found inhibit hepatic microsomal enzyme system dose 2 mg/kg/day.
936,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,tricyclic antidepressant,effect,report case adolescent altered consciousness caused DRUG overdose positive GROUP level alert clinicians cross reactivity carbamazepine toxicology screen tricyclic antidepressants.
937,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,tricyclic antidepressants,advise,report case adolescent altered consciousness caused carbamazepine overdose positive tricyclic antidepressant level alert clinicians cross reactivity DRUG toxicology screen GROUP .
938,"Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.",Exjade,aluminum,advise,Although deferasirox lower affinity aluminum iron BRAND taken DRUG containing antacid preparations.
939,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenylbutazone,mechanism,DRUG resin may delay reduce absorption concomitant oral medication GROUP warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
940,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,warfarin,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone DRUG thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
941,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thiazide diuretics,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin GROUP (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
942,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,propranolol,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) DRUG (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
943,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,tetracycline,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well DRUG penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
944,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,penicillin G,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline DRUG phenobarbital thyroid thyroxine preparations estrogens progestins digitalis.
945,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenobarbital,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G DRUG thyroid thyroxine preparations estrogens progestins digitalis.
946,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thyroxine,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid DRUG preparations estrogens progestins digitalis.
947,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,estrogens,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations GROUP progestins digitalis.
948,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,progestins,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens GROUP digitalis.
949,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,digitalis,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins GROUP .
950,"Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.",cholestyramine,digitalis,mechanism,Cholestyramine resin may interfere pharmacokinetics drugs undergo enterohepatic circulation discontinuance DRUG resin could pose hazard health potentially toxic drug GROUP filtrated maintenance level patient taking cholestyramine resin.
951,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,Acetazolamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: DRUG azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
952,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,azole antifungals,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide GROUP cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
953,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,cimetidine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals DRUG clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
954,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,clarithromycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine DRUG (1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
955,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,dalfopristin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) DRUG danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
956,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,danazol,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin DRUG delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
957,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,delavirdine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol DRUG diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
958,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,diltiazem,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine DRUG erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
959,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,erythromycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem DRUG (1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
960,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluoxetine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) DRUG fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
961,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluvoxamine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine DRUG grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
962,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,isoniazid,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice DRUG itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
963,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,itraconazole,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid DRUG ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
964,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,ketoconazole,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole DRUG loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
965,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,loratadine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole DRUG nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
966,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nefazodone,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine DRUG niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
967,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,niacinamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone DRUG nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
968,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nicotinamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide DRUG protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
969,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,protease inhibitors,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide GROUP propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
970,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,propoxyphene,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors DRUG quinine quinupristin troleandomycin valproate(1) verapamil zileuton.
971,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene DRUG quinupristin troleandomycin valproate(1) verapamil zileuton.
972,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinupristin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine DRUG troleandomycin valproate(1) verapamil zileuton.
973,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,troleandomycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin DRUG valproate(1) verapamil zileuton.
974,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,valproate,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin DRUG (1) verapamil zileuton.
975,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,verapamil,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) DRUG zileuton.
976,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,zileuton,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels BRAND following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil DRUG .
977,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Cisplatin,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: DRUG doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
978,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,doxorubicin HCL,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin DRUG felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
979,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,felbamate,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin doxorubicin HCL DRUG rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
980,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,rifampin,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin doxorubicin HCL felbamate DRUG phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
981,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,phenobarbital,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin doxorubicin HCL felbamate rifampin DRUG Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
982,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Phenytoin,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital DRUG (2) primidone methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
983,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,primidone,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) DRUG methsuximide theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
984,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,methsuximide,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone DRUG theophylline Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
985,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,theophylline,mechanism,Agents CYP inducers found expected decrease plasma levels BRAND following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide DRUG Thus patient titrated stable dosage EQUETROTM begins course treatment one CYP3A4 inducers reasonable expect dose increase EQUETROTM may necessary.
986,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Acetaminophen,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: DRUG alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
987,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,alprazolam,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen DRUG amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
988,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,amitriptyline,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam DRUG bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
989,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,bupropion,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline DRUG buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
990,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,buspirone,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion DRUG citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
991,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,citalopram,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone DRUG clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
992,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clobazam,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram DRUG clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
993,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clonazepam,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam DRUG clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
994,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clozapine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam DRUG cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
995,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,cyclosporin,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine DRUG delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
996,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,delavirdine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin DRUG desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
997,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,desipramine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine DRUG diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
998,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,diazepam,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine DRUG dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
999,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,dicumarol,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam DRUG doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1000,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,doxycycline,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol DRUG ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1001,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ethosuximide,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline DRUG felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1002,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felbamate,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide DRUG felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1003,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felodipine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate DRUG glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1004,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,glucocorticoids,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine GROUP haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1005,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,haloperidol,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids DRUG itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1006,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,itraconazole,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol DRUG lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1007,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lamotrigine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole DRUG levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1008,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,levothyroxine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine DRUG lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1009,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lorazepam,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine DRUG methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1010,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,methadone,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam DRUG midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1011,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,midazolam,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone DRUG mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1012,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,mirtazapine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam DRUG nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1013,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,nortriptyline,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine DRUG olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1014,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,olanzapine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline DRUG oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1015,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,contraceptives,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral GROUP (3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1016,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,oxcarbazepine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) DRUG Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1017,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Phenytoin,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine DRUG (4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1018,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,praziquantel,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) DRUG protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1019,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,protease inhibitors,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel GROUP quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1020,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,quetiapine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors DRUG risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1021,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,risperidone,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine DRUG theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1022,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,theophylline,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone DRUG topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1023,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,topiramate,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline DRUG tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1024,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tiagabine,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate DRUG tramadol triazolam valproate warfarin(5) ziprasidone zonisamide.
1025,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tramadol,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine DRUG triazolam valproate warfarin(5) ziprasidone zonisamide.
1026,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,triazolam,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol DRUG valproate warfarin(5) ziprasidone zonisamide.
1027,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,valproate,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam DRUG warfarin(5) ziprasidone zonisamide.
1028,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,warfarin,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate DRUG (5) ziprasidone zonisamide.
1029,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ziprasidone,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) DRUG zonisamide.
1030,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,zonisamide,mechanism,Agents found expected decreased plasma levels presence BRAND due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone DRUG .
1031,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Clomipramine HCl,mechanism,Agents Increased Levels Presence Carbamazepine: BRAND increases plasma levels following agents: DRUG Phenytoin(6) primidone Thus patient titrated stable dosage one agents category begins course treatment EQUETROTM reasonable expect dose decrease concomitant agent may necessary.
1032,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Phenytoin,mechanism,Agents Increased Levels Presence Carbamazepine: BRAND increases plasma levels following agents: Clomipramine HCl DRUG (6) primidone Thus patient titrated stable dosage one agents category begins course treatment EQUETROTM reasonable expect dose decrease concomitant agent may necessary.
1033,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,primidone,mechanism,Agents Increased Levels Presence Carbamazepine: BRAND increases plasma levels following agents: Clomipramine HCl Phenytoin(6) DRUG Thus patient titrated stable dosage one agents category begins course treatment EQUETROTM reasonable expect dose decrease concomitant agent may necessary.
1034,Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.,carbamazepine,lithium,effect,Pharmacological/Pharmacodynamic Interactions Carbamazepine Concomitant administration DRUG DRUG may increase risk neurotoxic side effects.
1035,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",anti-malarial drugs,carbamazepine,effect,Additionally GROUP chloroquine mefloquine may antagonize activity DRUG .
1036,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",chloroquine,carbamazepine,effect,Additionally anti malarial drugs DRUG mefloquine may antagonize activity DRUG .
1037,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",mefloquine,carbamazepine,effect,Additionally anti malarial drugs chloroquine DRUG may antagonize activity DRUG .
1038,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,centrally acting drugs,advise,primary CNS effect caution used BRAND taken GROUP alcohol.
1039,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,alcohol,advise,primary CNS effect caution used BRAND taken centrally acting drugs DRUG .
1040,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,monoamine oxidase inhibitors,effect,patients receiving another GROUP combination GROUP (MAOI) reports serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability possible rapid fluctuations vital signs mental status changes include extreme agitation progressing delirium coma.
1041,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,MAOI,effect,patients receiving another GROUP combination monoamine oxidase inhibitors ( GROUP ) reports serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability possible rapid fluctuations vital signs mental status changes include extreme agitation progressing delirium coma.
1042,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOIs,advise,Therefore recommended DRUG Tablets used combination GROUP within 14 days discontinuing treatment MAOI.
1043,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOI,advise,Therefore recommended DRUG Tablets used combination MAOIs within 14 days discontinuing treatment GROUP .
1044,"After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.",Fluvoxamine,MAOI,advise,stopping DRUG Tablets least 2 weeks allowed starting GROUP .
1045,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",Terfenadine,ketoconazole,mechanism,DRUG astemizole cisapride metabolized cytochrome P450IIIA4 isozyme demonstrated DRUG potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug.
1046,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",astemizole,ketoconazole,mechanism,Terfenadine DRUG cisapride metabolized cytochrome P450IIIA4 isozyme demonstrated DRUG potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug.
1047,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",cisapride,ketoconazole,mechanism,Terfenadine astemizole DRUG metabolized cytochrome P450IIIA4 isozyme demonstrated DRUG potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug.
1048,"Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.",fluvoxamine,alprazolam,int,Although definitively demonstrated fluvoxamine potent IIIA4 inhibitor likely given substantial interaction DRUG DRUG .
1049,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,terbinafine,advise,Consequently recommended DRUG used combination either DRUG astemizole cisapride.
1050,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,astemizole,advise,Consequently recommended DRUG used combination either terbinafine DRUG cisapride.
1051,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,cisapride,advise,Consequently recommended DRUG used combination either terbinafine astemizole DRUG .
1052,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",Benzodiazepines,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: GROUP metabolized hepatic oxidation (e.g. alprazolam midazolam triazolam elc.) used caution clearance drugs likely reduced DRUG .
1053,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",alprazolam,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e.g. DRUG midazolam triazolam elc.) used caution clearance drugs likely reduced DRUG .
1054,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",midazolam,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e.g. alprazolam DRUG triazolam elc.) used caution clearance drugs likely reduced DRUG .
1055,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",triazolam,fluvoxamine,mechanism,Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e.g. alprazolam midazolam DRUG elc.) used caution clearance drugs likely reduced DRUG .
1056,"Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",fluvoxamine maleate,alprazolam,mechanism,Alprazolam: DRUG (100 mg qd) DRUG (1 mg q.d. co administered steady state plasma concentration pharmacokinetics parameters (AUC Cmax T1/2 ) alprazolam approximately twice observed alprazolam administered alone;
1057,"This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.",alprazolam,Fluvoxamine,advise,interaction investigated using higher doses fluvoxamine may pronounced 300 mg daily dose co administered particularly since fluvoxamine exhibits non linear pharmacokinetics dosage range 100 300 mg. DRUG co administered DRUG Tablets initial alprazolam dosage least halved titration lowest effective dose recommended.
1058,Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.,Fluvoxamine,diazepam,advise,Diazepam: co administration DRUG Tablets DRUG generally advisable.
1059,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,diazepam,mechanism,DRUG reduces clearance DRUG active metabolite N desmethyldiazepam strong likelihood substantial accumulation species chronic co administration.
1060,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,N-desmethyldiazepam,mechanism,DRUG reduces clearance diazepam active metabolite DRUG_N strong likelihood substantial accumulation species chronic co administration.
1061,Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.,fluvoxamine,diazepam,advise,Evidence supporting conclusion inadvisable co administer DRUG DRUG derived study healthy volunteers taking 150 mg/day fluvoxamine administered single oral dose 10 mg diazepam.
1062,"Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.",alprazolam,fluvoxamine,effect,Moreover noted DRUG effect DRUG may even pronounced administered higher doses.
1063,"Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.",diazepam,fluvoxamine,advise,Accordingly DRUG DRUG ordinarily co administered.
1064,"Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.",theophylline,fluvoxamine maleate,advise,Therefore DRUG co administered DRUG dose reduced one third usual daily maintenance dose plasma concentrations theophylline monitored.
1065,"Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.",fluvoxamine maleate,warfarin,mechanism,Warfarin: DRUG (50 mg tid) administered concomitantly DRUG two weeks warfarin plasma concentrations increased 98% prothrombin times prolonged.
1066,Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.,anticoagulants,Fluvoxamine,advise,Thus patients receiving oral GROUP DRUG Tablets prothrombin time monitored anticoagulant dose adjusted accordingly.
1067,"Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).",nitazoxanide,warfarin,mechanism,Therefore caution used administering DRUG concurrently highly plasma protein bound drugs narrow therapeutic indices competition binding sites may occur (e.g. DRUG ).
1068,"Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agent,effect,Catecholamine depleting drugs (eg DRUG ) may additive effect given GROUP s.
1069,Calcium channel blockers may also have an additive effect when given with TENORMIN .,Calcium channel blockers,TENORMIN,effect,GROUP may also additive effect given BRAND .
1070,Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.,Beta blockers,clonidine,effect,GROUP may exacerbate rebound hypertension follow withdrawal DRUG .
1071,"If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.",beta blocker,clonidine,advise,two drugs coadministered GROUP withdrawn several days gradual withdrawal DRUG .
1072,"If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.",beta blockers,clonidine,advise,replacing clonidine beta blocker therapy introduction GROUP delayed several days DRUG administration stopped.
1073,"Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.",indomethacin,beta blockers,effect,Concomitant use prostaglandin synthase inhibiting drugs eg DRUG may decrease hypotensive effects GROUP .
1074,Amiodarone is known to raise serum digoxin levels. ,Amiodarone,digoxin,mechanism,DRUG known raise serum DRUG levels.
1075,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). ",amiodarone,digoxin,mechanism,DRUG administration systemic clearance DRUG reduced 234 +/ 72 ml/min (mean +/ standard deviation) 172 +/ 33 ml/min (p less 0.01).
1076,These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.,digoxin,amiodarone,mechanism,alterations DRUG pharmacokinetics produced DRUG explain increase serum digoxin level observed drug combination used clinically.
1077,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ",Physostigmine,alcohol,effect,DRUG pretreatment augmented depressant effect DRUG early components P1 N1 attenuating alcohol's influence components P2 P3.
1078,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ",Physostigmine,alcohol,effect,DRUG pretreatment augmented depressant effect alcohol early components P1 N1 attenuating DRUG 's influence components P2 P3.
1079,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,aspirin,int,Interactions may occur DRUG supplements BRAND non steroidal anti inflammatory drugs herbs garlic (Allium sativum) ginkgo (Ginkgo biloba).
1080,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,non-steroidal anti-inflammatory drugs,int,Interactions may occur DRUG supplements aspirin GROUP herbs garlic (Allium sativum) ginkgo (Ginkgo biloba).
1081,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,ginkgo,int,Interactions may occur DRUG supplements aspirin non steroidal anti inflammatory drugs herbs garlic (Allium sativum) DRUG (Ginkgo biloba).
1082,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,Ginkgo biloba,int,Interactions may occur DRUG supplements aspirin non steroidal anti inflammatory drugs herbs garlic (Allium sativum) ginkgo ( DRUG ).
1083,"When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.",amphotericin B,Antineoplastic agents,effect,administered concurrently following drugs may interact DRUG : GROUP : may enhance potential renal toxicity bronchospasm hypotension.
1084,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticosteroids,amphotericin B,effect,GROUP Corticotropin (ACTH): may potentiate DRUG induced hypokalemia may predispose patient cardiac dysfunction.
1085,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticotropin,amphotericin B,effect,Corticosteroids DRUG (ACTH): may potentiate DRUG induced hypokalemia may predispose patient cardiac dysfunction.
1086,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,ACTH,amphotericin B,effect,Corticosteroids Corticotropin ( GROUP ): may potentiate DRUG induced hypokalemia may predispose patient cardiac dysfunction.
1087,Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.,amphotericin B,digitalis,effect,Digitalis glycosides: DRUG induced hypokalemia may potentiate GROUP toxicity.
1088,"Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.",amphotericin B,flucytosine,effect,Flucytosine: synergistic relationship DRUG reported concomitant use may increase toxicity DRUG possibly increasing cellular uptake and/or impairing renal excretion.
1089,"Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.",imidazoles,amphotericin B,effect,Imidazoles (e. g. ketoconazole miconazole clotrimazole fluconazole etc.): vitro animal studies combination amphotericin B imidazoles suggest GROUP may induce fungal resistance DRUG .
1090,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,skeletal muscle relaxants,effect,Skeletal muscle relaxants: DRUG induced hypokalemia may enhance curariform effect GROUP (e.g. tubocurarine).
1091,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,tubocurarine,effect,Skeletal muscle relaxants: DRUG induced hypokalemia may enhance curariform effect skeletal muscle relaxants (e.g. DRUG ).
1092,Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.,amphotericin B,leukocyte transfusions,effect,Leukocyte transfusions: acute pulmonary toxicity reported patients receiving intravenous DRUG DRUG_N .
1093,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,iron,mechanism,absorption DRUG may affected simultaneous administration indigestion remedies DRUG zinc supplements.
1094,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,zinc,mechanism,absorption DRUG may affected simultaneous administration indigestion remedies iron DRUG supplements.
1095,Oral contraceptives may be less effective while you are taking lymecycline.,contraceptives,lymecycline,effect,Oral GROUP may less effective taking DRUG .
1096,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,diuretics,effect,Additional reductions blood pressure may occur BRAND administered GROUP antihypertensive agents vasodilators.
1097,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,antihypertensive agents,effect,Additional reductions blood pressure may occur BRAND administered diuretics GROUP vasodilators.
1098,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,vasodilators,effect,Additional reductions blood pressure may occur BRAND administered diuretics antihypertensive agents GROUP .
1099,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",antiplatelet agents,FLOLAN,effect,GROUP anticoagulants used concomitantly potential BRAND increase risk bleeding.
1100,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",anticoagulants,FLOLAN,effect,antiplatelet agents GROUP used concomitantly potential BRAND increase risk bleeding.
1101,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,FLOLAN,mechanism,clinical trials FLOLAN used digoxin diuretics anticoagulants oral vasodilators supplemental oxygen.In pharmacokinetic substudy patients congestive heart failure receiving DRUG digoxin therapy BRAND initiated apparent oral clearance values furosemide (n = 23) digoxin (n = 30) decreased 13% 15% respectively second day therapy returned baseline values day 87.
1102,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,FLOLAN,mechanism,clinical trials FLOLAN used digoxin diuretics anticoagulants oral vasodilators supplemental oxygen.In pharmacokinetic substudy patients congestive heart failure receiving furosemide DRUG therapy BRAND initiated apparent oral clearance values furosemide (n = 23) digoxin (n = 30) decreased 13% 15% respectively second day therapy returned baseline values day 87.
1103,"However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.",digoxin,FLOLAN,mechanism,However patients DRUG may show elevations digoxin concentrations initiation therapy BRAND may clinically significant patients prone digoxin toxicity.
1104,Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.,L-arginine,cyclosporin,effect,Cyclosporine DRUG may counteract antinaturetic effect DRUG .
1105,Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.,L-arginine,ibuprofen,mechanism,Ibuprofen DRUG may increase absorption DRUG taken concomitantly.
1106,Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.,L-arginine,nitrates,effect,Organic nitrates DRUG supplements theoretically may potentiate effects organic DRUG taken concomitantly.
1107,"Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.",L-arginine,sildenafil citrate,effect,Sildenafil citrate Theoretically DRUG supplements taken concomitantly DRUG may potentiate effects drug.
1108,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergotamine,AXERT,advise,theoretical basis effects may additive use DRUG containing ergot type medications (like dihydroergotamine methysergide) BRAND within 24 hours avoided.
1109,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergot-type medications,AXERT,advise,theoretical basis effects may additive use ergotamine containing GROUP (like dihydroergotamine methysergide) BRAND within 24 hours avoided.
1110,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",dihydroergotamine,AXERT,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like DRUG methysergide) BRAND within 24 hours avoided.
1111,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",methysergide,AXERT,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like dihydroergotamine DRUG ) BRAND within 24 hours avoided.
1112,Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.,moclobemide,almotriptan,mechanism,Monoamine Oxidase Inhibitors: Coadministration DRUG resulted 27% decrease DRUG clearance increase Cmax approximately 6%.
1113,Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.,5-HT1B/1D agonists,AXERT,advise,5 HT1B/1D Agonists Concomitant use GROUP within 24 hours treatment BRAND contraindicated.
1114,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): GROUP (e.g. fluoxetine fluvoxamine paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered GROUP .
1115,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. DRUG fluvoxamine paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered GROUP .
1116,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. fluoxetine DRUG paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered GROUP .
1117,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. fluoxetine fluvoxamine DRUG sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered GROUP .
1118,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g. fluoxetine fluvoxamine paroxetine DRUG ) rarely reported cause weakness hyperreflexia incoordination coadministered GROUP .
1119,"If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.",AXERT,SSRI,advise,concomitant treatment BRAND GROUP clinically warranted appropriate observation patient advised.
1120,Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.,almotriptan,verapamil,mechanism,Verapamil: Coadministration DRUG DRUG resulted 24% increase plasma concentrations almotriptan.
1121,Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.,almotriptan,ketoconazole,mechanism,Coadministration DRUG potent CYP3A4 inhibitor DRUG (400 mg q.d. 3 days) resulted approximately 60% increase area plasma concentration time curve maximal plasma concentrations almotriptan.
1122,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",itraconazole,almotriptan,advise,Although interaction almotriptan potent CYP3A4 inhibitors (e.g. DRUG ritonavir erythromycin) studied increased exposures almotriptan may expected DRUG used concomitantly medications.
1123,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",ritonavir,almotriptan,advise,Although interaction almotriptan potent CYP3A4 inhibitors (e.g. itraconazole DRUG erythromycin) studied increased exposures almotriptan may expected DRUG used concomitantly medications.
1124,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",erythromycin,almotriptan,advise,Although interaction almotriptan potent CYP3A4 inhibitors (e.g. itraconazole ritonavir DRUG ) studied increased exposures almotriptan may expected DRUG used concomitantly medications.
1125,Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.,Lamivudine,zalcitabine,effect,DRUG DRUG may inhibit intracellular phosphorylation one another.
1126,"Therefore, use of lamivudine in combination with zalcitabine is not recommended",lamivudine,zalcitabine,advise,Therefore use DRUG combination DRUG recommended
1127,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenobarbital,effect,DRUG large amounts may counteract antiepileptic effect DRUG phenytoin primidone increase frequency seizures susceptible pediatric patients.
1128,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenytoin,effect,DRUG large amounts may counteract antiepileptic effect phenobarbital DRUG primidone increase frequency seizures susceptible pediatric patients.
1129,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,primidone,effect,DRUG large amounts may counteract antiepileptic effect phenobarbital phenytoin DRUG increase frequency seizures susceptible pediatric patients.
1130,"However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.",leucovorin,methotrexate,effect,However high doses DRUG may reduce efficacy intrathecally administered DRUG .
1131,Leucovorin may enhance the toxicity of 5-fluorouracil.,Leucovorin,5-fluorouracil,effect,DRUG may enhance toxicity DRUG .
1132,"The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.",Ketoconazole,terfenadine,mechanism,following drug interactions identified involving NIZORAL Tablets drugs metabolized cytochrome P450 3A4 enzyme system: DRUG tablets inhibit metabolism DRUG resulting increased plasma concentration terfenadine delay elimination acid metabolite.
1133,"Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.",ketoconazole,astemizole,effect,Pharmacokinetic data indicate oral DRUG inhibits metabolism DRUG resulting elevated plasma levels astemizole active metabolite desmethylastemizole may prolong QT intervals.
1134,Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.,astemizole,ketoconazole,advise,Coadministration DRUG DRUG tablets therefore contraindicated.
1135,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.,ketoconazole,cisapride,mechanism,Human pharmacokinetics data indicate oral DRUG potently inhibits metabolism DRUG resulting mean eight fold increase AUC cisapride.
1136,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data suggest coadministration oral DRUG DRUG result prolongation QT interval ECG.
1137,Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.,ketoconazole,cisapride,advise,Therefore concomitant administration DRUG tablets DRUG contraindicated.
1138,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,cyclosporine,mechanism,DRUG tablets may alter metabolism DRUG tacrolimus methylprednisolone resulting elevated plasma concentrations latter drugs.
1139,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,tacrolimus,mechanism,DRUG tablets may alter metabolism cyclosporine DRUG methylprednisolone resulting elevated plasma concentrations latter drugs.
1140,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,methylprednisolone,mechanism,DRUG tablets may alter metabolism cyclosporine tacrolimus DRUG resulting elevated plasma concentrations latter drugs.
1141,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,midazolam,mechanism,Coadministration BRAND Tablets DRUG triazolam resulted elevated plasma concentrations latter two drugs.
1142,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,triazolam,mechanism,Coadministration BRAND Tablets midazolam DRUG resulted elevated plasma concentrations latter two drugs.
1143,"It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.",digoxin,ketoconazole,advise,therefore advisable monitor DRUG concentrations patients receiving DRUG .
1144,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",imidazole compounds,coumarin,effect,taken orally GROUP like ketoconazole may enhance anticoagulant effect GROUP like drugs.
1145,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",ketoconazole,coumarin,effect,taken orally imidazole compounds like DRUG may enhance anticoagulant effect GROUP like drugs.
1146,"In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.",imidazole drugs,coumarin drugs,advise,simultaneous treatment GROUP GROUP anticoagulant effect carefully titrated monitored.
1147,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.",miconazole,hypoglycemic agents,effect,severe hypoglycemia reported patients concomitantly receiving oral DRUG (an imidazole) oral GROUP potential interaction involving latter agents used concomitantly ketoconazole tablets (an imidazole) ruled out.
1148,Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.,ketoconazole,phenytoin,mechanism,Concomitant administration DRUG tablets DRUG may alter metabolism one drugs.
1149,It is suggested to monitor both ketoconazole and phenytoin.,ketoconazole,phenytoin,advise,suggested monitor DRUG DRUG .
1150,Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.,rifampin,ketoconazole,mechanism,Concomitant administration DRUG DRUG tablets reduces blood levels latter.
1151,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,INH,ketoconazole,mechanism,DRUG (Isoniazid) also reported affect DRUG concentrations adversely.
1152,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,Isoniazid,ketoconazole,mechanism,INH ( DRUG ) also reported affect DRUG concentrations adversely.
1153,"After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.",ketoconazole,loratadine,mechanism,coadministration 200 mg oral DRUG twice daily one 20 mg dose DRUG 11 subjects AUC Cmax loratadine averaged 302% ( 142 S.D.) 251% ( 68 S.D.) respectively obtained co treatment placebo.
1154,"Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.",cephalosporins,aminoglycosides,effect,Although occurrence reported Cefizox nephrotoxicity reported following concomitant administration GROUP GROUP .
1155,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroids,mechanism,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance GROUP may require increases corticosteroid dose achieve desired response.
1156,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroid,advise,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance corticosteroids may require increases GROUP dose achieve desired response.
1157,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance GROUP may require increases corticosteroid dose achieve desired response.
1158,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroid,advise,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance corticosteroids may require increases GROUP dose achieve desired response.
1159,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance GROUP may require increases corticosteroid dose achieve desired response.
1160,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroid,advise,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance corticosteroids may require increases GROUP dose achieve desired response.
1161,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,troleandomycin,corticosteroids,mechanism,Drugs DRUG ketoconazole may inhibit metabolism GROUP thus decrease clearance.
1162,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,ketoconazole,corticosteroids,mechanism,Drugs troleandomycin DRUG may inhibit metabolism GROUP thus decrease clearance.
1163,Corticosteroids may increase the clearance of chronic high dose aspirin.,Corticosteroids,aspirin,effect,GROUP may increase clearance chronic high dose BRAND .
1164,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.,salicylate,corticosteroid,effect,could lead decreased salicylate serum levels increase risk GROUP toxicity DRUG withdrawn.
1165,Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.,Aspirin,cortico-steroids,advise,BRAND used cautiously conjunction GROUP patients suffering hypopro thrombinemia.
1166,The effect of corticosteroids on oral anticoagulants is variable.,corticosteroids,anticoagulants,effect,effect GROUP oral GROUP variable.
1167,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.,anticoagulants,corticosteroids,effect,reports enhanced well diminished effects GROUP given concurrently GROUP .
1168,Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.,acetaminophen,caffeine,effect,Increased hepatotoxicity DRUG concomitant administration DRUG rat.
1169,Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.,acetaminophen,caffeine,effect,Careful observations hepatotoxicity suggested DRUG prescribed DRUG .
1170,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,aminoglycosides,advise,Co administration BRAND GROUP agents interfering neuromuscular transmission (e.g. curare like compounds) performed caution effect toxin may potentiated.
1171,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,curare-like compounds,advise,Co administration BRAND aminoglycosides agents interfering neuromuscular transmission (e.g. GROUP ) performed caution effect toxin may potentiated.
1172,Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.,botulinum toxin,botulinum toxin,effect,Excessive neuromuscular weakness may exacerbated administration another GROUP prior resolution effects previously administered GROUP .
1173,Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.,Fluvoxamine,alosetron,mechanism,DRUG increased mean DRUG plasma concentrations (AUC) approximately 6 fold prolonged half life approximately 3 fold.
1174,Concomitant administration of alosetron and fluvoxamine is contraindicated.,alosetron,fluvoxamine,advise,Concomitant administration DRUG DRUG contraindicated.
1175,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,quinolone antibiotics,advise,Concomitant administration DRUG moderate CYP1A2 inhibitors including GROUP cimetidine evaluated avoided unless clinically necessary similar potential drug interactions.
1176,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,cimetidine,advise,Concomitant administration DRUG moderate CYP1A2 inhibitors including quinolone antibiotics DRUG evaluated avoided unless clinically necessary similar potential drug interactions.
1177,Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.,Ketoconazole,alosetron,mechanism,DRUG increased mean DRUG plasma concentrations (AUC) 29%.
1178,Caution should be used when alosetron and ketoconazole are administered concomitantly.,alosetron,ketoconazole,advise,Caution used DRUG DRUG administered concomitantly.
1179,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,clarithromycin,advise,Coadministration DRUG strong CYP3A4 inhibitors DRUG telithromycin protease inhibitors voriconazole itraconazole evaluated undertaken caution similar potential drug interactions.
1180,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,telithromycin,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin DRUG protease inhibitors voriconazole itraconazole evaluated undertaken caution similar potential drug interactions.
1181,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,protease inhibitors,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin telithromycin GROUP voriconazole itraconazole evaluated undertaken caution similar potential drug interactions.
1182,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,voriconazole,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors DRUG itraconazole evaluated undertaken caution similar potential drug interactions.
1183,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,itraconazole,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors voriconazole DRUG evaluated undertaken caution similar potential drug interactions.
1184,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,isoniazid,effect,Although studied DRUG inhibition N acetyltransferase may clinically relevant consequences drugs DRUG procainamide hydralazine.
1185,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,procainamide,effect,Although studied DRUG inhibition N acetyltransferase may clinically relevant consequences drugs isoniazid DRUG hydralazine.
1186,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,hydralazine,effect,Although studied DRUG inhibition N acetyltransferase may clinically relevant consequences drugs isoniazid procainamide DRUG .
1187,Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.,Dipyridamole,adenosine,mechanism,Adenosine: DRUG reported increase plasma levels cardiovascular effects DRUG .
1188,"Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.",Dipyridamole,cholinesterase inhibitors,effect,Cholinesterase Inhibitors: DRUG may counteract anticholinesterase effect GROUP thereby potentially aggravating myasthenia gravis.
1189,"Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.",ipratropium bromide,anticholinergic medications,effect,Anticholinergic agents: Although DRUG minimally absorbed systemic circulation potential additive interaction concomitantly used GROUP .
1190,Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.,ATROVENT,anticholinergic,advise,Caution therefore advised coadministration BRAND Inhalation Aerosol GROUP containing drugs.
1191,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ,cimetidine,verografine,mechanism,[The effect cimetidine renal excretion verografin iodamide dogs] intravenous injection DRUG dose 20 mg/kg enhanced DRUG iodamide excretion chronic canine experiments.
1192,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ,cimetidine,iodamide,mechanism,[The effect cimetidine renal excretion verografin iodamide dogs] intravenous injection DRUG dose 20 mg/kg enhanced verografine DRUG excretion chronic canine experiments.
1193,"Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
",Misonidazole,CCNU,effect,DRUG_N protects mouse tumour normal tissues toxicity oral DRUG .
1194,Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. ,Misonidazole,CCNU,effect,DRUG_N reduced antitumour activity oral DRUG dose modifying factors (DMF) 0.58 0.71.
1195,Misonidazole has a complex effect on oral CCNU pharmacokinetics. ,Misonidazole,CCNU,mechanism,DRUG_N complex effect oral DRUG pharmacokinetics.
1196,We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. ,CCNU,misonidazole,mechanism,propose pharmacokinetic changes underlying mechanism reduction oral DRUG cytotoxicity DRUG_N .
1197,"An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.",lithium,HALDOL,effect,encephalopathic syndrome (characterized weakness lethargy fever tremulousness confusion extrapyramidal symptoms leukocytosis elevated serum enzymes BUN FBS) followed irreversible brain damage occurred patients treated DRUG plus BRAND .
1198,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,CNS depressants,effect,GROUP noted HALDOL may capable potentiating GROUP anesthetics opiates alcohol.
1199,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,anesthetics,effect,GROUP noted HALDOL may capable potentiating CNS depressants GROUP opiates alcohol.
1200,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,opiates,effect,GROUP noted HALDOL may capable potentiating CNS depressants anesthetics GROUP alcohol.
1201,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,alcohol,effect,GROUP noted HALDOL may capable potentiating CNS depressants anesthetics opiates DRUG .
1202,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,CNS depressants,effect,antipsychotic agents noted BRAND may capable potentiating GROUP anesthetics opiates alcohol.
1203,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,anesthetics,effect,antipsychotic agents noted BRAND may capable potentiating CNS depressants GROUP opiates alcohol.
1204,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,opiates,effect,antipsychotic agents noted BRAND may capable potentiating CNS depressants anesthetics GROUP alcohol.
1205,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,alcohol,effect,antipsychotic agents noted BRAND may capable potentiating CNS depressants anesthetics opiates DRUG .
1206,"In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",haloperidol,rifampin,mechanism,study 12 schizophrenic patients coadministered oral DRUG DRUG plasma haloperidol levels decreased mean 70% mean scores Brief Psychiatric Rating Scale increased baseline.
1207,"In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.",rifampin,haloperidol,mechanism,5 schizophrenic patients treated oral haloperidol rifampin discontinuation DRUG produced mean 3.3 fold increase DRUG concentrations.
1208,"Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.",rifampin,haloperidol,advise,Thus careful monitoring clinical status warranted DRUG administered discontinued DRUG treated patients.
1209,apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.,diphenidol,apomorphine,effect,apomorphine prior ingestion DRUG may decrease emetic response DRUG treatment poisoning.
1210,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",doxazosin,cimetidine,mechanism,placebo controlled trial normal volunteers administration single 1 mg dose DRUG day 1 four day regimen oral DRUG (400 mg twice daily) resulted 10% increase mean AUC doxazosin (p=0.006) slight statistically significant increase mean Cmax mean half life doxazosin.
1211,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,GROUP prolong intensify anticholinergic effects GROUP .
1212,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,alcohol,effect,GROUP may additive effects DRUG CNS depressants e.g. hypnotics sedatives tranquilizers antianxiety agents.
1213,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,CNS depressants,effect,GROUP may additive effects alcohol GROUP e.g. hypnotics sedatives tranquilizers antianxiety agents.
1214,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,hypnotics,effect,GROUP may additive effects alcohol CNS depressants e.g. GROUP sedatives tranquilizers antianxiety agents.
1215,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,sedatives,effect,GROUP may additive effects alcohol CNS depressants e.g. hypnotics GROUP tranquilizers antianxiety agents.
1216,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,tranquilizers,effect,GROUP may additive effects alcohol CNS depressants e.g. hypnotics sedatives GROUP antianxiety agents.
1217,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,antianxiety agents,effect,GROUP may additive effects alcohol CNS depressants e.g. hypnotics sedatives tranquilizers GROUP .
1218,The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.,cromolyn sodium,isoproterenol,effect,addition 540 mg/kg/day DRUG (approximately 340 times maximum recommended daily inhalation dose adults mg/m2 basis) 2.7 mg/kg/day DRUG (approximately 7 times maximum recommended daily inhalation dose adults mg/m2 basis) appears increased incidence resorptions malformations.
1219,Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.,naltrexone,Acamprosate,mechanism,Co administration DRUG DRUG produced 25% increase AUC 33% increase Cmax acamprosate.
1220,"Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.",Acamprosate,antidepressants,effect,Patients taking DRUG concomitantly GROUP commonly reported weight gain weight loss compared patients taking either medication alone.
1221,All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.,vasopressors,monoamine oxidase (MAO) inhibitors,advise,GROUP used cautiously patients taking GROUP .
1222,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,sympathomimetic drugs,advise,DRUG administered concomitantly GROUP (such isoproterenol) possible additive effects increased toxicity.
1223,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,isoproterenol,advise,DRUG administered concomitantly sympathomimetic drugs (such DRUG ) possible additive effects increased toxicity.
1224,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,cyclopropane,effect,Administration DRUG patients receiving DRUG halogenated hydrocarbon general anesthetics halothane sensitize myocardium may induce cardiac arrhythmia..
1225,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halogenated hydrocarbon general anesthetics,effect,Administration DRUG patients receiving cyclopropane GROUP halothane sensitize myocardium may induce cardiac arrhythmia..
1226,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halothane,effect,Administration DRUG patients receiving cyclopropane halogenated hydrocarbon general anesthetics DRUG sensitize myocardium may induce cardiac arrhythmia..
1227,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,digitalis,advise,DRUG also used cautiously drugs (e.g. GROUP glycosides) sensitize myocardium actions sympathomimetic drugs.
1228,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,glycosides,advise,DRUG also used cautiously drugs (e.g. digitalis GROUP ) sensitize myocardium actions sympathomimetic drugs.
1229,Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.,Diuretic agents,epinephrine,effect,GROUP may decrease vascular response pressor drugs DRUG .
1230,Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.,Epinephrine,guanethidine,effect,DRUG may antagonize neuron blockade produced DRUG resulting decreased antihypertensive effect requiring increased dosage latter.
1231,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.",CANCIDAS,tacrolimus,mechanism,BRAND reduced blood AUC0 12 DRUG approximately 20% peak blood concentration (Cmax) 16% 12 hour blood concentration (C12hr) 26% healthy subjects tacrolimus (2 doses 0.1 mg/kg 12 hours apart) administered 10th day CANCIDAS 70 mg daily compared results control period tacrolimus administered alone.
1232,"In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.",cyclosporine,caspofungin,mechanism,two clinical studies DRUG (one 4 mg/kg dose two 3 mg/kg doses) increased AUC DRUG approximately 35%.
1233,There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.,CANCIDAS,cyclosporine,effect,transient increases liver ALT AST BRAND DRUG co administered.
1234,A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.,rifampin,caspofungin,mechanism,drug drug interaction study DRUG healthy volunteers shown 30% decrease DRUG trough concentrations.
1235,Patients on rifampin should receive 70 mg of CANCIDAS daily.,rifampin,CANCIDAS,advise,Patients DRUG receive 70 mg BRAND daily.
1236,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",efavirenz,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance ( DRUG nevirapine phenytoin dexamethasone carbamazepine) BRAND may result clinically meaningful reductions caspofungin concentrations.
1237,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",nevirapine,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz DRUG phenytoin dexamethasone carbamazepine) BRAND may result clinically meaningful reductions caspofungin concentrations.
1238,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",phenytoin,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz nevirapine DRUG dexamethasone carbamazepine) BRAND may result clinically meaningful reductions caspofungin concentrations.
1239,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",dexamethasone,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz nevirapine phenytoin DRUG carbamazepine) BRAND may result clinically meaningful reductions caspofungin concentrations.
1240,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",carbamazepine,CANCIDAS,mechanism,addition results regression analyses patient pharmacokinetic data suggest co administration inducers drug clearance (efavirenz nevirapine phenytoin dexamethasone DRUG ) BRAND may result clinically meaningful reductions caspofungin concentrations.
1241,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,efavirenz,advise,BRAND co administered inducers drug clearance DRUG nevirapine phenytoin dexamethasone carbamazepine use daily dose 70 mg CANCIDAS considered
1242,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,nevirapine,advise,BRAND co administered inducers drug clearance efavirenz DRUG phenytoin dexamethasone carbamazepine use daily dose 70 mg CANCIDAS considered
1243,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,phenytoin,advise,BRAND co administered inducers drug clearance efavirenz nevirapine DRUG dexamethasone carbamazepine use daily dose 70 mg CANCIDAS considered
1244,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,dexamethasone,advise,BRAND co administered inducers drug clearance efavirenz nevirapine phenytoin DRUG carbamazepine use daily dose 70 mg CANCIDAS considered
1245,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,carbamazepine,advise,BRAND co administered inducers drug clearance efavirenz nevirapine phenytoin dexamethasone DRUG use daily dose 70 mg CANCIDAS considered
1246,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased nephrotoxicity reported following concomitant administration GROUP GROUP .
1247,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,DRUG may accentuate electrolyte loss associated GROUP therapy.
1248,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,barbiturates,effect,Tablets: GROUP including lorazepam produce CNS depressant effects administered medications GROUP alcohol.
1249,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,alcohol,effect,Tablets: GROUP including lorazepam produce CNS depressant effects administered medications barbiturates DRUG .
1250,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,barbiturates,effect,Tablets: benzodiazepines including DRUG produce CNS depressant effects administered medications GROUP alcohol.
1251,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,alcohol,effect,Tablets: benzodiazepines including DRUG produce CNS depressant effects administered medications barbiturates DRUG .
1252,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,ethyl alcohol,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered DRUG phenothiazines barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1253,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,phenothiazines,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol GROUP barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1254,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,barbiturates,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines GROUP MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1255,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,MAO inhibitors,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates GROUP antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1256,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,antidepressants,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors GROUP .When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1257,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,ethyl alcohol,effect,Injection: Lorazepam injection like injectable GROUP produces depression central nervous system administered DRUG phenothiazines barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1258,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,phenothiazines,effect,Injection: Lorazepam injection like injectable GROUP produces depression central nervous system administered ethyl alcohol GROUP barbiturates MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1259,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,barbiturates,effect,Injection: Lorazepam injection like injectable GROUP produces depression central nervous system administered ethyl alcohol phenothiazines GROUP MAO inhibitors antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1260,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,MAO inhibitors,effect,Injection: Lorazepam injection like injectable GROUP produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates GROUP antidepressants.When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1261,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,antidepressants,effect,Injection: Lorazepam injection like injectable GROUP produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors GROUP .When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed.
1262,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",scopolamine,lorazepam,effect,Injection: Lorazepam injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants.When DRUG used concomitantly injectable DRUG increased incidence sedation hallucinations irrational behavior observed.
1263,(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.,Femara,tamoxifen,mechanism,(See CLINICAL PHARMACOLOGY) Coadministration BRAND DRUG 20 mg daily resulted reduction letrozole plasma levels 38% average.
1264,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,narcotic analgesics,effect,DRUG combination GROUP general anesthetics phenothiazines tranquilizers sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1265,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,anesthetics,effect,DRUG combination narcotic analgesics general GROUP phenothiazines tranquilizers sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1266,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,phenothiazines,effect,DRUG combination narcotic analgesics general anesthetics GROUP tranquilizers sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1267,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,tranquilizers,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines GROUP sedative hypnotics CNS depressants (including alcohol) additive depressant effects.
1268,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,sedative-hypnotics,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines tranquilizers GROUP CNS depressants (including alcohol) additive depressant effects.
1269,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,CNS depressants,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics GROUP (including alcohol) additive depressant effects.
1270,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,alcohol,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative hypnotics CNS depressants (including DRUG ) additive depressant effects.
1271,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,Antabuse,advise,DRUG administered caution patients receiving BRAND (disulfiram Wyeth Ayerst Laboratories).
1272,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,disulfiram,advise,DRUG administered caution patients receiving Antabuse ( DRUG Wyeth Ayerst Laboratories).
1273,"In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.",MAO inhibitor,disulfiram,effect,single study rats given high intraperitoneal doses GROUP plus DRUG experienced severe toxicity including convulsions death.
1274,Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.,Isocarboxazid,psychotropic agents,advise,Concomitant use DRUG GROUP generally recommended possible potentiating effects.
1275,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,anesthetics,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration BRAND GROUP sedatives hypnotics opioids likely lead enhancement effects.
1276,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,sedatives,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration BRAND anesthetics GROUP hypnotics opioids likely lead enhancement effects.
1277,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,hypnotics,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration BRAND anesthetics sedatives GROUP opioids likely lead enhancement effects.
1278,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,opioids,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co administration BRAND anesthetics sedatives hypnotics GROUP likely lead enhancement effects.
1279,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,anesthetic,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage BRAND concomitant GROUP sedative hypnotic opioid may required.
1280,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,sedative,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage BRAND concomitant anesthetic GROUP hypnotic opioid may required.
1281,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,hypnotic,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage BRAND concomitant anesthetic sedative GROUP opioid may required.
1282,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,opioid,advise,However due possible pharmacodynamic interactions co administered PRECEDEX reduction dosage BRAND concomitant anesthetic sedative hypnotic GROUP may required.
1283,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,Digoxin,Adenocard,effect,DRUG verapamil use may rarely associated ventricular fibrillation combined BRAND .
1284,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,verapamil,Adenocard,effect,Digoxin DRUG use may rarely associated ventricular fibrillation combined BRAND .
1285,The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.,Adenocard,digitalis,effect,use BRAND patients receiving GROUP may rarely associated ventricular fibrillation.
1286,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,methylxanthines,effect,effects DRUG antagonized GROUP caffeine theophylline.
1287,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,caffeine,effect,effects DRUG antagonized methylxanthines DRUG theophylline.
1288,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,theophylline,effect,effects DRUG antagonized methylxanthines caffeine DRUG .
1289,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,presence GROUP larger doses DRUG may required adenosine may effective.
1290,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,presence GROUP larger doses adenosine may required DRUG may effective.
1291,Adenosine effects are potentiated by dipyridamole.,Adenosine,dipyridamole,effect,DRUG effects potentiated DRUG .
1292,"Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.",adenosine,dipyridamole,effect,Thus smaller doses DRUG may effective presence DRUG .
1293,"As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.",adenosine,carbamazepine,effect,primary effect DRUG decrease conduction V node higher degrees heart block may produced presence DRUG .
1294,"ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
",ADL 8-2698,morphine,effect,DRUG trans 3 4 dimethyl 4 (3 hydroxyphenyl) piperidine prevents gastrointestinal effects intravenous DRUG without affecting analgesia.
1295,ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ,ADL-8-2698,opioid,effect,DRUG novel peripherally restricted opioid antagonist may selectively prevent GROUP induced gastrointestinal effects without reversing analgesia.
1296,Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). ,Morphine,ADL 8-2698,effect,DRUG prolonged gastrointestinal transit time 69 103 minutes (P = .005); prevented DRUG (P = .004).
1297,We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.,ADL 8-2698,morphine,effect,conclude DRUG prevents DRUG induced increases gastrointestinal transit time means selective peripheral opioid anitagonism without affecting central opioid analgesia.
1298,"Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).",cimetidine,isradipine,mechanism,Cimetidine: study healthy volunteers one week course DRUG 400 mg b.i.d. single 5 mg dose DRUG sixth day showed increase isradipine mean peak plasma concentrations (36%) significant increase area curve (50%).
1299,If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.,isradipine,cimetidine,advise,DRUG therapy initiated patient currently receiving DRUG careful monitoring adverse reactions advised downward dose adjustment may required.
1300,"Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.",rifampicin,isradipine,mechanism,Rifampicin: study healthy volunteers six day course DRUG 600 mg/day followed single 5 mg dose DRUG resulted reduction isradipine levels detectable limits.
1301,"If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.",rifampicin,isradipine,mechanism,DRUG therapy required DRUG concentrations therapeutic effects likely markedly reduced abolished consequence increased metabolism higher clearance isradipine.
1302,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,beta blocker,effect,Fentanyl Anesthesia: Severe hypotension reported DRUG anesthesia concomitant use GROUP calcium channel blocker.
1303,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,calcium channel blocker,effect,Fentanyl Anesthesia: Severe hypotension reported DRUG anesthesia concomitant use beta blocker GROUP .
1304,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",phenobarbital,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg DRUG rifampin rifabutin) would expected increase clearance DRUG resulting lowered plasma concentrations.
1305,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifampin,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg phenobarbital DRUG rifabutin) would expected increase clearance DRUG resulting lowered plasma concentrations.
1306,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifabutin,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg phenobarbital rifampin DRUG ) would expected increase clearance DRUG resulting lowered plasma concentrations.
1307,"In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.",SUSTIVA,clarithromycin,effect,uninfected volunteers 46% developed rash receiving BRAND DRUG .
1308,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.,indinavir,SUSTIVA,mechanism,Increasing indinavir dose 1000 mg every 8 hours compensate increased DRUG metabolism due BRAND .
1309,"When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.",indinavir,SUSTIVA,mechanism,DRUG increased dose (1000 mg every 8 hours) given BRAND (600 mg daily) indinavir AUC Cmin decreased average 33 46% 39 57% respectively compared indinavir (800 mg every 8 hours) given alone.
1310,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,lopinavir,SUSTIVA,advise,dose increase DRUG /ritonavir 533/133 mg (4 capsules 6.5 mL) twice daily taken food recommended used combination BRAND .
1311,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,ritonavir,SUSTIVA,advise,dose increase lopinavir/ DRUG 533/133 mg (4 capsules 6.5 mL) twice daily taken food recommended used combination BRAND .
1312,"Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.",efavirenz,contraceptives,advise,potential interaction DRUG oral GROUP fully characterized reliable method barrier contraception used addition oral contraceptives.
1313,Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.,SUSTIVA,ritonavir,advise,Monitoring liver enzymes recommended BRAND used combination DRUG .
1314,Potential for reduction in anticonvulsant and/or efavirenz plasma levels;,anticonvulsant,efavirenz,mechanism,Potential reduction GROUP and/or DRUG plasma levels;
1315,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,itraconazole,mechanism,BRAND potential decrease plasma concentrations DRUG ketoconazole.
1316,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,ketoconazole,mechanism,BRAND potential decrease plasma concentrations itraconazole DRUG .
1317,"Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.",Indinavir,amprenavir,mechanism,DRUG steady state Cmax A.C. Cmin decreased 22% 38% 27% respectively concomitant DRUG .
1318,"Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.",Saquinavir,amprenavir,mechanism,DRUG steady state Cmax A.C. Cmin increased 21% decreased 19% decreased 48% respectively concomitant DRUG .
1319,"Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.",Nelfinavir,amprenavir,mechanism,DRUG steady state Cmax A.C. Cmin increased 12% 15% 14% respectively concomitant DRUG .
1320,Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.,amprenavir,methadone,effect,Methadone: Coadministration DRUG DRUG decrease plasma levels methadone.
1321,"Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.",amprenavir,methadone,mechanism,Coadministration DRUG DRUG compared non matched historicalcontrol group resulted 30% 27% 25% decrease serum amprenavir AUC Cmax andCmin respectively.
1322,"Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",Amprenavir,ritonavir,effect,Laboratory Tests: combination DRUG low dose DRUG associated elevations cholesterol triglycerides SGOT (AST) SGPT (ALT) patients.
1323,Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.,Amprenavir,ritonavir,advise,Appropriate laboratory testing considered prior initiating combination therapy DRUG DRUG periodic intervals clinical signs symptoms hyperlipidemia elevated liver function tests occur therapy.
1324,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,DRUG may accentuate electrolyte loss associated DRUG therapy.
1325,"Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.",nifedipine,beta-blocking agents,effect,Beta adrenergic Blocking Agents: Experience 1400 patients non comparative clinical trial shown concomitant administration DRUG GROUP usually well tolerated occasional literature reports suggesting combination may increase likelihood congestive heart failure severe hypotension exacerbation angina.
1326,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,int,Digitalis: Immediate Release Capsules: Since isolated reports patients elevated digoxin levels possible interaction DRUG DRUG recommended digoxin levels monitored initiating adjusting discontinuing nifedipine avoid possible digitalization.
1327,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,Digitalis: Immediate Release Capsules: Since isolated reports patients elevated digoxin levels possible interaction digoxin nifedipine recommended DRUG levels monitored initiating adjusting discontinuing DRUG avoid possible digitalization.
1328,Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.,digoxin,digoxin,mechanism,Extended Release Tablets: Administration nifedipine DRUG increased DRUG levels 9 12 normal volunteers.
1329,"Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,Since isolated reports patients elevated digoxin levels recommended DRUG levels monitored initiating adjusting discontinuing DRUG avoid possible digitalization.
1330,Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).,quinidine,nifedipine,mechanism,Quinidine: Immediate Release Capsules: rare reports interaction DRUG DRUG (with decreased plasma level quinidine).
1331,Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.,coumarin anticoagulants,nifedipine,effect,Coumarin Anticoagulants: rare reports increased prothrombin time patients taking GROUP DRUG administered.
1332,Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.,cimetidine,nifedipine,mechanism,Cimetidine: study 6 healthy volunteers shown significant increase peak nifedipine plasma levels (80%) area curve (74%) 1 week course DRUG 1000 mg per day DRUG 40 mg per day.
1333,"If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.",nifedipine,cimetidine,advise,DRUG therapy initiated patient currently receiving DRUG cautious titration advised.
1334,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: DRUG reported reduce intestinal absorption GROUP ;
1335,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,reports shown concomitant administration GROUP GROUP causes hypercalcemia.
1336,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: GROUP dosage must determined care patients undergoing treatment GROUP hypercalcemia patients may precipitate cardiac arrhythmias.
1337,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: DRUG may inhibit synthetic catabolic enzymes GROUP .
1338,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D,corticosteroids,effect,Corticosteroids: relationship functional antagonism exists GROUP analogues promote calcium absorption GROUP inhibit calcium absorption.
1339,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,effect,Magnesium: DRUG containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy GROUP patients chronic renal dialysis.
1340,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,effect,Magnesium: Magnesium containing preparations (eg GROUP ) may cause hypermagnesemia therefore taken therapy GROUP patients chronic renal dialysis.
1341,"In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.",diflunisal,indomethacin,mechanism,normal volunteers receiving indomethacin administration DRUG decreased renal clearance significantly increased plasma levels DRUG .
1342,"In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.",INDOCIN,diflunisal,effect,patients combined use BRAND DRUG associated fatal gastrointestinal hemorrhage.
1343,"Therefore, diflunisal and INDOCIN should not be used concomitantly.",diflunisal,INDOCIN,advise,Therefore DRUG BRAND used concomitantly.
1344,"In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.",aspirin,indomethacin,mechanism,study normal volunteers found chronic concurrent administration 3.6 g BRAND per day decreases DRUG blood levels approximately 20%.
1345,"The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",INDOCIN,NSAIDs,advise,concomitant use BRAND GROUP recommended due increased possibility gastrointestinal toxicity little increase efficacy.
1346,"However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.",INDOCIN,anticoagulant,advise,However additional drug including BRAND added treatment patients GROUP therapy patients observed alterations prothrombin time.
1347,"In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.",anticoagulants,INDOCIN,effect,post marketing experience bleeding reported patients concomitant treatment GROUP BRAND .
1348,Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.,INDOCIN,anticoagulants,advise,Caution exercised BRAND GROUP administered concomitantly.
1349,"When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.",INDOCIN,probenecid,mechanism,BRAND given patients receiving DRUG plasma levels indomethacin likely increased.
1350,Caution should be used if INDOCIN is administered simultaneously with methotrexate.,INDOCIN,methotrexate,advise,Caution used BRAND administered simultaneously DRUG .
1351,INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,INDOCIN,methotrexate,mechanism,BRAND reported decrease tubular secretion DRUG potentiate toxicity.
1352,"Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",non-steroidal anti-inflammatory drugs,cyclosporine,effect,Administration GROUP concomitantly DRUG associated increase cyclosporine induced toxicity possibly due decreased synthesis renal prostacyclin.
1353,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,GROUP used caution patients taking DRUG renal function carefully monitored.
1354,Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.,INDOCIN,lithium,mechanism,Capsules BRAND 50 mg t.i.d. produced clinically relevant elevation plasma DRUG reduction renal lithium clearance psychiatric patients normal subjects steady state plasma lithium concentrations.
1355,"As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.",INDOCIN,lithium,advise,consequence BRAND DRUG given concomitantly patient carefully observed signs lithium toxicity.
1356,INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.,INDOCIN,digoxin,mechanism,BRAND given concomitantly DRUG reported increase serum concentration prolong half life digoxin.
1357,"Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.",INDOCIN,digoxin,advise,Therefore BRAND DRUG used concomitantly serum digoxin levels closely monitored.
1358,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,loop diuretics,effect,patients administration BRAND reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
1359,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,potassium-sparing diuretics,effect,patients administration BRAND reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
1360,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,thiazide diuretics,effect,patients administration BRAND reduce diuretic natriuretic antihypertensive effects loop potassium sparing GROUP .
1361,It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.,triamterene,INDOCIN,effect,reported addition DRUG maintenance schedule BRAND resulted reversible acute renal failure two four healthy volunteers.
1362,INDOCIN and triamterene should not be administered together.,INDOCIN,triamterene,advise,BRAND DRUG administered together.
1363,The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.,INDOCIN,potassium-sparing diuretics,effect,potential effects BRAND GROUP potassium kinetics renal function considered agents administered concurrently.
1364,"Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.",diuretics,INDOCIN,effect,effects concerning GROUP attributed least part mechanisms involving inhibition prostaglandin synthesis BRAND .
1365,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,non-steroidal antiinflammatory drugs,effect,Blunting antihypertensive effect GROUP GROUP including INDOCIN reported.
1366,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,INDOCIN,effect,Blunting antihypertensive effect GROUP non steroidal antiinflammatory drugs including BRAND reported.
1367,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,captopril,effect,BRAND reduce antihypertensive effects DRUG losartan.
1368,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,losartan,effect,BRAND reduce antihypertensive effects captopril DRUG .
1369,"However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. ",antiretroviral drugs,antineoplastic drugs,advise,However careful attention must directed cross toxicity possible pharmacokinetic interactions antiretroviral G GROUP .
1370,"Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).",tamoxifen,anastrozole,advise,Based clinical pharmacokinetic results ATAC trial DRUG administered DRUG (see CLINICAL PHARMACOLOGY Drug Interactions CLINICAL PHARMACOLOGY Clinical Studies Adjuvant Treatment Breast Cancer Postmenopausal Women subsections).
1371,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.,anastrozole,tamoxifen,mechanism,Co administration DRUG DRUG resulted reduction anastrozole plasma levels 27% compared achieved anastrozole alone.
1372,Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.,Estrogen,ARIMIDEX,advise,GROUP containing therapies used BRAND may diminish pharmacologic action.
1373,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",ciclesonide,ketoconazole,mechanism,another drug interaction study co administration orally inhaled DRUG oral DRUG potent inhibitor cytochrome P450 3A4 increased exposure (AUC) des ciclesonide approximately 3.6 fold steady state levels ciclesonide remained unchanged.
1374,"Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.",ketoconazole,ciclesonide,advise,Therefore DRUG administered caution intranasal DRUG .
1375,"Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.",doxylamine,CNS depressant drugs,effect,Potential drug interactions doxylamine include increased sedation DRUG combined GROUP .
1376,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,heparin,effect,GROUP may partially counteract anticoagulation effects DRUG warfarin.
1377,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,warfarin,effect,GROUP may partially counteract anticoagulation effects heparin DRUG .
1378,Doxylamine may enhance the effects of epinephrine.,Doxylamine,epinephrine,effect,DRUG may enhance effects DRUG .
1379,The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.,NSAIDs,ACE inhibitors,effect,use GROUP patients receiving GROUP may potentiate renal disease states.
1380,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,Concomitant administration DRUG BRAND recommended naproxen displaced binding sites concomitant administration aspirin resulting lower plasma concentrations peak plasma levels.
1381,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,Concomitant administration naproxen aspirin recommended DRUG displaced binding sites concomitant administration BRAND resulting lower plasma concentrations peak plasma levels.
1382,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,propranolol,effect,DRUG NSAIDs reduce antihypertensive effect DRUG beta blockers.
1383,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,beta-blockers,effect,DRUG NSAIDs reduce antihypertensive effect propranolol GROUP .
1384,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,propranolol,effect,Naproxen GROUP reduce antihypertensive effect DRUG beta blockers.
1385,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,beta-blockers,effect,Naproxen GROUP reduce antihypertensive effect propranolol GROUP .
1386,Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.,Probenecid,naproxen,mechanism,DRUG given concurrently increases DRUG anion plasma levels extends plasma half life significantly.
1387,Caution should be used if naproxen is administered concomitantly with methotrexate.,naproxen,methotrexate,advise,Caution used DRUG administered concomitantly DRUG .
1388,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",Naproxen,methotrexate,mechanism,DRUG naproxen sodium NSAIDs reported reduce tubular secretion DRUG animal model possibly increasing toxicity methotrexate.
1389,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",naproxen sodium,methotrexate,mechanism,Naproxen DRUG NSAIDs reported reduce tubular secretion DRUG animal model possibly increasing toxicity methotrexate.
1390,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",NSAIDs,methotrexate,mechanism,Naproxen naproxen sodium GROUP reported reduce tubular secretion DRUG animal model possibly increasing toxicity methotrexate.
1391,"If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.",CEFOTAN,aminoglycoside,effect,BRAND GROUP used concomitantly renal function carefully monitored nephrotoxicity may potentiated.
1392,Colchicine is inhibited by acidifying agents.,Colchicine,acidifying agents,mechanism,DRUG inhibited GROUP .
1393,The action of colchicine is potentiated by alkalinizing agents.,colchicine,alkalinizing agents,mechanism,action DRUG potentiated GROUP .
1394,Colchicine may increase sensitivity to the CNS depressants.,Colchicine,CNS depressants,effect,DRUG may increase sensitivity GROUP .
1395,Response to sympathomimetic agents may be enhanced by colchicine.,sympathomimetic agents,colchicine,effect,Response GROUP may enhanced DRUG .
1396,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,diazepam,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas DRUG_N (1 mg/kg) removes antiedematous action DRUG phenazepam phenibut amizyl reduces action phentolamine.
1397,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phenazepam,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas DRUG_N (1 mg/kg) removes antiedematous action diazepam DRUG_N phenibut amizyl reduces action phentolamine.
1398,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phenibut,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas DRUG_N (1 mg/kg) removes antiedematous action diazepam phenazepam DRUG_N amizyl reduces action phentolamine.
1399,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,amizyl,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas DRUG_N (1 mg/kg) removes antiedematous action diazepam phenazepam phenibut DRUG_N reduces action phentolamine.
1400,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phentolamine,effect,[The GABA ergic system brain edema] shown rats experimental toxic traumatic edemas DRUG_N (1 mg/kg) removes antiedematous action diazepam phenazepam phenibut amizyl reduces action DRUG .
1401,"Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.",Anagrelide,aspirin,effect,DRUG alone effect platelet aggregation slightly enhance inhibition platelet aggregation BRAND .
1402,"It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.",fluvoxamine,anagrelide,mechanism,known CYP1A2 inhibited several medicinal products including DRUG medicinal products could theoretically adversely influence clearance DRUG .
1403,Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.,Anagrelide,theophylline,mechanism,DRUG demonstrates limited inhibitory activity towards CYP1A2 may present theoretical potential interaction coadministered medicinal products sharing clearance mechanism e.g. DRUG .
1404,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",milrinone,anagrelide,effect,effects medicinal products similar properties inotropes DRUG enoximone amrinone olprinone cilostazol may exacerbated DRUG .
1405,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",enoximone,anagrelide,effect,effects medicinal products similar properties inotropes milrinone DRUG amrinone olprinone cilostazol may exacerbated DRUG .
1406,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",amrinone,anagrelide,effect,effects medicinal products similar properties inotropes milrinone enoximone DRUG olprinone cilostazol may exacerbated DRUG .
1407,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",olprinone,anagrelide,effect,effects medicinal products similar properties inotropes milrinone enoximone amrinone DRUG_N cilostazol may exacerbated DRUG .
1408,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",cilostazol,anagrelide,effect,effects medicinal products similar properties inotropes milrinone enoximone amrinone olprinone DRUG may exacerbated DRUG .
1409,"There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.",sucralfate,anagrelide,mechanism,single case report suggests DRUG may interfere DRUG absorption.
1410,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,non-depolarising muscle relaxant,effect,BRAND augments action GROUP muscle relaxant effects aminoglycosides.
1411,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,aminoglycosides,effect,BRAND augments action non depolarising muscle relaxants muscle relaxant effects GROUP .
1412,FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.,FLUOTHANE,tubocurarine,effect,BRAND may augment hypotension caused ganglionic blocking effect DRUG .
1413,Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.,adrenaline,FLUOTHANE,advise,Caution exercised administration DRUG patients anaesthetised BRAND arrhythmias may precipitated.
1414,"Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects",Accutane,vitamin A,effect,Vitamin A: relationship BRAND GROUP patients advised taking vitamin supplements containing vitamin avoid additive toxic effects
1415,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,advise,Tetracyclines: Concomitant treatment BRAND GROUP avoided Accutane use associated number cases pseudotumor cerebri (benign intracranial hypertension) involved concomitant use tetracyclines
1416,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,effect,Tetracyclines: Concomitant treatment Accutane tetracyclines avoided BRAND use associated number cases pseudotumor cerebri (benign intracranial hypertension) involved concomitant use GROUP
1417,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.,progesterone,Accutane,effect,Micro dosed Progesterone Preparations: Micro dosed DRUG preparations (minipills contain estrogen) may inadequate method contraception BRAND therapy.
1418,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking,effect,Catecholamine depleting drugs (e.g. DRUG ) may additive effect given DRUG agents.
1419,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blockers,clonidine,advise,decided discontinue therapy patients receiving GROUP DRUG concurrently beta blocker discontinued slowly several days gradual withdrawal clonidine.
1420,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blocker,clonidine,advise,decided discontinue therapy patients receiving beta blockers clonidine concurrently GROUP discontinued slowly several days gradual withdrawal DRUG .
1421,"Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.",calcium antagonists,beta-adrenergic blocking agents,advise,Literature reports suggest oral GROUP may used combination GROUP heart function normal avoided patients impaired cardiac function.
1422,"Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.",beta-adrenergic blocking agents,calcium antagonist,effect,Hypotension AV conduction disturbances left ventricular failure reported patients receiving GROUP oral GROUP added treatment regimen.
1423,"Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",beta-blockers,epinephrine,effect,Risk Anaphylactic Reaction: Although known patients GROUP may refractory DRUG treatment anaphylactic shock beta blockers addition interfere modulation allergic reaction lead increased severity and/or frequency attacks.
1424,The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.,guanfacine,CNS-depressant drug,effect,potential increased sedation DRUG given GROUP appreciated.
1425,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenobarbital,mechanism,administration DRUG concomitantly known microsomal enzyme inducer ( DRUG phenytoin) two patients renal impairment reportedly resulted significant reductions elimination half life plasma concentration.
1426,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenytoin,mechanism,administration DRUG concomitantly known microsomal enzyme inducer (phenobarbital DRUG ) two patients renal impairment reportedly resulted significant reductions elimination half life plasma concentration.
1427,TCAs decrease the hypotensive effect of guanfacine.,TCAs,guanfacine,effect,GROUP decrease hypotensive effect DRUG .
1428,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",Noncardioselective beta-blockers,guanfacine,effect,GROUP (nadolol porpranolol timolol) may exacerbate rebound hypertension DRUG withdrawn.
1429,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",nadolol,guanfacine,effect,Noncardioselective beta blockers ( DRUG porpranolol timolol) may exacerbate rebound hypertension DRUG withdrawn.
1430,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",timolol,guanfacine,effect,Noncardioselective beta blockers (nadolol porpranolol DRUG ) may exacerbate rebound hypertension DRUG withdrawn.
1431,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",METH,SCH-23390,effect,Using situ hybridization observed DRUG caused rapid transient dose dependent increase arc mRNA level striatum cortex abolished pretreatment specific dopamine D1 receptor antagonist DRUG_N atypical neuroleptic clozapine.
1432,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,however 150 mg DRUG q12h 3 days increased DRUG C max 23% ceftibuten AUC 16%.
1433,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,however 150 mg DRUG q12h 3 days increased ceftibuten C max 23% DRUG AUC 16%.
1434,FLEXERIL may have life-threatening interactions with MAO inhibitors.,FLEXERIL,MAO inhibitors,int,BRAND may life threatening interactions GROUP .
1435,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,alcohol,effect,BRAND may enhance effects DRUG barbiturates CNS depressants.
1436,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,barbiturates,effect,BRAND may enhance effects alcohol GROUP CNS depressants.
1437,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,CNS depressants,effect,BRAND may enhance effects alcohol barbiturates GROUP .
1438,Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.,Tricyclic antidepressants,guanethidine,effect,GROUP may block antihypertensive action DRUG similarly acting compounds.
1439,Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol,Tricyclic antidepressants,tramadol,effect,GROUP may enhance seizure risk patients taking DRUG
1440,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,Urinary acidifying agents agents ( DRUG sodium acid phosphate etc.) increase concentration ionized species DRUG molecule thereby increasing urinary excretion.
1441,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,Urinary acidifying agents agents (ammonium chloride DRUG etc.) increase concentration ionized species DRUG molecule thereby increasing urinary excretion.
1442,Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic blockers GROUP inhibited GROUP .
1443,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,tricyclic antidepressants,effect,Antidepressants tricyclic GROUP may enhance activity DRUG sympathomimetic agents;
1444,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,Antidepressants tricyclic GROUP may enhance activity tricyclic antidepressants GROUP ;
1445,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,DRUG DRUG protriptyline possibly tricyclics cause striking sustained increases concentration amphetamine brain;
1446,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,DRUG desipramine DRUG possibly tricyclics cause striking sustained increases concentration amphetamine brain;
1447,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,DRUG desipramine protriptyline possibly GROUP cause striking sustained increases concentration amphetamine brain;
1448,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,MAO inhibitors GROUP well metabolite furazolidone slow DRUG metabolism.
1449,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,MAO inhibitors MAOI antidepressants well metabolite DRUG slow DRUG metabolism.
1450,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines: GROUP may counteract sedative effect GROUP .
1451,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives: GROUP may antagonize hypotensive effects DRUG .
1452,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,Chlorpromazine: DRUG blocks dopamine norepinephrine receptors thus inhibiting central stimulant effects GROUP used treat amphetamine poisoning.
1453,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide: GROUP may delay intestinal absorption DRUG .
1454,"Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,Haloperidol: DRUG blocks dopamine receptors thus inhibiting central stimulant effects GROUP .
1455,Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium carbonate: anorectic stimulatory effects GROUP may inhibited DRUG .
1456,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine: GROUP potentiate analgesic effect DRUG .
1457,"Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.",amphetamines,methenamine,mechanism,Methenamine therapy Urinary excretion GROUP increased efficacy reduced acidifying agents used DRUG therapy.
1458,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine: GROUP enhance adrenergic effect DRUG .
1459,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital: GROUP may delay intestinal absorption DRUG ;
1460,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin: GROUP may delay intestinal absorption DRUG ;
1461,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,Propoxyphene: cases DRUG overdosage DRUG CNS stimulation potentiated fatal convulsions occur.
1462,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum alkaloids: GROUP inhibit hypotensive effect GROUP .
1463,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",Intestinal adsorbents,Acarbose,mechanism,GROUP (e. g. charcoal) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. amylase pancreatin) may reduce effect DRUG taken concomitantly.
1464,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",charcoal,Acarbose,mechanism,Intestinal adsorbents (e. g. DRUG ) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. amylase pancreatin) may reduce effect DRUG taken concomitantly.
1465,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",amylase,Acarbose,mechanism,Intestinal adsorbents (e. g. charcoal) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. DRUG pancreatin) may reduce effect DRUG taken concomitantly.
1466,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",pancreatin,Acarbose,mechanism,Intestinal adsorbents (e. g. charcoal) digestive enzyme preparations containing carbohydrate splitting enzymes (e. g. amylase DRUG ) may reduce effect DRUG taken concomitantly.
1467,"Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.",Acarbose,digoxin,mechanism,DRUG shown change bioavailabillty DRUG co administered may require digoxin dose adjustment.
1468,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",metformin,Acarbose,mechanism,However peak plasma level DRUG reduced approximately 20% taking DRUG due slight delay absorption metformin.
1469,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",Acarbose,metformin,mechanism,However peak plasma level metformin reduced approximately 20% taking DRUG due slight delay absorption DRUG .
1470,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,carbachol,effect,DRUG may interfere anti glaucoma action DRUG pilocarpine;
1471,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,pilocarpine,effect,DRUG may interfere anti glaucoma action carbachol DRUG ;
1472,A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.,amiodarone,indinavir,mechanism,case report one patient taking DRUG 200 mg DRUG 800 mg three times day resulted increases amiodarone concentrations 0.9 mg/L 1.3 mg/L.
1473,Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.,amiodarone,protease inhibitor,advise,Monitoring amiodarone toxicity serial measurement DRUG serum concentration concomitant GROUP therapy considered.
1474,Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.,Histamine H2 antagonists,Cimetidine,mechanism,GROUP : DRUG inhibits CYP3A4 increase serum amiodarone levels.
1475,"On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.",amiodarone,digitalis,advise,administration oral DRUG need GROUP therapy reviewed dose reduced approximately 50% discontinued.
1476,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",Nafazodone,Xanax,advise,DRUG fluvoxamine cimetidine (consider BRAND dose reduction).
1477,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",fluvoxamine,Xanax,advise,Nafazodone DRUG cimetidine (consider BRAND dose reduction).
1478,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",cimetidine,Xanax,advise,Nafazodone fluvoxamine DRUG (consider BRAND dose reduction).
1479,Concomitant use of calcium supplements and L-lysine may increase calcium absorption,calcium,L-lysine,mechanism,Concomitant use DRUG supplements DRUG may increase calcium absorption
1480,Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.,sympathomimetic amines,monoamine oxidase inhibitors,effect,Hypertensive crises resulted GROUP used concomitantly within14 days following use GROUP .
1481,DIDREX should not be used concomitantly with other CNS stimulants.,DIDREX,CNS stimulants,advise,BRAND used concomitantly GROUP .
1482,Amphetamines may decrease the hypotensive effect of antihypertensives.,Amphetamines,antihypertensives,effect,GROUP may decrease hypotensive effect GROUP .
1483,Amphetamines may enhance the effects of tricyclic antidepressants.,Amphetamines,tricyclic antidepressants,effect,GROUP may enhance effects GROUP .
1484,Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.,Urinary acidifying,amphetamines,mechanism,DRUG agents decrease blood levels increase excretion GROUP .
1485,"In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.",labetalol HCl,tricyclic antidepressants,effect,one survey 2.3% patients taking DRUG combination GROUP experienced tremor compared 0.7% reported occur labetalol HCl alone.
1486,Cimetidine has been shown to increase the bioavailability of labetalol HCl.,Cimetidine,labetalol HCl,mechanism,DRUG shown increase bioavailability DRUG .
1487,Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.,halothane,labetalol HCl,effect,Synergism shown DRUG anesthesia intravenously administered DRUG .
1488,"During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.",labetalol HCl,halothane,effect,controlled hypotensive anesthesia using DRUG association DRUG high concentrations (3% above) halothane used degree hypotension increased possibility large reduction cardiac output increase central venous pressure.
1489,Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.,Labetalol HCl,nitroglycerin,effect,DRUG blunts reflex tachycardia produced DRUG without preventing hypotensive effect.
1490,"If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.",labetalol HCl,nitroglycerin,effect,DRUG used DRUG patients angina pectoris additional antihypertensive effects may occur.
1491,Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.,labetalol,calcium antagonist,advise,Care taken DRUG used concomitantly GROUP verapamil type.
1492,These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.,lead,alcohol,effect,results suggest exposure environmental DRUG_N may alter biological behavioral responsiveness animal DRUG .
1493,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing DRUG norepinephrine patients receiving GROUP tricyclic antidepressants may produce severe prolonged hypertension.
1494,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors GROUP may produce severe prolonged hypertension.
1495,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine DRUG patients receiving GROUP tricyclic antidepressants may produce severe prolonged hypertension.
1496,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors GROUP may produce severe prolonged hypertension.
1497,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,GROUP butyrophenones may reduce reverse pressor effect DRUG .
1498,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines GROUP may reduce reverse pressor effect DRUG .
1499,Apraclonidine should not be used in patients receiving MAO inhibitors..,Apraclonidine,MAO inhibitors,advise,DRUG used patients receiving GROUP ..
1500,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,CNS depressants,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies BRAND 0.5% Ophthalmic Solution possibility additive potentiating effect GROUP (alcohol barbiturates opiates sedatives anesthetics) considered.
1501,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,alcohol,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies BRAND 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants ( DRUG barbiturates opiates sedatives anesthetics) considered.
1502,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,barbiturates,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies BRAND 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol GROUP opiates sedatives anesthetics) considered.
1503,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,opiates,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies BRAND 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates GROUP sedatives anesthetics) considered.
1504,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,sedatives,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies BRAND 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates GROUP anesthetics) considered.
1505,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,anesthetics,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies BRAND 0.5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives GROUP ) considered.
1506,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.,Tricyclic antidepressants,clonidine,effect,GROUP reported blunt hypotensive effect systemic DRUG .
1507,An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.,clonidine,neuroleptic,effect,additive hypotensive effect reported combination systemic DRUG GROUP therapy.
1508,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,beta-blockers,advise,Since DRUG may reduce pulse blood pressure caution using drugs GROUP (ophthalmic systemic) antihypertensives cardiac glycosides advised.
1509,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,antihypertensives,advise,Since DRUG may reduce pulse blood pressure caution using drugs beta blockers (ophthalmic systemic) GROUP cardiac glycosides advised.
1510,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,cardiac glycosides,advise,Since DRUG may reduce pulse blood pressure caution using drugs beta blockers (ophthalmic systemic) antihypertensives GROUP advised.
1511,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip,anticoagulants of the coumarin type,effect,Bezalip Bezalip retard used time medicines substances following interactions must taken account: BRAND Bezalip retard may enhance action GROUP .
1512,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip retard,anticoagulants of the coumarin type,effect,Bezalip Bezalip retard used time medicines substances following interactions must taken account: Bezalip BRAND may enhance action GROUP .
1513,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,reason dose DRUG reduced 30 50% start treatment BRAND Bezalip retard titrated according blood clotting parameters
1514,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,reason dose DRUG reduced 30 50% start treatment Bezalip BRAND retard titrated according blood clotting parameters
1515,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip,effect,action GROUP insulin may enhanced BRAND Bezalip retard.
1516,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip retard,effect,action GROUP insulin may enhanced Bezalip BRAND .
1517,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip,effect,action sulphonylureas DRUG may enhanced BRAND Bezalip retard.
1518,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip retard,effect,action sulphonylureas DRUG may enhanced Bezalip BRAND .
1519,"- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.",immuno-suppressant,bezafibrate,effect,isolated cases pronounced though reversible impairment renal function (accompanied corresponding increase serum creatinine level) reported organ transplant patients receiving GROUP therapy concomitant DRUG .
1520,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,anion-exchange resins,advise,BRAND Bezalip retard used concurrently GROUP (e.g. cholestryramine) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1521,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,cholestryramine,advise,BRAND Bezalip retard used concurrently anion exchange resins (e.g. DRUG ) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1522,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,anion-exchange resins,advise,Bezalip BRAND used concurrently GROUP (e.g. cholestryramine) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1523,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,cholestryramine,advise,Bezalip BRAND used concurrently anion exchange resins (e.g. DRUG ) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1524,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip,advise,DRUG MAO inhibitors (with hepatotoxic potential) must administered together BRAND Bezalip retard.
1525,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip retard,advise,DRUG MAO inhibitors (with hepatotoxic potential) must administered together Bezalip BRAND .
1526,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip,advise,Perhexiline hydrogen maleate GROUP (with hepatotoxic potential) must administered together BRAND Bezalip retard.
1527,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip retard,advise,Perhexiline hydrogen maleate GROUP (with hepatotoxic potential) must administered together Bezalip BRAND .
1528,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitric oxide donor compounds,INOmax,effect,Although study data evaluate possibility GROUP including sodium nitroprusside nitroglycerin may additive effect BRAND risk developing methemoglobinemia.
1529,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",sodium nitroprusside,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds including DRUG nitroglycerin may additive effect BRAND risk developing methemoglobinemia.
1530,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitroglycerin,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds including sodium nitroprusside DRUG may additive effect BRAND risk developing methemoglobinemia.
1531,Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.,ketoconazole,budesonide,mechanism,Concomitant oral administration DRUG (a known inhibitor CYP3A4 activity liver intestinal mucosa) caused eight fold increase systemic exposure oral DRUG .
1532,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ketoconazole,budesonide,advise,treatment inhibitors CYP3A4 activity (such DRUG intraconazole ritonavir indinavir saquinavir erythromycin etc.) indicated reduction DRUG dose considered.
1533,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",intraconazole,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole DRUG ritonavir indinavir saquinavir erythromycin etc.) indicated reduction DRUG dose considered.
1534,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ritonavir,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole DRUG indinavir saquinavir erythromycin etc.) indicated reduction DRUG dose considered.
1535,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",indinavir,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir DRUG saquinavir erythromycin etc.) indicated reduction DRUG dose considered.
1536,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",saquinavir,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir indinavir DRUG erythromycin etc.) indicated reduction DRUG dose considered.
1537,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",erythromycin,budesonide,advise,treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir indinavir saquinavir DRUG etc.) indicated reduction DRUG dose considered.
1538,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,warfarin-type anticoagulants,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism GROUP phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1539,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,phenytoin,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants DRUG propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1540,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,propranolol,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin DRUG nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1541,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,nifedipine,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol DRUG chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1542,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,chlordiazepoxide,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine DRUG diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1543,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,diazepam,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide DRUG certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1544,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,tricyclic antidepressants,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain GROUP lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1545,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,lidocaine,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants DRUG theophylline metronidazole thereby delaying elimination increasing blood levels drugs.
1546,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,theophylline,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine DRUG metronidazole thereby delaying elimination increasing blood levels drugs.
1547,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,metronidazole,mechanism,BRAND apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline DRUG thereby delaying elimination increasing blood levels drugs.
1548,"therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.",anticoagulant,Tagamet,advise,therefore close monitoring prothrombin time recommended adjustment GROUP dose may necessary BRAND administered concomitantly.
1549,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,theophylline,mechanism,However crossover study healthy subjects receiving either BRAND 300 mg q.i.d. 800 mg h.s. concomitantly 300 mg b.i.d. dosage DRUG (Theo Dur Key Pharmaceuticals Inc.) demonstrated less alteration steady state theophylline peak serum levels 800 mg h.s. regimen particularly subjects aged 54 years older.
1550,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,Theo-Dur,mechanism,However crossover study healthy subjects receiving either BRAND 300 mg q.i.d. 800 mg h.s. concomitantly 300 mg b.i.d. dosage theophylline ( BRAND Key Pharmaceuticals Inc.) demonstrated less alteration steady state theophylline peak serum levels 800 mg h.s. regimen particularly subjects aged 54 years older.
1551,"Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.",ELLENCE,calcium channel blockers,advise,Concomitant use BRAND cardioactive compounds could cause heart failure (e.g. GROUP ) requires close monitoring cardiac function throughout treatment.
1552,Cimetidine increased the AUC of epirubicin by 50%.,Cimetidine,epirubicin,mechanism,DRUG increased AUC DRUG 50%.
1553,Cimetidine treatment should be stopped during treatment with ELLENCE.,Cimetidine,ELLENCE,advise,DRUG treatment stopped treatment BRAND .
1554,MAO inhibitors prolong and intensify the effects of antihistamines.,MAO inhibitors,antihistamines,effect,GROUP prolong intensify effects GROUP .
1555,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,alcohol,effect,Concomitant use GROUP DRUG tricyclic antidepressants barbiturates central nervous system depressants may additive effect.
1556,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,tricyclic antidepressants,effect,Concomitant use GROUP alcohol GROUP barbiturates central nervous system depressants may additive effect.
1557,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,barbiturates,effect,Concomitant use GROUP alcohol tricyclic antidepressants GROUP central nervous system depressants may additive effect.
1558,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,central nervous system depressants,effect,Concomitant use GROUP alcohol tricyclic antidepressants barbiturates GROUP may additive effect.
1559,"When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.",sympathomimetic drugs,monoamine oxidase inhibitors,effect,GROUP given patients receiving GROUP hypertensive reactions including hypertensive crises may occur.
1560,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",methyldopa,sympathomimetics,effect,antihypertensive effects DRUG mecamylamine reserpine veratrum alkaloids may reduced GROUP .
1561,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",mecamylamine,sympathomimetics,effect,antihypertensive effects methyldopa DRUG reserpine veratrum alkaloids may reduced GROUP .
1562,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",reserpine,sympathomimetics,effect,antihypertensive effects methyldopa mecamylamine DRUG veratrum alkaloids may reduced GROUP .
1563,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",veratrum alkaloids,sympathomimetics,effect,antihypertensive effects methyldopa mecamylamine reserpine DRUG may reduced GROUP .
1564,Beta-adrenergic blocking agents may also interact with sympathomimetics.,Beta-adrenergic blocking agents,sympathomimetics,int,GROUP may also interact GROUP .
1565,Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.,pseudoephedrine,digitalis,effect,Increased ectopic pacemaker activity occur DRUG used concomitantly GROUP .
1566,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",Antacids,pseudoephedrine,mechanism,GROUP increase rate absorption DRUG kaolin decreases it.
1567,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",pseudoephedrine,kaolin,mechanism,Antacids increase rate absorption DRUG DRUG decreases it.
1568,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,int,DRUG interact DRUG CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1569,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,int,DRUG interact alcohol GROUP (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1570,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,int,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) GROUP medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1571,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,int,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) GROUP (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1572,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).",TAXOL,cisplatin,effect,Phase trial using escalating doses TAXOL (110 200 mg/m2) cisplatin (50 75 mg/m2) given sequential infusions myelosuppression profound BRAND given DRUG alternate sequence (ie TAXOL cisplatin).
1573,Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.,TAXOL,cisplatin,mechanism,Pharmacokinetic data patients demonstrated decrease paclitaxel clearance approximately 33% BRAND administered following DRUG .
1574,Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.,paclitaxel,doxorubicin,mechanism,Reports literature suggest plasma levels doxorubicin (and active metabolite doxorubicinol) may increased DRUG DRUG used combination.
1575,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",cyclosporin,TAXOL,advise,Hypersensitivity Reactions: Patients history severe hypersensitivity reactions products containing Cremophor EL (eg DRUG injection concentrate teniposide injection concentrate) treated BRAND .
1576,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",teniposide,TAXOL,advise,Hypersensitivity Reactions: Patients history severe hypersensitivity reactions products containing Cremophor EL (eg cyclosporin injection concentrate DRUG injection concentrate) treated BRAND .
1577,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including GROUP azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1578,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,azoles,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents GROUP drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1579,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound GROUP sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1580,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates GROUP chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1581,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides DRUG probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1582,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol DRUG coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
1583,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid GROUP monoamine oxidase inhibitors beta adrenergic blocking agents.
1584,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins GROUP beta adrenergic blocking agents.
1585,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,Immediate Extended Release Tablets hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors GROUP .
1586,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,int,potential interaction oral DRUG oral GROUP leading severe hypoglycemia reported.
1587,The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.,fluconazole,glipizide,int,effect concomitant administration DRUG DRUG demonstrated placebo controlled crossover study normal volunteers.
1588,The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).,glipizide,fluconazole,mechanism,mean percentage increase DRUG AUC DRUG administration 56.9% (range: 35 81).
1589,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",barbiturates,contraceptives,effect,Interactions may occur following: adrenocorticoids (cortisone like medicine) anticoagulants (blood thinners) carbamazepine corticotropin (barbiturates may decrease effects medicines) central nervous system (CNS) depressants (using medicines barbiturates may result increased CNS depressant effects) divalproex sodium valproic acid (using medicines barbiturates may change amount either medicine need take) oral contraceptives containing estrogens ( GROUP may decrease effectiveness oral GROUP may need change different type birth control).
1590,ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,ACE inhibitors Reports suggest GROUP may diminish antihypertensive effect GROUP .
1591,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.,NSAIDs,ACE-inhibitors,advise,interaction given consideration patients taking GROUP concomitantly GROUP .
1592,"Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.",Lodine,aspirin,mechanism,Aspirin: BRAND administered BRAND protein binding reduced although clearance free etodolac altered.
1593,"however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.",Lodine,aspirin,advise,however NSAIDs concomitant administration BRAND BRAND generally recommended potential increased adverse effects.
1594,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,cyclosporine,mechanism,Cyclosporine Digoxin Methotrexate BRAND like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels DRUG digoxin methotrexate increased toxicity.
1595,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,digoxin,mechanism,Cyclosporine Digoxin Methotrexate BRAND like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine DRUG methotrexate increased toxicity.
1596,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,methotrexate,mechanism,Cyclosporine Digoxin Methotrexate BRAND like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin DRUG increased toxicity.
1597,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,cyclosporine,mechanism,Cyclosporine Digoxin Methotrexate Lodine like GROUP effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels DRUG digoxin methotrexate increased toxicity.
1598,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,digoxin,mechanism,Cyclosporine Digoxin Methotrexate Lodine like GROUP effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine DRUG methotrexate increased toxicity.
1599,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,methotrexate,mechanism,Cyclosporine Digoxin Methotrexate Lodine like GROUP effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin DRUG increased toxicity.
1600,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,furosemide,effect,Nevertheless clinical studies well postmarketing observations shown BRAND reduce natriuretic effect DRUG thiazides patients.
1601,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,thiazides,effect,Nevertheless clinical studies well postmarketing observations shown BRAND reduce natriuretic effect furosemide GROUP patients.
1602,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: GROUP produced elevation plasma DRUG levels reduction renal lithium clearance.
1603,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,effect,Thus GROUP DRUG administered concurrently subjects observed carefully signs lithium toxicity.
1604,Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.,Phenylbutazone,etodolac,mechanism,Phenylbutazone: DRUG causes increase (by 80%) free fraction DRUG .
1605,"Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.",etodolac,phenylbutazone,advise,Although vivo studies done see DRUG clearance changed coadministration DRUG recommended coadministered.
1606,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.",warfarin,NSAIDs,effect,Warfarin: effects DRUG GROUP GI bleeding synergistic users drugs together risk serious GI bleeding higher users either drug alone.
1607,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,Lodine,mechanism,Short term pharmacokinetic studies demonstrated concomitant administration DRUG BRAND (etodolac capsules tablets) results reduced protein binding warfarin change clearance free warfarin.
1608,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,etodolac,mechanism,Short term pharmacokinetic studies demonstrated concomitant administration DRUG Lodine ( DRUG capsules tablets) results reduced protein binding warfarin change clearance free warfarin.
1609,"However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.",etodolac,warfarin,effect,However caution exercised spontaneous reports prolonged prothrombin times without bleeding DRUG treated patients receiving concomitant DRUG therapy.
1610,"In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.",aspirin,nizatidine,mechanism,patients given high doses (3900 mg) BRAND daily increases serum salicylate levels seen DRUG 150 mg b.i.d. administered concurrently.
1611,Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ,ethanol,disulfiram,effect,Core temperature decreased rats dose dependent manner DRUG administered rats treated DRUG 8 hours ethanol challenge.
1612,"Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ",Acetaminophen,theophylline,mechanism,DRUG diminished binding DRUG human serum net change 5.7% (percentage increase free drug fraction [FDF] 11.0%) 662 micromol/L net change 7.1% (percentage increase FDF 13.7%) 1324 micromol/L.
1613,"Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; ",Theophylline,acetaminophen,mechanism,DRUG decreased binding DRUG net change 6.8% (percentage increase FDF 8.8%) 277.5 micromol/L;
1614,"Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. ",Valproic acid,phenobarbital,mechanism,DRUG diminished binding DRUG net change 9.9% (percentage increase FDF 21.2%) 1732 micromol/L.
1615,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",acetaminophen,theophylline,effect,Coingestion DRUG DRUG phenobarbital acetaminophen valproic acid phenobarbital high toxic concentrations decreases binding target drug.
1616,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",phenobarbital,acetaminophen,effect,Coingestion acetaminophen theophylline DRUG DRUG valproic acid phenobarbital high toxic concentrations decreases binding target drug.
1617,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",valproic acid,phenobarbital,effect,Coingestion acetaminophen theophylline phenobarbital acetaminophen DRUG DRUG high toxic concentrations decreases binding target drug.
1618,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,CNS depressants,effect,Additive CNS depression may occur GROUP administered concomitantly GROUP including barbiturates tranquilizers alcohol.
1619,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,barbiturates,effect,Additive CNS depression may occur GROUP administered concomitantly CNS depressants including GROUP tranquilizers alcohol.
1620,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,tranquilizers,effect,Additive CNS depression may occur GROUP administered concomitantly CNS depressants including barbiturates GROUP alcohol.
1621,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,alcohol,effect,Additive CNS depression may occur GROUP administered concomitantly CNS depressants including barbiturates tranquilizers DRUG .
1622,Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.,antihistamines,CNS depressant drugs,advise,Patients receiving GROUP advised concurrent use GROUP .
1623,Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.,Monoamine oxidase (MAO) inhibitors,antihistamines,effect,GROUP prolong intensify anticholinergic effects GROUP .
1624,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,sympathomimetic,effect,Administration DRUG patients receiving GROUP monoamine oxidase inhibiting drugs may result additive pressor effect .
1625,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,monoamine oxidase inhibiting drugs,effect,Administration DRUG patients receiving sympathomimetic GROUP may result additive pressor effect .
1626,"In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.",doxapram,muscle relaxant drugs,effect,patients received muscle relaxants DRUG may temporarily mask residual effects GROUP .
1627,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,ERGOMAR,triacetyloleandomycin,mechanism,effects BRAND may potentiated DRUG inhibits metabolism ergotamine.
1628,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,triacetyloleandomycin,ergotamine,mechanism,effects ERGOMAR may potentiated DRUG inhibits metabolism DRUG .
1629,The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.,ERGOMAR,vasoconstrictor drugs,effect,pressor effects BRAND GROUP combine cause dangerous hypertension.
1630,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",xanthine bronchodilators,sympathomimetic bronchodilators,effect,Synergism GROUP (e.g. theophylline) ephedrine GROUP reported.
1631,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",theophylline,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators (e.g. DRUG ) ephedrine GROUP reported.
1632,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",ephedrine,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators (e.g. theophylline) DRUG GROUP reported.
1633,"Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .",dyphylline,probenecid,mechanism,Concurrent administration DRUG DRUG competes tubular secretion shown increase plasma half life dyphylline .
1634,"However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.",carbonic anhydrase inhibitors,salicylate,int,However patients treated oral GROUP rare instances drug interactions occurred high dose DRUG therapy.
1635,Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.,levetiracetam,AEDs,mechanism,Effect AEDs Pediatric Patients 22% increase apparent total body clearance DRUG co administered enzyme inducing GROUP .
1636,"When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.",probenecid,ertapenem,mechanism,ertapenem co administered probenecid (500 mg p.o. every 6 hours) DRUG competes active tubular secretion reduces renal clearance DRUG .
1637,"Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.",ertapenem,probenecid,mechanism,Based total DRUG concentrations DRUG increased AUC 25% reduced plasma renal clearances 20% 35% respectively.
1638,"Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.",probenecid,ertapenem,advise,small effect half life coadministration DRUG extend half life DRUG recommended.
1639,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",ketoconazole,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 DRUG itraconazole erythromycin gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma DRUG concentrations.
1640,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",itraconazole,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 ketoconazole DRUG erythromycin gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma DRUG concentrations.
1641,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",erythromycin,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 ketoconazole itraconazole DRUG gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma DRUG concentrations.
1642,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",gemfibrozil,bexarotene,mechanism,basis metabolism bexarotene cytochrome P450 3A4 ketoconazole itraconazole erythromycin DRUG grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma DRUG concentrations.
1643,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",rifampin,bexarotene,mechanism,Furthermore DRUG phenytoin phenobarbital inducers cytochrome P450 3A4 may cause reduction plasma DRUG concentrations.
1644,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenytoin,bexarotene,mechanism,Furthermore rifampin DRUG phenobarbital inducers cytochrome P450 3A4 may cause reduction plasma DRUG concentrations.
1645,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenobarbital,bexarotene,mechanism,Furthermore rifampin phenytoin DRUG inducers cytochrome P450 3A4 may cause reduction plasma DRUG concentrations.
1646,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.",Targretin,gemfibrozil,mechanism,Concomitant administration BRAND capsules DRUG resulted substantial increases plasma concentrations bexarotene probably least partially related cytochrome P450 3A4 inhibition gemfibrozil.
1647,Concomitant administration of gemfibrozil with Targretin capsules is not recommended.,gemfibrozil,Targretin,advise,Concomitant administration DRUG BRAND capsules recommended.
1648,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,effect,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered DRUG concomitant use apomorphine drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron palonosetron alosetron) contraindicated .
1649,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,5HT3 antagonist class,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use DRUG drugs GROUP (including example ondansetron granisetron dolasetron palonosetron alosetron) contraindicated .
1650,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example DRUG granisetron dolasetron palonosetron alosetron) contraindicated .
1651,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,granisetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron DRUG dolasetron palonosetron alosetron) contraindicated .
1652,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,dolasetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron granisetron DRUG palonosetron alosetron) contraindicated .
1653,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,palonosetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron DRUG alosetron) contraindicated .
1654,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,alosetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness apomorphine administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron palonosetron DRUG ) contraindicated .
1655,"Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.",antihypertensive medications,vasodilators,effect,Antihypertensive Medications Vasodilators: following adverse events experienced commonly patients receiving concomitant GROUP GROUP (n = 94) compared patients receiving concomitant drugs (n = 456): hypotension 10% vs 4% myocardial infarction 3% vs 1% serious pneumonia 5% vs 3% serious falls 9% vs 3% bone joint injuries 6% vs 2%.
1656,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",dopamine antagonists,metoclopramide,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible GROUP neuroleptics (phenothiazines butyrophenones thioxanthenes) DRUG may diminish effectiveness APOKYN.
1657,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",phenothiazines,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics ( GROUP butyrophenones thioxanthenes) metoclopramide may diminish effectiveness BRAND .
1658,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",butyrophenones,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines GROUP thioxanthenes) metoclopramide may diminish effectiveness BRAND .
1659,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",thioxanthenes,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones GROUP ) metoclopramide may diminish effectiveness BRAND .
1660,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",metoclopramide,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) DRUG may diminish effectiveness BRAND .
1661,"Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.",neuroleptics,dopamine agonists,advise,Patients major psychotic disorders treated GROUP treated GROUP potential benefits outweigh risks.
1662,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing DRUG norepinephrine patients receiving GROUP tricyclic antidepressants may produce severe prolonged hypertension.
1663,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors GROUP may produce severe prolonged hypertension.
1664,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine DRUG patients receiving GROUP tricyclic antidepressants may produce severe prolonged hypertension.
1665,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors GROUP may produce severe prolonged hypertension.
1666,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,GROUP butyrophenones may reduce reverse pressor effect DRUG .
1667,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines GROUP may reduce reverse pressor effect DRUG .
1668,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,centrally acting drugs,advise,Drug Drug Interactions Given primary CNS effects aripiprazole caution used BRAND taken combination GROUP alcohol.
1669,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,alcohol,advise,Drug Drug Interactions Given primary CNS effects aripiprazole caution used BRAND taken combination centrally acting drugs DRUG .
1670,"1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.",aripiprazole,antihypertensive agents,effect,1 adrenergic receptor antagonism DRUG potential enhance effect certain GROUP .
1671,"Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.",carbamazepine,aripiprazole,mechanism,Agents induce CYP3A4 (eg DRUG ) could cause increase DRUG clearance lower blood levels.
1672,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",ketoconazole,aripiprazole,mechanism,Inhibitors CYP3A4 (eg DRUG ) CYP2D6 (eg quinidine fluoxetine paroxetine) inhibit DRUG elimination cause increased blood levels.
1673,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",quinidine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg DRUG fluoxetine paroxetine) inhibit DRUG elimination cause increased blood levels.
1674,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",fluoxetine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine DRUG paroxetine) inhibit DRUG elimination cause increased blood levels.
1675,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",paroxetine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine fluoxetine DRUG ) inhibit DRUG elimination cause increased blood levels.
1676,"Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.",ketoconazole,aripiprazole,mechanism,Ketoconazole: Coadministration DRUG (200 mg/day 14 days) 15 mg single dose DRUG increased AUC aripiprazole active metabolite 63% 77% respectively.
1677,"When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.",ketoconazole,aripiprazole,advise,concomitant administration DRUG DRUG occurs aripiprazole dose reduced one half normal dose.
1678,"Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.",aripiprazole,quinidine,mechanism,Quinidine: Coadministration 10 mg single dose DRUG DRUG (166 mg/day 13 days) potent inhibitor CYP2D6 increased AUC aripiprazole 112% decreased AUC active metabolite dehydroaripiprazole 35%.
1679,Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.,quinidine,aripiprazole,advise,Aripiprazole dose reduced one half normal dose concomitant administration DRUG DRUG occurs.
1680,"Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",carbamazepine,aripiprazole,mechanism,Carbamazepine: Coadministration DRUG (200 mg BID) potent CYP3A4 inducer DRUG (30 mg QD) resulted approximate 70% decrease Cmax AUC values aripiprazole active metabolite dehydro aripiprazole.
1681,"When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.",carbamazepine,aripiprazole,advise,DRUG added DRUG therapy aripiprazole dose doubled.
1682,"When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.",carbamazepine,aripiprazole,advise,DRUG withdrawn combination therapy DRUG dose reduced.
1683,"As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY",alcohol,ABILIFY,advise,psychoactive medications patients advised avoid DRUG taking BRAND
1684,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,effect,DRUG interact DRUG CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1685,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,effect,DRUG interact alcohol GROUP (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1686,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,effect,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) GROUP medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1687,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,effect,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) GROUP (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines).
1688,Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.,cholestyramine,vitamin K,mechanism,Cholestyramine Concomitant intake DRUG GROUP may reduce absorption vitamin K.
1689,Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.,colestipol,vitamin K,mechanism,Colestipol Concomitant intake DRUG GROUP may reduce absorption vitamin K.
1690,Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.,mineral oil,vitamin K,mechanism,Mineral Oil Concomitant intake DRUG_N GROUP may reduce absorption vitamin K.
1691,Orlistat-Orlistat may decrease the absorption of vitamin K.,Orlistat,vitamin K,mechanism,Orlistat DRUG may decrease absorption GROUP .
1692,Warfarin-Vitamin K can antagonize the effect of warfarin,Vitamin K,warfarin,effect,Warfarin GROUP antagonize effect DRUG
1693,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ,Amprenavir,rifabutin,mechanism,DRUG significantly increased area curve steady state (AUC(ss)) DRUG 2.93 fold AUC(ss) 25 desacetylrifabutin 13.3 fold.
1694,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ,Amprenavir,25-O-desacetylrifabutin,mechanism,DRUG significantly increased area curve steady state (AUC(ss)) rifabutin 2.93 fold AUC(ss) DRUG_N 13.3 fold.
1695,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",Rifampin,amprenavir,mechanism,DRUG significantly decreased AUC(ss) DRUG 82% amprenavir effect rifampin pharmacokinetics.
1696,"Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. ",Amprenavir,rifabutin,effect,DRUG plus DRUG poorly tolerated 5 11 subjects discontinued therapy.
1697,"Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. ",Rifampin,amprenavir,mechanism,DRUG markedly increases metabolic clearance DRUG coadministration contraindicated.
1698,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",Amprenavir,rifabutin,mechanism,DRUG significantly decreases clearance DRUG 25 desacetylrifabutin combination poorly tolerated.
1699,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",Amprenavir,25-O-desacetylrifabutin,mechanism,DRUG significantly decreases clearance rifabutin DRUG_N combination poorly tolerated.
1700,A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.,nisoldipine,cimetidine 400 mg,mechanism,30 45% increase AUC Cmax DRUG observed concomitant administration DRUG twice daily.
1701,Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.,phenytoin,SULAR,mechanism,Coadministration DRUG 40 mg BRAND tablets epileptic patients lowered nisoldipine plasma concentrations undetectable levels.
1702,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.,SULAR,phenytoin,advise,Coadministration BRAND DRUG known CYP3A4 inducer avoided alternative antihypertensive therapy considered.
1703,Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.,Propranolol,nisoldipine,effect,DRUG attenuated heart rate increase following administration immediate release DRUG .
1704,The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.,SULAR,atenolol,effect,blood pressure effect BRAND tended greater patients DRUG patients antihypertensive therapy.
1705,"Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.",Quinidine,nisoldipine,mechanism,DRUG 648 mg bid decreased bioavailability (AUC) DRUG 26% peak concentration.
1706,"The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.",nisoldipine,quinidine,mechanism,immediate release coat core formulation DRUG increased plasma DRUG concentrations 20%.
1707,"It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.",buspirone hydrochloride,MAO inhibitors,advise,recommended DRUG used concomitantly GROUP effects concomitant administration buspirone HCl psychotropic drugs studied concomitant use buspirone HCl CNS active drugs approached caution.
1708,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,trazodone hydrochloride,buspirone HCl,effect,one report suggesting concomitant use DRUG (Desyrel) DRUG may caused 3 6 fold elevations SGPT (ALT) patients.
1709,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,Desyrel,buspirone HCl,effect,one report suggesting concomitant use trazodone hydrochloride ( BRAND ) DRUG may caused 3 6 fold elevations SGPT (ALT) patients.
1710,"In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.",buspirone HCl,haloperidol,mechanism,study normal volunteers concomitant administration DRUG DRUG resulted increased serum haloperidol concentrations.
1711,"However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.",buspirone,warfarin,effect,However one report prolonged prothrombin time DRUG added regimen patient treated DRUG .
1712,"In vitro, buspirone may displace less firmly bound drugs like digoxin.",buspirone,digoxin,mechanism,vitro DRUG may displace less firmly bound drugs like DRUG .
1713,Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.,L-phenylalanine,non-selective MAO inhibitors,effect,Concomitant use DRUG GROUP may cause hypertension.
1714,Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.,L-phenylalanine,selegiline,effect,Selegiline DRUG selective MAO inhibitor DRUG may synergistic antidepressant activity used concomitantly.
1715,Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.,Neuroleptic Drugs,L-phenylalanine,effect,GROUP DRUG may potentiate tardive dyskinesia side reactions neuroleptic drugs used concomitantly them.
1716,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,psychoactive drugs,advise,DRUG administered caution patients taking GROUP CNS depressants including alcohol barbiturates narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1717,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,CNS depressants,advise,DRUG administered caution patients taking psychoactive drugs GROUP including alcohol barbiturates narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1718,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,alcohol,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including DRUG barbiturates narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1719,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,barbiturates,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including alcohol GROUP narcotic analgesics history psychiatric disorder (including manic depressive illness schizophrenia).
1720,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,narcotic analgesics,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including alcohol barbiturates GROUP history psychiatric disorder (including manic depressive illness schizophrenia).
1721,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,diazepam,effect,DRUG shown additive CNS depressant effect given either DRUG secobarbitone sodium alcohol codeine.
1722,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,secobarbitone sodium,effect,DRUG shown additive CNS depressant effect given either diazepam BRAND alcohol codeine.
1723,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,alcohol,effect,DRUG shown additive CNS depressant effect given either diazepam secobarbitone sodium DRUG codeine.
1724,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,codeine,effect,DRUG shown additive CNS depressant effect given either diazepam secobarbitone sodium alcohol DRUG .
1725,"Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",warfarin,ketorolac tromethamine,mechanism,Warfarin Digoxin Salicylate Heparin vitro binding DRUG plasma proteins slightly reduced DRUG (99.5% control vs 99.3%) ketorolac plasma concentrations reach 5 to10 g/mL.
1726,"In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.",salicylate,ketorolac,mechanism,vitro studies indicate therapeutic concentrations GROUP (300 g/mL) binding DRUG reduced approximately 99.2% 97.5% representing potential twofold increase unbound ketorolac plasma levels.
1727,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.",TORADOL,anticoagulants,advise,Although results indicate significant interaction TORADOL warfarin heparin administration BRAND patients taking GROUP done extremely cautiously patients closely monitored.
1728,Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,TORADOL,furosemide,effect,Furosemide: BRAND IV/IM reduced diuretic response DRUG normovolemic healthy subjects approximately 20% (mean sodium urinary output decreased 17%).
1729,Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,TORADOL,probenecid,mechanism,Probenecid: Concomitant administration BRAND ORAL DRUG resulted decreased clearance ketorolac significant increases ketorolac plasma levels (total AUC increased approximately threefold 5.4 17.8 g/h/mL) terminal half life increased approximately twofold 6.6 15.1 hours.
1730,"Therefore, concomitant use of TORADOL and probenecid is contraindicated.",TORADOL,probenecid,advise,Therefore concomitant use BRAND DRUG contraindicated.
1731,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.",lithium,TORADOL,mechanism,effect TORADOL plasma lithium studied cases increased DRUG plasma levels BRAND therapy reported.
1732,"Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.",methotrexate,NSAIDs,mechanism,Methotrexate: Concomitant administration DRUG GROUP reported reduce clearance methotrexate enhancing toxicity methotrexate.
1733,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,antiepileptic drugs,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use BRAND GROUP (phenytoin carbamazepine).
1734,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,phenytoin,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use BRAND antiepileptic drugs ( DRUG carbamazepine).
1735,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,carbamazepine,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use BRAND antiepileptic drugs (phenytoin DRUG ).
1736,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,psychoactive drugs,effect,Psychoactive Drugs: Hallucinations reported BRAND used patients taking GROUP (fluoxetine thiothixene alprazolam).
1737,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,fluoxetine,effect,Psychoactive Drugs: Hallucinations reported BRAND used patients taking psychoactive drugs ( DRUG thiothixene alprazolam).
1738,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,thiothixene,effect,Psychoactive Drugs: Hallucinations reported BRAND used patients taking psychoactive drugs (fluoxetine DRUG alprazolam).
1739,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,alprazolam,effect,Psychoactive Drugs: Hallucinations reported BRAND used patients taking psychoactive drugs (fluoxetine thiothixene DRUG ).
1740,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,ACE inhibitors,mechanism,Lithium Reversible increases serum lithium concentrations toxicity reported concomitant administration DRUG GROUP angiotensin II receptor antagonists.
1741,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,angiotensin II receptor antagonists,mechanism,Lithium Reversible increases serum lithium concentrations toxicity reported concomitant administration DRUG ACE inhibitors GROUP .
1742,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.",lithium,ATACAND,mechanism,increase serum lithium concentration reported concomitant administration DRUG BRAND careful monitoring serum lithium levels recommended concomitant use.
1743,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,alcohol,int,DRUG may interact DRUG blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1744,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,blood thinner,int,DRUG may interact alcohol GROUP decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1745,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,decongestant drugs,int,DRUG may interact alcohol blood thinners GROUP (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1746,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,lithium,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs DRUG norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications.
1747,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,norepinephrine,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium DRUG NSAIDs like Aleve Ibuprofen high blood pressure medications.
1748,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,NSAIDs,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine GROUP like Aleve Ibuprofen high blood pressure medications.
1749,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Aleve,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like BRAND Ibuprofen high blood pressure medications.
1750,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Ibuprofen,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve DRUG high blood pressure medications.
1751,"The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.",alcohol,bromocriptine mesylate,effect,risk using bromocriptine mesylate combination drugs systematically evaluated DRUG may potentiate side effects DRUG .
1752,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,dopamine antagonists,int,DRUG may interact GROUP butyrophenones certain agents.
1753,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,butyrophenones,int,DRUG may interact dopamine antagonists GROUP certain agents.
1754,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,phenothiazines,effect,Compounds categories result decreased efficacy DRUG : GROUP haloperidol metoclopramide pimozide.
1755,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,haloperidol,effect,Compounds categories result decreased efficacy DRUG : phenothiazines DRUG metoclopramide pimozide.
1756,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,metoclopramide,effect,Compounds categories result decreased efficacy DRUG : phenothiazines haloperidol DRUG pimozide.
1757,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,pimozide,effect,Compounds categories result decreased efficacy DRUG : phenothiazines haloperidol metoclopramide DRUG .
1758,Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.,bromocriptine mesylate,ergot alkaloids,advise,Concomitant use DRUG GROUP recommended.
1759,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,coumarin-derivative anticoagulants,effect,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding reported patients taking DRUG concomitantly GROUP warfarin phenprocoumon.
1760,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,phenprocoumon,effect,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding reported patients taking DRUG concomitantly coumarin derivative anticoagulants warfarin DRUG .
1761,Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).,coumarin-derivative anticoagulants,capecitabine,advise,Patients taking GROUP concomitantly DRUG monitored regularly alterations coagulation parameters (PT INR).
1762,Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.,5-fluorouracil,leucovorin,mechanism,Leucovorin: concentration DRUG increased toxicity may enhanced DRUG .
1763,"Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.",leucovorin,fluorouracil,effect,Deaths severe enterocolitis diarrhea dehydration reported elderly patients receiving weekly DRUG DRUG .
1764,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",Iodine,Carbimazole,effect,DRUG iodine excess may decrease effect DRUG iodine deficiency increase effect Carbimazole.
1765,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",iodine,Carbimazole,effect,Iodine iodine excess may decrease effect Carbimazole DRUG deficiency increase effect DRUG .
1766,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digoxin,antithyroid agents,mechanism,Serum concentration DRUG digitoxin may increase patients take GROUP .
1767,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digitoxin,antithyroid agents,mechanism,Serum concentration digoxin DRUG may increase patients take GROUP .
1768,"Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.",Antithyroid agents,sodium iodide I131,effect,GROUP may decrease thyroidal uptake DRUG rebound uptake may occur 5 days sudden withdrawal Carbimazole.
1769,"Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.",buprenorphine,benzodiazepines,int,Based anecdotal reports may interaction DRUG GROUP .
1770,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.,buprenorphine,benzodiazepines,effect,number reports post marketing experience coma death associated concomitant intravenous misuse DRUG DRUG addicts.
1771,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBUTEX,benzodiazepines,advise,BRAND SUBOXONE prescribed caution patients GROUP drugs act central nervous system regardless whether drugs taken advice physician taken drugs abuse.
1772,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBOXONE,benzodiazepines,advise,SUBUTEX BRAND prescribed caution patients GROUP drugs act central nervous system regardless whether drugs taken advice physician taken drugs abuse.
1773,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBOXONE,advise,Patients warned potential danger intravenous self administration GROUP treatment BRAND SUBUTEX.
1774,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBUTEX,advise,Patients warned potential danger intravenous self administration GROUP treatment SUBOXONE BRAND .
1775,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,cimetidine,mechanism,Blood levels hydrodolasetron increased 24% DRUG coadministered DRUG (nonselective inhibitor cytochrome P 450) 7 days decreased 28% coadministration rifampin (potent inducer cytochrome P 450) 7 days.
1776,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,rifampin,mechanism,Blood levels hydrodolasetron increased 24% DRUG coadministered cimetidine (nonselective inhibitor cytochrome P 450) 7 days decreased 28% coadministration DRUG (potent inducer cytochrome P 450) 7 days.
1777,Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.,dolasetron mesylate,atenolol,mechanism,Clearance hydrodolasetron decreased 27% DRUG administered intravenously concomitantly DRUG .
1778,Chlorprothixene may increase the plasma-level of concomitantly given lithium.,Chlorprothixene,lithium,mechanism,DRUG may increase plasma level concomitantly given DRUG .
1779,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,advise,DRUG given concomitantly GROUP opioid dose reduced (by approx. 50%) chlorprothixene amplifies therapeutic actions side effects opioids massively.
1780,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,effect,chlorprothixene given concomitantly opioids opioid dose reduced (by approx. 50%) DRUG amplifies therapeutic actions side effects GROUP massively.
1781,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,tramadol,advise,Avoid concomitant use DRUG DRUG (Ultram).
1782,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,Ultram,advise,Avoid concomitant use DRUG tramadol ( BRAND ).
1783,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,benzodiazepines,effect,Consider additive sedative effects confusional states emerge DRUG given GROUP barbituates.
1784,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,barbituates,effect,Consider additive sedative effects confusional states emerge DRUG given benzodiazepines GROUP .
1785,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,anticholinergic drugs,advise,Exert particular caution combining DRUG GROUP (tricyclic antidepressants antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
1786,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,tricyclic antidepressants,advise,Exert particular caution combining DRUG anticholinergic drugs ( GROUP antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
1787,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,antiparkinsonian agents,advise,Exert particular caution combining DRUG anticholinergic drugs (tricyclic antidepressants GROUP ): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
1788,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,antiepileptic drugs,mechanism,Use Conjunction Antiepileptic Drugs: addition BRAND GROUP (AEDs) affects steady state plasma concentrations AEDs.
1789,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,AEDs,mechanism,Use Conjunction Antiepileptic Drugs: addition BRAND antiepileptic drugs ( GROUP ) affects steady state plasma concentrations AEDs.
1790,Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.,Felbatol,phenytoin,mechanism,Specific Effects Felbatol Antiepileptic Drugs Phenytoin: BRAND causes increase steady state DRUG plasma concentrations.
1791,Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.,felbamate,phenytoin,mechanism,Increasing DRUG dose 1800 mg/day six subjects increased steady state DRUG Cmin 25 7 micrograms/mL.
1792,"In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.",felbamate,phenytoin,advise,order maintain phenytoin levels limit adverse experiences achieve DRUG dose 3600 mg/day DRUG dose reduction approximately 40% necessary eight 10 subjects.
1793,Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.,Felbatol,carbamazepine,mechanism,Carbamazepine: BRAND causes decrease steady state DRUG plasma concentrations increase steady state carbamazepine epoxide plasma concentration.
1794,"The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.",carbamazepine,felbamate,mechanism,DRUG steady state Cmin decreased 31% 5 1 micrograms/mL DRUG (3000 mg/day divided three doses) coadministered.
1795,Valproate: Felbatol  causes an increase in steady-state valproate concentrations.,Felbatol,valproate,mechanism,Valproate: BRAND causes increase steady state DRUG concentrations.
1796,Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.,felbamate,valproate,mechanism,Increasing DRUG dose 2400 mg/day increased steadystate DRUG Cmin 96 25 micrograms/mL.
1797,"Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.",felbamate,phenobarbital,mechanism,Phenobarbital: Coadministration DRUG DRUG causes increase phenobarbital plasma concentrations 12 otherwise healthy male volunteers ingesting phenobarbital steady state trough (Cmin) phenobarbital concentration 14.2 micrograms/mL.
1798,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,Felbatol,mechanism,Effects Antiepileptic Drugs Felbatol Phenytoin: DRUG causes approximate doubling clearance BRAND (felbamate) steady state therefore addition phenytoin causes approximate 45% decrease steady state trough concentrations Felbatol compared dose Felbatol given monotherapy.
1799,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,felbamate,mechanism,Effects Antiepileptic Drugs Felbatol Phenytoin: DRUG causes approximate doubling clearance Felbatol ( DRUG ) steady state therefore addition phenytoin causes approximate 45% decrease steady state trough concentrations Felbatol compared dose Felbatol given monotherapy.
1800,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",phenytoin,Felbatol,mechanism,Effects Antiepileptic Drugs Felbatol Phenytoin: Phenytoin causes approximate doubling clearance Felbatol (felbamate) steady state therefore addition DRUG causes approximate 45% decrease steady state trough concentrations BRAND compared dose Felbatol given monotherapy.
1801,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Carbamazepine,Felbatol,mechanism,Carbamazepine: DRUG causes approximate 50% increase clearance BRAND steady state therefore addition carbamazepine results approximate 40% decrease steady state trough concentrations Felbatol compared dose Felbatol given monotherapy.
1802,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",carbamazepine,Felbatol,mechanism,Carbamazepine: Carbamazepine causes approximate 50% increase clearance Felbatol steady state therefore addition DRUG results approximate 40% decrease steady state trough concentrations BRAND compared dose Felbatol given monotherapy.
1803,Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.,phenobarbital,felbamate,mechanism,Phenobarbital: appears DRUG may reduce plasma DRUG concentrations.
1804,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.",Felbamate,gestodene,mechanism,DRUG treatment resulted 42% decrease DRUG AUC 0 24 clinically relevant effect observed pharmacokinetic parameters ethinyl estradiol.
1805,Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.,Chirocaine,anesthetics,advise,BRAND used caution patients receiving local GROUP agents structurally related amide type local anesthetics since toxic effects drugs could additive.
1806,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenytoin,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such DRUG phenobarbital rifampin) CYP3A4 inhibitors (azole antimycotics e.g. ketoconazole;
1807,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenobarbital,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such phenytoin DRUG rifampin) CYP3A4 inhibitors (azole antimycotics e.g. ketoconazole;
1808,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,rifampin,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such phenytoin phenobarbital DRUG ) CYP3A4 inhibitors (azole antimycotics e.g. ketoconazole;
1809,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,ketoconazole,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such phenytoin phenobarbital rifampin) CYP3A4 inhibitors (azole antimycotics e.g. DRUG ;
1810,Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.,Nicotinic acid,ganglionic blocking agents,effect,Interactions Vitamin B3 (Niacin): Antihypertensive Therapy: DRUG may potentiate effects GROUP vasoactive drugs resulting postural hypotension.
1811,Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.,aspirin,nicotinic acid,mechanism,Aspirin: Concomitant BRAND may decrease metabolic clearance DRUG .
1812,Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.,irbesartan,aliskiren,mechanism,Co administration DRUG reduced DRUG Cmax 50% multiple dosing.
1813,Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.,atorvastatin,aliskiren,mechanism,Co administration DRUG resulted 50% increase DRUG Cmax AUC multiple dosing.
1814,Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.,ketoconazole,aliskiren,mechanism,Ketoconazole: Co administration 200 mg twice daily DRUG DRUG resulted approximate 80% increase plasma levels aliskiren.
1815,"Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.",aliskiren,furosemide,mechanism,Furosemide: DRUG co administered DRUG AUC Cmax furosemide reduced 30% 50% respectively.
1816,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,ibogaine,morphine,effect,DRUG_N 18 MC block DRUG induced nicotine induced dopamine release nucleus accumbens;
1817,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,ibogaine,nicotine,effect,DRUG_N 18 MC block morphine induced DRUG induced dopamine release nucleus accumbens;
1818,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,18-MC,morphine,effect,ibogaine DRUG_N block DRUG induced nicotine induced dopamine release nucleus accumbens;
1819,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,18-MC,nicotine,effect,ibogaine DRUG_N block morphine induced DRUG induced dopamine release nucleus accumbens;
1820,only ibogaine enhances cocaine-induced increases in accumbal dopamine. ,ibogaine,cocaine,effect,DRUG_N enhances DRUG induced increases accumbal dopamine.
1821,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ",Ibogaine,morphine,effect,DRUG_N attenuates 18 MC potentiates acute locomotor effects DRUG ;
1822,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ",18-MC,morphine,effect,Ibogaine attenuates DRUG_N potentiates acute locomotor effects DRUG ;
1823,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,phenothiazines,effect,response BRAND may blunted GROUP dopamine antagonists cause rise prolactin.
1824,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,dopamine antagonists,effect,response BRAND may blunted phenothiazines GROUP cause rise prolactin.
1825,"Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.",diuretics,Lotensin,effect,Diuretics: Patients GROUP especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy BRAND .
1826,The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.,diuretic,Lotensin,advise,possibility hypotensive effects Lotensin minimized either discontinuing GROUP increasing salt intake prior initiation treatment BRAND .
1827,Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.,Potassium-Sparing Diuretics,thiazide diuretics,effect,Potassium Supplements GROUP Lotensin attenuate potassium loss caused GROUP .
1828,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.,ACE inhibitors,lithium,mechanism,Lithium: Increased serum lithium levels symptoms lithium toxicity reported patients receiving GROUP therapy DRUG .
1829,"If a diuretic is also used, the risk of lithium toxicity may be increased.",diuretic,lithium,effect,GROUP also used risk DRUG toxicity may increased.
1830,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",Benazepril,beta-adrenergic blockers,effect,DRUG like ACE inhibitors less additive effects GROUP presumably drugs lower blood pressure inhibiting parts renin angiotensin system
1831,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",ACE inhibitors,beta-adrenergic blockers,effect,Benazepril like GROUP less additive effects GROUP presumably drugs lower blood pressure inhibiting parts renin angiotensin system
1832,Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. ,fluoxetine,cisapride,mechanism,Coadministration DRUG significantly decreased DRUG plasma concentrations.
1833,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,Geocillin,probenecid,mechanism,BRAND (carbenicillin indanyl sodium) blood levels may increased prolonged concurrent administration DRUG .
1834,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,carbenicillin indanyl sodium,probenecid,mechanism,Geocillin ( DRUG ) blood levels may increased prolonged concurrent administration DRUG .
1835,"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
",verapamil,bombesin,effect,Suppression DRUG DRUG_N enhanced peritoneal metastasis intestinal adenocarcinomas induced azoxymethane wistar rats.
1836,"Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. ",Verapamil,bombesin,effect,DRUG also significantly decreased incidence lymphatic invasion adenocarcinomas enhanced DRUG_N .
1837,Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.,aspirin,valdecoxib,effect,Aspirin: Concomitant administration BRAND DRUG may result increased risk GI ulceration complications compared valdecoxib alone.
1838,ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,ACE inhibitors:Reports suggest GROUP may diminish antihypertensive effect GROUP .
1839,This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.,BEXTRA,ACE-inhibitors,advise,interaction given consideration patients taking BRAND concomitantly GROUP .
1840,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect DRUG thiazides patients.
1841,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect furosemide GROUP patients.
1842,Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).,valdecoxib,phenytoin,mechanism,Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) DRUG (40 mg BID 12 days) decreased 27% co administered multiple doses (300 mg QD 12 days) DRUG (a CYP 3A4 inducer).
1843,Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.,valdecoxib,phenytoin,advise,Patients already stabilized DRUG closely monitored loss symptom control DRUG coadministration.
1844,"Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.",valdecoxib,dextromethorphan,mechanism,Coadministration DRUG (40 mg BID 7 days) resulted significant increase DRUG plasma levels suggesting doses valdecoxib weak inhibitor 2D6.
1845,Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.,dextromethorphan,valdecoxib,mechanism,Even DRUG plasma concentrations presence high doses DRUG almost 5 fold lower seen CYP 2D6 poor metabolizers suggesting dose adjustment necessary.
1846,Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.,Valdecoxib,lithium,mechanism,Lithium: DRUG 40 mg BID 7 days produced significant decreases DRUG serum clearance (25%) renal clearance (30%) 34% higher serum exposure compared lithium alone.
1847,Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.,BEXTRA,lithium,advise,Lithium serum concentrations monitored closely initiating changing therapy BRAND patients receiving DRUG .
1848,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,R-warfarin,mechanism,DRUG caused statistically significant increase plasma exposures DRUG warfarin (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) warfarin.
1849,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,S-warfarin,mechanism,DRUG caused statistically significant increase plasma exposures R warfarin DRUG (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) warfarin.
1850,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,warfarin,effect,DRUG caused statistically significant increase plasma exposures R warfarin warfarin (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) DRUG .
1851,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.",BEXTRA,warfarin,advise,Anticoagulant therapy monitored particularly first weeks initiating therapy BRAND patients receiving DRUG similar agents.
1852,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,ketoconazole,mechanism,Concomitant single dose administration DRUG 20 mg multiple doses DRUG fluconazole produced significant increase exposure valdecoxib.
1853,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,fluconazole,mechanism,Concomitant single dose administration DRUG 20 mg multiple doses ketoconazole DRUG produced significant increase exposure valdecoxib.
1854,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,fluconazole,mechanism,Plasma exposure (AUC) DRUG increased 62% coadministered DRUG 38% coadministered ketoconazole.
1855,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,ketoconazole,mechanism,Plasma exposure (AUC) DRUG increased 62% coadministered fluconazole 38% coadministered DRUG .
1856,Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.,valdecoxib,glyburide,mechanism,Coadministration DRUG (40 mg BID (day 1) 40 mg QD (days 2 7)) DRUG (10 mg glyburide BID) resulted 21% increase glyburide AUC0 12 16% increase glyburide Cmax leading 16% decrease glucose AUC0 24.
1857,"Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.",glyburide,valdecoxib,advise,changes glucose concentrations valdecoxib coadministration within normal variability individual glucose concentrations near 70 mg/dL dose adjustment DRUG (5 mg QD 10 mg BID) DRUG coadministration (up 40 mg QD) indicated.
1858,Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.,valdecoxib,omeprazole,mechanism,Coadministration DRUG increased exposure DRUG (AUC) 46%.
1859,"Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.",valdecoxib,Ortho-Novum,mechanism,Coadministration DRUG BRAND 1/35 increased exposure norethindrone ethinyl estradiol 20% 34% respectively.
1860,These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.,contraceptive,valdecoxib,advise,increased exposures norethindrone ethinyl estradiol taken consideration selecting oral GROUP women taking DRUG .
1861,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.",diazepam,valdecoxib,mechanism,Plasma exposure DRUG (10 mg BID) increased 28% following administration DRUG (40 mg BID) 12 days plasma exposure valdecoxib (40 mg BID) substantially increased following administration diazepam (10 mg BID) 12 days.
1862,"Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.",valdecoxib,diazepam,effect,Although magnitude changes diazepam plasma exposure coadministered DRUG sufficient warrant dosage adjustments patients may experience enhanced sedative side effects caused increased exposure DRUG circumstance.
1863,"Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.",Clozapine,alcohol,effect,Given primary CNS effects DRUG caution advised using concomitantly CNS active drugs DRUG .
1864,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,benzodiazepine,advise,Although established interaction Clozapine benzodiazepines psychotropics caution advised DRUG initiated patients taking GROUP psychotropic drug.
1865,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,psychotropic drug,advise,Although established interaction Clozapine benzodiazepines psychotropics caution advised DRUG initiated patients taking benzodiazepine GROUP .
1866,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,antihypertensive drugs,effect,DRUG may potentiate hypotensive effects GROUP anticholinergic effects atropine type drugs.
1867,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,atropine,effect,DRUG may potentiate hypotensive effects antihypertensive drugs anticholinergic effects DRUG type drugs.
1868,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",Phenytoin,Clozapine,mechanism,DRUG nicotine rifampin may decrease DRUG plasma levels resulting decrease effectiveness previously effective Clozapine dose.
1869,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",nicotine,Clozapine,mechanism,Phenytoin DRUG rifampin may decrease DRUG plasma levels resulting decrease effectiveness previously effective Clozapine dose.
1870,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",rifampin,Clozapine,mechanism,Phenytoin nicotine DRUG may decrease DRUG plasma levels resulting decrease effectiveness previously effective Clozapine dose.
1871,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",Cimetidine,Clozapine,mechanism,DRUG caffeine erythromycin may increase plasma levels DRUG potentially resulting adverse effects.
1872,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",caffeine,Clozapine,mechanism,Cimetidine DRUG erythromycin may increase plasma levels DRUG potentially resulting adverse effects.
1873,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",erythromycin,Clozapine,mechanism,Cimetidine caffeine DRUG may increase plasma levels DRUG potentially resulting adverse effects.
1874,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",Clozapine,carbamazepine,advise,Although concomitant use DRUG DRUG recommended noted discontinuation concomitant carbamazepine administration may result increase Clozapine plasma levels.
1875,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",carbamazepine,Clozapine,mechanism,Although concomitant use Clozapine carbamazepine recommended noted discontinuation concomitant DRUG administration may result increase DRUG plasma levels.
1876,Paroxetine produced only minor changes in the levels of clozapine and its metabolites.,Paroxetine,clozapine,mechanism,DRUG produced minor changes levels DRUG metabolites.
1877,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,paroxetine,mechanism,However published reports describe modest elevations (less two fold) clozapine metabolite concentrations DRUG taken DRUG fluoxetine sertraline.
1878,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,fluoxetine,mechanism,However published reports describe modest elevations (less two fold) clozapine metabolite concentrations DRUG taken paroxetine DRUG sertraline.
1879,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,sertraline,mechanism,However published reports describe modest elevations (less two fold) clozapine metabolite concentrations DRUG taken paroxetine fluoxetine DRUG .
1880,"Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.",Clozapine,fluvoxamine,advise,Therefore combined treatment approached caution patients monitored closely DRUG combined drugs particularly DRUG .
1881,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,antidepressants,advise,Therefore co administration DRUG drugs metabolized isozyme including GROUP phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1882,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,phenothiazines,advise,Therefore co administration DRUG drugs metabolized isozyme including antidepressants GROUP carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1883,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,carbamazepine,advise,Therefore co administration DRUG drugs metabolized isozyme including antidepressants phenothiazines DRUG Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1884,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,Type 1C antiarrhythmics,advise,Therefore co administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine GROUP (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1885,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,propafenone,advise,Therefore co administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. DRUG flecainide encainide) inhibit enzyme (e.g. quinidine) approached caution.
1886,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,flecainide,advise,Therefore co administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone DRUG encainide) inhibit enzyme (e.g. quinidine) approached caution.
1887,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,encainide,advise,Therefore co administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide DRUG ) inhibit enzyme (e.g. quinidine) approached caution.
1888,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,quinidine,advise,Therefore co administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e.g. propafenone flecainide encainide) inhibit enzyme (e.g. DRUG ) approached caution.
1889,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",quinolones,caffeine,mechanism,GROUP including ciprofloxacin also shown interfere metabolism DRUG .
1890,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",ciprofloxacin,caffeine,mechanism,quinolones including DRUG also shown interfere metabolism DRUG .
1891,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",quinolones,cyclosporine,effect,GROUP including ciprofloxacin associated transient elevations serum creatinine patients receiving DRUG concomitantly.
1892,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",ciprofloxacin,cyclosporine,effect,quinolones including DRUG associated transient elevations serum creatinine patients receiving DRUG concomitantly.
1893,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,sulfonylurea,effect,Glyburide: concomitant administration DRUG GROUP glyburide rare occasions resulted severe hypoglycemia.
1894,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,glyburide,effect,Glyburide: concomitant administration DRUG sulfonylurea DRUG rare occasions resulted severe hypoglycemia.
1895,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.",methotrexate,ciprofloxacin,mechanism,Methotrexate Renal tubular transport DRUG may inhibited concomitant administration DRUG potentially leading increased plasma levels methotrexate.
1896,"Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.",methotrexate,ciprofloxacin,advise,Therefore patients DRUG therapy carefully monitored concomitant DRUG therapy indicated.
1897,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,magnesium,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products DRUG aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1898,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,aluminum,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products magnesium DRUG antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1899,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,antacids,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products magnesium aluminum GROUP sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1900,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,sucralfate,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products magnesium aluminum antacids DRUG VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1901,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,VIDEX,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate BRAND chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1902,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,calcium,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing DRUG iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1903,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,iron,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium DRUG zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1904,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,zinc,mechanism,Multivalent Cation Containing Products: Concurrent administration GROUP including ciprofloxacin multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron DRUG may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1905,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,magnesium,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products DRUG aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1906,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,aluminum,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium DRUG antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1907,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,antacids,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium aluminum GROUP sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1908,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,sucralfate,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium aluminum antacids DRUG VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1909,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,VIDEX,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium aluminum antacids sucralfate BRAND chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1910,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,calcium,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing DRUG iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1911,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,iron,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium DRUG zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1912,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,zinc,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron DRUG may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired.
1913,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,ciprofloxacin,mechanism,Multivalent Cation Containing Products: Concurrent administration quinolone including DRUG multivalent cation containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired.
1914,"This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.",ciprofloxacin,antacids,advise,time window different oral formulations DRUG usually administered 2 hours 6 hours GROUP .
1915,Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.,phenytoin,ciprofloxacin,mechanism,Phenytoin: Altered serum levels DRUG (increased decreased) reported patients receiving concomitant DRUG .
1916,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid: DRUG interferes renal tubular secretion DRUG produces increase level ciprofloxacin serum.
1917,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid: DRUG interferes renal tubular secretion ciprofloxacin produces increase level DRUG serum.
1918,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",quinolones,theophylline,mechanism,Theophylline: GROUP concurrent administration ciprofloxacin DRUG may lead elevated serum concentrations theophylline prolongation elimination half life.
1919,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",ciprofloxacin,theophylline,mechanism,Theophylline: quinolones concurrent administration DRUG DRUG may lead elevated serum concentrations theophylline prolongation elimination half life.
1920,Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.,Quinolones,warfarin,effect,Warfarin: GROUP reported enhance effects oral anticoagulant DRUG derivatives.
1921,"Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.",Bismuth subsalicylate,enoxacin,mechanism,Bismuth: DRUG given concomitantly DRUG 60 minutes following enoxacin administration decreased enoxacin bioavailability approximately 25%.
1922,"Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.",enoxacin,bismuth subsalicylate,advise,Thus concomitant administration DRUG DRUG avoided.
1923,Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Caffeine: DRUG potent inhibitor cytochrome P 450 isozymes responsible metabolism GROUP .
1924,"In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.",enoxacin,caffeine,mechanism,multiple dose study DRUG caused dose related increase mean elimination half life DRUG thereby decreasing clearance caffeine 80% leading five fold increase AUC half life caffeine.
1925,Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.,caffeine,enoxacin,mechanism,Trough plasma enoxacin levels also 20% higher DRUG DRUG administered concomitantly.
1926,Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.,caffeine,enoxacin,effect,Caffeine related adverse effects occurred patients consuming DRUG therapy DRUG .
1927,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine: Elevated serum levels cyclosporine reported concomitant use DRUG members GROUP .
1928,Digoxin: Enoxacin may raise serum digoxin levels in some individuals.,Enoxacin,digoxin,mechanism,Digoxin: DRUG may raise serum DRUG levels individuals.
1929,"If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",enoxacin,digoxin,effect,signs symptoms suggestive digoxin toxicity occur DRUG DRUG given concomitantly physicians advised obtain serum digoxin levels adjust digoxin doses appropriately.
1930,Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.,enoxacin,fenbufen,effect,Non steroidal anti inflammatory agents: Seizures reported patients taking DRUG concomitantly nonsteroidal anti inflammatory drug DRUG .
1931,or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.,zinc,quinolone,mechanism,multivitamins containing DRUG may substantially interfere drug absorption result insufficient plasma tissue GROUP concentrations.
1932,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,aluminum hydroxide,enoxacin,mechanism,Antacids containing DRUG magnesium hydroxide reduce oral absorption DRUG 75%.
1933,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,magnesium hydroxide,enoxacin,mechanism,Antacids containing aluminum hydroxide DRUG reduce oral absorption DRUG 75%.
1934,The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.,enoxacin,ranitidine,mechanism,oral bioavailability DRUG reduced 60% coadministration DRUG .
1935,Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Theophylline: DRUG potent inhibitor cytochrome P 450 isozymes responsible metabolism GROUP .
1936,Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.,Enoxacin,theophylline,mechanism,DRUG interferes metabolism DRUG resulting 42% 74% dose related decrease theophylline clearance subsequent 260% 350% increase serum theophylline levels.
1937,Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.,theophylline,enoxacin,effect,Theophylline related adverse effects occurred patients DRUG DRUG coadministered.
1938,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",Quinolones,R-warfarin,mechanism,Warfarin: GROUP including enoxacin decrease clearance DRUG less active isomer racemic warfarin.
1939,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",enoxacin,R-warfarin,mechanism,Warfarin: Quinolones including DRUG decrease clearance DRUG less active isomer racemic warfarin.
1940,"Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.",warfarin,enoxacin,advise,Nevertheless prothrombin time suitable coagulation test monitored DRUG derivatives DRUG given concomitantly.
1941,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",calcium,Ibandronate,mechanism,Products containing DRUG multivalent cations (such aluminum magnesium iron) likely interfere absorption DRUG .
1942,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",aluminum,Ibandronate,mechanism,Products containing calcium multivalent cations (such DRUG magnesium iron) likely interfere absorption DRUG .
1943,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",magnesium,Ibandronate,mechanism,Products containing calcium multivalent cations (such aluminum DRUG iron) likely interfere absorption DRUG .
1944,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",iron,Ibandronate,mechanism,Products containing calcium multivalent cations (such aluminum magnesium DRUG ) likely interfere absorption DRUG .
1945,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,antacids,advise,DRUG taken least 60 minutes oral medications containing multivalent cations (including GROUP supplements vitamins).
1946,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,vitamins,advise,DRUG taken least 60 minutes oral medications containing multivalent cations (including antacids supplements GROUP ).
1947,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",aspirin,Ibandronate,advise,However since aspirin NSAIDs bisphosphonates associated gastrointestinal irritation caution exercised concomitant use BRAND NSAIDs DRUG .
1948,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",NSAIDs,Ibandronate,advise,However since aspirin NSAIDs bisphosphonates associated gastrointestinal irritation caution exercised concomitant use aspirin GROUP DRUG .
1949,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,azathioprine,mechanism,Total body clearance BRAND reduced average 22% 51% DRUG mycophenolate mofetil respectively added regimen consisting cyclosporine USP (MODIFIED) corticosteroids.
1950,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,mycophenolate mofetil,mechanism,Total body clearance BRAND reduced average 22% 51% azathioprine DRUG respectively added regimen consisting cyclosporine USP (MODIFIED) corticosteroids.
1951,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,central nervous system depressants,effect,Interactions CNS Agents: Concurrent use BRAND GROUP (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1952,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,alcohol,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg DRUG sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1953,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,sedatives,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol GROUP hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1954,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,hypnotics,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives GROUP opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1955,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,opioids,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics GROUP general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1956,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,anesthetics,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics opioids general GROUP barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1957,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,barbiturates,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics GROUP tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1958,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tricyclic antidepressants,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates GROUP phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1959,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,phenothiazines,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants GROUP tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1960,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tranquilizers,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines GROUP skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects.
1961,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,skeletal muscle relaxants,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers GROUP antihistamines) may result additive central nervous system depressant effects.
1962,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,antihistamines,effect,Interactions CNS Agents: Concurrent use BRAND central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants GROUP ) may result additive central nervous system depressant effects.
1963,"Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.",Levo-Dromoran,MAO inhibitors,advise,Although interaction MAO inhibitors BRAND observed recommended use GROUP .
1964,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",Agonist/antagonist analgesics,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: GROUP (eg pentazocine nalbuphine butorphanol dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic BRAND .
1965,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pentazocine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg DRUG nalbuphine butorphanol dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic BRAND .
1966,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",nalbuphine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine DRUG butorphanol dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic BRAND .
1967,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",butorphanol,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine DRUG dezocine buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic BRAND .
1968,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",dezocine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol DRUG buprenorphine) administered patient received receiving course therapy pure agonist opioid analgesic BRAND .
1969,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",buprenorphine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine DRUG ) administered patient received receiving course therapy pure agonist opioid analgesic BRAND .
1970,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pure agonist opioid analgesic,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine buprenorphine) administered patient received receiving course therapy GROUP BRAND .
1971,"In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
",prostaglandin F2alpha,oxytocin,int,vitro interaction DRUG DRUG placental vessels.
1972,PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. ,PGF2alpha,oxytocin,effect,DRUG produced significantly increased vasoconstriction single administration DRUG .
1973,There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.,PGF2alpha,oxytocin,effect,thus enhancement effect DRUG upon reaction placental vessels DRUG vitro.
1974,Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.,cinacalcet,amitriptyline,mechanism,Amitriptyline: Concurrent administration 25 mg 100 mg DRUG 50 mg DRUG increased amitriptyline exposure nortriptyline (active metabolite) exposure approximately 20% CYP2D6 extensive metabolizers.
1975,"Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.",ketoconazole,cinacalcet,mechanism,Co administration DRUG strong inhibitor CYP3A4 increased DRUG exposure following single 90 mg dose Sensipar 2.3 fold.
1976,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,ketoconazole,advise,Dose adjustment BRAND may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e.g. DRUG erythromycin itraconazole;
1977,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,erythromycin,advise,Dose adjustment BRAND may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e.g. ketoconazole DRUG itraconazole;
1978,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,itraconazole,advise,Dose adjustment BRAND may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e.g. ketoconazole erythromycin DRUG ;
1979,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",alcohol,ethchlorvynol,effect,depressasnts DRUG barbiturates MAOIs may enhance CNS depression administered DRUG .
1980,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",barbiturates,ethchlorvynol,effect,depressasnts alcohol GROUP MAOIs may enhance CNS depression administered DRUG .
1981,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",MAOIs,ethchlorvynol,effect,depressasnts alcohol barbiturates GROUP may enhance CNS depression administered DRUG .
1982,"Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
",99mTc-methylene diphosphonate,gentamicin,effect,Therapeutic drug monitoring avoid iatrogenic alterations caused DRUG (MDP) DRUG interaction.
1983,"Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. ",gentamicin,99mTc-MDP,mechanism,Due nephrotoxicity DRUG may cause abnormal renal uptake seen DRUG bone scintigraphy.
1984,"In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.",cerivastatin sodium,cholestyramine,mechanism,first study concomitant administration 0.2 mg DRUG 12 g DRUG resulted decreases 22% AUC 40% Cmax compared dosing cerivastatin sodium alone.
1985,"However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.",cholestyramine,cerivastatin sodium,mechanism,However second study administration 12 g DRUG 1 hour evening meal 0.3 mg DRUG approximately 4 hours evening meal resulted decrease cerivastatin AUC less 8% decrease Cmax 30% compared dosing cerivastatin sodium alone.
1986,"ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.",cerivastatin,erythromycin,mechanism,ERYTHROMYCIN: hypercholesterolemic patients steady state DRUG AUC Cmax increased approximately 50% 24% respectively 10 days co administration DRUG known inhibitor cytochrome P450 3A4.
1987,Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).,allopurinol,VIDEX,mechanism,Allopurinol: AUC didanosine increased 4 fold DRUG 300 mg/day coadministered single 200 mg dose BRAND two patients renal impairment (CLcr=15 18 mL/min).
1988,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,antacids,VIDEX,effect,Antacids: Concomitant administration GROUP containing magnesium aluminum BRAND Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components.
1989,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,magnesium,VIDEX,effect,Antacids: Concomitant administration antacids containing DRUG aluminum BRAND Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components.
1990,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,aluminum,VIDEX,effect,Antacids: Concomitant administration antacids containing magnesium DRUG BRAND Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components.
1991,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,ketoconazole,VIDEX,advise,Drugs Whose Absorption Affected Level Acidity Stomach: Drugs DRUG itraconazole administered least 2 hours prior dosing BRAND .
1992,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,itraconazole,VIDEX,advise,Drugs Whose Absorption Affected Level Acidity Stomach: Drugs ketoconazole DRUG administered least 2 hours prior dosing BRAND .
1993,Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).,VIDEX,ganciclovir,mechanism,Ganciclovir: Administration BRAND 2 hours prior concurrent oral DRUG associated 111 (114)% increase steady state AUC didanosine (n = 12).
1994,"A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).",VIDEX,ganciclovir,mechanism,21 (17)% decrease steady state AUC ganciclovir observed BRAND administered 2 hours prior DRUG two drugs administered simultaneously (n = 12).
1995,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",VIDEX,ciprofloxacin,advise,Quinolone Antibiotics: BRAND administered least 2 hours 6 hours dosing DRUG plasma concentrations ciprofloxacin decreased administered antacids containing magnesium calcium aluminum.
1996,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,magnesium,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing ciprofloxacin plasma concentrations DRUG decreased administered antacids containing DRUG calcium aluminum.
1997,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,calcium,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing ciprofloxacin plasma concentrations DRUG decreased administered antacids containing magnesium DRUG aluminum.
1998,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,aluminum,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing ciprofloxacin plasma concentrations DRUG decreased administered antacids containing magnesium calcium DRUG .
1999,"In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.",ciprofloxacin,VIDEX,mechanism,eight HIV infected patients steady state AUC ciprofloxacin decreased average 26% (95% CI = 14% 37%) DRUG administered 2 hours prior marketed chewable/dispersible tablet formulation BRAND .
2000,The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.,ciprofloxacin,didanosine,mechanism,AUC ciprofloxacin decreased average 15 fold 12 healthy subjects given DRUG DRUG placebo tablets concurrently.
2001,"In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.",ciprofloxacin,didanosine,mechanism,single subject given one dose DRUG 2 hours dose DRUG placebo tablets greater 50% reduction AUC ciprofloxacin observed.
2002,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,magnesium,mechanism,Plasma concentrations GROUP decreased administered antacids containing DRUG calcium aluminum.
2003,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,calcium,mechanism,Plasma concentrations GROUP decreased administered antacids containing magnesium DRUG aluminum.
2004,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,aluminum,mechanism,Plasma concentrations GROUP decreased administered antacids containing magnesium calcium DRUG .
2005,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,delavirdine,VIDEX,mechanism,Interactions Antiretroviral Drugs: Significant decreases AUC DRUG (20%) indinavir (84%) occurred following simultaneous administration agents BRAND .
2006,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,indinavir,VIDEX,mechanism,Interactions Antiretroviral Drugs: Significant decreases AUC delavirdine (20%) DRUG (84%) occurred following simultaneous administration agents BRAND .
2007,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",delavirdine,VIDEX,advise,avoid interaction DRUG indinavir given 1 hour prior dosing BRAND .
2008,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",indinavir,VIDEX,advise,avoid interaction delavirdine DRUG given 1 hour prior dosing BRAND .
2009,The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.,SSRI,TCA,effect,extent GROUP GROUP interactions may pose clinical problems depend degree inhibition pharmacokinetics SSRI involved.
2010,"Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.",TCAs,SSRIs,advise,Nevertheless caution indicated coadministration GROUP GROUP also switching one class other.
2011,"Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.",amitriptyline HCl,anticholinergic,effect,Hyperpyrexia reported DRUG administered DRUG agents neuroleptic drugs particularly hot weather.
2012,Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.,tricyclic antidepressants,anticholinergic,effect,Paralytic ileus may occur patients taking DRUG combination DRUG type drugs.
2013,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.",Cimetidine,tricyclic antidepressants,mechanism,DRUG reported reduce hepatic metabolism certain DRUG thereby delaying elimination increasing steady state concentrations drugs.
2014,Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.,tricyclic antidepressants,cimetidine,effect,Clinically significant effects reported DRUG used concomitantly DRUG .
2015,"Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.",tricyclic antidepressants,cimetidine,mechanism,Increases plasma levels DRUG frequency severity side effects particularly anticholinergic reported DRUG added drug regimen.
2016,Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.,tricyclic antidepressants,cimetidine,mechanism,Discontinuation cimetidine well controlled patients receiving DRUG DRUG may decrease plasma levels efficacy antidepressants.
2017,Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.,ethchlorvynol,amitriptyline HCl,effect,Transient delirium reported patients treated one gram DRUG 75 150 mg DRUG .
2018,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,beta-blockers,Tiazac,effect,Pharmacologic studies indicate may additive effects prolonging AV conduction using GROUP digitalis concomitantly BRAND .
2019,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,digitalis,Tiazac,effect,Pharmacologic studies indicate may additive effects prolonging AV conduction using beta blockers GROUP concomitantly BRAND .
2020,Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.,diltiazem hydrochloride,propranolol,mechanism,Administration DRUG concomitantly DRUG five normal volunteers resulted increased propranolol levels subjects bioavailability propranolol increased approximately 50%.
2021,"In vitro, propranolol appears to be displaced from its binding sites by diltiazem.",propranolol,diltiazem,mechanism,vitro DRUG appears displaced binding sites DRUG .
2022,A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.,cimetidine,diltiazem,mechanism,study six healthy volunteers shown significant increase peak diltiazem plasma levels (58%) AUC (53%) 1 week course DRUG 1200 mg/day single dose DRUG 60mg.
2023,"The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.",cimetidine,diltiazem,mechanism,effect may mediated DRUG known inhibition hepatic cytochrome P 450 enzyme system responsible first pass metabolism DRUG .
2024,Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.,diltiazem,cimetidine,advise,Patients currently receiving DRUG therapy carefully monitored change pharmacological effect initiating discontinuing therapy DRUG .
2025,Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.,diltiazem hydrochloride,digoxin,mechanism,Administration DRUG DRUG 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
2026,"Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.",digoxin,diltiazem hydrochloride,advise,Since conflicting results regarding effect digoxin levels recommended DRUG levels monitored initiating adjusting discontinuing DRUG therapy avoid possible digitalization.
2027,"The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.",anesthetics,calcium channel blockers,effect,depression cardiac contractility conductivity automaticity well vascular dilation associated GROUP may potentiated GROUP .
2028,"When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.",anesthetics,calcium channel blockers,advise,used concomitantly GROUP GROUP titrated carefully.
2029,A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.,diltiazem,cyclosporine,int,pharmacokinetic interaction DRUG DRUG observed studies involving renal cardiac transplant patients.
2030,"In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.",cyclosporine,diltiazem,mechanism,renal cardiac transplant recipients reduction DRUG dose ranging 15% 48% necessary maintain cyclosporine trough concentrations similar seen prior addition DRUG .
2031,"If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.",cyclosporine,diltiazem,advise,agents administered concurrently DRUG concentrations monitored especially DRUG therapy initiated adjusted discontinued.
2032,"Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.",diltiazem,carbamazepine,mechanism,Concomitant administration DRUG DRUG reported result elevated serum levels carbamazepine (40% 72% increase) resulting toxicity cases.
2033,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,midazolam,mechanism,Studies showed DRUG increased AUC DRUG triazolam 3 4 fold Cmax 2 fold compared placebo.
2034,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,triazolam,mechanism,Studies showed DRUG increased AUC midazolam DRUG 3 4 fold Cmax 2 fold compared placebo.
2035,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,midazolam,diltiazem,mechanism,elimination half life DRUG triazolam also increased (1.5 2.5 fold) coadministration DRUG .
2036,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,triazolam,diltiazem,mechanism,elimination half life midazolam DRUG also increased (1.5 2.5 fold) coadministration DRUG .
2037,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,midazolam,effect,pharmacokinetic effects seen DRUG coadministration result increased clinical effects (e.g. prolonged sodation)of DRUG triazolam.
2038,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,triazolam,effect,pharmacokinetic effects seen DRUG coadministration result increased clinical effects (e.g. prolonged sodation)of midazolam DRUG .
2039,"In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;",diltiazem,lovastatin,mechanism,ten subject study coadministration DRUG (120 mg bid) DRUG resulted 3 4 times increase mean lovastatin AUC Cmax vs. lovastatin alone;
2040,Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.,rifampin,diltiazem,mechanism,Coadministration DRUG DRUG lowered diltiazem plasma concentrations undetectable levels.
2041,"Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.",diltiazem,rifampin,advise,Coadministration DRUG DRUG known CYP3A4 inducer avoided possible alternative therapy considered.
2042,Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.,CRIXIVAN,atazanavir,advise,Combinations drugs studied coadministration BRAND DRUG recommended.
2043,Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.,CRIXIVAN,delavirdine,advise,Dose reduction BRAND 600 mg every 8 hours considered taking DRUG 400 mg three times day.
2044,Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.,Indinavir,didanosine,advise,DRUG DRUG formulations containing buffer administered least one hour apart empty stomach.
2045,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.,indinavir,efavirenz,mechanism,Increasing indinavir dose 1000 mg every 8 hours compensate increased DRUG metabolism due DRUG .
2046,Indinavir concentrations may be decreased in the presence of nevirapine.,Indinavir,nevirapine,mechanism,DRUG concentrations may decreased presence DRUG .
2047,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.,indinavir,ritonavir,effect,Preliminary clinical data suggest incidence nephrolithiasis higher patients receiving DRUG combination DRUG receiving CRIXIVAN 800 mg q8h.
2048,Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.,antiarrhythmics,CRIXIVAN,advise,Caution warranted therapeutic concentration monitoring recommended GROUP coadministered BRAND .
2049,CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.,CRIXIVAN,indinavir,effect,BRAND may effective due decreased DRUG concentrations patients taking agents concomitantly.
2050,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",atorvastatin,CRIXIVAN,advise,Use lowest possible dose DRUG careful monitoring consider HMG CoA reductase inhibitors primarily metabolized CYP3A4 pravastatin fluvastatin rosuvastatin combination BRAND .
2051,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",HMG-CoA reductase inhibitors,CRIXIVAN,advise,Use lowest possible dose atorvastatin careful monitoring consider GROUP primarily metabolized CYP3A4 pravastatin fluvastatin rosuvastatin combination BRAND .
2052,Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.,CRIXIVAN,itraconazole,advise,Dose reduction BRAND 600 mg every 8 hours recommended administering DRUG concurrently.
2053,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.,rifabutin,CRIXIVAN,advise,Dose reduction rifabutin half standard dose dose increase CRIXIVAN 1000 mg (three 333 mg capsules) every 8 hours recommended DRUG BRAND coadministered.
2054,Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.,Sildenafil,indinavir,advise,DRUG dose exceed maximum 25 mg 48 hour period patients receiving concomitant DRUG therapy.
2055,Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.,Tadalafil,indinavir,advise,DRUG dose exceed maximum 10 mg 72 hour period patients receiving concomitant DRUG therapy.
2056,Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.,Vardenafil,indinavir,advise,DRUG dose exceed maximum 2.5 mg 24 hour period patients receiving concomitant DRUG therapy.
2057,"Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",digoxin,conivaptan,mechanism,Digoxin: Coadministration DRUG P glycoprotein substrate oral DRUG resulted reduction clearance increase digoxin Cmax AUC values.
2058,"Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.",digoxin,VAPRISOL,mechanism,Therefore DRUG administered BRAND clinician alert possibility increases digoxin levels.
2059,There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.,etidronate,warfarin,effect,isolated reports patients experiencing increases prothrombin times DRUG added DRUG therapy.
2060,Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.,escitalopram,non-selective MAO inhibitor,advise,Wait 5 weeks stopping DRUG starting GROUP .
2061,Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.,MAO inhibitor,escitalopram,advise,Wait 2 weeks stopping GROUP starting DRUG .
2062,Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.,Erythromycin,theophylline,effect,DRUG use patients receiving high doses DRUG may associated increase serum theophylline levels potential theophylline toxicity.
2063,"In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.",theophylline,erythromycin,advise,case theophylline toxicity and/or elevated serum theophylline levels dose DRUG reduced patient receiving concomitant DRUG therapy.
2064,Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Concomitant administration DRUG DRUG reported result elevated digoxin serum levels.
2065,There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,reports increased anticoagulant effects DRUG oral GROUP used concomitantly.
2066,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Concurrent use DRUG DRUG dihydroergotamine associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2067,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Concurrent use DRUG ergotamine DRUG associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2068,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,triazolam,mechanism,DRUG reported decrease clearance DRUG midazolam thus may increase pharmacologic effect benzodiazepines.
2069,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,midazolam,mechanism,DRUG reported decrease clearance triazolam DRUG thus may increase pharmacologic effect benzodiazepines.
2070,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,benzodiazepines,effect,DRUG reported decrease clearance triazolam midazolam thus may increase pharmacologic effect GROUP .
2071,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,carbamazepine,int,reports interactions DRUG DRUG cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2072,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cyclosporine,int,reports interactions DRUG carbamazepine DRUG tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2073,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,tacrolimus,int,reports interactions DRUG carbamazepine cyclosporine DRUG hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2074,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,hexobarbital,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus DRUG phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2075,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,phenytoin,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital DRUG alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2076,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,alfentanil,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin DRUG cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2077,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cisapride,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil DRUG disopyramide lovastatin bromocriptine valproate terfenadine astemizole.
2078,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,disopyramide,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride DRUG lovastatin bromocriptine valproate terfenadine astemizole.
2079,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,lovastatin,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide DRUG bromocriptine valproate terfenadine astemizole.
2080,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,bromocriptine,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin DRUG valproate terfenadine astemizole.
2081,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,valproate,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine DRUG terfenadine astemizole.
2082,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,terfenadine,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate DRUG astemizole.
2083,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,astemizole,int,reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine DRUG .
2084,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,terfenadine,mechanism,DRUG reported significantly alter metabolism nonsedating antihistamines DRUG astemizole taken concomitantly.
2085,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,astemizole,mechanism,DRUG reported significantly alter metabolism nonsedating antihistamines terfenadine DRUG taken concomitantly.
2086,"In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.",terfenadine,erythromycin,effect,addition deaths reported rarely concomitant administration DRUG DRUG .
2087,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",erythromycin,cisapride,effect,postmarketing reports drug interactions DRUG coadministered DRUG resulting QT prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation torsades de pointes like due inhibition hepatic metabolism cisapride erythromycin.
2088,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",cisapride,erythromycin,mechanism,postmarketing reports drug interactions erythromycin coadministered cisapride resulting QT prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation torsades de pointes like due inhibition hepatic metabolism DRUG DRUG .
2089,Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;,lovastatin,erythromycin,advise,Patients receiving concomitant DRUG DRUG carefully monitored;
2090,"Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ",neomycin,ACTH,effect,Studies rats shown DRUG administration attenuates certain types adrenocortical steroid dependent hypertension including DRUG hypertension.
2091,"Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,GROUP shown depress plasma prothrombin activity patients GROUP therapy may require downward adjustment anticoagulant dosage.
2092,"Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.",tetracycline class,penicillins,effect,Since bacteriostatic drugs GROUP antibiotics may interfere bactericidal action GROUP advisable administer drugs concomitantly.
2093,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent use GROUP oral GROUP may render oral contraceptives less effective.
2094,Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.,warfarin,flutamide,effect,Increases prothrombin time noted patients receiving long term DRUG therapy DRUG initiated.
2095,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.",EULEXIN,warfarin,advise,Therefore close monitoring prothrombin time recommended adjustment anticoagulant dose may necessary BRAND Capsules administered concomitantly DRUG .
2096,"in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.",terfenadine,dirithromycin,mechanism,one man C max terfenadine 8.1 ng/mL terfenadine alone 7.2 ng/mL DRUG plus DRUG .
2097,The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.,terfenadine,dirithromycin,effect,mean QT c interval (msec) 369 terfenadine alone 367 DRUG plus DRUG .
2098,"Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.",erythromycin,terfenadine,int,Thus interaction observed DRUG DRUG expected dirithromycin.
2099,"Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.",terfenadine,macrolide antibiotics,effect,Serious cardiac dysrhythmias resulting death occurred patients receiving DRUG concomitantly GROUP .
2100,"In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.",macrolides,terfenadine,advise,addition GROUP contraindicated patients receiving DRUG therapy pre existing cardiac abnormalities (arrhythmia bradycardia QT c interval prolongation ischemic heart disease congestive heart failure etc.) electrolyte disturbances.
2101,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,antacids,mechanism,Antacids H 2 receptor antagonists: DRUG administered immediately following GROUP H 2 receptor antagonists absorption dirithromycin slightly enhanced.
2102,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,H 2 -receptor antagonists,mechanism,Antacids H 2 receptor antagonists: DRUG administered immediately following antacids GROUP absorption dirithromycin slightly enhanced.
2103,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,mechanism,Triazolam: DRUG reported decrease clearance DRUG thus may increase pharmacologic effect triazolam.
2104,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,effect,Triazolam: DRUG reported decrease clearance triazolam thus may increase pharmacologic effect DRUG .
2105,Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Digoxin: Concomitant administration DRUG DRUG reported result elevated digoxin serum levels.
2106,Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,Anticoagulants: reports increased anticoagulant effects DRUG oral GROUP used concomitantly.
2107,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Ergotamine: Concurrent use DRUG DRUG dihydroergotamine associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2108,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Ergotamine: Concurrent use DRUG ergotamine DRUG associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia.
2109,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,cyclosporine,int,drugs Drug interactions reported concomitant administration DRUG medications including DRUG hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2110,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,hexobarbital,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine DRUG carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2111,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,carbamazepine,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital DRUG alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2112,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,alfentanil,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine DRUG disopyramide phenytoin bromocriptine valproate astemizole lovastatin.
2113,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,disopyramide,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil DRUG phenytoin bromocriptine valproate astemizole lovastatin.
2114,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,phenytoin,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide DRUG bromocriptine valproate astemizole lovastatin.
2115,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,bromocriptine,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin DRUG valproate astemizole lovastatin.
2116,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,valproate,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine DRUG astemizole lovastatin.
2117,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,astemizole,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate DRUG lovastatin.
2118,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,lovastatin,int,drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole DRUG .
2119,"The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.",REVIA,disulfiram,effect,safety efficacy concomitant use BRAND DRUG unknown concomitant use two potentially hepatotoxic medications ordinarily recommended unless probable benefits outweigh known risks.
2120,Lethargy and somnolence have been reported following doses of REVIA and thioridazine.,REVIA,thioridazine,effect,Lethargy somnolence reported following doses BRAND DRUG .
2121,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid,effect,Patients taking BRAND may benefit GROUP containing medicines cough cold preparations antidiarrheal preparations opioid analgesics.
2122,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid analgesics,effect,Patients taking BRAND may benefit opioid containing medicines cough cold preparations antidiarrheal preparations GROUP .
2123,"In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.",REVIA,opioid,effect,emergency situation opioid analgesia must administered patient receiving BRAND amount GROUP required may greater usual resulting respiratory depression may deeper prolonged.
2124,Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.,hydrochlorothiazide,anionic exchange resins,mechanism,Cholestyramine colestipol resins: Absorption DRUG impaired presence GROUP .
2125,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",cholestyramine,hydrochlorothiazide,mechanism,Single doses either DRUG colestipol resins bind DRUG reduce absorption gastrointestinal tract 85 43 percent respectively.
2126,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",colestipol,hydrochlorothiazide,mechanism,Single doses either cholestyramine DRUG resins bind DRUG reduce absorption gastrointestinal tract 85 43 percent respectively.
2127,Lithium: generally should not be given with diuretics.,Lithium,diuretics,advise,DRUG : generally given GROUP .
2128,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,GROUP reduce renal clearance DRUG add high risk lithium toxicity.
2129,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,effect,GROUP reduce renal clearance lithium add high risk DRUG toxicity.
2130,Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.,lithium,Hydrochlorothiazide,advise,Refer package insert DRUG preparations use preparations DRUG .
2131,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2132,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2133,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing GROUP .
2134,"Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",Hydrochlorothiazide,non-steroidal anti-inflammatory agents,advise,Therefore DRUG GROUP used concomitantly patient observed closely determine desired effect diuretic obtained.
2135,"The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. ",trichlorfon,coumaphos,effect,treatment ewes intravenous (IV) injection DRUG_N insufficient produce significant inhibition erythrocyte acetylcholinesterase (AChE) activity appeared produce additive effects produced subsequent treatment 4 mg DRUG_N /kg/day.
2136,"In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. ",phenobarbital sodium,coumaphos,effect,ewes given 40 mg DRUG /kg 5 days intraperitoneally (IP) anticholinesterase effect 4 mg DRUG_N /kg significantly reduced signs toxicity present.
2137,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased nephrotoxicity reported following concomitant administration GROUP GROUP .
2138,Sulfacetamide preparations are incompatible with silver preparations.,Sulfacetamide,silver,int,DRUG preparations incompatible DRUG preparations.
2139,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,vasodilators,effect,However DRUG potential increase hypotensive effect GROUP antihypertensive agents.
2140,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,antihypertensive agents,effect,However DRUG potential increase hypotensive effect vasodilators GROUP .
2141,"Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.",iloprost,anticoagulants,effect,Since DRUG inhibits platelet function potential increased risk bleeding particularly patients maintained GROUP .
2142,RAPTIVA should not be used with other immunosuppressive drugs.,RAPTIVA,immunosuppressive drugs,advise,BRAND used GROUP .
2143,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",Acellular vaccines,RAPTIVA,advise,Acellular live live attenuated GROUP administered BRAND treatment.
2144,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live vaccines,RAPTIVA,advise,Acellular live live attenuated GROUP administered BRAND treatment.
2145,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live-attenuated vaccines,RAPTIVA,advise,Acellular live GROUP administered BRAND treatment.
2146,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,fat-soluble vitamins,mechanism,DRUG interferes absorption GROUP including vitamin preparations.
2147,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,vitamin D preparations,mechanism,DRUG interferes absorption fat soluble vitamins including GROUP .
2148,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.,thiazide diuretics,ergocalciferol,effect,Administration GROUP hypoparathyroid patients concurrently treated DRUG may cause hypercalcemia.
2149,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,loop diuretics,advise,DRUG administered concomitantly potent GROUP furosemide ethacrynic acid potential ototoxicity enhanced combination.
2150,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,furosemide,advise,DRUG administered concomitantly potent loop diuretics DRUG ethacrynic acid potential ototoxicity enhanced combination.
2151,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,ethacrynic acid,advise,DRUG administered concomitantly potent loop diuretics furosemide DRUG potential ototoxicity enhanced combination.
2152,"When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.",amiloride,angiotensin-converting enzyme inhibitor,effect,DRUG HCl administered concomitantly GROUP risk hyperkalemia may increased.
2153,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally given GROUP reduce renal clearance add high risk lithium toxicity.
2154,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2155,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2156,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing GROUP .
2157,"Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",MIDAMOR,non-steroidal anti-inflammatory agents,advise,Therefore BRAND GROUP used concomitantly patient observed closely determine desired effect diuretic obtained.
2158,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,potassium-sparing diuretics,effect,Since DRUG GROUP including MIDAMOR may associated increased serum potassium levels potential effects potassium kinetics renal function considered agents administered concurrently.
2159,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,MIDAMOR,effect,Since DRUG potassium sparing diuretics including BRAND may associated increased serum potassium levels potential effects potassium kinetics renal function considered agents administered concurrently.
2160,"- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.",bumetanide,aminoglycoside antibiotics,advise,Drugs ototoxic potential: Especially presence impaired renal function use parenterally administered DRUG patients GROUP also given avoided except life threatening conditions.
2161,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,Lithium: DRUG generally given GROUP (such bumetanide) reduce renal clearance add high risk lithium toxicity.
2162,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,bumetanide,advise,Lithium: DRUG generally given diuretics (such DRUG ) reduce renal clearance add high risk lithium toxicity.
2163,- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.,probenecid,bumetanide,effect,Probenecid: Pretreatment DRUG reduces natriuresis hyperreninemia produced DRUG .
2164,This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.,probenecid,bumetanide,mechanism,antagonistic effect DRUG DRUG natriuresis due direct action sodium excretion probably secondary inhibitory effect renal tubular secretion bumetanide.
2165,"Thus, probenecid should not be administered concurrently with bumetanide.",probenecid,bumetanide,advise,Thus DRUG administered concurrently DRUG .
2166,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,mechanism,Indomethacin: DRUG blunts increases urine volume sodium excretion seen DRUG treatment inhibits bumetanide induced increase plasma renin activity.
2167,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,effect,Indomethacin: DRUG blunts increases urine volume sodium excretion seen bumetanide treatment inhibits DRUG induced increase plasma renin activity.
2168,"- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.",Bumetanide,antihypertensive drugs,effect,Antihypertensives: DRUG may potentiate effect various GROUP necessitating reduction dosage drugs.
2169,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,hypoglycemic action GROUP may potentiated certain drugs including GROUP drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2170,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound GROUP sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2171,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates GROUP chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2172,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides DRUG probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2173,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol DRUG coumarins monoamine oxidase inhibitors beta adrenergic blocking agents.
2174,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid GROUP monoamine oxidase inhibitors beta adrenergic blocking agents.
2175,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins GROUP beta adrenergic blocking agents.
2176,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,hypoglycemic action GROUP may potentiated certain drugs including nonsteroidal anti inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors GROUP .
2177,"A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.",glyburide,ciprofloxacin,int,possible interaction DRUG DRUG fluoroquinolone antibiotic reported resulting potentiation hypoglycemic action glyburide.
2178,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,effect,potential interaction oral DRUG oral GROUP leading severe hypoglycemia reported.
2179,"Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.",anticoagulants,chlordiazepoxide,effect,Although clinical studies established cause effect relationship physicians aware variable effects blood coagulation reported rarely patients receiving oral GROUP DRUG .
2180,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,amikacin,advise,DRUG administered concomitantly DRUG ciprofloxacin gentamicin netilmicin tobramycin.
2181,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,ciprofloxacin,advise,DRUG administered concomitantly amikacin DRUG gentamicin netilmicin tobramycin.
2182,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,gentamicin,advise,DRUG administered concomitantly amikacin ciprofloxacin DRUG netilmicin tobramycin.
2183,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,netilmicin,advise,DRUG administered concomitantly amikacin ciprofloxacin gentamicin DRUG tobramycin.
2184,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,tobramycin,advise,DRUG administered concomitantly amikacin ciprofloxacin gentamicin netilmicin DRUG .
2185,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,didanosine,mechanism,Concurrent administration DRUG DRUG significantly reduces level exposure indinavir unclear soon didanosine administration indinavir may given safely.
2186,Median gastric pH was significantly higher when indinavir was taken after didanosine administration; ,indinavir,didanosine,mechanism,Median gastric pH significantly higher DRUG taken DRUG administration;
2187,Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.,Indinavir,didanosine,advise,DRUG may taken light meal 1 h following administration 400 mg DRUG .
2188,"Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.",vitamin B12,folic acid,int,Medications interfere folate utilization including: anticonvulsant medications (such phenytoin primidone) metformin (sometimes prescribed control blood sugar type 2 diabetes) sulfasalazine (used control inflammation associated Crohns disease ulcerative colitis) triamterene (a diuretic) Methotrexate concern interaction DRUG DRUG .
2189,"Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.",magnesium trisilicate,nitrofurantoin,mechanism,Antacids containing DRUG administered concomitantly DRUG reduce rate extent absorption.
2190,The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.,nitrofurantoin,magnesium trisilicate,mechanism,mechanism interaction probably adsorption DRUG onto surface DRUG .
2191,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",Uricosuric drugs,nitrofurantoin,mechanism,GROUP probenecid sulfinpyrazone inhibit renal tubular secretion DRUG .
2192,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",probenecid,nitrofurantoin,mechanism,Uricosuric drugs DRUG sulfinpyrazone inhibit renal tubular secretion DRUG .
2193,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",sulfinpyrazone,nitrofurantoin,mechanism,Uricosuric drugs probenecid DRUG inhibit renal tubular secretion DRUG .
2194,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",aminoglycosides,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. GROUP indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate asparaginase) effects BRAND may increase toxicity organ systems.
2195,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",indomethacin,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides DRUG ) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate asparaginase) effects BRAND may increase toxicity organ systems.
2196,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",cytotoxic,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. GROUP chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate asparaginase) effects BRAND may increase toxicity organ systems.
2197,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",doxorubicin,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. DRUG ) hepatotoxic (e.g. methotrexate asparaginase) effects BRAND may increase toxicity organ systems.
2198,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",methotrexate,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. DRUG asparaginase) effects BRAND may increase toxicity organ systems.
2199,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",asparaginase,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e.g. aminoglycosides indomethacin) myelotoxic (e.g. cytotoxic chemotherapy) cardiotoxic (e.g. doxorubicin) hepatotoxic (e.g. methotrexate DRUG ) effects BRAND may increase toxicity organ systems.
2200,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,antineoplastic agents,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose BRAND GROUP specifically dacarbazine cis platinum tamoxifen interferon alfa.
2201,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,dacarbazine,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose BRAND antineoplastic agents specifically DRUG cis platinum tamoxifen interferon alfa.
2202,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,cis-platinum,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose BRAND antineoplastic agents specifically dacarbazine DRUG tamoxifen interferon alfa.
2203,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,tamoxifen,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose BRAND antineoplastic agents specifically dacarbazine cis platinum DRUG interferon alfa.
2204,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,interferon-alfa,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose BRAND antineoplastic agents specifically dacarbazine cis platinum tamoxifen DRUG .
2205,"Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.",PROLEUKIN,interferon-alfa,effect,Myocardial injury including myocardial infarction myocarditis ventricular hypokinesia severe rhabdomyolysis appear increased patients receiving BRAND DRUG concurrently.
2206,"Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.",interferon-alfa,PROLEUKIN,effect,Exacerbation initial presentation number autoimmune inflammatory disorders observed following concurrent use DRUG BRAND including crescentic IgA glomerulonephritis oculo bulbar myasthenia gravis inflammatory arthritis thyroiditis bullous pemphigoid Stevens Johnson syndrome.
2207,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",glucocorticoids,PROLEUKIN,effect,Although GROUP shown reduce BRAND induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents PROLEUKIN may reduce antitumor effectiveness PROLEUKIN thus avoided. 12 Beta blockers antihypertensives may potentiate hypotension seen PROLEUKIN.
2208,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",Beta-blockers,PROLEUKIN,effect,Although glucocorticoids shown reduce PROLEUKIN induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents PROLEUKIN may reduce antitumor effectiveness PROLEUKIN thus avoided. 12 GROUP antihypertensives may potentiate hypotension seen BRAND .
2209,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",antihypertensives,PROLEUKIN,effect,Although glucocorticoids shown reduce PROLEUKIN induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents PROLEUKIN may reduce antitumor effectiveness PROLEUKIN thus avoided. 12 Beta blockers GROUP may potentiate hypotension seen BRAND .
2210,"Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.",interleukin-2,radiographic iodinated contrast media,effect,Delayed Adverse Reactions Iodinated Contrast Media: review literature revealed 12.6% (range 11 28%) 501 patients treated various DRUG containing regimens subsequently administered GROUP experienced acute atypical adverse reactions.
2211,"Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.",Cevimeline,beta adrenergic antagonists,advise,DRUG administered caution patients taking GROUP possibility conduction disturbances.
2212,PROSTIN E2 may augment the activity of other oxytocic drugs.,PROSTIN E2,oxytocic drugs,effect,BRAND may augment activity GROUP .
2213,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: DRUG reported reduce intestinal absorption GROUP ;
2214,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration DRUG phenobarbital affect plasma concentrations vitamin may reduce endogenous plasma levels DRUG /ergocalcitriol accelerating metabolism.
2215,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,Phenytoin/Phenobarbital: coadministration phenytoin DRUG affect plasma concentrations vitamin may reduce endogenous plasma levels DRUG /ergocalcitriol accelerating metabolism.
2216,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,reports shown concomitant administration GROUP GROUP causes hypercalcemia.
2217,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: GROUP dosage must determined care patients undergoing treatment GROUP hypercalcemia patients may precipitate cardiac arrhythmias.
2218,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: DRUG may inhibit synthetic catabolic enzymes GROUP .
2219,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,Corticosteroids: relationship functional antagonism exists GROUP promote calcium absorption GROUP inhibit calcium absorption.
2220,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,Magnesium: DRUG containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy GROUP patients chronic renal dialysis.
2221,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,Magnesium: Magnesium containing preparations (eg GROUP ) may cause hypermagnesemia therefore taken therapy GROUP patients chronic renal dialysis.
2222,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",cholestyramine,thiazide diuretics,effect,May interact following: DRUG colestipol (use GROUP may prevent diuretic working properly;
2223,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",colestipol,thiazide diuretics,effect,May interact following: cholestyramine DRUG (use GROUP may prevent diuretic working properly;
2224,Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. ,antidepressant drugs,hypoglycemic agents,int,Treatment GROUP directly interfere blood glucose levels may interact GROUP .
2225,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",CNS depressant drugs,INAPSINE,effect,GROUP (e.g. barbiturates tranquilizers opioids general anesthetics) additive potentiating effects BRAND .
2226,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",barbiturates,INAPSINE,effect,CNS depressant drugs (e.g. GROUP tranquilizers opioids general anesthetics) additive potentiating effects BRAND .
2227,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",tranquilizers,INAPSINE,effect,CNS depressant drugs (e.g. barbiturates GROUP opioids general anesthetics) additive potentiating effects BRAND .
2228,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",opioids,INAPSINE,effect,CNS depressant drugs (e.g. barbiturates tranquilizers GROUP general anesthetics) additive potentiating effects BRAND .
2229,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",anesthetics,INAPSINE,effect,CNS depressant drugs (e.g. barbiturates tranquilizers opioids general GROUP ) additive potentiating effects BRAND .
2230,"Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.",INAPSINE,CNS depressant drugs,advise,Following administration BRAND dose GROUP reduced.
2231,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. ",pentazocine,tripelennamine,effect,Twelve strains Staphylococcus aureus (a frequent cause infection heroin DRUG DRUG addicts) completely inhibited drug combination.
2232,"Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. ",tripelennamine,pentazocine,effect,Dose response curves (derived results using tablets well pure powders) showed DRUG responsible inhibitory activity partially antagonized DRUG .
2233,"Interaction of ketamine and halothane in rats.
",ketamine,halothane,int,Interaction DRUG DRUG rats.
2234,"However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. ",halothane,ketamine,mechanism,However DRUG anesthetic requirement (i.e. MAC) depressed dose dependent fashion much 56% 1 2 hours much 14% 5 6 hours injection DRUG 50 mg/kg im.
2235,The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ,ketamine,halothane,mechanism,half life DRUG plasma brain longer presence DRUG ketamine given alone.
2236,It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.,ketamine,halothane,effect,concluded DRUG short acting drug concomitant use DRUG would expected prolong duration action central nervous system.
2237,Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.,Isoproterenol hydrochloride,epinephrine,advise,DRUG injection DRUG administered simultaneously drugs direct cardiac stimulants combined effects may induce serious arrhythmias.
2238,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,anesthetics,advise,BRAND used caution potent inhalational GROUP halothane employed potential sensitize myocardium effects sympathomimetic amines.
2239,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,halothane,advise,BRAND used caution potent inhalational anesthetics DRUG employed potential sensitize myocardium effects sympathomimetic amines.
2240,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,phenytoin,effect,effectiveness GROUP pills reduced hepatic enzyme inducing drugs anticonvulsants DRUG carbamazepine barbiturates antituberculosis drug rifampin.
2241,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,carbamazepine,effect,effectiveness GROUP pills reduced hepatic enzyme inducing drugs anticonvulsants phenytoin DRUG barbiturates antituberculosis drug rifampin.
2242,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,barbiturates,effect,effectiveness GROUP pills reduced hepatic enzyme inducing drugs anticonvulsants phenytoin carbamazepine GROUP antituberculosis drug rifampin.
2243,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,rifampin,effect,effectiveness GROUP pills reduced hepatic enzyme inducing drugs anticonvulsants phenytoin carbamazepine barbiturates antituberculosis drug DRUG .
2244,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,calcium carbonate,mechanism,Concomitant administration BRAND DRUG cimetidine omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2245,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,cimetidine,mechanism,Concomitant administration BRAND calcium carbonate DRUG omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2246,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,omeprazole,mechanism,Concomitant administration BRAND calcium carbonate cimetidine DRUG estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2247,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,estrogen,mechanism,Concomitant administration BRAND calcium carbonate cimetidine omeprazole GROUP /progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2248,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,progesterone,mechanism,Concomitant administration BRAND calcium carbonate cimetidine omeprazole estrogen/ DRUG oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2249,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,contraceptive,mechanism,Concomitant administration BRAND calcium carbonate cimetidine omeprazole estrogen/progesterone oral GROUP produced minor changes pharmacokinetics gemifloxacin considered without clinical significance.
2250,Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.,FACTIVE,probenecid,mechanism,Concomitant administration BRAND DRUG resulted 45% increase systemic exposure gemifloxacin.
2251,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolones,warfarin,effect,However GROUP reported enhance anticoagulant effects DRUG derivatives patients prothrombin time suitable coagulation test closely monitored quinolone antimicrobial administered concomitantly warfarin derivatives.
2252,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,However quinolones reported enhance anticoagulant effects warfarin derivatives patients prothrombin time suitable coagulation test closely monitored GROUP administered concomitantly DRUG derivatives.
2253,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,aluminum,mechanism,absorption oral DRUG significantly reduced concomitant administration antacid containing DRUG magnesium.
2254,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,magnesium,mechanism,absorption oral DRUG significantly reduced concomitant administration antacid containing aluminum DRUG .
2255,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Magnesium,FACTIVE,advise,DRUG and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2256,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",aluminum,FACTIVE,advise,Magnesium and/or DRUG containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2257,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",ferrous sulfate,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing DRUG (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2258,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",iron,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate ( DRUG ) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2259,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",multivitamin preparations,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) GROUP containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2260,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",zinc,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing DRUG metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2261,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Videx,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations BRAND (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2262,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",didanosine,FACTIVE,advise,Magnesium and/or aluminum containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx ( DRUG ) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours BRAND .
2263,Sucralfate should not be taken within 2 hours of FACTIVE.,Sucralfate,FACTIVE,advise,DRUG taken within 2 hours BRAND .
2264,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Steroids,edetate calcium disodium,effect,GROUP enhance renal toxicity DRUG animals. 7 Edetate calcium disodium interferes action zinc insulin preparations chelating zinc. 7
2265,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Edetate calcium disodium,zinc insulin,mechanism,Steroids enhance renal toxicity edetate calcium disodium animals. 7 DRUG interferes action DRUG preparations chelating zinc. 7
2266,(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.),thiazide diuretics,digitalis,effect,(Concurrent use GROUP may enhance possibility GROUP toxicity associated hypokalemia.)
2267,"for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;",hypoglycemic medications,thiazide diuretic,advise,adult onset diabetics dosage adjustment GROUP may necessary GROUP therapy;
2268,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,loop diuretics,effect,(In patients GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2269,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,potassium sparing diuretics,effect,(In patients GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2270,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,thiazide diuretics,effect,(In patients GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing GROUP .
2271,"Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)",hydroflumethiazide,nonsteroidal anti-inflammatory agents,advise,Therefore DRUG GROUP used concomitantly patient observed closely determine desired effect diuretic obtained.)
2272,(Thiazides may decrease arterial responsiveness to norepinephrine.,Thiazides,norepinephrine,effect,( GROUP may decrease arterial responsiveness DRUG .
2273,(Thiazide drugs may increase the responsiveness to tubocurarine.),Thiazide drugs,tubocurarine,effect,( GROUP may increase responsiveness DRUG .)
2274,"Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.",HMG-CoA reductase inhibitors,Fentanyl,advise,Experience co administration HMG CoA reductase inhibitors Fentanyl patients limited therefore consideration given temporarily suspending use GROUP patients receiving DRUG .
2275,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,acetaminophen,effect,Acetaminophen methotrexate DRUG may decrease hepatic toxicity DRUG overdosage taking methotrexate.
2276,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,methotrexate,effect,Acetaminophen methotrexate DRUG may decrease hepatic toxicity acetaminophen overdosage taking DRUG .
2277,Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.,Methionine,gentamicin,effect,Gentamicin DRUG may protect ototoxic effects DRUG .
2278,"Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.",BETAGAN,epinephrine,effect,Although BETAGAN used alone little effect pupil size mydriasis resulting concomitant therapy BRAND DRUG may occur.
2279,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.",beta-blocker,reserpine,advise,Close observation patient recommended GROUP administered patients receiving catecholamine depleting drugs DRUG possible additive effects production hypotension and/or marked bradycardia may produce vertigo syncope postural hypotension.
2280,"Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.",beta-adrenergic blocking agents,calcium antagonists,advise,Patients receiving GROUP along either oral intravenous GROUP monitored possible atrioventricular conduction disturbances left ventricular failure hypotension.
2281,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,digitalis,effect,concomitant use GROUP GROUP calcium antagonists may additive effects prolonging atrioventricular conduction time.
2282,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,calcium antagonist,effect,concomitant use GROUP digitalis GROUP may additive effects prolonging atrioventricular conduction time.
2283,Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.,Phenothiazine-related compounds,beta-adrenergic blocking agents,mechanism,GROUP GROUP may additive hypotensite effects due inhibition metabolism.
2284,International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.,warfarin,IRESSA,effect,International Normalized Ratio (INR) elevations and/or bleeding events reported patients taking DRUG BRAND therapy.
2285,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg DRUG itraconazole) decrease DRUG metabolism increase gefitinib plasma concentrations.
2286,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg DRUG itraconazole) decrease gefitinib metabolism increase DRUG plasma concentrations.
2287,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole DRUG ) decrease DRUG metabolism increase gefitinib plasma concentrations.
2288,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole DRUG ) decrease gefitinib metabolism increase DRUG plasma concentrations.
2289,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,histamine H2-receptor antagonists,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH ( GROUP ranitidine cimetidine) may reduce plasma concentrations BRAND therefore potentially may reduce efficacy.
2290,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,ranitidine,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2 receptor antagonists DRUG cimetidine) may reduce plasma concentrations BRAND therefore potentially may reduce efficacy.
2291,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,cimetidine,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2 receptor antagonists ranitidine DRUG ) may reduce plasma concentrations BRAND therefore potentially may reduce efficacy.
2292,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.",IRESSA,vinorelbine,effect,Phase II clinical trial data IRESSA vinorelbine used concomitantly indicate BRAND may exacerbate neutropenic effect DRUG .
2293,"There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.",loxapine,lorazepam,effect,rare reports significant respiratory depression stupor and/or hypotension concomitant use DRUG DRUG .
2294,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,ketoconazole,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering BRAND inhibitors CYP3A4 family (e.g. DRUG itraconazole erythromycin clarithromycin).
2295,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,itraconazole,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering BRAND inhibitors CYP3A4 family (e.g. ketoconazole DRUG erythromycin clarithromycin).
2296,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,erythromycin,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering BRAND inhibitors CYP3A4 family (e.g. ketoconazole itraconazole DRUG clarithromycin).
2297,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,clarithromycin,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering BRAND inhibitors CYP3A4 family (e.g. ketoconazole itraconazole erythromycin DRUG ).
2298,There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).,Gleevec,ketoconazole,mechanism,significant increase exposure imatinib BRAND coadministered DRUG (CYP3A4 inhibitor).
2299,"Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).",rifampin,Gleevec,mechanism,Pretreatment healthy volunteers multiple doses DRUG followed single dose BRAND increased Gleevec oral dose clearance 3.8 fold significantly (p 0.05) decreased mean cmax AUC(0 8).
2300,"Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.",Gleevec,simvastatin,mechanism,Drugs may plasma concentration altered Gleevec BRAND increases mean cmax AUC DRUG (CYP3A4 substrate) 2 3.5 fold respectively suggesting inhibition CYP3A4 Gleevec.
2301,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,cyclosporine,advise,Particular caution recommended administering BRAND CYP3A4 substrates narrow therapeutic window (e.g. DRUG pimozide).
2302,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,pimozide,advise,Particular caution recommended administering BRAND CYP3A4 substrates narrow therapeutic window (e.g. cyclosporine DRUG ).
2303,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,benzodiazepines,mechanism,BRAND increase plasmaconcentration CYP3A4 metabolized drugs (e.g. triazolo GROUP dihydropyridine calcium channel blockers certain HMG CoA reductase inhibitors etc.).
2304,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,dihydropyridine calcium channel blockers,mechanism,BRAND increase plasmaconcentration CYP3A4 metabolized drugs (e.g. triazolo benzodiazepines GROUP certain HMG CoA reductase inhibitors etc.).
2305,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,HMG-CoA reductase inhibitors,mechanism,BRAND increase plasmaconcentration CYP3A4 metabolized drugs (e.g. triazolo benzodiazepines dihydropyridine calcium channel blockers certain GROUP etc.).
2306,Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.,acetaminophen,Gleevec,mechanism,Systemic exposure DRUG expected increased coadministered BRAND .
2307,A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.,FOSCAVIR,pentamidine,int,possible drug interaction BRAND intravenous DRUG described.
2308,Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;,FOSCAVIR,pentamidine,effect,Concomitant treatment four patients United Kingdom BRAND intravenous DRUG may caused hypocalcemia;
2309,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,aminoglycosides,advise,foscarnets tendency cause renal impairment use BRAND avoided combination potentially nephrotoxic drugs GROUP amphotericin B intravenous pentamidine unless potential benefits outweigh risks patient.
2310,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,amphotericin B,advise,foscarnets tendency cause renal impairment use BRAND avoided combination potentially nephrotoxic drugs aminoglycosides DRUG intravenous pentamidine unless potential benefits outweigh risks patient.
2311,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,pentamidine,advise,foscarnets tendency cause renal impairment use BRAND avoided combination potentially nephrotoxic drugs aminoglycosides amphotericin B intravenous DRUG unless potential benefits outweigh risks patient.
2312,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergotamine,naratriptan,advise,theoretical basis effects may additive use DRUG containing ergot type medications (like dihydroergotamine methysergide) DRUG within 24 hours contraindicated.
2313,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergot-type medications,naratriptan,advise,theoretical basis effects may additive use ergotamine containing GROUP (like dihydroergotamine methysergide) DRUG within 24 hours contraindicated.
2314,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",dihydroergotamine,naratriptan,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like DRUG methysergide) DRUG within 24 hours contraindicated.
2315,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",methysergide,naratriptan,advise,theoretical basis effects may additive use ergotamine containing ergot type medications (like dihydroergotamine DRUG ) DRUG within 24 hours contraindicated.
2316,"Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.",naratriptan,5-HT1 agonists,advise,vasospastic effects may additive coadministration DRUG GROUP within 24 hours recommended.
2317,"If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",naratriptan,SSRI,advise,concomitant treatment DRUG GROUP clinically warranted appropriate observation patient advised.
2318,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,fluconazole,int,Clinical studies DRUG identified potentially significant interactions DRUG lithium.
2319,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,lithium,int,Clinical studies DRUG identified potentially significant interactions fluconazole DRUG .
2320,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,furosemide,int,Experience GROUP (NSAIDs) suggests potential interactions DRUG ACE inhibitors.
2321,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,ACE inhibitors,int,Experience GROUP (NSAIDs) suggests potential interactions furosemide GROUP .
2322,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,furosemide,int,Experience nonsteroidal anti inflammatory drugs ( GROUP ) suggests potential interactions DRUG ACE inhibitors.
2323,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,ACE inhibitors,int,Experience nonsteroidal anti inflammatory drugs ( GROUP ) suggests potential interactions furosemide GROUP .
2324,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE inhibitors: Reports suggest GROUP may diminish antihypertensive effect GROUP .
2325,This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.,CELEBREX,ACE-inhibitors,advise,interaction given consideration patients taking BRAND concomitantly GROUP .
2326,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect DRUG thiazides patients.
2327,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown GROUP reduce natriuretic effect furosemide GROUP patients.
2328,Aspirin: CELEBREX can be used with low dose aspirin.,CELEBREX,aspirin,advise,Aspirin: BRAND used low dose BRAND .
2329,"However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.",aspirin,CELEBREX,effect,However concomitant administration BRAND BRAND may result increased rate GI ulceration complications compared use CELEBREX alone.
2330,Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.,fluconazole,celecoxib,mechanism,Fluconazole: Concomitant administration DRUG 200 mg QD resulted two fold increase DRUG plasma concentration.
2331,This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).,celecoxib,fluconazole,mechanism,increase due inhibition DRUG metabolism via P450 2C9 DRUG (see CLINICAL PHARMACOLOGY Pharmacokinetics: Metabolism).
2332,CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.,CELEBREX,fluconazole,advise,BRAND introduced lowest recommended dose patients receiving DRUG .
2333,"Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.",lithium,CELEBREX,mechanism,Lithium: study conducted healthy subjects mean steady state lithium plasma levels increased approximately 17% subjects receiving DRUG 450 mg BID BRAND 200 mg BID compared subjects receiving lithium alone.
2334,Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.,lithium,CELEBREX,advise,Patients DRUG treatment closely monitored BRAND introduced withdrawn.
2335,"However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.",CELEBREX,warfarin,advise,However caution used administering BRAND DRUG since patients increased risk bleeding complications.
2336,Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.,L-histidine,medroxyprogesterone acetate,effect,Medroxyprogesterone Acetate DRUG observed enhance (in tissue culture) effect DRUG reducing number human breast cancer cells phase.
2337,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H1 blockers,effect,H1 H2 Blockers Although reported DRUG via metabolism histamine might decrease efficacy H1 H2 GROUP .
2338,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H2 blockers,effect,H1 H2 Blockers Although reported DRUG via metabolism histamine might decrease efficacy H1 GROUP .
2339,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,Dexamethasone,EGF,effect,DRUG retinyl acetate similarly inhibit stimulate DRUG_N insulin induced proliferation prostatic epithelium.
2340,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,Dexamethasone,insulin,effect,DRUG retinyl acetate similarly inhibit stimulate EGF DRUG induced proliferation prostatic epithelium.
2341,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,retinyl acetate,EGF,effect,Dexamethasone DRUG similarly inhibit stimulate DRUG_N insulin induced proliferation prostatic epithelium.
2342,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,retinyl acetate,insulin,effect,Dexamethasone DRUG similarly inhibit stimulate EGF DRUG induced proliferation prostatic epithelium.
2343,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",dexamethasone,EGF,effect,Although neither DRUG retinyl acetate affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect DRUG_N insulin.
2344,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",dexamethasone,insulin,effect,Although neither DRUG retinyl acetate affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect EGF DRUG .
2345,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",retinyl acetate,EGF,effect,Although neither dexamethasone DRUG affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect DRUG_N insulin.
2346,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",retinyl acetate,insulin,effect,Although neither dexamethasone DRUG affected proliferation prostatic epithelium RPMI1640 containing transferrin alone modify mitogenic effect EGF DRUG .
2347,Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ,Dexamethasone,EGF,effect,DRUG 10( 10) retinyl acetate 3 X 10( 9) inhibits proliferation stimulated DRUG_N .
2348,Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ,retinyl acetate,EGF,effect,Dexamethasone 10( 10) DRUG 3 X 10( 9) inhibits proliferation stimulated DRUG_N .
2349,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ,dexamethasone,EGF,effect,Higher concentrations DRUG (10( 8) 10( 6) M) retinyl acetate (3 X 10( 8) 10( 7) M) enhance mitogenic activity DRUG_N .
2350,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ,retinyl acetate,EGF,effect,Higher concentrations dexamethasone (10( 8) 10( 6) M) DRUG (3 X 10( 8) 10( 7) M) enhance mitogenic activity DRUG_N .
2351,"However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. ",retinyl acetate,insulin,effect,However DRUG stimulated significantly inhibit proliferation presence DRUG .
2352,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",dexamethasone,insulin,effect,results suggest DRUG retinyl acetate possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity DRUG EGF.
2353,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",dexamethasone,EGF,effect,results suggest DRUG retinyl acetate possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin DRUG_N .
2354,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinyl acetate,insulin,effect,results suggest dexamethasone DRUG possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity DRUG EGF.
2355,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinyl acetate,EGF,effect,results suggest dexamethasone DRUG possibly glucocorticoids retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin DRUG_N .
2356,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",glucocorticoids,insulin,effect,results suggest dexamethasone retinyl acetate possibly GROUP retinoids may regulate proliferation prostate epithelium dose dependent modification activity DRUG EGF.
2357,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",glucocorticoids,EGF,effect,results suggest dexamethasone retinyl acetate possibly GROUP retinoids may regulate proliferation prostate epithelium dose dependent modification activity insulin DRUG_N .
2358,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinoids,insulin,effect,results suggest dexamethasone retinyl acetate possibly glucocorticoids GROUP may regulate proliferation prostate epithelium dose dependent modification activity DRUG EGF.
2359,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinoids,EGF,effect,results suggest dexamethasone retinyl acetate possibly glucocorticoids GROUP may regulate proliferation prostate epithelium dose dependent modification activity insulin DRUG_N .
2360,"An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. ",perchlorate,pertechnetate,mechanism,intravenous injection DRUG_N given later also produces complete immediately beginning depletion DRUG already accumulated thyroid within period 195 min 99m TcO 4 injection corresponding increase blood levels.
2361,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,theophylline,mechanism,However systemic administration GROUP shown elevate plasma concentrations DRUG interfere metabolism caffeine enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly.
2362,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,caffeine,mechanism,However systemic administration GROUP shown elevate plasma concentrations theophylline interfere metabolism DRUG enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly.
2363,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,warfarin,effect,However systemic administration GROUP shown elevate plasma concentrations theophylline interfere metabolism caffeine enhance effects oral anticoagulant DRUG derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly.
2364,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,cyclosporine,effect,However systemic administration GROUP shown elevate plasma concentrations theophylline interfere metabolism caffeine enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic DRUG concomitantly.
2365,Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.,Erythromycin,vardenafil,mechanism,DRUG (500 mg t.i.d) produced 4 fold increase DRUG AUC 3 fold increase Cmax co administered Vardenafil 5 mg healthy volunteers.
2366,It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.,Vardenafil,erythromycin,advise,recommended exceed single 5 mg dose DRUG 24 hour period used combination DRUG .
2367,Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.,Ketoconazole,vardenafil,mechanism,DRUG (200 mg daily) produced 10 fold increase DRUG AUC 4 fold increase Cmax co administered Vardenafil (5 mg) healthy volunteers.
2368,A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.,Vardenafil,ketoconazole,advise,5 mg DRUG dose exceeded used combination 200 mg daily DRUG .
2369,"Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.",Vardenafil,ketoconazole,advise,Since higher doses ketoconazole (400 mg daily) may result higher increases Cmax AUC single 2.5 mg dose DRUG exceeded 24 hour period used combination DRUG 400 mg daily.
2370,"HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.",Indinavir,Vardenafil,mechanism,HIV Protease Inhibitors: DRUG (800 mg t.i.d.) co administered DRUG 10 mg resulted 16 fold increase vardenafil AUC 7 fold increase vardenafil Cmax 2 fold increase vardenafil half life.
2371,It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.,Vardenafil,indinavir,advise,recommended exceed single 2.5 mg DRUG dose 24 hour period used combination DRUG .
2372,Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.,Ritonavir,Vardenafil,mechanism,DRUG (600 mg b.i.d.) co administered DRUG 5 mg resulted 49 fold increase vardenafil AUC 13 fold increase vardenafil Cmax.
2373,"The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.",vardenafil,ritonavir,mechanism,interaction consequence blocking hepatic metabolism DRUG DRUG highly potent CYP3A4 inhibitor also inhibits CYP2C9.
2374,Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.,Ritonavir,vardenafil,mechanism,DRUG significantly prolonged half life DRUG 26 hours.
2375,"Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.",Vardenafil,ritonavir,advise,Consequently recommended exceed single 2.5 mg DRUG dose 72 hour period used combination DRUG .
2376,"In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.",nitrates,vardenafil,mechanism,vivo studies: Nitrates: blood pressure lowering effects sublingual GROUP (0.4 mg) taken 1 4 hours DRUG increases heart rate taken 1 4 8 hours potentiated 20 mg dose Vardenafil healthy middle aged subjects.
2377,"Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.",Vardenafil,nitrates,advise,Potentiation hypotensive effects nitrates patients ischemic heart disease evaluated concomitant use DRUG GROUP contraindicated.
2378,"In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.",nifedipine,Vardenafil,effect,patients whose hypertension controlled DRUG DRUG 20 mg produced mean additional supine systolic/diastolic blood pressure reductions 6/5 mm Hg compared placebo.
2379,"Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.",Vardenafil,terazosin,effect,Alpha blockers: DRUG 10 20 mg given healthy volunteers either simultaneously 6 hours 10 mg dose DRUG significant hypotension developed substantial number subjects.
2380,"With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,simultaneous dosing DRUG 10 mg DRUG 10 mg 6 8 subjects experienced standing systolic blood pressure less 85 mm Hg.
2381,"With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,simultaneous dosing DRUG 20 mg DRUG 10 mg 2 9 subjects experienced standing systolic blood pressure less 85 mm Hg.
2382,"When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.",Vardenafil,terazosin,effect,DRUG dosing separated DRUG 10 mg 6 hours 7 28 subjects received 20 mg Vardenafil experienced decrease standing systolic blood pressure 85 mm Hg.
2383,"In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.",Vardenafil,tamsulosin,effect,similar study tamsulosin healthy volunteers 1 24 subjects dosed DRUG 20 mg DRUG 0.4 mg separated 6 hours experienced standing systolic blood pressure 85 mm Hg.
2384,Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.,Vardenafil,tamsulosin,effect,Two 16 subjects dosed simultaneously DRUG 10 mg DRUG 0.4 mg experienced standing systolic blood pressure 85 mm Hg.
2385,"Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.",Vardenafil,alpha-blocker,advise,Based data DRUG used patients GROUP therapy.
2386,"Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.",Vardenafil,ritonavir,mechanism,Ritonavir indinavir: Upon concomitant administration 5 mg DRUG 600 mg BID DRUG Cmax AUC ritonavir reduced approximately 20%.
2387,"Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.",Vardenafil,indinavir,mechanism,Upon administration 10 mg DRUG 800 mg TID DRUG Cmax AUC indinavir reduced 40% 30% respectively.
2388,"High-dose cisplatin with sodium thiosulfate protection.
",cisplatin,sodium thiosulfate,effect,High dose DRUG DRUG protection.
2389,Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. ,Sodium thiosulfate,cisplatin,effect,DRUG neutralizing agent DRUG protects renal damage.
2390,This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.,thiosulfate,cisplatin,mechanism,study demonstrates concurrent administration DRUG permits least twofold increase dose total exposure DRUG .
2391,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",b-lactam antibiotics,probenecid,mechanism,Probenecid: GROUP renal excretion loracarbef inhibited DRUG resulted approximate 80% increase AUC loracarbef.
2392,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",loracarbef,probenecid,mechanism,Probenecid: b lactam antibiotics renal excretion DRUG inhibited DRUG resulted approximate 80% increase AUC loracarbef.
2393,Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.,anticoagulants,thyroid,advise,Patients stabilized oral GROUP found require GROUP replacement therapy watched closely thyroid started.
2394,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T4,mechanism,Cholestyramine: DRUG binds DRUG T3 intestine thus impairing absorption thyroid hormones.
2395,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T3,mechanism,Cholestyramine: DRUG binds T4 DRUG intestine thus impairing absorption thyroid hormones.
2396,"Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.",cholestyramine,thyroid hormones,advise,Therefore 4 5 hours elapse administration DRUG GROUP .
2397,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.",levothyroxine,estrogens,mechanism,patient nonfunctioning thyroid gland receiving thyroid replacement therapy free DRUG may decreased GROUP started thus increasing thyroid requirements.
2398,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,estrogens,advise,Therefore patients without functioning GROUP gland thyroid replacement therapy may need increase thyroid dose GROUP estrogen containing oral contraceptives given.
2399,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,contraceptives,advise,Therefore patients without functioning GROUP gland thyroid replacement therapy may need increase thyroid dose estrogens estrogen containing oral GROUP given.
2400,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,imipramine,effect,Tricyclic Antidepressants: Use GROUP DRUG tricyclic antidepressants may increase receptor sensitivity enhance antidepressant activity transient cardiac arrhythmias observed.
2401,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,tricyclic antidepressants,effect,Tricyclic Antidepressants: Use GROUP imipramine GROUP may increase receptor sensitivity enhance antidepressant activity transient cardiac arrhythmias observed.
2402,Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.,Thyroid preparations,digitalis,effect,Digitalis: GROUP may potentiate toxic effects GROUP .
2403,"Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.",thyroid preparation,anesthetic,effect,Ketamine: administered patients GROUP parenteral GROUP may cause hypertension tachycardia.
2404,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,epinephrine,effect,Vasopressors: DRUG increases adrenergic effect catecholamines DRUG norepinephrine.
2405,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,norepinephrine,effect,Vasopressors: DRUG increases adrenergic effect catecholamines epinephrine DRUG .
2406,Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.,antacids,lactulose,mechanism,Results preliminary studies humans rats suggest nonabsorbable GROUP given concurrently DRUG may inhibit desired lactulose induced drop colonic pH.
2407,Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.,Digitalis,Bretylium Tosylate,effect,GROUP toxicity may aggravated initial release norepinephrine caused DRUG Injection.
2408,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,catecholamines,Bretylium Tosylate,effect,pressor effects GROUP dopamine norepinephrine enhanced DRUG .
2409,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,dopamine,Bretylium Tosylate,effect,pressor effects catecholamines DRUG norepinephrine enhanced DRUG .
2410,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,norepinephrine,Bretylium Tosylate,effect,pressor effects catecholamines dopamine DRUG enhanced DRUG .
2411,"Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ",Sildenafil,long-acting nitrates,advise,DRUG contraindicated patients using GROUP may need use short acting nitrates combination may cause sharp fall blood pressure.
2412,"Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ",Sildenafil,short-acting nitrates,advise,DRUG contraindicated patients using long acting nitrates may need use GROUP combination may cause sharp fall blood pressure.
2413,"Interaction of clindamycin and gentamicin in vitro.
",clindamycin,gentamicin,int,Interaction DRUG DRUG vitro.
2414,Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. ,clindamycin,gentamicin,effect,Combinations DRUG DRUG indifferent 29 strains synergistic 33 strains.
2415,Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. ,clindamycin,gentamicin,effect,Combinations DRUG DRUG indifferent 16 synergistic 11 resistant strains.
2416,These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; ,ethanol,acetaldehyde,effect,results suggest hepatoxicity DRUG alcoholic beverages enhanced interaction congeners DRUG_N ;
2417,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,muscle relaxants,effect,DRUG potentiates muscle relaxant effect GROUP notably nondepolarizing muscle relaxants MAC (minimum alveolar concentration) reduced concomitant administration N 2O.
2418,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,nondepolarizing muscle relaxants,effect,DRUG potentiates muscle relaxant effect muscle relaxants notably GROUP MAC (minimum alveolar concentration) reduced concomitant administration N 2O.
2419,Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.,MAO inhibitors,dopamine HCl,advise,Patients treated GROUP within two three weeks prior administration DRUG receive initial doses dopamine HCl greater one tenth (1/10) usual dose.
2420,Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.,dopamine HCl,diuretic agents,effect,Concurrent administration low dose DRUG GROUP may produce additive potentiating effect urine flow.
2421,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,beta-adrenergic blocking agents,effect,Cardiac effects DRUG antagonized GROUP propranolol metoprolol.
2422,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,propranolol,effect,Cardiac effects DRUG antagonized beta adrenergic blocking agents DRUG metoprolol.
2423,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,metoprolol,effect,Cardiac effects DRUG antagonized beta adrenergic blocking agents propranolol DRUG .
2424,The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.,dopamine HCl,alpha-adrenergic blocking agents,effect,peripheral vasoconstriction caused high doses DRUG antagonized GROUP .
2425,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,Butyrophenones,dopamine,effect,GROUP (such haloperidol) phenothiazines suppress DRUG rgic renal mesenteric vasodilation induced low dose dopamine infusion.
2426,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,haloperidol,dopamine,effect,Butyrophenones (such DRUG ) phenothiazines suppress DRUG rgic renal mesenteric vasodilation induced low dose dopamine infusion.
2427,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,phenothiazines,dopamine,effect,Butyrophenones (such haloperidol) GROUP suppress DRUG rgic renal mesenteric vasodilation induced low dose dopamine infusion.
2428,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,catecholamines,effect,DRUG halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered GROUP dopamine.
2429,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,dopamine,effect,DRUG halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines DRUG .
2430,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,catecholamines,effect,Cyclopropane GROUP increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered GROUP dopamine.
2431,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,dopamine,effect,Cyclopropane GROUP increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines DRUG .
2432,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,cyclopropane,advise,Therefore EXTREME CAUTION exercised administering DRUG patients receiving DRUG halogenated hydrocarbon anesthetics.
2433,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,halogenated hydrocarbon anesthetics,advise,Therefore EXTREME CAUTION exercised administering DRUG patients receiving cyclopropane GROUP .
2434,It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.,dopamine,propranolol,effect,reported results studies animals indicate DRUG induced ventricular arrhythmias anesthesia reversed DRUG .
2435,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",vasopressor,oxytocic drugs,effect,concomitant use GROUP vasoconstricting agents (such ergonovine) GROUP may result severe hypertension.
2436,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",ergonovine,oxytocic drugs,effect,concomitant use vasopressors vasoconstricting agents (such DRUG ) GROUP may result severe hypertension.
2437,Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.,phenytoin,dopamine HCl,effect,Administration DRUG patients receiving DRUG reported lead hypotension bradycardia.
2438,"It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.",dopamine HCl,phenytoin,advise,suggested patients receiving DRUG alternatives DRUG used anticonvulsant therapy needed.
2439,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,narcotic analgesics,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain GROUP meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2440,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,meperidine,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics DRUG phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2441,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,phenothiazines,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine GROUP antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2442,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antipsychotics,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines GROUP tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2443,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,tricyclic antidepressants,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics GROUP certain antiarrhythmics quinidine salts antihistamines.
2444,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antiarrhythmics,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain GROUP quinidine salts antihistamines.
2445,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,quinidine,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics DRUG salts antihistamines.
2446,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antihistamines,effect,Drug Interactions: central GROUP syndrome occur anticholinergic agents AKINETON administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts GROUP .
2447,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,narcotic analgesics,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain GROUP meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2448,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,meperidine,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics DRUG phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2449,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,phenothiazines,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine GROUP antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2450,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antipsychotics,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines GROUP tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines.
2451,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,tricyclic antidepressants,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics GROUP certain antiarrhythmics quinidine salts antihistamines.
2452,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antiarrhythmics,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain GROUP quinidine salts antihistamines.
2453,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,quinidine,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics DRUG salts antihistamines.
2454,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antihistamines,effect,Drug Interactions: central anticholinergic syndrome occur anticholinergic agents BRAND administered concomitantly drugs secondary anticholinergic actions e.g. certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts GROUP .
2455,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ritonavir,mechanism,concomitant use transdermal DRUG DRUG potent 3A4 inhibitors ketoconazole itraconazole troleandomycin clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2456,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ketoconazole,mechanism,concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors DRUG itraconazole troleandomycin clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2457,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,itraconazole,mechanism,concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole DRUG troleandomycin clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2458,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,troleandomycin,mechanism,concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole itraconazole DRUG clarithromycin nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2459,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,clarithromycin,mechanism,concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole itraconazole troleandomycin DRUG nelfinavir nefazadone may result increase fentanyl plasma concentrations.
2460,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,nelfinavir,mechanism,concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole itraconazole troleandomycin clarithromycin DRUG nefazadone may result increase fentanyl plasma concentrations.
2461,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",diltiazem,fentanyl,mechanism,concomitant use CYP3A4 inhibitors DRUG erythromycin transdermal DRUG may also result increase fentanyl plasma concentrations could increase prolong adverse drug effects may cause serious respiratory depression.
2462,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",erythromycin,fentanyl,mechanism,concomitant use CYP3A4 inhibitors diltiazem DRUG transdermal DRUG may also result increase fentanyl plasma concentrations could increase prolong adverse drug effects may cause serious respiratory depression.
2463,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,central nervous system depressants,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) GROUP including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2464,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,opioids,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited GROUP sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2465,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,sedatives,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids GROUP hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2466,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,hypnotics,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives GROUP tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2467,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,tranquilizers,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics GROUP (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2468,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,benzodiazepines,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. GROUP ) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2469,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,anesthetics,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general GROUP phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2470,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,phenothiazines,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics GROUP skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2471,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,skeletal muscle relaxants,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines GROUP alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2472,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,alcohol,effect,Central Nervous System Depressants: concomitant use BRAND (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants DRUG may cause respiratory depression hypotension profound sedation potentially result coma death.
2473,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,central nervous system depressants,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) GROUP including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2474,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,opioids,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited GROUP sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2475,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,sedatives,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids GROUP hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2476,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,hypnotics,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids sedatives GROUP tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2477,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,tranquilizers,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids sedatives hypnotics GROUP (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2478,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,benzodiazepines,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. GROUP ) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2479,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,anesthetics,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general GROUP phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2480,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,phenothiazines,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics GROUP skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2481,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,skeletal muscle relaxants,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines GROUP alcohol may cause respiratory depression hypotension profound sedation potentially result coma death.
2482,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,alcohol,effect,Central Nervous System Depressants: concomitant use DURAGESIC ( DRUG transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e.g. benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants DRUG may cause respiratory depression hypotension profound sedation potentially result coma death.
2483,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,DURAGESIC,MAOI,advise,MAO Inhibitors: BRAND recommended use patients received GROUP within 14 days severe unpredictable potentiation MAO inhibitors reported opioid analgesics
2484,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,MAO inhibitors,opioid analgesics,advise,MAO Inhibitors: DURAGESIC recommended use patients received MAOI within 14 days severe unpredictable potentiation GROUP reported GROUP
2485,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,coumarin anticoagulant,mechanism,vitro studies shown BRAND displace GROUP warfarin protein binding sites.
2486,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,warfarin,mechanism,vitro studies shown BRAND displace coumarin anticoagulants DRUG protein binding sites.
2487,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,coumarin anticoagulants,advise,recommended BRAND started patients already receiving GROUP prothrombin times closely monitored adjustment anticoagulant dose may necessary.
2488,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,anticoagulant,advise,recommended BRAND started patients already receiving coumarin anticoagulants prothrombin times closely monitored adjustment GROUP dose may necessary.
2489,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,tricyclic antidepressants,effect,administration local GROUP containing epinephrine norepinephrine patients receiving monoamine oxidase inhibitors GROUP phenothiazines may produce severe prolonged hypotension hypertension.
2490,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,phenothiazines,effect,administration local GROUP containing epinephrine norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants GROUP may produce severe prolonged hypotension hypertension.
2491,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing DRUG norepinephrine patients receiving GROUP tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension.
2492,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors GROUP phenothiazines may produce severe prolonged hypotension hypertension.
2493,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,phenothiazines,effect,administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants GROUP may produce severe prolonged hypotension hypertension.
2494,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,administration local anesthetic solutions containing epinephrine DRUG patients receiving GROUP tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension.
2495,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,tricyclic antidepressants,effect,administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors GROUP phenothiazines may produce severe prolonged hypotension hypertension.
2496,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,phenothiazines,effect,administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants GROUP may produce severe prolonged hypotension hypertension.
2497,"Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.",vasopressor drugs,ergot-type oxytocic drugs,effect,Concurrent administration GROUP (for treatment hypotension related obstetric blocks) GROUP may cause severe persistent hypertension cerebrovascular accidents.
2498,"Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.",chloroprocaine,sulfonamide drug,advise,Therefore DRUG used condition GROUP employed.
2499,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;",Anticholinergic agents,digoxin,mechanism,GROUP may affect gastrointestinal absorption various drugs slowly dissolving dosage forms DRUG ;
2500,"Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.",Anticholinergic drugs,metoclopramide,mechanism,GROUP may antagonize effects drugs alter gastrointestinal motility DRUG .
2501,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.",antacids,anticholinergic agents,mechanism,GROUP may interfere absorption GROUP simultaneous use drugs avoided.
2502,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).",ENBREL,anakinra,effect,study patients active RA treated 24 weeks concurrent BRAND DRUG therapy 7% rate serious infections observed higher observed ENBREL alone (0%).
2503,Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).,ENBREL,anakinra,effect,Two percent patients treated concurrently BRAND DRUG developed neutropenia (ANC 1 x 109/L).
2504,"Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.",sulfasalazine,ENBREL,effect,Patients clinical study established therapy DRUG BRAND added noted develop mild decrease mean neutrophil counts comparison groups treated either ENBREL CI sulfasalazine alone.
2505,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,nabumetone,warfarin,advise,Caution exercised administering DRUG DRUG since interactions seen NSAIDs.
2506,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,warfarin,NSAIDs,int,Caution exercised administering nabumetone DRUG since interactions seen GROUP .
2507,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",ofloxacin,KRM-1648,effect,combined DRUG DRUG_N exhibited strong synergistic activity additive effects observed combination rifampicin (or rifabutin) ofloxacin.
2508,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",rifampicin,ofloxacin,effect,combined ofloxacin KRM 1648 exhibited strong synergistic activity additive effects observed combination DRUG (or rifabutin) DRUG .
2509,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",rifabutin,ofloxacin,effect,combined ofloxacin KRM 1648 exhibited strong synergistic activity additive effects observed combination rifampicin (or DRUG ) DRUG .
2510,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,central nervous system depressants,effect,Concurrent use DRUG GROUP (e.g. alcohol barbiturates tranquilizers antihistamines) may result increased central nervous system depressant effects.
2511,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,alcohol,effect,Concurrent use DRUG central nervous system depressants (e.g. DRUG barbiturates tranquilizers antihistamines) may result increased central nervous system depressant effects.
2512,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,barbiturates,effect,Concurrent use DRUG central nervous system depressants (e.g. alcohol GROUP tranquilizers antihistamines) may result increased central nervous system depressant effects.
2513,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,tranquilizers,effect,Concurrent use DRUG central nervous system depressants (e.g. alcohol barbiturates GROUP antihistamines) may result increased central nervous system depressant effects.
2514,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,antihistamines,effect,Concurrent use DRUG central nervous system depressants (e.g. alcohol barbiturates tranquilizers GROUP ) may result increased central nervous system depressant effects.
2515,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.",STADOL NS,sumatriptan,mechanism,However another study healthy volunteers pharmacokinetics butorphanol significantly altered (29% decrease AUC 38% decrease Cmax) 1 mg dose BRAND administered 1 minute 20 mg dose DRUG nasal spray.
2516,"When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.",STADOL NS,sumatriptan,mechanism,BRAND administered 30 minutes DRUG nasal spray AUC butorphanol increased 11% Cmax decreased 18%.
2517,"These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.",STADOL NS,sumatriptan,effect,results suggest analgesic effect BRAND may diminished administered shortly DRUG nasal spray 30 minutes reduction effect minimal.
2518,"It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.",butorphanol,erythromycin,advise,known effects DRUG altered concomitant medications affect hepatic metabolism drugs ( DRUG etc.) physicians alert possibility smaller initial dose longer intervals doses may needed.
2519,"Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.",STADOL NS,nasal vasoconstrictor,effect,Therefore slower onset anticipated BRAND administered concomitantly immediately following GROUP .
2520,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalapril,effect,Hypotension: Patients Diuretic Therapy: Patients DRUG especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy DRUG enalaprilat.
2521,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalaprilat,effect,Hypotension: Patients Diuretic Therapy: Patients DRUG especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy enalapril DRUG .
2522,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalapril,diuretic,effect,possibility hypotensive effects DRUG enalaprilat minimized either discontinuing DRUG increasing salt intake prior initiation treatment enalapril enalaprilat.
2523,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalaprilat,diuretic,effect,possibility hypotensive effects enalapril DRUG minimized either discontinuing DRUG increasing salt intake prior initiation treatment enalapril enalaprilat.
2524,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,Agents Causing Renin Release: antihypertensive effect DRUG enalapril IV augmented GROUP cause renin release (e.g. diuretics).
2525,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,Agents Causing Renin Release: antihypertensive effect DRUG enalapril IV augmented antihypertensive agents cause renin release (e.g. GROUP ).
2526,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,Agents Causing Renin Release: antihypertensive effect enalapril DRUG IV augmented GROUP cause renin release (e.g. diuretics).
2527,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,Agents Causing Renin Release: antihypertensive effect enalapril DRUG IV augmented antihypertensive agents cause renin release (e.g. GROUP ).
2528,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.",nonsteroidal anti-inflammatory drugs,enalapril,effect,Non steroidal Anti inflammatory Agents: patients compromised renal function treated GROUP co administration DRUG may result deterioration renal function.
2529,"However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.",NSAIDs,ACE inhibitors,effect,However reports suggest GROUP may diminish antihypertensive effect GROUP .
2530,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking GROUP concomitantly GROUP .
2531,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,Enalapril,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: DRUG enalapril IV attenuate potassium loss caused GROUP .
2532,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,enalapril,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: Enalapril DRUG IV attenuate potassium loss caused GROUP .
2533,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,Lithium: Lithium toxicity reported patients receiving DRUG concomitantly drugs cause elimination sodium including GROUP .
2534,It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.,enalapril,lithium,advise,recommended serum lithium levels monitored frequently DRUG administered concomitantly DRUG .
2535,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,Colchicine,vitamin B12,mechanism,DRUG para aminosalicylic acid heavy alcohol intake longer 2 weeks may produce malabsorption DRUG .
2536,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,para-aminosalicylic acid,vitamin B12,mechanism,Colchicine DRUG heavy alcohol intake longer 2 weeks may produce malabsorption DRUG .
2537,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,alcohol,vitamin B12,mechanism,Colchicine para aminosalicylic acid heavy DRUG intake longer 2 weeks may produce malabsorption DRUG .
2538,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,probenecid,effect,Uricosuric Agents: BRAND may decrease effects DRUG sulfinpyrazone phenylbutazone.
2539,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,sulfinpyrazone,effect,Uricosuric Agents: BRAND may decrease effects probenecid DRUG phenylbutazone.
2540,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,phenylbutazone,effect,Uricosuric Agents: BRAND may decrease effects probenecid sulfinpyrazone DRUG .
2541,Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.,Alcohol,aspirin,effect,DRUG : synergistic effect BRAND causing gastrointestinal bleeding.
2542,Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.,Corticosteroids,aspirin,effect,GROUP : Concomitant administration BRAND may increase risk gastrointestinal ulceration may reduce serum salicylate levels.
2543,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",Pyrazolone Derivatives,aspirin,effect,GROUP (phenylbutazone oxyphenbutazone possibly dipyrone): Concomitant administration DRUG may increase risk gastrointestinal ulceration.
2544,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",phenylbutazone,aspirin,effect,Pyrazolone Derivatives ( DRUG oxyphenbutazone possibly dipyrone): Concomitant administration DRUG may increase risk gastrointestinal ulceration.
2545,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",oxyphenbutazone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone DRUG possibly dipyrone): Concomitant administration DRUG may increase risk gastrointestinal ulceration.
2546,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",dipyrone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone oxyphenbutazone possibly DRUG ): Concomitant administration DRUG may increase risk gastrointestinal ulceration.
2547,Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.,Aspirin,nonsteroidal anti-inflammatory,advise,Nonsteroidal Antiinflammatory Agents: DRUG contraindicated patients hypersensitive DRUG agents.
2548,Phenobarbital: Decreases aspirin effectiveness by enzyme induction.,Phenobarbital,aspirin,mechanism,DRUG : Decreases BRAND effectiveness enzyme induction.
2549,Phenytoin: Serum phenytoin levels may be increased by aspirin.,phenytoin,aspirin,effect,Phenytoin: Serum DRUG levels may increased BRAND .
2550,Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.,Propranolol,aspirins,effect,DRUG : May decrease BRAND anti inflammatory action competing receptors.
2551,"Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.",Aspirin,antacids,advise,Antacids: Enteric Coated BRAND given concurrently GROUP since increase pH stomach may effect enteric coating tablets.
2552,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ketoconazole,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg DRUG itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2553,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,itraconazole,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole DRUG erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2554,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,erythromycin,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole DRUG clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2555,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,clarithromycin,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin DRUG ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2556,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ritonavir,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin DRUG atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2557,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,atazanavir,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir DRUG indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2558,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,indinavir,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir DRUG nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2559,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nefazodone,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir DRUG nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided.
2560,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nelfinavir,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone DRUG saquinavir telithromycin) may increase exposure dasatinib avoided.
2561,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,saquinavir,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir DRUG telithromycin) may increase exposure dasatinib avoided.
2562,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,telithromycin,mechanism,Concomitant use BRAND drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir DRUG ) may increase exposure dasatinib avoided.
2563,Simultaneous administration of SPRYCEL with antacids should be avoided.,SPRYCEL,antacids,advise,Simultaneous administration BRAND GROUP avoided.
2564,"If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.",antacid,SPRYCEL,advise,GROUP therapy needed antacid dose administered least 2 hours prior 2 hours dose BRAND .
2565,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",H2 blockers,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion GROUP proton pump inhibitors (eg famotidine omeprazole) likely reduce DRUG exposure.
2566,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",proton pump inhibitors,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion H2 blockers GROUP (eg famotidine omeprazole) likely reduce DRUG exposure.
2567,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",famotidine,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg DRUG omeprazole) likely reduce DRUG exposure.
2568,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",omeprazole,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg famotidine DRUG ) likely reduce DRUG exposure.
2569,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,H2 blockers,SPRYCEL,advise,concomitant use GROUP proton pump inhibitors BRAND recommended.
2570,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,proton pump inhibitors,SPRYCEL,advise,concomitant use H2 blockers GROUP BRAND recommended.
2571,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,H2 blockers,SPRYCEL,advise,use antacids considered place GROUP proton pump inhibitors patients receiving BRAND therapy.
2572,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,proton pump inhibitors,SPRYCEL,advise,use antacids considered place H2 blockers GROUP patients receiving BRAND therapy.
2573,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",alfentanil,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index DRUG astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2574,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",astemizole,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil DRUG terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2575,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",terfenadine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole DRUG cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2576,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cisapride,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine DRUG cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2577,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cyclosporine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride DRUG fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2578,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",fentanyl,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine DRUG pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2579,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",pimozide,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl DRUG quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2580,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",quinidine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide DRUG sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2581,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",sirolimus,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine DRUG tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2582,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",tacrolimus,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus DRUG ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2583,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergot alkaloids,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus GROUP (ergotamine dihydroergotamine) administered caution patients receiving BRAND .
2584,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergotamine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids ( DRUG dihydroergotamine) administered caution patients receiving BRAND .
2585,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",dihydroergotamine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine DRUG ) administered caution patients receiving BRAND .
2586,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",interferon beta-1a,TYSABRI,mechanism,multiple dosing DRUG (AVONEX 30 mcg IM weekly) reduced BRAND clearance approximately 30%.
2587,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",AVONEX,TYSABRI,mechanism,multiple dosing interferon beta 1a ( BRAND 30 mcg IM weekly) reduced BRAND clearance approximately 30%.
2588,"Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.",terfenadine,Itraconazole,mechanism,Coadministration DRUG DRUG led elevated plasma concentrations terfenadine resulting rare instances life threatening cardiac dysrhythmias one death.
2589,"Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.",ketoconazole,astemizole,mechanism,Another oral azole antifungal DRUG inhibits metabolism DRUG resulting elevated plasma concentrations astemizole active metabolite desmethylastermizole may prolong QT intervals.
2590,"In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.",itraconazole,astemizole,mechanism,vitro data suggest DRUG compared ketoconazole less pronounced effect biotransformation system responsible metabolism DRUG .
2591,"Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.",astemizole,itraconazole,advise,Based chemical resemblance itraconazole ketoconazole coadministration DRUG DRUG contraindicated.
2592,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.,ketoconazole,cisapride,mechanism,Human pharmacokinetics data indicate oral DRUG potently inhibits metabolism DRUG resulting eight fold increase mean AUC cisapride.
2593,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data suggest coadministration oral DRUG DRUG result prolongation QT interval ECG.
2594,In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;,itraconazole,cisapride,mechanism,vitro data suggest DRUG also markedly inhibits biotransformation system mainly responsible metabolism DRUG ;
2595,therefore concomitant administration of Itraconazole with cisapride is contraindicated.,Itraconazole,cisapride,advise,therefore concomitant administration DRUG DRUG contraindicated.
2596,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,midazolam,mechanism,Coadministration DRUG oral DRUG triazolam resulted elevated plasma concentrations latter two drugs.
2597,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,triazolam,mechanism,Coadministration DRUG oral midazolam DRUG resulted elevated plasma concentrations latter two drugs.
2598,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,cyclosporine,mechanism,Coadministration DRUG DRUG tacrolimus digoxin led increased plasma concentrations latter three drugs.
2599,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,tacrolimus,mechanism,Coadministration DRUG cyclosporine DRUG digoxin led increased plasma concentrations latter three drugs.
2600,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,digoxin,mechanism,Coadministration DRUG cyclosporine tacrolimus DRUG led increased plasma concentrations latter three drugs.
2601,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",Cyclosporine,Itraconazole,advise,DRUG tacrolimus digoxin concentrations monitored initiation DRUG therapy frequently thereafter dose three drug products adjusted appropriately.
2602,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",tacrolimus,Itraconazole,advise,Cyclosporine DRUG digoxin concentrations monitored initiation DRUG therapy frequently thereafter dose three drug products adjusted appropriately.
2603,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",digoxin,Itraconazole,advise,Cyclosporine tacrolimus DRUG concentrations monitored initiation DRUG therapy frequently thereafter dose three drug products adjusted appropriately.
2604,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,immunosuppressive drugs,effect,Rhabdomyolysis observed patients receiving GROUP administered alone (at recommended dosages) concomitantly GROUP including cyclosporine.
2605,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,cyclosporine,effect,Rhabdomyolysis observed patients receiving GROUP administered alone (at recommended dosages) concomitantly immunosuppressive drugs including DRUG .
2606,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,phenytoin,mechanism,DRUG coadministered DRUG rifampin H2antagonists reduced plasma concentrations itraconazole reported.
2607,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,rifampin,mechanism,DRUG coadministered phenytoin DRUG H2antagonists reduced plasma concentrations itraconazole reported.
2608,"Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;",Itraconazole,phenytoin,mechanism,Although studies conducted concomitant administration DRUG DRUG may alter metabolism phenytoin;
2609,"therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.",phenytoin,Itraconazole,advise,therefore plasma concentrations DRUG also monitored given concurrently DRUG .
2610,It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.,Itraconazole,coumarin,effect,reported DRUG enhances anticoagulant effect GROUP like drugs.
2611,"Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.",Itraconazole,coumarin,advise,Therefore prothrombin time carefully monitored patients receiving DRUG GROUP like drugs simultaneously.
2612,Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.,azole antifungal agents,isoniazid,mechanism,Plasma concentrations GROUP reduced given concurrently DRUG .
2613,Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.,Itraconazole,isoniazid,advise,Itraconazole plasma concentrations monitored DRUG DRUG coadministered.
2614,Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.,azole antifungal agents,hypoglycemic agents,effect,Severe hypoglycemia reported patients concomitantly receiving GROUP oral GROUP .
2615,Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.,Itraconazole,hypoglycemic agents,advise,Blood glucose concentrations carefully monitored DRUG oral GROUP coadministered.
2616,Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.,Itraconazole,quinidine,effect,Tinnitus decreased hearing reported patients concomitantly receiving DRUG DRUG .
2617,Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.,Itraconazole,dihydropyridine calcium channel blockers,effect,Edema reported patients concomitantly receiving DRUG GROUP .
2618,"Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. ",Cytochalasin D,carbachol,effect,DRUG_N 10 microM preferentially blocked secretory effect DRUG synergism cAMP whereas effect histamine cAMP stimulated acid secretion within 15 min.
2619,Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. ,Cytochalasin D,carbachol,effect,DRUG_N inhibited DRUG stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due release Ca(2+) store.
2620,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,DRUG bacteriostatic antibiotic may antagonize bactercidal effect DRUG concurrent use drugs avoided.
2621,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",clarithromycin,cisapride,mechanism,Antibiotics: vitro and/or vivo data show DRUG erythromycin troleandomycin markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2622,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",erythromycin,cisapride,mechanism,Antibiotics: vitro and/or vivo data show clarithromycin DRUG troleandomycin markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2623,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",troleandomycin,cisapride,mechanism,Antibiotics: vitro and/or vivo data show clarithromycin erythromycin DRUG markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2624,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",anticholinergic compounds,cisapride,effect,Anticholinergics: Concurrent administration certain GROUP belladonna alkaloids dicyclomine would expected compromise beneficial effects DRUG .
2625,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",belladonna alkaloids,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds GROUP dicyclomine would expected compromise beneficial effects DRUG .
2626,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",dicyclomine,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds belladonna alkaloids DRUG would expected compromise beneficial effects DRUG .
2627,"It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.",cisapride,anticoagulant,advise,advisable check coagulation time within first days start discontinuation DRUG therapy appropriate adjustment GROUP dose necessary.
2628,"Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",nefazodone,cisapride,mechanism,Antidepressants: vitro data indicate DRUG inhibits metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2629,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",fluconazole,cisapride,mechanism,Antifungals: vitro and/or vivo data indicate DRUG itraconazole oral ketoconazole markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2630,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",itraconazole,cisapride,mechanism,Antifungals: vitro and/or vivo data indicate fluconazole DRUG oral ketoconazole markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2631,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",ketoconazole,cisapride,mechanism,Antifungals: vitro and/or vivo data indicate fluconazole itraconazole oral DRUG markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2632,"Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.",ketoconazole,cisapride,mechanism,Human pharmacokinetic data indicate oral DRUG markedly inhibits metabolism DRUG resulting mean eight fold increase AUC cisapride.
2633,A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.,cisapride,ketoconazole,effect,study 14 normal male female volunteers suggests coadministration DRUG DRUG result prolongation QT interval ECG.
2634,"H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.",Cimetidine,cisapride,mechanism,H2 Receptor Antagonists: DRUG coadministration leads increased peak plasma concentration AUC DRUG effect cisapride absorption coadministered ranitidine.
2635,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,cimetidine,cisapride,mechanism,gastrointestinal absorption DRUG ranitidine accelerated coadministered DRUG .
2636,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,ranitidine,cisapride,mechanism,gastrointestinal absorption cimetidine DRUG accelerated coadministered DRUG .
2637,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,indinavir,cisapride,mechanism,Protease Inhibitors: vitro data indicate DRUG ritonavir markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2638,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,ritonavir,cisapride,mechanism,Protease Inhibitors: vitro data indicate indinavir DRUG markedly inhibit metabolism DRUG result increase plasma cisapride levels prolongation QT interval ECG.
2639,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,antiarrhythmics,advise,DRUG used concomitantly drugs known prolong QT interval: certain GROUP including Class IA (such quinidine procainamide) Class III (such sotalol);
2640,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,quinidine,advise,DRUG used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such DRUG procainamide) Class III (such sotalol);
2641,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,procainamide,advise,DRUG used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such quinidine DRUG ) Class III (such sotalol);
2642,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,sotalol,advise,DRUG used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such quinidine procainamide) Class III (such DRUG );
2643,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,antidepressants,int,DRUG may interact GROUP aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2644,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,aspirin,int,DRUG may interact antidepressants BRAND barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2645,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,barbiturates,int,DRUG may interact antidepressants aspirin GROUP bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2646,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,bromocriptine,int,DRUG may interact antidepressants aspirin barbiturates DRUG calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2647,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,calcium,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine DRUG supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2648,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticosteroids,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements GROUP corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2649,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticotropin,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids DRUG cyclosporine dantrolene nicotine somatropin tamoxifen warfarin.
2650,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,cyclosporine,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin DRUG dantrolene nicotine somatropin tamoxifen warfarin.
2651,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,dantrolene,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine DRUG nicotine somatropin tamoxifen warfarin.
2652,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,nicotine,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene DRUG somatropin tamoxifen warfarin.
2653,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,somatropin,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine DRUG tamoxifen warfarin.
2654,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,tamoxifen,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin DRUG warfarin.
2655,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,warfarin,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen DRUG .
2656,"Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ",estradiol,noradrenaline,effect,Aortic rings intact endothelium high dose (4 mg/kg/day) DRUG group supersensitive DRUG compared vehicle low dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/ 0.09 7.30+/ 0.11 7.35+/ 0.04 respectively).
2657,"Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ",estradiol,noradrenaline,effect,Endothelium intact aortic rings high DRUG rats supersensitive DRUG compared vehicle progesterone progesterone + high estradiol treated rats (pD2 values = 7.77+/ 0.12 7.21+/ 0.13 6.93+/ 0.04 7.22+/ 0.18 respectively).
2658,"In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.",central nervous system depressants,heroin,effect,combination GROUP DRUG_N may still kill even experienced users particularly tolerance drug reduced strength usual dose increased.
2659,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,central nervous system depressants,effect,Toxicology studies DRUG_N related deaths reveal frequent involvement GROUP including alcohol benzodiazepines diazepam (Valium) rising degree methadone.
2660,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,alcohol,effect,Toxicology studies DRUG_N related deaths reveal frequent involvement central nervous system depressants including DRUG benzodiazepines diazepam (Valium) rising degree methadone.
2661,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,benzodiazepines,effect,Toxicology studies DRUG_N related deaths reveal frequent involvement central nervous system depressants including alcohol GROUP diazepam (Valium) rising degree methadone.
2662,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,diazepam,effect,Toxicology studies DRUG_N related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines DRUG (Valium) rising degree methadone.
2663,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,Valium,effect,Toxicology studies DRUG_N related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam ( BRAND ) rising degree methadone.
2664,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,methadone,effect,Toxicology studies DRUG_N related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam (Valium) rising degree DRUG .
2665,Cocaine sometimes proves to be fatal when used in combination with heroin.,Cocaine,heroin,effect,DRUG sometimes proves fatal used combination DRUG_N .
2666,"however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. ",nitrate,sildenafil,effect,however patients moderate severe cardiovascular disease taking GROUP therapy increased risk potentially serious cardiovascular adverse effects DRUG therapy.
2667,It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. ,MPTP,pargyline,effect,observed DRUG_N induced long lasting depletions striatal dopamine concentrations neurotoxic effect could prevented DRUG pretreatment.
2668,The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ,MPTP,amphetamine,effect,DRUG induced neuronal damage produced tolerance disruptive effects DRUG supersensitivity disruptive effects apomorphine rats responding schedule controlled paradigm.
2669,The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ,MPTP,apomorphine,effect,DRUG induced neuronal damage produced tolerance disruptive effects amphetamine supersensitivity disruptive effects DRUG rats responding schedule controlled paradigm.
2670,"Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. ",Methamphetamine,pargyline,effect,DRUG like MPTP produced depletions striatal dopamine actions potentiated DRUG pretreatment.
2671,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,Cholestytamine,thiazide diuretics,mechanism,Cholestyramine colestipol resins: DRUG colestipol resins potential binding GROUP reducing diuretic absorption gastrointestinal tract
2672,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,colestipol,thiazide diuretics,mechanism,Cholestyramine colestipol resins: Cholestytamine DRUG resins potential binding GROUP reducing diuretic absorption gastrointestinal tract
2673,- Lithium: Generally should not be given with diuretics.,Lithium,diuretics,advise,DRUG : Generally given GROUP .
2674,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,GROUP reduce renal clearance DRUG add high risk lithium toxicity.
2675,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,GROUP reduce renal clearance lithium add high risk DRUG toxicity.
2676,Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide,lithium,chlorothiazide,advise,Refer package insert DRUG preparations use preparations DRUG
2677,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2678,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2679,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,Non steroidal Anti inflammatory Drugs: patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing DRUG .
2680,"Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained",chlorothiazide,non-steroidal anti-inflammatory agents,advise,Therefore DRUG GROUP used concomitantly patient observed closely determine desired effect diuretic obtained
2681,Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.,antidiabetic agents,VELCADE,advise,Patients oral GROUP receiving BRAND treatment may require close monitoring blood glucose levels adjustment dose antidiabetic medication.
2682,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,tricyclic antidepressants,effect,GROUP may enhance effects GROUP barbiturates alcohol CNS depressants.
2683,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,barbiturates,effect,GROUP may enhance effects tricyclic antidepressants GROUP alcohol CNS depressants.
2684,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,alcohol,effect,GROUP may enhance effects tricyclic antidepressants barbiturates DRUG CNS depressants.
2685,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,CNS depressants,effect,GROUP may enhance effects tricyclic antidepressants barbiturates alcohol GROUP .
2686,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,GROUP prolong intensify anticholinergic effects GROUP .
2687,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,reserpine,effect,GROUP may reduce antihypertensive effects DRUG veratrum alkaloids methyldopa mecamylamine.
2688,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,veratrum alkaloids,effect,GROUP may reduce antihypertensive effects reserpine GROUP methyldopa mecamylamine.
2689,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,methyldopa,effect,GROUP may reduce antihypertensive effects reserpine veratrum alkaloids DRUG mecamylamine.
2690,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,mecamylamine,effect,GROUP may reduce antihypertensive effects reserpine veratrum alkaloids methyldopa DRUG .
2691,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,MAO inhibitors,effect,Effects GROUP increased GROUP beta adrenergic blockers.
2692,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,beta adrenergic blockers,effect,Effects GROUP increased MAO inhibitors GROUP .
2693,"Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.",halofantrine,Mefloquine,advise,danger potentially fatal prolongation QTc interval DRUG must given simultaneously subsequent DRUG .
2694,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinine,effect,Concomitant administration DRUG related compounds (eg DRUG quinidine chloroquine) may produce electrocardiographic abnormalities increase risk convulsions.
2695,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinidine,effect,Concomitant administration DRUG related compounds (eg quinine DRUG chloroquine) may produce electrocardiographic abnormalities increase risk convulsions.
2696,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,chloroquine,effect,Concomitant administration DRUG related compounds (eg quinine quinidine DRUG ) may produce electrocardiographic abnormalities increase risk convulsions.
2697,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,anti-arrhythmic,effect,appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg DRUG beta adrenergic blocking agents calcium channel blockers antihistamines H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2698,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,beta-adrenergic blocking agents,effect,appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic GROUP calcium channel blockers antihistamines H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2699,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,calcium channel blockers,effect,appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents GROUP antihistamines H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2700,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,antihistamines,effect,appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers GROUP H1 blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2701,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,H1-blocking agents,effect,appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers antihistamines GROUP tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval.
2702,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,tricyclic antidepressants,effect,appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers antihistamines H1 blocking agents GROUP phenothiazines) might also contribute prolongation QTc interval.
2703,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,phenothiazines,effect,appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti arrhythmic beta adrenergic blocking agents calcium channel blockers antihistamines H1 blocking agents tricyclic antidepressants GROUP ) might also contribute prolongation QTc interval.
2704,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",anticonvulsant,Mefloquine,effect,patients taking GROUP (eg valproic acid carbamazepine phenobarbital phenytoin) concomitant use DRUG may reduce seizure control lowering plasma levels anticonvulsant.
2705,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",valproic acid,Mefloquine,effect,patients taking anticonvulsant (eg DRUG carbamazepine phenobarbital phenytoin) concomitant use DRUG may reduce seizure control lowering plasma levels anticonvulsant.
2706,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",carbamazepine,Mefloquine,effect,patients taking anticonvulsant (eg valproic acid DRUG phenobarbital phenytoin) concomitant use DRUG may reduce seizure control lowering plasma levels anticonvulsant.
2707,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenobarbital,Mefloquine,effect,patients taking anticonvulsant (eg valproic acid carbamazepine DRUG phenytoin) concomitant use DRUG may reduce seizure control lowering plasma levels anticonvulsant.
2708,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenytoin,Mefloquine,effect,patients taking anticonvulsant (eg valproic acid carbamazepine phenobarbital DRUG ) concomitant use DRUG may reduce seizure control lowering plasma levels anticonvulsant.
2709,"When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.",Mefloquine,live typhoid vaccines,effect,DRUG taken concurrently oral GROUP attenuation immunization cannot excluded.
2710,"Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.",Mefloquine,anticoagulants,advise,Nevertheless effects DRUG travelers receiving comedication particularly diabetics patients using GROUP checked departure.
2711,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,mechanism,DRUG generally given GROUP reduce renal clearance add high risk lithium toxicity.
2712,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,aminoglycoside,effect,BRAND may increase ototoxic potential drugs GROUP cephalosporin antibiotics.
2713,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,cephalosporin antibiotics,effect,BRAND may increase ototoxic potential drugs aminoglycoside GROUP .
2714,"A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;",ethacrynic acid,warfarin,mechanism,number drugs including DRUG shown displace DRUG plasma protein;
2715,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,loop diuretics,effect,patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2716,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,potassium- sparing diuretics,effect,patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide GROUP .
2717,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,thiazide diuretics,effect,patients administration GROUP reduce diuretic natriuretic antihypertensive effects loop potassium sparing GROUP .
2718,"Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",EDECRIN,non- steroidal anti- inflammatory agents,effect,Therefore BRAND GROUP used concomitantly patient observed closely determine desired effect diuretic obtained.
2719,"Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.",L-tyrosine,MAO inhibitors,effect,Non selective MAO inhibitors including tranylcypromine sulfate phenelzine sulfate pargyline HC1: Concomitant use DRUG non selective GROUP may cause hypertension.
2720,"Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. ",thiabendazole,melarsoprol,effect,Among risk factors studied two appear increase risk ARE: prescription DRUG treat strongyloidiasis DRUG cure bad general clinical conditions patients.
2721,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,cimetidine,advise,Based adult data lower doses DRUG may needed following coadministration drugs reported decrease caffeine elimination (e.g. DRUG ketoconazole) higher caffeine doses may needed following coadministration drugs increase caffeine elimination (e.g. phenobarbital phenytoin).
2722,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,ketoconazole,advise,Based adult data lower doses DRUG may needed following coadministration drugs reported decrease caffeine elimination (e.g. cimetidine DRUG ) higher caffeine doses may needed following coadministration drugs increase caffeine elimination (e.g. phenobarbital phenytoin).
2723,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenobarbital,advise,Based adult data lower doses caffeine may needed following coadministration drugs reported decrease caffeine elimination (e.g. cimetidine ketoconazole) higher DRUG doses may needed following coadministration drugs increase caffeine elimination (e.g. DRUG phenytoin).
2724,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenytoin,advise,Based adult data lower doses caffeine may needed following coadministration drugs reported decrease caffeine elimination (e.g. cimetidine ketoconazole) higher DRUG doses may needed following coadministration drugs increase caffeine elimination (e.g. phenobarbital DRUG ).
2725,Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.,Caffeine,ketoprofen,effect,DRUG administered concurrently DRUG reduced urine volume 4 healthy volunteers.
2726,The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.,nevirapine,warfarin,int,vitro interaction DRUG antithrombotic agent DRUG complex.
2727,"When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.",warfarin,nevirapine,advise,DRUG co administered DRUG anticoagulation levels monitored frequently.
2728,Clarithromycin exposure was significantly decreased by nevirapine;,Clarithromycin,nevirapine,mechanism,DRUG exposure significantly decreased DRUG ;
2729,"Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.",contraceptives,nevirapine,advise,Oral GROUP hormonalmethods birth control usedas sole method contraception inwomen taking DRUG since nevirapinemay lower plasma levels thesemedications.
2730,Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.,Nevirapine,ketoconazole,advise,DRUG DRUG beadministered concomitantly becausedecreases ketoconazole plasmaconcentrations may reduce efficacy drug.
2731,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,lopinavir,nevirapine,advise,dose increase DRUG /ritonavir 533/133 mg twice daily food isrecommended combination DRUG .
2732,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,ritonavir,nevirapine,advise,dose increase lopinavir/ DRUG 533/133 mg twice daily food isrecommended combination DRUG .
2733,Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.,Methadone,nevirapine,advise,Methadone levels may decreased; increased dosages may required prevent symptoms opiate withdrawal. DRUG maintained patients beginning DRUG therapy monitored forevidence withdrawal methadone dose adjusted accordingly.
2734,Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.,Nevirapine,rifampin,advise,DRUG DRUG beadministered concomitantly becausedecreases nevirapine plasmaconcentrations may reduce efficacy ofthe drug.
2735,"aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.",nevirapine,methadone,effect,aBased reports narcotic withdrawal syndrome patients treated DRUG DRUG concurrently evidence decreased plasma concentrations methadone.
2736,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",ketamine,ouabain,effect,comparison digitalis tolerance dogs anesthetized DRUG Innovar Vet pentobarbital dosage DRUG needed cause ventricular tachycardia significantly higher LD50 ouabain ketamine Innovar pentobarbital.
2737,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",Innovar Vet,ouabain,effect,comparison digitalis tolerance dogs anesthetized ketamine BRAND pentobarbital dosage DRUG needed cause ventricular tachycardia significantly higher LD50 ouabain ketamine Innovar pentobarbital.
2738,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",pentobarbital,ouabain,effect,comparison digitalis tolerance dogs anesthetized ketamine Innovar Vet DRUG dosage DRUG needed cause ventricular tachycardia significantly higher LD50 ouabain ketamine Innovar pentobarbital.
2739,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,Innovar,effect,Ventricular tachycardia induced DRUG generally converted sinus rhythm following administration BRAND ketamine droperidol administration fentayl alone pentobarbital.
2740,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,ketamine,effect,Ventricular tachycardia induced DRUG generally converted sinus rhythm following administration Innovar DRUG droperidol administration fentayl alone pentobarbital.
2741,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,droperidol,effect,Ventricular tachycardia induced DRUG generally converted sinus rhythm following administration Innovar ketamine DRUG administration fentayl alone pentobarbital.
2742,"Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.",ketoconazole,lapatinib,mechanism,Ketoconazole: healthy subjects receiving DRUG CYP3A4 inhibitor 200 mg twice daily 7 days systemic exposure (AUC) DRUG increased approximately 3.6 fold control half life increased 1.7 fold control.
2743,"Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.",carbamazepine,lapatinib,mechanism,Carbamazepine: healthy subjects receiving CYP3A4 inducer DRUG 100 mg twice daily 3 days 200 mg twice daily 17 days systemic exposure (AUC) DRUG decreased approximately 72%.
2744,MAO inhibitors should be used with caution in patients receiving hydralazine.,MAO inhibitors,hydralazine,advise,GROUP used caution patients receiving DRUG .
2745,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,diazoxide,effect,potent parental GROUP DRUG used combination hydralazine patients continuously observed several hours excessive fall blood pressure.
2746,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,hydralazine,effect,potent parental GROUP diazoxide used combination DRUG patients continuously observed several hours excessive fall blood pressure.
2747,Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.,diazoxide,hydralazine,effect,Profound hypotensive episodes may occur DRUG infection DRUG used concomitantly.
2748,Propranolol increases hydralazines serum concentrations.,Propranolol,hydralazine,mechanism,DRUG increases DRUG serum concentrations.
2749,NSAIDs may decrease the hemodynamic effects of hydralazine;,NSAIDs,hydralazine,effect,GROUP may decrease hemodynamic effects DRUG ;
2750,Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.,carbamazepine,SUPRAX,mechanism,Carbamazepine: Elevated DRUG levels reported postmarketing experience BRAND administered concomitantly.
2751,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Warfarin,cefixime,effect,DRUG Anticoagulants: Increased prothrombin time without clinical bleeding reported DRUG administered concomitantly.
2752,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Anticoagulants,cefixime,effect,Warfarin GROUP : Increased prothrombin time without clinical bleeding reported DRUG administered concomitantly.
2753,Cimetidine: Cimetidine increases nicardipine HCl plasma levels.,Cimetidine,nicardipine HCl,mechanism,Cimetidine: DRUG increases DRUG plasma levels.
2754,Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.,calcium blockers,digitalis preparations,mechanism,Digoxin: GROUP may increase concentration GROUP blood.
2755,"Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.",digoxin,nicardipine HCl,advise,Nicardipine HCl usually alter plasma levels digoxin however serum DRUG levels evaluated concomitant therapy DRUG initiated.
2756,"Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.",cyclosporine,nicardipine,advise,Plasma concentrations DRUG therefore closely monitored dosage reduced accordingly patients treated DRUG .
2757,Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.,proton pump inhibitors,warfarin,effect,Patients treated GROUP DRUG concomitantly may need monitored increases INR prothrombin time.
2758,"Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.",esomeprazole,diazepam,mechanism,Coadministration DRUG 30 mg DRUG CYP2C19 substrate resulted 45% decrease clearance diazepam.
2759,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,ketoconazole,mechanism,Therefore DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg DRUG iron salts digoxin).
2760,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,iron,mechanism,Therefore DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole DRUG salts digoxin).
2761,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,digoxin,mechanism,Therefore DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole iron salts DRUG ).
2762,Concomitant administration of clarithromycin with pimozide is contraindicated.,clarithromycin,pimozide,advise,Concomitant administration DRUG DRUG contraindicated.
2763,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,advise,Aspirin: Concomitant administration DRUG BRAND recommended diclofenac displaced binding sites concomitant administration aspirin resulting lower plasma concentrations peak plasma levels AUC values.
2764,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,mechanism,Aspirin: Concomitant administration diclofenac aspirin recommended DRUG displaced binding sites concomitant administration BRAND resulting lower plasma concentrations peak plasma levels AUC values.
2765,"Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.",diclofenac,NSAIDs,advise,Anticoagulants: studies shown DRUG interact anticoagulants warfarin type caution exercised nonetheless since interactions seen GROUP .
2766,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",NSAIDs,warfarin,advise,prostaglandins play important role hemostasis NSAIDs affect platelet function well concurrent therapy GROUP including diclofenac DRUG requires close monitoring patients certain change anticoagulant dosage required.
2767,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",diclofenac,warfarin,advise,prostaglandins play important role hemostasis NSAIDs affect platelet function well concurrent therapy NSAIDs including DRUG DRUG requires close monitoring patients certain change anticoagulant dosage required.
2768,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,digoxin,mechanism,Ingestion DRUG may increase serum concentrations DRUG methotrexate increase cyclosporine nephrotoxicity.
2769,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,methotrexate,mechanism,Ingestion DRUG may increase serum concentrations digoxin DRUG increase cyclosporine nephrotoxicity.
2770,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,cyclosporine,effect,Ingestion DRUG may increase serum concentrations digoxin methotrexate increase DRUG nephrotoxicity.
2771,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,digoxin,effect,Patients begin taking DRUG increase diclofenac dose NSAID taking DRUG methotrexate cyclosporine may develop toxicity characteristics drugs.
2772,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,methotrexate,effect,Patients begin taking DRUG increase diclofenac dose NSAID taking digoxin DRUG cyclosporine may develop toxicity characteristics drugs.
2773,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,cyclosporine,effect,Patients begin taking DRUG increase diclofenac dose NSAID taking digoxin methotrexate DRUG may develop toxicity characteristics drugs.
2774,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,digoxin,effect,Patients begin taking diclofenac increase diclofenac dose GROUP taking DRUG methotrexate cyclosporine may develop toxicity characteristics drugs.
2775,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,methotrexate,effect,Patients begin taking diclofenac increase diclofenac dose GROUP taking digoxin DRUG cyclosporine may develop toxicity characteristics drugs.
2776,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,cyclosporine,effect,Patients begin taking diclofenac increase diclofenac dose GROUP taking digoxin methotrexate DRUG may develop toxicity characteristics drugs.
2777,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium: DRUG decreases DRUG renal clearance increases lithium plasma levels.
2778,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium: DRUG decreases lithium renal clearance increases DRUG plasma levels.
2779,"In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.",diclofenac,lithium,effect,patients taking DRUG DRUG concomitantly lithium toxicity may develop.
2780,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",insulin,diclofenac,effect,rare reports however marketing experiences changes effects DRUG oral hypoglycemic agents presence DRUG necessitated changes doses agents.
2781,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",hypoglycemic agents,diclofenac,effect,rare reports however marketing experiences changes effects insulin oral GROUP presence DRUG necessitated changes doses agents.
2782,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,insulin,effect,direct causal relationship established physicians consider possibility DRUG may alter diabetic patient response DRUG oral hypoglycemic agents.
2783,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,hypoglycemic agents,effect,direct causal relationship established physicians consider possibility DRUG may alter diabetic patient response insulin oral GROUP .
2784,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,Diclofenac,diuretics,effect,Diuretics: DRUG NSAIDs inhibit activity GROUP .
2785,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,NSAIDs,diuretics,effect,Diuretics: Diclofenac GROUP inhibit activity GROUP .
2786,Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.,phenobarbital,diclofenac,effect,Phenobarbital toxicity reported occurred patient chronic DRUG treatment following initiation DRUG therapy.
2787,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,salicylic acid,mechanism,Protein Binding vitro DRUG interferes minimally protein binding DRUG (20% decrease binding) tolbutamide prednisolone (10% decrease binding) warfarin.
2788,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,tolbutamide,mechanism,Protein Binding vitro DRUG interferes minimally protein binding salicylic acid (20% decrease binding) DRUG prednisolone (10% decrease binding) warfarin.
2789,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,prednisolone,mechanism,Protein Binding vitro DRUG interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide DRUG (10% decrease binding) warfarin.
2790,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,warfarin,mechanism,Protein Binding vitro DRUG interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide prednisolone (10% decrease binding) DRUG .
2791,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.,aminoglycosides,MAXIPIME,advise,Renal function monitored carefully high doses GROUP administered BRAND increased potential nephrotoxicity ototoxicity aminoglycoside antibiotics.
2792,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity reported following concomitant administration GROUP potent GROUP furosemide.
2793,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity reported following concomitant administration GROUP potent diuretics DRUG .
2794,Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.,Potassium-depleting diuretics,digitalis,effect,GROUP major contributing factor GROUP toxicity.
2795,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",Quinidine,digoxin,mechanism,DRUG verapamil amiodarone propafenone indomethacin itraconazole alprazolam spironolactone raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2796,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",verapamil,digoxin,mechanism,Quinidine DRUG amiodarone propafenone indomethacin itraconazole alprazolam spironolactone raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2797,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",amiodarone,digoxin,mechanism,Quinidine verapamil DRUG propafenone indomethacin itraconazole alprazolam spironolactone raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2798,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",propafenone,digoxin,mechanism,Quinidine verapamil amiodarone DRUG indomethacin itraconazole alprazolam spironolactone raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2799,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",indomethacin,digoxin,mechanism,Quinidine verapamil amiodarone propafenone DRUG itraconazole alprazolam spironolactone raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2800,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",itraconazole,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin DRUG alprazolam spironolactone raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2801,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",alprazolam,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin itraconazole DRUG spironolactone raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2802,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",spironolactone,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin itraconazole alprazolam DRUG raise serum DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result.
2803,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",Erythromycin,digoxin,mechanism,DRUG clarithromycin (and possibly macrolide antibiotics) tetracycline may increase DRUG absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2804,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",clarithromycin,digoxin,mechanism,Erythromycin DRUG (and possibly macrolide antibiotics) tetracycline may increase DRUG absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2805,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",macrolide antibiotics,digoxin,mechanism,Erythromycin clarithromycin (and possibly GROUP ) tetracycline may increase DRUG absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2806,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",tetracycline,digoxin,mechanism,Erythromycin clarithromycin (and possibly macrolide antibiotics) DRUG may increase DRUG absorption patients inactivate digoxin bacterial metabolism lower intestine digitalis intoxication may result.
2807,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",Propantheline,digoxin,mechanism,DRUG diphenoxylate decreasing gut motility may increase DRUG absorption.
2808,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",diphenoxylate,digoxin,mechanism,Propantheline DRUG decreasing gut motility may increase DRUG absorption.
2809,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",Antacids,digoxin,mechanism,GROUP kaolin pectin sulfasalazine neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal DRUG absorption resulting unexpectedly low serum concentrations.
2810,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",kaolin,digoxin,mechanism,Antacids DRUG pectin sulfasalazine neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal DRUG absorption resulting unexpectedly low serum concentrations.
2811,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",sulfasalazine,digoxin,mechanism,Antacids kaolin pectin DRUG neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal DRUG absorption resulting unexpectedly low serum concentrations.
2812,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",neomycin,digoxin,mechanism,Antacids kaolin pectin sulfasalazine DRUG cholestyramine certain anticancer drugs metoclopramide may interfere intestinal DRUG absorption resulting unexpectedly low serum concentrations.
2813,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",cholestyramine,digoxin,mechanism,Antacids kaolin pectin sulfasalazine neomycin DRUG certain anticancer drugs metoclopramide may interfere intestinal DRUG absorption resulting unexpectedly low serum concentrations.
2814,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",metoclopramide,digoxin,mechanism,Antacids kaolin pectin sulfasalazine neomycin cholestyramine certain anticancer drugs DRUG may interfere intestinal DRUG absorption resulting unexpectedly low serum concentrations.
2815,"Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.",Rifampin,digoxin,mechanism,DRUG may decrease serum DRUG concentration especially patients renal dysfunction increasing non renal clearance digoxin.
2816,"Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.",Thyroid,digoxin,advise,GROUP administration digitalized hypothyroid patient may increase dose requirement DRUG .
2817,Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.,digoxin,sympathomimetics,effect,Concomitant use DRUG GROUP increases risk cardiac arrhythmias.
2818,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",beta-adrenergic blockers,digoxin,effect,Although GROUP calcium channel blockers DRUG may useful combination control atrial fibrillation additive effects AV node conduction result advanced complete heart block.
2819,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",calcium channel blockers,digoxin,effect,Although beta adrenergic blockers GROUP DRUG may useful combination control atrial fibrillation additive effects AV node conduction result advanced complete heart block.
2820,"In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.",theophylline,cetirizine,mechanism,multiple dose study DRUG (400 mg daily 3 days) DRUG (20 mg daily 3 days) 16% decrease clearance cetirizine observed.
2821,There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;,cetirizine,theophylline,mechanism,small decrease clearance DRUG caused 400 mg dose DRUG ;
2822,Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.,dapsone,Lamprene,effect,Preliminary data suggest DRUG may inhibit anti inflammatory activity BRAND confirmed.
2823,"If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.",dapsone,clofazimine,advise,leprosy associated inflammatory reactions develop patients treated DRUG DRUG still advisable continue treatment drugs.
2824,Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. ,Diazepam,morphine,effect,DRUG doses 0.25 mg/kg 2.5 mg/kg injected DRUG found decrease antinociceptive effect morphine.
2825,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ",diazepam,metamizol,effect,Similarly DRUG decreased antinociceptive effect DRUG (only tail flick test) indomethacin.
2826,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ",diazepam,indomethacin,effect,Similarly DRUG decreased antinociceptive effect metamizol (only tail flick test) DRUG .
2827,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,morphine,effect,DRUG used doses 1.25 mg/kg 2.5 mg/kg decreased antinociceptive effect DRUG metamizol (only tail flick test) indomethacin.
2828,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,metamizol,effect,DRUG used doses 1.25 mg/kg 2.5 mg/kg decreased antinociceptive effect morphine DRUG (only tail flick test) indomethacin.
2829,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,indomethacin,effect,DRUG used doses 1.25 mg/kg 2.5 mg/kg decreased antinociceptive effect morphine metamizol (only tail flick test) DRUG .
2830,Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).,piperazine,phenothiazine,effect,Phenothiazines Taking DRUG GROUP together may increase risk convulsions (seizures).
2831,"Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.",piperazine,pyrantel,effect,Pyrantel (e.g. Antiminth) Taking DRUG DRUG together may decrease effects piperazine.
2832,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,alcohol,effect,DRUG additive effects DRUG CNS depressants (hypnotics sedatives tranquilizers etc).
2833,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,CNS depressants,effect,DRUG additive effects alcohol GROUP (hypnotics sedatives tranquilizers etc).
2834,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,hypnotics,effect,DRUG additive effects alcohol CNS depressants ( GROUP sedatives tranquilizers etc).
2835,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,sedatives,effect,DRUG additive effects alcohol CNS depressants (hypnotics GROUP tranquilizers etc).
2836,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,tranquilizers,effect,DRUG additive effects alcohol CNS depressants (hypnotics sedatives GROUP etc).
2837,MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.,MAO inhibitors,antihistamines,effect,GROUP prolong intensify anticholinergic (drying) effects GROUP .
2838,Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.,anticoagulants,Atromid-S,advise,Caution exercised GROUP given conjunction BRAND .
2839,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,phenytoin,mechanism,BRAND may displace acidic drugs DRUG tolbutamide binding sites.
2840,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,tolbutamide,mechanism,BRAND may displace acidic drugs phenytoin DRUG binding sites.
2841,The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.,tolbutamide,Atromid-S,effect,hypoglycemic effect DRUG reported increase BRAND given concurrently.
2842,Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.,fibrate,lovastatin,effect,Fulminant rhabdomyolysis seen early three weeks initiation combined therapy another GROUP DRUG may seen several months.
2843,"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.",lovastatin,fibrate,effect,reasons felt subjects unsatisfactory lipid response either drug alone possible benefits combined therapy DRUG GROUP outweigh risks severe myopathy rhabdomyolysis acute renal failure.
2844,"Therefore, the combined use of lovastatin with fibrates should generally be avoided.",lovastatin,fibrates,advise,Therefore combined use DRUG GROUP generally avoided.
2845,Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.,PEGASYS,theophylline,mechanism,Treatment BRAND weekly 4 weeks healthy subjects associated inhibition P450 1A2 25% increase DRUG AUC.
2846,Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.,theophylline,PEGASYS,advise,Theophylline serum levels monitored appropriate dose adjustments considered patients given DRUG BRAND .
2847,Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.,COPEGUS,didanosine,advise,Nucleoside Analogues Didanosine Co administration BRAND DRUG recommended.
2848,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,stavudine,effect,Stavudine Zidovudine DRUG antagonize vitro antiviral activity DRUG zidovudine HIV.
2849,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,zidovudine,effect,Stavudine Zidovudine DRUG antagonize vitro antiviral activity stavudine DRUG HIV.
2850,"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
",simvastatin,clarithromycin,effect,Rhabdomyolysis secondary drug interaction DRUG DRUG .
2851,"DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. ",Clarithromycin,simvastatin,mechanism,DISCUSSION: DRUG potent inhibitor CYP3A4 major enzyme responsible DRUG metabolism.
2852,The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. ,macrolide antibiotics,hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors,effect,concomitant administration GROUP GROUP resulted previous reports rhabdomyolysis.
2853,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,atorvastatin,mechanism,CONCLUSIONS: GROUP inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. DRUG cerivastatin lovastatin simvastatin).
2854,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,cerivastatin,mechanism,CONCLUSIONS: GROUP inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. atorvastatin DRUG lovastatin simvastatin).
2855,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,lovastatin,mechanism,CONCLUSIONS: GROUP inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. atorvastatin cerivastatin DRUG simvastatin).
2856,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,simvastatin,mechanism,CONCLUSIONS: GROUP inhibit metabolism HMG CoA reductase inhibitors metabolized CYP3A4 (i.e. atorvastatin cerivastatin lovastatin DRUG ).
2857,"The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.",CAMPTOSAR,antineoplastic agents,effect,adverse effects BRAND myelosuppression diarrhea would expected exacerbated GROUP similar adverse effects.
2858,"Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.",CAMPTOSAR,dexamethasone,effect,Lymphocytopenia reported patients receiving BRAND possible administration DRUG antiemetic prophylaxis may enhanced likelihood effect.
2859,"The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).",prochlorperazine,CAMPTOSAR,effect,incidence akathisia clinical trials weekly dosage schedule greater (8.5% 4/47 patients) DRUG administered day BRAND drugs given separate days (1.3% 1/80 patients).
2860,"It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.",laxative,CAMPTOSAR,effect,would expected GROUP use therapy BRAND would worsen incidence severity diarrhea studied.
2861,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.",diuretics,CAMPTOSAR,effect,view potential risk dehydration secondary vomiting and/or diarrhea induced CAMPTOSAR physician may wish withhold GROUP dosing BRAND certainly periods active vomiting diarrhea.
2862,"Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",etanercept,anakinra,effect,Concurrent administration DRUG (another TNF blocking agent) DRUG (an interleukin 1 antagonist) associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone.
2863,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,TNFa-blocking agents,anakinra,effect,GROUP (including REMICADE) used combination DRUG may also result similar toxicities.
2864,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,REMICADE,anakinra,effect,TNFa blocking agents (including BRAND ) used combination DRUG may also result similar toxicities.
2865,"Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).",dorzolamide,carbonic anhydrase inhibitors,effect,Although acid base electrolyte disturbances reported clinical trials DRUG disturbances reported oral GROUP instances resulted drug interactions (e.g. toxicity associated high dose salicylate therapy).
2866,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,mercaptopurine,mechanism,Mercaptopurine/Azathioprine: DRUG inhibits enzymatic oxidation DRUG azathioprine 6 thiouric acid.
2867,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,azathioprine,mechanism,Mercaptopurine/Azathioprine: DRUG inhibits enzymatic oxidation mercaptopurine DRUG 6 thiouric acid.
2868,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,mercaptopurine,advise,patients receiving mercaptopurine (Purinethol) azathioprine (Imuran) concomitant administration 300 600 mg DRUG per day require reduction dose approximately one third one fourth usual dose DRUG azathioprine.
2869,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,azathioprine,advise,patients receiving mercaptopurine (Purinethol) azathioprine (Imuran) concomitant administration 300 600 mg DRUG per day require reduction dose approximately one third one fourth usual dose mercaptopurine DRUG .
2870,"Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.",allopurinol,dicumarol,mechanism,Dicumarol: reported DRUG prolongs half life anticoagulant DRUG .
2871,"Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.",uricosuric agents,oxipurinol,mechanism,Uricosuric Agents: Since excretion oxipurinol similar urate GROUP increase excretion urate also likely increase excretion DRUG thus lower degree inhibition xanthine oxidase.
2872,The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.,uricosuric agents,allopurinol,mechanism,concomitant administration GROUP DRUG associated decrease excretion oxypurines (hypoxanthine xanthine) increase urinary uric acid excretion compared observed allopurinol alone.
2873,Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.,allopurinol,thiazide diuretics,effect,Thiazide Diuretics: reports concomitant use DRUG GROUP may contribute enhancement allopurinol toxicity patients reviewed attempt establish cause effect relationship mechanism causation.
2874,"Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..",thiazide diuretics,allopurinol,advise,Although causal mechanism cause effect relationship established current evidence suggests renal function monitored patients GROUP DRUG even absence renal failure dosage levels even conservatively adjusted patients combined therapy diminished renal function detected..
2875,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,ampicillin,allopurinol,effect,Ampicillin/Amoxicillin: increase frequency skin rash reported among patients receiving DRUG amoxicillin concurrently DRUG compared patients receiving drugs.
2876,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,amoxicillin,allopurinol,effect,Ampicillin/Amoxicillin: increase frequency skin rash reported among patients receiving ampicillin DRUG concurrently DRUG compared patients receiving drugs.
2877,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cyclophosphamide,allopurinol,effect,Cytotoxic Agents: Enhanced bone marrow suppression DRUG cytotoxic agents reported among patients neoplastic disease except leukemia presence DRUG .
2878,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cytotoxic agents,allopurinol,effect,Cytotoxic Agents: Enhanced bone marrow suppression cyclophosphamide GROUP reported among patients neoplastic disease except leukemia presence DRUG .
2879,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",Chlorpropamide,allopurinol,mechanism,Chlorpropamide: DRUG plasma half life may prolonged DRUG since allopurinol chlorpropamide may compete excretion renal tubule.
2880,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",allopurinol,chlorpropamide,mechanism,Chlorpropamide: Chlorpropamides plasma half life may prolonged allopurinol since DRUG DRUG may compete excretion renal tubule.
2881,The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.,allopurinol,chlorpropamide,effect,risk hypoglycemia secondary mechanism may increased DRUG DRUG given concomitantly presence renal insufficiency.
2882,Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.,cyclosporine,allopurinol sodium,mechanism,Cyclosporin: Reports indicate DRUG levels may increased concomitant treatment DRUG injection.
2883,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",Catecholamine-depleting drugs,beta-blocking agents,effect,GROUP reserpine may additive effect given GROUP .
2884,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agents,effect,Catecholamine depleting drugs DRUG may additive effect given GROUP .
2885,"Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.",acebutolol,catecholamine depletors,advise,Patients treated DRUG plus GROUP therefore observed closely evidence marked bradycardia hypotension may present vertigo syncope/presyncope orthostatic changes blood pressure without compensatory tachycardia.
2886,"Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.",beta-adrenergic antagonists,alpha-adrenergic stimulants,effect,Exaggerated hypertensive responses reported combined use GROUP GROUP including contained proprietary cold remedies vasoconstrictive nasal drops.
2887,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.,beta-adrenoceptor blocking agents,nonsteroidal anti-inflammatory drugs,effect,Blunting antihypertensive effect GROUP GROUP reported.
2888,"These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.",antibiotics,anticholinesterase,advise,GROUP used myasthenic patient definitely indicated careful adjustment made adjunctive GROUP dosage.
2889,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ,cocaine,norepinephrine,effect,uptake inhibitors DRUG desipramine (3 mumol/liter) potentiated positive inotropic effects DRUG nonfailing myocardium (p < 0.05) functional class IV myocardium.
2890,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ,desipramine,norepinephrine,effect,uptake inhibitors cocaine DRUG (3 mumol/liter) potentiated positive inotropic effects DRUG nonfailing myocardium (p < 0.05) functional class IV myocardium.
2891,Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.,Betaseron,antipyrine,mechanism,BRAND administration three cancer patients dose range 0.025 mg 2.2 mg led dose dependent inhibition DRUG elimination.14 effect alternate day administration 0.25 mg Betaseron drug metabolism MS patients unknown.
2892,Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.,piperacillin,aminoglycoside,effect,Aminoglycosides: mixing DRUG GROUP vitro result substantial inactivation aminoglycoside.
2893,"Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.",piperacillin,vecuronium,effect,Vecuronium: used perioperative period DRUG implicated prolongation neuromuscular blockade DRUG .
2894,"In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.",piperacillin,vecuronium,effect,one controlled clinical study ureidopenicillins including DRUG reported prolong action DRUG .
2895,"Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.",non-depolarizing muscle relaxants,piperacillin,effect,Due similar mechanism action expected neuromuscular blockade produced GROUP could prolonged presence DRUG .
2896,Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.,probenecid,PIPRACIL,mechanism,Probenecid: oral combination DRUG intramuscular injection BRAND produces increase piperacillin peak serum level 30%.
2897,Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.,Piperacillin sodium,methotrexate,mechanism,Methotrexate: DRUG may reduce excretion DRUG .
2898,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,alcohol,effect,DRUG may interact DRUG CNS depressants causing increased sedative effects.
2899,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,CNS depressants,effect,DRUG may interact alcohol GROUP causing increased sedative effects.
2900,"Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.",Ethopropazine,chlorpromazine,mechanism,DRUG interact DRUG increasing metabolism chlorpromazine.
2901,"Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.",reserpine,beta blocking agents,effect,Catecholamine depleting drugs e.g. DRUG may additive effect given GROUP .
2902,"BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.",BREVIBLOC,warfarin,mechanism,BRAND concentrations equivocally higher given DRUG likely clinically important.
2903,"When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.",digoxin,BREVIBLOC,mechanism,DRUG BRAND concomitantly administered intravenously normal volunteers 10 20% increase digoxin blood levels time points.
2904,"When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.",BREVIBLOC,morphine,mechanism,intravenous morphine BREVIBLOC concomitantly administered normal subjects effect morphine blood levels seen BRAND steady state blood levels increased 46% presence DRUG .
2905,"The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.",succinylcholine,BREVIBLOC,effect,onset neuromuscular blockade DRUG unaffected BRAND duration neuromuscular blockade prolonged 5 minutes 8 minutes.
2906,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,digoxin,advise,Although interactions observed studies appear major clinical importance BRAND titrated caution patients treated concurrently DRUG morphine succinylcholine warfarin.
2907,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,morphine,advise,Although interactions observed studies appear major clinical importance BRAND titrated caution patients treated concurrently digoxin DRUG succinylcholine warfarin.
2908,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,succinylcholine,advise,Although interactions observed studies appear major clinical importance BRAND titrated caution patients treated concurrently digoxin morphine DRUG warfarin.
2909,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,warfarin,advise,Although interactions observed studies appear major clinical importance BRAND titrated caution patients treated concurrently digoxin morphine succinylcholine DRUG .
2910,Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.,BREVIBLOC,verapamil,advise,Caution exercised considering use BRAND DRUG patients depressed myocardial function.
2911,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,dopamine,advise,Additionally BRAND used control supraventricular tachycardia presence agents vasoconstrictive inotropic DRUG epinephrine norepinephrine danger blocking cardiac contractility systemic vascular resistance high.
2912,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,epinephrine,advise,Additionally BRAND used control supraventricular tachycardia presence agents vasoconstrictive inotropic dopamine DRUG norepinephrine danger blocking cardiac contractility systemic vascular resistance high.
2913,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,norepinephrine,advise,Additionally BRAND used control supraventricular tachycardia presence agents vasoconstrictive inotropic dopamine epinephrine DRUG danger blocking cardiac contractility systemic vascular resistance high.
2914,"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
",neurotensin,enkephalins,effect,Interaction antinociceptive effect DRUG_N DRUG_N tuftsin.
2915,"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
",neurotensin,tuftsin,effect,Interaction antinociceptive effect DRUG_N enkephalins DRUG_N .
2916,It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. ,neurotensin,enkephalins,effect,shown DRUG_N antagonized evidently antinociceptive effect DRUG_N analogue.
2917,"On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. ",neurotensin,tuftsin,effect,contrary DRUG_N DRUG_N agonists induction analgesia.
2918,It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.,neurotensin,tuftsin,effect,concluded DRUG_N modulates opposite way function enkephalinergic neurons central action DRUG_N .
2919,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,succinylcholine,int,Possible drug interactions BRAND DRUG anticholinesterase agents.
2920,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,anticholinesterase agents,int,Possible drug interactions BRAND succinylcholine GROUP .
2921,"When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.",idoxuridine,boric acid,advise,using DRUG especially important health care professional know using following: Eye product containing DRUG .
2922,Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.,Boric acid,idoxuridine,mechanism,DRUG may interact DRUG preparation causing gritty substance form may interact preservative idoxuridine preparation causing toxic effect eye.
2923,Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.,nelfinavir,azithromycin,effect,Co administration DRUG steady state single dose DRUG (2 x 600 mg tablets) results increased azithromycin serum concentrations.
2924,"Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.",azithromycin,nelfinavir,advise,Although dose adjustment DRUG recommended administered combination DRUG close monitoring known side effects azithromycin liver enzyme abnormalities hearing impairment warranted.
2925,"However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.",azithromycin,warfarin,advise,However prudent medical practice dictates careful monitoring prothrombin time patients treated DRUG DRUG concomitantly.
2926,Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.,macrolides,warfarin,effect,Concurrent use GROUP DRUG clinical practice associated increased anticoagulant effects.
2927,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,atorvastatin,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics DRUG carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2928,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,carbamazepine,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin DRUG cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2929,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,cetirizine,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine DRUG didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2930,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,didanosine,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine DRUG efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2931,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,efavirenz,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine DRUG fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2932,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,fluconazole,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz DRUG indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2933,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,indinavir,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole DRUG midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2934,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,midazolam,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir DRUG rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2935,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,rifabutin,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam DRUG sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2936,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sildenafil,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin DRUG theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2937,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,theophylline,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil DRUG (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine.
2938,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,triazolam,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) DRUG trimethoprim/sulfamethoxazole zidovudine.
2939,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,trimethoprim,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam DRUG /sulfamethoxazole zidovudine.
2940,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sulfamethoxazole,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/ DRUG zidovudine.
2941,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,zidovudine,mechanism,used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole DRUG .
2942,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,efavirenz,azithromycin,mechanism,Co administration DRUG fluconazole modest effect pharmacokinetics DRUG .
2943,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,fluconazole,azithromycin,mechanism,Co administration efavirenz DRUG modest effect pharmacokinetics DRUG .
2944,Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.,probenecid,acyclovir,mechanism,Co administration DRUG DRUG shown increase mean half life area concentration time curve.
2945,"Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.",Rifampin,losartan,mechanism,DRUG inducer drug metabolism decreased concentrations DRUG active metabolite.
2946,"Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.",Fluconazole,losartan,mechanism,DRUG inhibitor P450 2C9 decreased active metabolite concentration increased DRUG concentration.
2947,"As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin",losartan,indomethacin,effect,antihypertensive agents antihypertensive effect DRUG may blunted non steroidal anti inflammatory drug DRUG
2948,"Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.",Probenecid,cephalosporins,mechanism,DRUG may decrease renal tubular secretion GROUP used concurrently resulting increased prolonged cephalosporin blood levels.
2949,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Sucralfate,lomefloxacin,mechanism,Antacids sucralfate: DRUG antacids containing magnesium aluminum well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes DRUG interfere bioavailability.
2950,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",magnesium,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing DRUG aluminum well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes DRUG interfere bioavailability.
2951,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",aluminum,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium DRUG well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes DRUG interfere bioavailability.
2952,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Videx,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium aluminum well formulations containing divalent trivalent cations BRAND (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes DRUG interfere bioavailability.
2953,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",didanosine,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium aluminum well formulations containing divalent trivalent cations Videx ( DRUG ) chewable/buffered tablets pediatric powder oral solution form chelation complexes DRUG interfere bioavailability.
2954,Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).,Sucralfate,lomefloxacin,mechanism,DRUG administered 2 hours DRUG resulted slower absorption (mean C max decreased 30% mean max increased 1 hour) lesser extent absorption (mean AUC decreased approximately 25%).
2955,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",Magnesium,lomefloxacin,mechanism,DRUG aluminum containing antacids administered concomitantly DRUG significantly decreased bioavailability (48%) lomefloxacin.
2956,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",aluminum,lomefloxacin,mechanism,Magnesium DRUG containing antacids administered concomitantly DRUG significantly decreased bioavailability (48%) lomefloxacin.
2957,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",antacids,lomefloxacin,mechanism,Magnesium aluminum containing GROUP administered concomitantly DRUG significantly decreased bioavailability (48%) lomefloxacin.
2958,Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;,antacid,lomefloxacin,mechanism,Separating doses GROUP DRUG minimizes decrease bioavailability;
2959,"Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.",quinolones,caffeine,mechanism,GROUP demonstrated moderate marked interference metabolism DRUG resulting reduced clearance prolongation plasma half life increase symptoms accompany high levels caffeine.
2960,Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.,Cimetidine,quinolones,mechanism,Cimetidine: DRUG demonstrated interfere elimination GROUP .
2961,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine: Elevated serum levels cyclosporine reported concomitant use DRUG members GROUP .
2962,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,anticoagulant,effect,Warfarin: GROUP may enhance effects oral GROUP warfarin derivatives.
2963,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,warfarin,effect,Warfarin: GROUP may enhance effects oral anticoagulant DRUG derivatives.
2964,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,S(-) warfarin,mechanism,DRUG shown induce metabolism DRUG tolbutamide metabolized CYP2C9.
2965,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,tolbutamide,mechanism,DRUG shown induce metabolism S( ) warfarin DRUG metabolized CYP2C9.
2966,"Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.",Aprepitant,phenytoin,mechanism,Coadministration DRUG drugs drugs known metabolized CYP2C9 DRUG may result lower plasma concentrations drugs.
2967,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,Corticosteroids: Dexamethasone: DRUG given regimen 125mg DRUG coadministered orally 20 mg Day 1 Aprepitant given 80 mg/day dexamethasone coadministered orally 8 mg Days 2 5 increased AUC dexamethasone CYP3A4 substrate 2.2 fold Days 1 5.
2968,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,Corticosteroids: Dexamethasone: Aprepitant given regimen 125mg dexamethasone coadministered orally 20 mg Day 1 DRUG given 80 mg/day DRUG coadministered orally 8 mg Days 2 5 increased AUC dexamethasone CYP3A4 substrate 2.2 fold Days 1 5.
2969,"The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.",dexamethasone,Aprepitant,advise,oral DRUG doses reduced approximately 50% coadministered DRUG achieve exposures dexamethasone similar obtained given without Aprepitant.
2970,The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.,dexamethasone,Aprepitant,mechanism,daily dose DRUG administered clinical studies DRUG reflects approximate 50% reduction dose dexamethasone.
2971,"Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.",Aprepitant,methylprednisolone,mechanism,DRUG given regimen 125 mg Day 1 80 mg/day Days 2 3 increased AUC DRUG CYP3A4 substrate 1.34 fold Day 1 2.5 fold Day 3 methylprednisolone coadministered intravenously 125 mg Day 1 orally 40 mg Days 2 3.
2972,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,IV DRUG dose reduced approximately 25% oral methylprednisolone dose reduced approximately 50% coadministered DRUG achieve exposures methylprednisolone similar obtained given without Aprepitant.
2973,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,IV methylprednisolone dose reduced approximately 25% oral DRUG dose reduced approximately 50% coadministered DRUG achieve exposures methylprednisolone similar obtained given without Aprepitant.
2974,"Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",S(-)warfarin,Aprepitant,mechanism,Although effect Aprepitant plasma AUC R(+) S( ) warfarin determined Day 3 34% decrease DRUG (a CYP2C9 substrate) trough concentration accompanied 14% decrease prothrombin time (reported International Normalized Ratio INR) 5 days completion dosing DRUG .
2975,"In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.",warfarin,Aprepitant,advise,patients chronic DRUG therapy prothrombin time (INR) closely monitored 2 week period particularly 7 10 days following initiation 3 day regimen DRUG chemotherapy cycle.
2976,"Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",tolbutamide,Aprepitant,mechanism,Tolbutamide: Aprepitant given 125 mg Day 1 80 mg/day Days 2 3 decreased AUC tolbutamide (a CYP2C9 substrate) 23% Day 4 28% Day 8 15% Day 15 single dose DRUG 500 mg admini stered orally prior administration 3 day regimen DRUG Days 4 8 15.
2977,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,ethinyl estradiol,mechanism,Oral contraceptives: DRUG given daily 14 days 100 mg capsule oral contraceptive containing 35 mcg DRUG 1 mg norethindrone decreased AUC ethinyl estradiol 43% decreased AUC norethindrone 8%;
2978,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,norethindrone,mechanism,Oral contraceptives: DRUG given daily 14 days 100 mg capsule oral contraceptive containing 35 mcg ethinyl estradiol 1 mg DRUG decreased AUC ethinyl estradiol 43% decreased AUC norethindrone 8%;
2979,"therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.",contraceptives,Aprepitant,effect,therefore efficacy oral GROUP administration DRUG may reduced.
2980,"Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.",Aprepitant,contraceptives,advise,Although 3 day regimen DRUG given concomitantly oral GROUP studied alternative back methods contraception used.
2981,"Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.",Aprepitant,midazolam,mechanism,Midazolam: DRUG increased AUC DRUG sensitive CYP3A4 substrate 2.3 fold Day 1 3.3 fold Day 5 single oral dose midazolam 2 mg coadministered Day 1 Day 5 regimen Aprepitant 125 mg Day 1 80 mg/day Days 2 5.
2982,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",midazolam,Aprepitant,advise,potential effects increased plasma concentrations DRUG benzodiazepines metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents DRUG .
2983,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",benzodiazepines,Aprepitant,advise,potential effects increased plasma concentrations midazolam GROUP metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents DRUG .
2984,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",alprazolam,Aprepitant,advise,potential effects increased plasma concentrations midazolam benzodiazepines metabolized via CYP3A4 ( DRUG triazolam) considered coadministering agents DRUG .
2985,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",triazolam,Aprepitant,advise,potential effects increased plasma concentrations midazolam benzodiazepines metabolized via CYP3A4 (alprazolam DRUG ) considered coadministering agents DRUG .
2986,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased AUC DRUG 25% Day 4 decreased AUC midazolam 19% Day 8 relative dosing Aprepitant Days 1 3.
2987,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased AUC midazolam 25% Day 4 decreased AUC DRUG 19% Day 8 relative dosing Aprepitant Days 1 3.
2988,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ketoconazole,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e.g. DRUG itraconazole nefazodone troleandomycin clarithromycin ritonavir nelfinavir) approached caution.
2989,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,itraconazole,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e.g. ketoconazole DRUG nefazodone troleandomycin clarithromycin ritonavir nelfinavir) approached caution.
2990,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nefazodone,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole DRUG troleandomycin clarithromycin ritonavir nelfinavir) approached caution.
2991,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,troleandomycin,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone DRUG clarithromycin ritonavir nelfinavir) approached caution.
2992,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,clarithromycin,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone troleandomycin DRUG ritonavir nelfinavir) approached caution.
2993,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ritonavir,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone troleandomycin clarithromycin DRUG nelfinavir) approached caution.
2994,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nelfinavir,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e.g. ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir DRUG ) approached caution.
2995,"Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.",diltiazem,aprepitant,advise,moderate CYP3A4 inhibitors (e.g. DRUG ) result 2 fold increase plasma concentrations DRUG concomitant administration also approached caution.
2996,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,rifampin,mechanism,therefore coadministration DRUG drugs strongly induce CYP3A4 activity (e.g. DRUG carbamazepine phenytoin) may result reduced plasma concentrations aprepitant may result decreased efficacy Aprepitant.
2997,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,phenytoin,mechanism,therefore coadministration DRUG drugs strongly induce CYP3A4 activity (e.g. rifampin carbamazepine DRUG ) may result reduced plasma concentrations aprepitant may result decreased efficacy Aprepitant.
2998,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,aprepitant,mechanism,therefore coadministration DRUG drugs strongly induce CYP3A4 activity (e.g. rifampin carbamazepine phenytoin) may result reduced plasma concentrations DRUG may result decreased efficacy Aprepitant.
2999,"Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.",Aprepitant,ketoconazole,mechanism,Ketoconazole: single 125 mg dose DRUG administered Day5 10 day regimen 400 mg/day DRUG strong CYP3A4 inhibitor AUC aprepitant increased approximately 5 fold mean terminal half life aprepitant increased approximately 3 fold.
3000,"Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.",Aprepitant,rifampin,mechanism,Rifampin: single 375 mg dose DRUG administered Day9 14 day regimen 600 mg/day DRUG strong CYP3A4 inducer AUC aprepitant decreased approximately 11 fold mean terminal half life decreased approximately 3 fold.
3001,"Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.",aprepitant,diltiazem,mechanism,Diltiazem: patients mild moderate hypertension administration DRUG daily tablet formulation comparable 230 mg capsule formulation DRUG 120 mg 3 times daily 5 days resulted 2 fold increase aprepitant AUC simultaneous 1.7 fold increase diltiazem AUC.
3002,"Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",aprepitant,paroxetine,mechanism,Paroxetine: Coadministration daily doses DRUG tablet formulation comparable 85 mg 170 mg capsule formulation DRUG 20 mg daily resulted decrease AUC approximately 25% Cmax approximately 20% aprepitant paroxetine.
3003,"Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. ",Cholestyramine,fluvastatin,mechanism,DRUG anionic binding resin considerable effect lowering rate extent DRUG bioavailability.
3004,"Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. ",cholestyramine,fluvastatin,effect,Although effect noted even DRUG given 4 hours prior DRUG regimen result diminished efficacy.
3005,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,GROUP shown depress plasma prothrombin activity patients GROUP therapy may require downward adjustment anticoagulant dosage.
3006,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.",tetracyclines,penicillin,advise,Since bacteriostatic drugs may interfere bactericidal action penicillin advisable avoid giving GROUP conjunction GROUP .
3007,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,aluminum,mechanism,Absorption GROUP impaired antacids containing DRUG calcium magnesium iron containing preparations.
3008,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,calcium,mechanism,Absorption GROUP impaired antacids containing aluminum DRUG magnesium iron containing preparations.
3009,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,magnesium,mechanism,Absorption GROUP impaired antacids containing aluminum calcium DRUG iron containing preparations.
3010,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,iron,mechanism,Absorption GROUP impaired antacids containing aluminum calcium magnesium DRUG containing preparations.
3011,Absorption of tetracycline is impaired by bismuth subsalicylate.,tetracycline,bismuth subsalicylate,mechanism,Absorption DRUG impaired DRUG .
3012,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",Barbiturates,doxycycline,mechanism,GROUP carbamazepine phenytoin decrease half life DRUG .
3013,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",carbamazepine,doxycycline,mechanism,Barbiturates DRUG phenytoin decrease half life DRUG .
3014,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",phenytoin,doxycycline,mechanism,Barbiturates carbamazepine DRUG decrease half life DRUG .
3015,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,Penthrane,effect,concurrent use DRUG BRAND (methoxyflurane) reported result fatal renal toxicity.
3016,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,methoxyflurane,effect,concurrent use DRUG Penthrane ( DRUG ) reported result fatal renal toxicity.
3017,Concurrent use of tetracycline may render oral contraceptives less effective.,tetracycline,contraceptives,effect,Concurrent use DRUG may render oral GROUP less effective.
3018,Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. ,Etofibrate,heparin,effect,DRUG elicited 62% enhancement post DRUG lipolytic activity 100% increase 3H triglyceride fractional clearance rate compared placebo treatment.
3019,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",narcotic analgesics,hydrocodone,effect,Patients receiving GROUP antipsychotics antianxiety agents CNS depressants (including alcohol) concomitantly DRUG acetaminophen tablets may exhibit additive CNS depression.
3020,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antipsychotics,hydrocodone,effect,Patients receiving narcotic analgesics GROUP antianxiety agents CNS depressants (including alcohol) concomitantly DRUG acetaminophen tablets may exhibit additive CNS depression.
3021,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antianxiety agents,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics GROUP CNS depressants (including alcohol) concomitantly DRUG acetaminophen tablets may exhibit additive CNS depression.
3022,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",CNS depressants,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents GROUP (including alcohol) concomitantly DRUG acetaminophen tablets may exhibit additive CNS depression.
3023,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",alcohol,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents CNS depressants (including DRUG ) concomitantly DRUG acetaminophen tablets may exhibit additive CNS depression.
3024,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,MAO inhibitors,hydrocodone,effect,use GROUP tricyclic antidepressants DRUG preparations may increase effect either antidepressant hydrocodone.
3025,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,tricyclic antidepressants,hydrocodone,effect,use MAO inhibitors GROUP DRUG preparations may increase effect either antidepressant hydrocodone.
3026,The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.,anticholinergics,hydrocodone,effect,concurrent use GROUP DRUG may produce paralytic ileus.
3027,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergotamine,FROVA,advise,Due theoretical risk pharmacodynamic interaction use DRUG containing ergot type medications (like dihydroergotamine methysergide) BRAND within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3028,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergot-type medications,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine containing GROUP (like dihydroergotamine methysergide) BRAND within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3029,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",dihydroergotamine,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine containing ergot type medications (like DRUG methysergide) BRAND within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3030,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",methysergide,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine containing ergot type medications (like dihydroergotamine DRUG ) BRAND within 24 hours avoided (see href= frova_od.htm#CI CONTRAINDICATIONS).
3031,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",Selective serotonin reuptake inhibitors,5-HT1 agonists,effect,GROUP (SSRIs) (e.g. fluoxetine fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered GROUP .
3032,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors ( GROUP ) (e.g. fluoxetine fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered GROUP .
3033,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. DRUG fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered GROUP .
3034,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine DRUG paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered GROUP .
3035,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine fluvoxamine DRUG sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered GROUP .
3036,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine fluvoxamine paroxetine DRUG ) reported rarely cause weakness hyperreflexia incoordination coadministered GROUP .
3037,"If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",frovatriptan,SSRI,advise,concomitant treatment DRUG GROUP clinically warranted appropriate observation patient advised.
3038,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",decongestants,tricyclic antidepressants,advise,Avoid use preparations GROUP local anesthetics contain sympathomimetic amine (e.g. epinephrine norepinephrine) since reported GROUP potentiate effects catecholamines.
3039,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",anesthetics,tricyclic antidepressants,advise,Avoid use preparations decongestants local GROUP contain sympathomimetic amine (e.g. epinephrine norepinephrine) since reported GROUP potentiate effects catecholamines.
3040,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",sympathomimetic amine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain GROUP (e.g. epinephrine norepinephrine) since reported GROUP potentiate effects catecholamines.
3041,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",epinephrine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine (e.g. DRUG norepinephrine) since reported GROUP potentiate effects catecholamines.
3042,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",norepinephrine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine (e.g. epinephrine DRUG ) since reported GROUP potentiate effects catecholamines.
3043,Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.,Imipramine hydrochloride,CNS depressant drugs,effect,DRUG may potentiate effects GROUP .
3044,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,cimetidine,mechanism,plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e.g. DRUG fluoxetine) decrease concomitant administration hepatic enzyme inducers (e.g. barbiturates phenytoin) adjustment dosage imipramine may therefore necessary.
3045,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,fluoxetine,mechanism,plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e.g. cimetidine DRUG ) decrease concomitant administration hepatic enzyme inducers (e.g. barbiturates phenytoin) adjustment dosage imipramine may therefore necessary.
3046,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,barbiturates,mechanism,plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e.g. cimetidine fluoxetine) decrease concomitant administration hepatic enzyme inducers (e.g. GROUP phenytoin) adjustment dosage imipramine may therefore necessary.
3047,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,phenytoin,mechanism,plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e.g. cimetidine fluoxetine) decrease concomitant administration hepatic enzyme inducers (e.g. barbiturates DRUG ) adjustment dosage imipramine may therefore necessary.
3048,"The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.",SSRI,TCA,int,extent GROUP GROUP interactions may pose clinical problems depend degree inhibition pharmacokinetics SSRI involved.
3049,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,Antacids,chloroquine,mechanism,Antacids kaolin: GROUP kaolin reduce absorption DRUG ;
3050,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,kaolin,chloroquine,mechanism,Antacids kaolin: Antacids DRUG reduce absorption DRUG ;
3051,"Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.",Cimetidine,chloroquine,mechanism,Cimetidine: DRUG inhibit metabolism DRUG increasing plasma level.
3052,"Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.",chloroquine,ampicillin,mechanism,Ampicillin: study healthy volunteers DRUG significantly reduced bioavailability DRUG .
3053,"Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.",chloroquine,cyclosporin,mechanism,Cyclosporin: introduction DRUG (oral form) sudden increase serum DRUG level reported.
3054,The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.,aspirin,fenoprofen,mechanism,coadministration BRAND decreases biologic half life DRUG increase metabolic clearance results greater amount hydroxylated fenoprofen urine.
3055,"Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.",fenoprofen,aspirin,mechanism,Although mechanism interaction DRUG BRAND totally known enzyme induction displacement fenoprofen plasma albumin binding sites possibilities.
3056,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",aspirin,Nalfon,mechanism,Nalfon shown produce additional effect beyond obtained aspirin alone BRAND increases rate excretion BRAND concomitant use Nalfon salicylates recommended.
3057,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",Nalfon,salicylates,advise,Nalfon shown produce additional effect beyond obtained aspirin alone aspirin increases rate excretion Nalfon concomitant use BRAND GROUP recommended.
3058,"Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.",phenobarbital,fenoprofen,mechanism,Chronic administration DRUG known enzyme inducer may associated decrease plasma half life DRUG .
3059,"When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.",phenobarbital,Nalfon,advise,DRUG added withdrawn treatment dosage adjustment BRAND may required.
3060,"In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.",coumarin-type anticoagulants,Nalfon,effect,patients receiving GROUP addition BRAND therapy could prolong prothrombin time.
3061,Patients treated with Nalfon may be resistant to the effects of loop diuretics.,Nalfon,loop diuretics,effect,Patients treated BRAND may resistant effects GROUP .
3062,"In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.",Nalfon,steroid,advise,patients receiving BRAND GROUP concomitantly reduction steroid dosage gradual order avoid possible complications sudden steroid withdrawal.
3063,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,verapamil,mechanism,BRAND decreased Cmax AUC sustained release DRUG (Calan SR ) approximately 31% 11% respectively.
3064,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,Calan SR,mechanism,BRAND decreased Cmax AUC sustained release verapamil ( BRAND ) approximately 31% 11% respectively.
3065,"Clinical implications of warfarin interactions with five sedatives.
",warfarin,sedatives,int,Clinical implications DRUG interactions five GROUP .
3066,Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ,Barbiturates,coumarin drugs,advise,GROUP glutethimide administered patients receiving GROUP .
3067,Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ,glutethimide,coumarin drugs,advise,Barbiturates DRUG administered patients receiving GROUP .
3068,"Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ",Chloral hydrate,anticoagulant agents,int,DRUG methaqualone interact pharmacologically orally administered GROUP effect clinically significant.
3069,"Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ",methaqualone,anticoagulant agents,int,Chloral hydrate DRUG interact pharmacologically orally administered GROUP effect clinically significant.
3070,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,BRAND modifies DRUG metabolism increased serum levels phenytoin.
3071,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,BRAND modifies phenytoin metabolism increased serum levels DRUG .
3072,"By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.",DIAMOX,primidone,mechanism,decreasing gastrointestinal absorption primidone BRAND may decrease serum concentrations DRUG metabolites consequent possible decrease anticonvulsant effect.
3073,"Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.",DIAMOX,primidone,advise,Caution advised beginning discontinuing changing dose BRAND patients receiving DRUG .
3074,Acetazolamide may increase the effects of other folic acid antagonists.,Acetazolamide,folic acid antagonists,effect,DRUG may increase effects GROUP .
3075,Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.,Acetazolamide,amphetamine,mechanism,DRUG decreases urinary excretion DRUG may enhance magnitude duration effect.
3076,Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.,Acetazolamide,quinidine,mechanism,DRUG reduces urinary excretion DRUG may enhance effect.
3077,Acetazolamide may prevent the urinary antiseptic effect of methenamine.,Acetazolamide,methenamine,effect,DRUG may prevent urinary antiseptic effect DRUG .
3078,Acetazolamide increases lithium excretion and the lithium may be decreased.,Acetazolamide,lithium,mechanism,DRUG increases DRUG excretion lithium may decreased.
3079,Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.,Acetazolamide,sodium bicarbonate,effect,DRUG DRUG used concurrently increases risk renal calculus formation.
3080,Acetazolamide may elevate cyclosporine levels.,Acetazolamide,cyclosporine,mechanism,DRUG may elevate DRUG levels.
3081,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,ketoconazole,advise,Since PLETAL extensively metabolized cytochrome P 450 isoenzymes caution exercised BRAND coadministered inhibitors C.P.A. DRUG erythromycin inhibitors CYP2C19 omeprazole.
3082,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,erythromycin,advise,Since PLETAL extensively metabolized cytochrome P 450 isoenzymes caution exercised BRAND coadministered inhibitors C.P.A. ketoconazole DRUG inhibitors CYP2C19 omeprazole.
3083,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,omeprazole,advise,Since PLETAL extensively metabolized cytochrome P 450 isoenzymes caution exercised BRAND coadministered inhibitors C.P.A. ketoconazole erythromycin inhibitors CYP2C19 DRUG .
3084,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,omeprazole,cilostazol,mechanism,Pharmacokinetic studies demonstrated DRUG erythromycin significantly increased systemic exposure DRUG and/or major metabolites.
3085,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,erythromycin,cilostazol,mechanism,Pharmacokinetic studies demonstrated omeprazole DRUG significantly increased systemic exposure DRUG and/or major metabolites.
3086,"Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..",cilostazol,diltiazem,mechanism,Population pharmacokinetic studies showed higher concentrations DRUG among patients concurrently treated DRUG inhibitor C.P.A..
3087,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,hexobarbital,effect,Animal experience indicates DRUG prolongs sleeping time DRUG ethyl alcohol increases inhibitory effects chlorpromazine exhibit monoamine oxidase inhibition.
3088,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,ethyl alcohol,effect,Animal experience indicates DRUG prolongs sleeping time hexobarbital DRUG increases inhibitory effects chlorpromazine exhibit monoamine oxidase inhibition.
3089,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,chlorpromazine,effect,Animal experience indicates DRUG prolongs sleeping time hexobarbital ethyl alcohol increases inhibitory effects DRUG exhibit monoamine oxidase inhibition.
3090,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,barbiturates,effect,actions GROUP may potentiated GROUP narcotics phenothiazines monoamine oxidase inhibitors antidepressants.
3091,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,narcotics,effect,actions GROUP may potentiated barbiturates GROUP phenothiazines monoamine oxidase inhibitors antidepressants.
3092,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,phenothiazines,effect,actions GROUP may potentiated barbiturates narcotics GROUP monoamine oxidase inhibitors antidepressants.
3093,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,monoamine oxidase inhibitors,effect,actions GROUP may potentiated barbiturates narcotics phenothiazines GROUP antidepressants.
3094,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,antidepressants,effect,actions GROUP may potentiated barbiturates narcotics phenothiazines monoamine oxidase inhibitors GROUP .
3095,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,aminoglycoside antibiotics,effect,Nephrotoxicity reported following concomitant administration GROUP GROUP potent diuretics furosemide.
3096,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity reported following concomitant administration GROUP aminoglycoside antibiotics potent GROUP furosemide.
3097,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity reported following concomitant administration GROUP aminoglycoside antibiotics potent diuretics DRUG .
3098,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,beta-lactam antibiotics,effect,DRUG shown antagonistic GROUP including ceftazidime based vitro studies time kill curves enteric gram negative bacilli.
3099,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,ceftazidime,effect,DRUG shown antagonistic beta lactam antibiotics including DRUG based vitro studies time kill curves enteric gram negative bacilli.
3100,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",anakinra,TNF-blocking agent,effect,Anakinra: Concurrent administration DRUG (an interleukin 1 antagonist) another GROUP associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone.
3101,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",interleukin-1 antagonist,TNF-blocking agent,effect,Anakinra: Concurrent administration anakinra (an GROUP ) another GROUP associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone.
3102,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,TNF-blocking agents,effect,Therefore combination DRUG GROUP including HUMIRA may also result n similar toxicities.
3103,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,HUMIRA,effect,Therefore combination DRUG TNF blocking agents including BRAND may also result n similar toxicities.
3104,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,antiparkinsonian drug,effect,concurrent use two drugs anticholinergic activity GROUP (eg chlorpromazine) GROUP (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3105,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,trihexyphenidyl,effect,concurrent use two drugs anticholinergic activity GROUP (eg chlorpromazine) antiparkinsonian drug (eg DRUG ) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3106,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity GROUP (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or GROUP (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3107,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,amitriptyline,effect,concurrent use two drugs anticholinergic activity GROUP (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg DRUG ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3108,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,antiparkinsonian drug,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg DRUG ) GROUP (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3109,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,trihexyphenidyl,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg DRUG ) antiparkinsonian drug (eg DRUG ) and/or tricyclic antidepressant (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3110,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg DRUG ) antiparkinsonian drug (eg trihexyphenidyl) and/or GROUP (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3111,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,amitriptyline,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg DRUG ) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg DRUG ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3112,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) GROUP (eg trihexyphenidyl) and/or GROUP (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3113,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,amitriptyline,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) GROUP (eg trihexyphenidyl) and/or tricyclic antidepressant (eg DRUG ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3114,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,tricyclic antidepressant,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg DRUG ) and/or GROUP (eg amitriptyline) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3115,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,amitriptyline,effect,concurrent use two drugs anticholinergic activity antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg DRUG ) and/or tricyclic antidepressant (eg DRUG ) commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia.
3116,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",Isoflurane,NUROMAX,mechanism,DRUG enflurane halothane decrease ED50 BRAND 30% 45%.
3117,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",enflurane,NUROMAX,mechanism,Isoflurane DRUG halothane decrease ED50 BRAND 30% 45%.
3118,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",halothane,NUROMAX,mechanism,Isoflurane enflurane DRUG decrease ED50 BRAND 30% 45%.
3119,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,antibiotics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain GROUP (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3120,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,aminoglycosides,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. GROUP tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3121,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,tetracyclines,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides GROUP bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3122,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,bacitracin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines GROUP polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3123,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,polymyxins,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin GROUP lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3124,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lincomycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins DRUG clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3125,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,clindamycin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin DRUG colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3126,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,colistin,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin DRUG sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
3127,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,sodium colistimethate,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin DRUG ) magnesium salts lithium local anesthetics procainamide quinidine.
3128,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,magnesium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) DRUG salts lithium local anesthetics procainamide quinidine.
3129,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lithium,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts DRUG local anesthetics procainamide quinidine.
3130,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,anesthetics,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local GROUP procainamide quinidine.
3131,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,procainamide,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics DRUG quinidine.
3132,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,quinidine,effect,drugs may enhance neuromuscular blocking action nondepolarizing agents BRAND include certain antibiotics (e. g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide DRUG .
3133,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,phenytoin,effect,GROUP time onset neuromuscular block induced NUROMAX lengthened duration block shortened patients receiving DRUG carbamazepine.
3134,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,carbamazepine,effect,GROUP time onset neuromuscular block induced NUROMAX lengthened duration block shortened patients receiving phenytoin DRUG .
3135,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,phenytoin,effect,nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced BRAND lengthened duration block shortened patients receiving DRUG carbamazepine.
3136,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,carbamazepine,effect,nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced BRAND lengthened duration block shortened patients receiving phenytoin DRUG .
3137,Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.,anticonvulsant agents,cisplatin,mechanism,Plasma levels GROUP may become subtherapeutic DRUG therapy.
3138,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",quinidine,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such DRUG fluoxetine paroxetine propafenone) studied drugs would expected increase blood levels R(+) enantiomer DRUG .
3139,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",fluoxetine,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such quinidine DRUG paroxetine propafenone) studied drugs would expected increase blood levels R(+) enantiomer DRUG .
3140,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",paroxetine,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such quinidine fluoxetine DRUG propafenone) studied drugs would expected increase blood levels R(+) enantiomer DRUG .
3141,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",propafenone,carvedilol,effect,poor metabolizers debrisoquin: Interactions carvedilol strong inhibitors CYP2D6 (such quinidine fluoxetine paroxetine DRUG ) studied drugs would expected increase blood levels R(+) enantiomer DRUG .
3142,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,reserpine,effect,Catecholamine depleting Agents: Patients taking GROUP drug deplete catecholamines (e.g. DRUG monoamine oxidase inhibitors) observed closely signs hypotension and/or severe bradycardia.
3143,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,monoamine oxidase inhibitors,effect,Catecholamine depleting Agents: Patients taking GROUP drug deplete catecholamines (e.g. reserpine GROUP ) observed closely signs hypotension and/or severe bradycardia.
3144,Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.,clonidine,agents with b-blocking properties,effect,Clonidine: Concomitant administration DRUG GROUP may potentiate blood pressure heart rate lowering effects.
3145,"When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.",agents with b-blocking properties,clonidine,advise,concomitant treatment GROUP DRUG terminated b blocking agent discontinued first.
3146,Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.,cyclosporine,carvedilol,mechanism,Cyclosporine: Modest increases mean trough DRUG concentrations observed following initiation DRUG treatment 21 renal transplant patients suffering chronic vascular rejection.
3147,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",cyclosporine,carvedilol,advise,Due wide interindividual variability dose adjustment required recommended DRUG concentrations monitored closely initiation DRUG therapy dose cyclosporine adjusted appropriate.
3148,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",carvedilol,cyclosporine,advise,Due wide interindividual variability dose adjustment required recommended cyclosporine concentrations monitored closely initiation DRUG therapy dose DRUG adjusted appropriate.
3149,Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.,digoxin,carvedilol,mechanism,Digoxin: Digoxin concentrations increased 15% DRUG DRUG administered concomitantly.
3150,Both digoxin and COREG slow AV conduction.,digoxin,COREG,effect,DRUG BRAND slow AV conduction.
3151,"Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.",digoxin,COREG,advise,Therefore increased monitoring DRUG recommended initiating adjusting discontinuing BRAND .
3152,Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.,Rifampin,carvedilol,mechanism,Inducers Inhibitors Hepatic Metabolism: DRUG reduced plasma concentrations DRUG 70%.
3153,Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.,COREG,diltiazem,effect,Calcium Channel Blockers: Isolated cases conduction disturbance (rarely hemodynamic compromise) observed BRAND co administered DRUG .
3154,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,verapamil,advise,agents b blocking properties BRAND administered orally calcium channel blockers DRUG diltiazem type recommended ECG blood pressure monitored.
3155,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,diltiazem,advise,agents b blocking properties BRAND administered orally calcium channel blockers verapamil DRUG type recommended ECG blood pressure monitored.
3156,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,insulin,effect,Insulin Oral Hypoglycemics: GROUP may enhance blood sugar reducing effect DRUG oral hypoglycemics.
3157,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,hypoglycemics,effect,Insulin Oral Hypoglycemics: GROUP may enhance blood sugar reducing effect insulin oral GROUP .
3158,Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.,baclofen,morphine,effect,Interactions attributed combined use DRUG injection epidural DRUG include hypotension dyspnea.
3159,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,calcium channel blockers,advise,recommended combination intravenous DRUG GROUP verapamil used together management malignant hyperthermia crisis relevance findings humans established.
3160,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,verapamil,advise,recommended combination intravenous DRUG calcium channel blockers DRUG used together management malignant hyperthermia crisis relevance findings humans established.
3161,Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.,dantrolene,vecuronium,effect,Administration DRUG may potentiate DRUG induced neuromuscular block.
3162,The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.,nitroglycerin,vasodilators,effect,vasodilating effects DRUG may additive GROUP .
3163,Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.,calcium channel blockers,nitrates,effect,Marked symptomatic orthostatic hypotension reported GROUP organic GROUP used combination.
3164,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,serotoninergic agents,effect,patients receiving nonselective GROUP (MAOIs) (e.g. selegiline hydrochloride) combination GROUP (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3165,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluoxetine,effect,patients receiving nonselective GROUP (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. DRUG fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3166,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluvoxamine,effect,patients receiving nonselective GROUP (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine DRUG paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3167,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,paroxetine,effect,patients receiving nonselective GROUP (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine DRUG sertraline venlafaxine) reports serious sometimes fatal reactions.
3168,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,sertraline,effect,patients receiving nonselective GROUP (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine DRUG venlafaxine) reports serious sometimes fatal reactions.
3169,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,venlafaxine,effect,patients receiving nonselective GROUP (MAOIs) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline DRUG ) reports serious sometimes fatal reactions.
3170,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,serotoninergic agents,effect,patients receiving nonselective monoamine oxidase inhibitors ( GROUP ) (e.g. selegiline hydrochloride) combination GROUP (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3171,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluoxetine,effect,patients receiving nonselective monoamine oxidase inhibitors ( GROUP ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. DRUG fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3172,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluvoxamine,effect,patients receiving nonselective monoamine oxidase inhibitors ( GROUP ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine DRUG paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3173,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,paroxetine,effect,patients receiving nonselective monoamine oxidase inhibitors ( GROUP ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine DRUG sertraline venlafaxine) reports serious sometimes fatal reactions.
3174,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,sertraline,effect,patients receiving nonselective monoamine oxidase inhibitors ( GROUP ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine DRUG venlafaxine) reports serious sometimes fatal reactions.
3175,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,venlafaxine,effect,patients receiving nonselective monoamine oxidase inhibitors ( GROUP ) (e.g. selegiline hydrochloride) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline DRUG ) reports serious sometimes fatal reactions.
3176,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,serotoninergic agents,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. DRUG ) combination GROUP (e.g. fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3177,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluoxetine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. DRUG ) combination serotoninergic agents (e.g. DRUG fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3178,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluvoxamine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. DRUG ) combination serotoninergic agents (e.g. fluoxetine DRUG paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions.
3179,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,paroxetine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. DRUG ) combination serotoninergic agents (e.g. fluoxetine fluvoxamine DRUG sertraline venlafaxine) reports serious sometimes fatal reactions.
3180,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,sertraline,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. DRUG ) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine DRUG venlafaxine) reports serious sometimes fatal reactions.
3181,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,venlafaxine,effect,patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g. DRUG ) combination serotoninergic agents (e.g. fluoxetine fluvoxamine paroxetine sertraline DRUG ) reports serious sometimes fatal reactions.
3182,"Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.",dexfenfluramine,MAO inhibitor,advise,dexfenfluramine serotonin releaser reuptake inhibitor DRUG used concomitantly GROUP .
3183,At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.,MAO inhibitor,dexfenfluramine,advise,least 14 days elapse discontinuation GROUP initiation treatment DRUG .
3184,At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.,dexfenfluramine,MAO inhibitor,advise,least 3 weeks elapse discontinuation DRUG initiation treatment GROUP .
3185,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,Imitrex,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use GROUP (SSRIs) agents migraine therapy BRAND (sumatriptan succinate) dihydroergotamine.
3186,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,sumatriptan succinate,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use GROUP (SSRIs) agents migraine therapy Imitrex ( DRUG ) dihydroergotamine.
3187,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,dihydroergotamine,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use GROUP (SSRIs) agents migraine therapy Imitrex (sumatriptan succinate) DRUG .
3188,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,Imitrex,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors ( GROUP ) agents migraine therapy BRAND (sumatriptan succinate) dihydroergotamine.
3189,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,sumatriptan succinate,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors ( GROUP ) agents migraine therapy Imitrex ( DRUG ) dihydroergotamine.
3190,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,dihydroergotamine,effect,rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors ( GROUP ) agents migraine therapy Imitrex (sumatriptan succinate) DRUG .
3191,Dexfenfluramine should not be administered with other serotoninergic agents.,Dexfenfluramine,serotoninergic agents,advise,DRUG administered GROUP .
3192,"Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.",Itraconazole,busulfan,mechanism,DRUG decreases DRUG clearance 25% may produce AUCs 1500 min patients.
3193,"Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.",Phenytoin,busulfan,mechanism,DRUG increases clearance DRUG 15% possibly due induction glutathione transferase.
3194,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.",BUSULFEX,phenytoin,mechanism,Since pharmacokinetics BRAND studied patients treated DRUG clearance BUSULFEX recommended dose may lower exposure (AUC) higher patients treated phenytoin.
3195,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.",acetaminophen,BUSULFEX,mechanism,busulfan eliminated body via conjugation glutathione use DRUG prior ( 72 hours) concurrent BRAND may result reduced busulfan clearance based upon known property acetaminophen decrease glutathione levels blood tissues.
3196,Trecator has been found to temporarily raise serum concentrations of isoniazid.,Trecator,isoniazid,mechanism,BRAND found temporarily raise serum concentrations DRUG .
3197,Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.,Trecator,antituberculous drugs,effect,BRAND may potentiate adverse effects GROUP administered concomitantly.
3198,"In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.",ethionamide,cycloserine,effect,particular convulsions reported DRUG administered DRUG special care taken treatment regimen includes drugs.
3199,"Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).",danazol,lovastatin,effect,Danazol: risk myopathy/rhabdomyolysis increased concomitant administration DRUG particularly higher doses DRUG (see WARNINGS Myopathy/Rhabdomyolysis).
3200,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",amiodarone,HMG-CoA reductase inhibitor class,effect,Amiodarone Verapamil: risk myopathy/rhabdomyolysis increased either DRUG verapamil used concomitantly closely related member GROUP (see WARNINGS Myopathy/Rhabdomyolysis).
3201,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",verapamil,HMG-CoA reductase inhibitor class,effect,Amiodarone Verapamil: risk myopathy/rhabdomyolysis increased either amiodarone DRUG used concomitantly closely related member GROUP (see WARNINGS Myopathy/Rhabdomyolysis).
3202,"However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.",HMG-CoA reductase inhibitor,warfarin,effect,However another GROUP found produce less two second increase prothrombin time healthy volunteers receiving low doses DRUG .
3203,"Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.",coumarin anticoagulant,lovastatin,effect,Also bleeding and/or increased prothrombin time reported patients taking GROUP concomitantly DRUG .
3204,"It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.",anticoagulants,lovastatin,advise,recommended patients taking GROUP prothrombin time determined starting DRUG frequently enough early therapy insure significant alteration prothrombin time occurs.
